



UNIVERSITY OF NAIROBI

**PHYTOCHEMICAL ANALYSIS OF SELECTED *TEPHROSIA* SPECIES FOR
ANTI-INFLAMMATORY PRINCIPLES**

BY

OWOR RICHARD ORIKO

I80/50120/2015

**A THESIS SUBMITTED IN FULFILLMENT OF THE REQUIREMENTS FOR
THE AWARD OF THE DEGREE OF DOCTOR OF PHILOSOPHY IN
CHEMISTRY OF THE UNIVERSITY OF NAIROBI**

2021

DECLARATION

I declare that this Ph.D. thesis is my original work and has not been submitted elsewhere for examination or award of a degree. Where other people's work has been used, this has properly been acknowledged and referenced as per the University of Nairobi's requirements.

Signature:  Date: **10.05.2021**

Owor Richard Oriko
(I80/50120/2015)
Department of Chemistry
University of Nairobi


This Ph.D. thesis is submitted to the University of Nairobi with our approval as research supervisors.

Supervisors

Signature


Date

Dr. Albert Ndakala
Department of Chemistry
University of Nairobi
P.O Box 30197-00100
Nairobi Kenya
andakala@uonbi.ac.ke

..... 

..... **31.05.2021**

Dr. Solomon Derese
Department of Chemistry
University of Nairobi
P.O Box 30197-00100
Nairobi Kenya
sderese@uonbi.ac.ke

..... 

..... **31.05.2021**

Dr. George O. Ong'amo
School of Biological Sciences
University of Nairobi
P.O Box 30197-00100
Nairobi Kenya
gongamo@unobi.ac.ke

..... 

..... **31.05.2021**

DEDICATION

This worked is dedicated to my devoted wife Sophie Moreen Byantaka and my loving children
(Annastashia Rashina Atono, Shadrick Oriko Owor and Richlene Oriko Siem)

ACKNOWLEDGEMENT

My profound gratitude goes to my supervisors: Dr. Albert Ndakala, Dr. Solomon Derese and Dr. George O. Ong'amo for their invaluable expertise, guidance and encouragement throughout my research. I extend special thanks to Prof. Abiy Yenesew, who although not my supervisor but has always been open to discussion and has offered me a lot of guidance throughout my studies. I extend my gratitude and appreciation to Prof. Dr. Dr. Michael Spitteller, INFU, TU Dortmund and his entire group particularly Dr. Kibrom Gebrehiwot Bedane and Dr. Sebastian Zühlke for hosting me in his laboratory for a nine-month research visit and guiding me in structure characterization and biological assay.

I would like to acknowledge support from the academic and technical staff of the Department of Chemistry, University of Nairobi for the assistance accorded to me whenever I needed it. My special thanks are due to my fellow Ph.D and MSc colleagues in the Natural Products Group of the University of Nairobi, who better understood my everyday struggles in the lab and were always willing to share constructive ideas with me, I owe my success to you all! Mr. Patrick Mutiso (University Herbarium, School of Biological Sciences, University of Nairobi) is acknowledged for the collection and authentication of the plants.













I am grateful to the German Academic Exchange Services (DAAD) for a doctoral scholarship which was offered through the Natural Products Research Network for Eastern and Central Africa (NAPRECA) and also funded my research visit to TU Dortmund, Germany. I am grateful to Busitema University for granting me a study leave which made my work easier.

Lastly, I am indebted to my family members ... words cannot appropriately express how your persistent prayers and encouragement have helped me to surmount the difficult moments. Above all, to the Almighty God for strength and wisdom.

ABSTRACT

Inflammation is a vital immune process in the restoration of inflamed tissues and it is regulated by mediators such as cytokines. However, dysregulation of inflammation is associated with the onset and development of chronic respiratory diseases and cancer. The management of inflammation and associated diseases using currently available anti-inflammatory drugs such as ibuprofen has been linked with adverse side effects. Thus, there is a need to develop alternative anti-inflammatory drugs. Plants of the genus *Tephrosia* Pers. (Fabaceae) have been used widely in ethnomedicine in the management of various ailments and they elaborate diversity of flavonoids. Although flavonoids are reported to have anti-inflammatory effects, little has been reported on the anti-inflammatory properties of flavonoids from the genus *Tephrosia*. Therefore, in this study selected *Tephrosia* species (*T. linearis*, *T. hildebrandtii*, *T. vogelii*, *T. elata*, and *T. rhodesica*) were phytochemically analyzed with the aims of identifying flavonoids with anti-inflammatory effects. The methanol-dichloromethane (1:1) crude extracts of these plants were fractionated on silica gel and purified using Sephadex LH-20, chromatotron and preparative HPLC. HRESIMS, ECD and NMR data were used to characterize the compounds. The anti-inflammatory activities of the isolated compounds as well as the crude extracts were evaluated for inhibition of cytokine production [interleukins (IL-1 β , IL-2, IL-6), interferon-*gamma* (IFN- γ), granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-*alpha* (TNF- α)] from lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells (PBMCs). Ibuprofen was used as a standard drug for anti-inflammation. Overall, fifty-six (56) compounds were identified from the selected *Tephrosia* species, eleven of which were new compounds and one derivative was prepared. From the aerial parts of *T. linearis*, seven new flavonoids [lineaflavone A-D (**1-4**), 6-methoxygeraldone (**5**), acetylobovatin (**6**) and 5-hydroxy-7-methoxysaniculamin A (**7**)] and seventeen known compounds (**8-24**) were isolated. From the aerial parts of *T. hildebrandtii*, a new flavone, hildeflavone (**25**) and ten known compounds (**22, 26-34**) were isolated. *T. vogelii* seedpods yielded two new isoflavones [vogeliso flavone A (**35**) and vogeliso flavone B (**36**)] and ten known compounds (**34, 37-43**). From the stem of *T. elata* one new isoflavone, elatiso flavone (**44**) and three known isoflavones (**45-47**) were isolated. Eleven known compounds (**21, 23** and **48-56**) were isolated from the extract of stem of *T. rhodesica* stem. Pyrazoisopongaflavone (**57**), a pyrazole derivative of isopongaflavone (**38**) was prepared. Lineaflavone B (**2**), luteolin (**13**), patuletin-3-*O*-rhamnoside (**16**), pisatin (**30**), vogeliso flavone B (**36**), isopongaflavone (**38**) and genistein (**55**) exhibited stronger anti-inflammatory activities

compared to the standard drug, ibuprofen. In synergetic studies, combinations of flavonoids showed superior anti-inflammatory activities over the individual flavonoids. The findings of this study imply that flavonoids from the genus *Tephrosia* could be used as templates for anti-inflammatory drug discovery.



LIST OF PUBLICATIONS FROM THIS THESIS

1. **Owor, R. O.**, Bedane, K. G., Openda, Y. I., Zühlke, S., Derese, S., Ong'amo, G., Ndakala, A., and Spiteller, M. (2020). Synergistic anti-inflammatory activities of a new flavone and other flavonoids from *Tephrosia hildebrandtii* vatke. *Natural Product Research*, 1-8.
2. **Owor, R. O.**, Bedane, K. G., Zühlke, S., Derese, S., Ong'amo, G. O., Ndakala, A., and Spiteller, M. (2020). Anti-inflammatory Flavanones and Flavones from *Tephrosia linearis*. *Journal of Natural Products*, 83(4), 996-1004.
3. **Owor, R. O.**, Derese, S., Bedane, K. G., Zühlke, S., Ndakala, A., and Spiteller, M. (2020). Isoflavones from the seedpods of *Tephrosia vogelii* and pyrazoisopongaflavone with anti-inflammatory effects. *Fitoterapia*, 146, 104695.
4. **Owor, R. O.**, Derese, S., Bedane, K. G., Zühlke, S., Ndakala, A., and Spiteller, M. (2021). Anti-inflammatory and synergistic activities of flavonoids from two *Tephrosia* species. *Drafted manuscript*, xxxxxx.
5. **Owor, R. O.**, Derese, S., Bedane, K. G., Zühlke, S., Ndakala, A., and Spiteller, M. (2021). Anti-inflammatory isoflavones from *Tephrosia elata*. *Drafted manuscript*, xxxxxx

TABLE OF CONTENTS

DECLARATION.....	II
DEDICATION	III
ACKNOWLEDGEMENT	IV
ABSTRACT.....	V
LIST OF PUBLICATIONS FROM THIS THESIS	VII
LIST OF TABLES	XIII
LIST OF FIGURES	XV
LIST OF SCHEMES.....	XVI
LISTS OF ABBREVIATIONS/ACRONYMS AND SYMBOLS	XVII
CHAPTER 1: INTRODUCTION.....	1
1.1: Background.....	1
1.2: Statement of the Problem.....	3
1.3: Objectives	4
1.3.1: <i>General Objective</i>	4
1.3.2: <i>Specific Objectives</i>	4
1.4: Justification and Significance	4
CHAPTER 2: LITERATURE REVIEW	6
2.1: Inflammation.....	6
2.1.1: <i>Biosynthesis of Eicosanoids</i>	6
2.1.2: <i>Biosynthesis of Cytokines</i>	7
2.2: Anti-inflammatory Drugs.....	9
2.2.1: <i>Steroidal Anti-inflammatory Drugs</i>	9
2.2.2: <i>Nonsteroidal Anti-inflammatory Drugs (NSAIDs)</i>	10
2.2.3: <i>Anti-cytokine Drugs</i>	10
2.3: Anti-inflammatory Flavonoids.....	11
2.4: Botany of the Genus <i>Tephrosia</i>	15
2.4.1: <i>Tephrosia linearis</i>	15
2.4.2: <i>Tephrosia hildebrandtii</i>	16
2.4.3: <i>Tephrosia vogelii</i>	17
2.4.4: <i>Tephrosia elata</i>	18
2.4.5: <i>Tephrosia rhodesica</i>	18
2.5: Traditional Uses of the Genus <i>Tephrosia</i>	19
2.6: Phytochemistry of the Genus <i>Tephrosia</i>	20
2.6.1: <i>Chalconoids from the Genus Tephrosia</i>	20
2.6.2: <i>Flavans of the Genus Tephrosia</i>	23
2.6.3: <i>Flavanones</i>	25
2.6.4: <i>Flavones and Flavonols of the Genus Tephrosia</i>	28
2.6.5: <i>Isoflavonoids of the Genus Tephrosia</i>	32
2.7: Biological Activities of Compounds Isolated from the Genus <i>Tephrosia</i>	38
CHAPTER 3: MATERIALS AND METHODS	42

3.1 Column Chromatography.....	42
3.2 Preparative High-Performance Liquid Chromatography.....	42
3.3 High-Resolution Electron Spray Ionization Mass Spectrometry.....	42
3.4 Nuclear Magnetic Resonance Spectroscopy.....	43
3.5 Optical Rotation and Circular Dichroism.....	43
3.6: Plant Materials.....	43
3.7: Extraction and Isolation.....	44
3.7.1: <i>The Aerial Parts of Tephrosia linearis</i>	44
3.7.2: <i>The Aerial Parts of Tephrosia hildebrandtii</i>	45
3.7.3: <i>The Seedpods of Tephrosia vogelii</i>	46
3.7.4: <i>The Stems of Tephrosia elata</i>	46
3.7.5: <i>The Stems of Tephrosia rhodesica</i>	47
3.8: Synthesis of the Pyrazoline Derivative of Isopongaflavone.....	47
3.9: Anti-inflammatory Assay.....	48
CHAPTER 4: RESULTS AND DISCUSSION.....	50
4.1: Characterization of Compounds Isolated from <i>Tephrosia linearis</i>	50
4.1.1: <i>Lineaflavone A (1)</i>	50
4.1.2: <i>Lineaflavone B (2)</i>	52
4.1.3: <i>Lineaflavone C (3)</i>	55
4.1.4: <i>Lineaflavone D (4)</i>	55
4.1.5: <i>6-Methoxygeraldone (5)</i>	58
4.1.6: <i>Acetylobovatin (6)</i>	59
4.1.7: <i>5-Hydroxy-7-methoxysaniculamin A (7)</i>	61
4.1.8: <i>7-O-Methyl-6-prenylnaringenin (8)</i>	64
4.1.9: <i>Erylivingstone I (9)</i>	65
4.1.10: <i>6-C-Prenylapigenin (10)</i>	67
4.1.11: <i>5,7,4',2''-Tetrahydroxy-6-[3''-methylbut-3''-enyl]flavone (11)</i>	68
4.1.12: <i>Apigenin (12)</i>	70
4.1.13: <i>Luteolin (13)</i>	70
4.1.14: <i>Geraldone (14)</i>	73
4.1.15: <i>Atalantoflavone (15)</i>	74
4.1.16: <i>Patuletin-3-O-rhamnoside (16)</i>	75
4.1.17: <i>Eupatolitin-3-O-rhamnoside (17)</i>	77
4.1.18: <i>Munduserone (18)</i>	79
4.1.19: <i>cis-12a-Hydroxymunduserone (19)</i>	80
4.1.20: <i>Rotenone (20)</i>	81
4.1.21: <i>12a-Hydroxyrotenone (21)</i>	83
4.1.22: <i>Deguelin (22)</i>	85
4.1.23: <i>Tephrosin (23)</i>	85
4.1.24: <i>Maackiain (24)</i>	88
4.2: Characterization of Compounds Isolated from <i>Tephrosia hildebrandtii</i>	90
4.2.1: <i>Hildeflavone (25)</i>	90
4.2.2: <i>5,7,3'-Trihydroxy-4'-methoxy-8-prenylisoflavone (26)</i>	91
4.2.3: <i>5,3'-Dihydroxy-4'-methoxy-2'',2''-dimethylpyrano[5'',6'':8,7]isoflavone (27)</i>	92
4.2.4: <i>4'-Hydroxyemoroidocarpin (28)</i>	95
4.2.5: <i>Hildecarpin (29)</i>	96

4.2.6: Pisatin (30)	97
4.2.7: Pongachin (31)	100
4.2.8: Emoroidenone (32)	101
4.2.9: Desmoxyphyllin A (33)	103
4.2.10: Pinoresinol (34)	103
4.3: Characterization of Compounds Isolated from <i>Tephrosia vogelii</i>	106
4.3.1: Vogelisoflavone A (35)	106
4.3.2: Vogelisoflavone B (36)	107
4.3.3: Onogenin (37)	109
4.3.4: Isopongaflavone (38)	110
4.3.5: 4',7-Dihydroxy-3'-methoxyflavanone (39)	112
4.3.6: Trans- <i>p</i> -hydroxycinnamic Acid (40)	113
4.3.7: 2-Methoxygliricidol (41)	115
4.3.8: Dehydrorotenone (42)	116
4.3.9: 6a,12a-Dehydro- α -toxicarol (43)	117
4.4: Characterization of Compounds Isolated from <i>Tephrosia elata</i>	120
4.4.1: Elatisoflavone (44)	120
4.4.2: Barbigerone (45)	121
4.4.3: Calopogoniumisoflavone B (46)	123
4.4.4: Jamaicin (47)	124
4.5: Characterization of Compounds Isolated from <i>Tephrosia rhodesica</i>	126
4.5.1: 3-Methoxycoumestrol (48)	126
4.5.2: Glabranin (49)	127
4.5.3: 7-O-Methylglabranin (50)	128
4.5.4: Liquiritigenin (51)	131
4.5.5: Naringenin (52)	131
4.5.6: Rhodiflavan C (53)	134
4.5.7: 3'-O-Methylorobol (54)	135
4.5.8: Genistein (55)	136
4.5.9: Edunol (56)	138
4.6: Synthesis of Pyrazoisopongaflavone (57)	139
4.7: Anti-inflammatory Activity	141
4.7.1: Activity of Compounds Isolated from <i>Tephrosia linearis</i>	141
4.7.2: Activity of Compounds Isolated from <i>Tephrosia hildebrandtii</i>	144
4.7.3: Activity of Compounds Isolated from <i>Tephrosia vogelii</i>	146
4.7.4: Activity of Compounds Isolated from <i>Tephrosia elata</i>	147
4.7.5: Activity of Compounds Isolated from <i>Tephrosia rhodesica</i>	149
4.7.6: Anti-inflammatory Activity of Pyrazoisopongaflavone (57)	150
4.7.7: Synergistic Anti-inflammatory Activities of the Isolated compounds	151
CHAPTER 5: CONCLUSIONS AND RECOMMENDATIONS	153
5.1: Conclusions	153
5.2: Recommendations	154
REFERENCE	155
APPENDIX A: SPECTRA FOR THE ISOLATED COMPOUNDS	193

Appendix A1: Spectra for compound 1	194
Appendix A2: Spectra for compound 2	198
Appendix A3: Spectra for compound 3	202
Appendix A4: Spectra for compound 4	206
Appendix A5: Spectra for compound 5	210
Appendix A6: Spectra for compound 6	214
Appendix A7: Spectra for compound 7	218
Appendix A8: Spectra for compound 8	222
Appendix A9: Spectra for compound 9	225
Appendix A10: Spectra for compound 10	228
Appendix A11: Spectra for compound 11	231
Appendix A12: Spectra for compound 12	234
Appendix A13: Spectra for compound 13	237
Appendix A14: Spectra for compound 14	240
Appendix A15: Spectra for compound 15	243
Appendix A16: Spectra for compound 16	246
Appendix A17: Spectra for compound 17	249
Appendix A18: Spectra for compound 18	252
Appendix A19: Spectra for compound 19	255
Appendix A20: Spectra for compound 20	258
Appendix A21: Spectra for compound 21	261
Appendix A22: Spectra for compound 22	264
Appendix A23: Spectra for compound 23	267
Appendix A24: Spectra for compound 24	270
Appendix A25: Spectra for compound 25	273
Appendix A26: Spectra for compound 26	277
Appendix A27: Spectra for compound 27	280
Appendix A28: Spectra for compound 28	283
Appendix A29: Spectra for compound 29	286
Appendix A30: Spectra for compound 30	289
Appendix A31: Spectra for compound 31	292
Appendix A32: Spectra for compound 32	295
Appendix A33: Spectra for compound 33	298
Appendix A34: Spectra for compound 34	301
Appendix A35: Spectra for compound 35	304
Appendix A36: Spectra for compound 36	307
Appendix A37: Spectra for compound 37	310
Appendix A38: Spectra for compound 38	313
Appendix A39: Spectra for compound 39	316
Appendix A40: Spectra for compound 40	319
Appendix A41: Spectra for compound 41	322
Appendix A43: Spectra for compound 43	328
Appendix A44: Spectra for compound 44	331
Appendix A45: Spectra for compound 45	334
Appendix A46: Spectra for compound 46	337
Appendix A47: Spectra for compound 47	340

Appendix A48: Spectra for compound 48	343
Appendix A49: Spectra for compound 49	346
Appendix A50: Spectra for compound 50	349
Appendix A51: Spectra for compound 51	352
Appendix A52: Spectra for compound 52	355
Appendix A53: Spectra for compound 53	358
Appendix A54: Spectra for compound 54	361
Appendix A55: Spectra for compound 55	364
Appendix A56: Spectra for compound 56	367
Appendix A57: Spectra for compound 57	370
APPENDIX B: DATA FOR ANTI-INFLAMMATORY ASSAY	373
APPENDIX C: EXTRACT OF FIRST PAGE OF PUBLICATIONS FROM THIS THESIS	382

LIST OF TABLES

Table 2.1: Anti-inflammatory Effects of flavonoids.....	12
Table 2.2: Chalconoids from the Genus <i>Tephrosia</i>	21
Table 2.3: Flavans of the Genus <i>Tephrosia</i>	24
Table 2.4: Flavanones of the Genus <i>Tephrosia</i>	26
Table 2.5: Flavones and Flavonols of the Genus <i>Tephrosia</i>	29
Table 2.6: Isoflavones Reported from the <i>Tephrosia</i> species.....	33
Table 2.7: Coumestans Reported from the Genus <i>Tephrosia</i>	35
Table 2.8: Pterocarpan Reported from the Genus <i>Tephrosia</i>	35
Table 2.9: Rotenoids Reported in the Genus <i>Tephrosia</i>	36
Table 2.10: Biological Activities of Compounds Isolated from the Genus <i>Tephrosia</i>	38
Table 3.1: Plant collection and voucher details	44
Table 4.1: NMR Data for Compounds 1 and 2 in Acetone-d ₆ (600 MHz).....	54
Table 4.2: NMR Data for Compounds 3 and 4 in Acetone-d ₆ (600 MHz).....	57
Table 4.3: NMR Data for Compound 5 in Acetone-d ₆ (600 MHz)	59
Table 4.4: NMR Data for Compounds 6 and 7 in Acetone-d ₆ (600 MHz)	63
Table 4.5: NMR Data for Compounds 8 and 9 in Acetone-d ₆ (600 MHz)	66
Table 4.6: NMR Data for Compounds 10 and 11 in Acetone-d ₆ (600 MHz)	69
Table 4.7: NMR Data for Compounds 12 and 13 in Acetone-d ₆ (600 MHz).....	72
Table 4.8: NMR Data for Compound 14 in Acetone-d ₆ (600 MHz)	74
Table 4.9: NMR Data for Compound 15 in Acetone-d ₆ (600 MHz)	75
Table 4.10: NMR Data for Compounds 16 and 17 in Acetone-d ₆ (600 MHz).....	78
Table 4.11: NMR Data for Compound 18 in Acetone-d ₆ (600 MHz)	80
Table 4.12: NMR Data for Compound 19 in Acetone-d ₆ (600 MHz)	81
Table 4.13: NMR Data for Compounds 20 and 21 in Acetone-d ₆ (600 MHz).....	84
Table 4.14: NMR Data for Compounds 22 and 23 in Acetone-d ₆ (600 MHz).....	87
Table 4.15: NMR Data for Compound 24 in Acetone-d ₆ (600 MHz)	89
Table 4.16: NMR Data for Compound 25 in Acetone-d ₆ (600 MHz)	91
Table 4.17: NMR Data for Compounds 26 and 27 in Acetone-d ₆ (600 MHz).....	94
Table 4.18: NMR Data for Compound 28 in Acetone-d ₆ (600 MHz)	96
Table 4.19: NMR data for Compounds 29 and 30 in Acetone-d ₆ (600 MHz).....	99
Table 4.20: NMR Data for Compounds 31 and 32 in Acetone-d ₆ (600 MHz).....	102
Table 4.21: NMR Data for Compounds 33 and 34 in Acetone-d ₆ (600 MHz).....	105
Table 4.22: NMR Data for Compounds 35 and 36 in Acetone-d ₆ (600 MHz).....	108
Table 4.23: NMR Data for Compounds 37 and 38 in Acetone-d ₆ (600 MHz).....	111

Table 4.24: NMR Data for Compounds 39 and 40 in Acetone-d ₆ (600 MHz).....	114
Table 4.25: NMR Data for Compound 41 in Acetone-d ₆ (600 MHz)	116
Table 4.26: NMR Data for Compounds 42 and 43 in Acetone-d ₆ (600 MHz).....	119
Table 4.27: NMR Data for Compounds 44 and 45 in Acetone-d ₆ (600 MHz).....	122
Table 4.28: NMR Data for Compounds 46 and 47 in Acetone-d ₆ (600 MHz),.....	125
Table 4.29: NMR Data for Compound 48 in Acetone-d ₆ (600 MHz),	127
Table 4.30: NMR Data for Compounds 49 and 50 in Acetone-d ₆ (600 MHz),.....	130
Table 4.31: NMR data for Compounds 51 and 52 in Acetone-d ₆ (600 MHz),.....	133
Table 4.32: NMR Data for Compound 53 in Acetone-d ₆ (600 MHz)	135
Table 4.33: NMR Data for Compounds 54 and 55 in Acetone-d ₆ (600 MHz).....	137
Table 4.34: NMR Data for Compound 57 in Acetone-d ₆ (600 MHz)	139
Table 4.35: NMR Data for Compound 57 in Acetone-d ₆ (600 MHz)	140
Table 4.36: The Percentage of Cytokine Release in Comparison to Lipopolysaccharide Control after Incubation with Compounds from <i>Tephrosia linearis</i>	144
Table 4.37: The Percentage of Cytokine Release in Comparison to Lipopolysaccharide Control after Incubation with Compounds from <i>Tephrosia hildebrandtii</i>	146
Table 4.38: The Percentage of Cytokine Release in Comparison to Lipopolysaccharide Control after Incubation with Compounds from <i>Tephrosia vogelii</i>	147
Table 4.39: The Percentage of Cytokine Release in Comparison to Lipopolysaccharide Control after Incubation with Compounds from <i>Tephrosia elata</i>	148
Table 4.40: The Percentage of Cytokine Release in Comparison to Lipopolysaccharide Control after Incubation with Compounds from <i>Tephrosia rhodesica</i>	150
Table 4.41: The Percentage of Cytokine Release in Comparison to Lipopolysaccharide Control after Incubation with combinations of isolated compounds.....	152
Table 5.1: Summary of the Compounds Characterized from the five <i>Tephrosia</i> species	153

LIST OF FIGURES

Figure 2.1: Pathways for Biosynthesis of Prostaglandins and Cytokines.....	9
Figure 2.2: Photograph of <i>Tephrosia linearis</i>	15
Figure 2.3: Photograph of <i>Tephrosia hildebrandtii</i>	16
Figure 2.4: Photograph of <i>Tephrosia vogelii</i>	17
Figure 2.5: Photograph of <i>Tephrosia elata</i>	18
Figure 2.6: Photograph of <i>Tephrosia rhodesica</i>	19
Figure 4.1: ECD spectrum of compound 6	60
Figure 4.2: ECD spectrum of compound 7	62
Figure 4.3: The LPS stimulated the secretion of the cytokines in comparison to untreated control cells and ibuprofen (mean \pm SD, n=3 for medium and n = 4 for LPS and ibuprofen).....	142
Figure 4.4: The cytokine release after LPS stimulated PMBCs incubated with the crude extracts and isolated compounds from <i>Tephrosia linearis</i>	143
Figure 4.5: The cytokine release after LPS stimulated PMBCs incubated with the crude extracts and isolated compounds from <i>Tephrosia hildebrandtii</i>	145
Figure 4.6: The cytokine release after LPS stimulated PMBCs incubated with the crude extracts and isolated compounds from <i>Tephrosia vogelii</i>	147
Figure 4.7: The cytokine release after LPS stimulated PMBCs incubated with the crude extracts and isolated compounds from <i>Tephrosia elata</i>	148
Figure 4.8: IL-1 β , IFN- γ , GM-CSF and TNF- α release after LPS stimulated PMBCs incubated with the crude extracts and isolated compounds from <i>Tephrosia rhodesica</i>	149
Figure 4.9: IL-1 β , IFN- γ , GM-CSF and TNF- α release after LPS stimulated PMBCs incubated with the crude extracts and combinations of isolated compounds.....	152

LIST OF SCHEMES

Scheme 2.1: Basic Skeletons of Subclasses of Chalconoids	21
Scheme 2.2: Basic Skeletons of Subclasses of Flavans	23
Scheme 2.3: Basic Skeleton of Subclasses of flavanones.....	25
Scheme 2.4: Basic Skeletons of Flavones and Flavonols	29
Scheme 2.5: Basic Skeletons of Isoflavonoids	33
Scheme 4.1: Collision-Induced Dissociation (CID) Mass Fragments of Compound 1	52

LISTS OF ABBREVIATIONS/ACRONYMS AND SYMBOLS

^{13}C NMR	Carbon-13 Nuclear Magnetic Resonance
1D NMR	One-Dimensional Nuclear Magnetic Resonance
^1H NMR	Proton Nuclear Magnetic Resonance
2D NMR	Two-Dimensional Nuclear Magnetic Resonance
AP-1	Activator Protein-1
CID	Collision-Induced Dissociation
COSY	Correlation Spectroscopy
COX	Cyclooxygenase
DMSO	dimethyl sulfoxide
ECD	Electronic Circular Dichroism
EtOAc	Ethyl acetate
EtOH	Ethanol
GM-CSF	Granulocyte-macrophage colony-stimulating factor
HMBC	Heteronuclear Multiple Bond Correlation
HPLC	High performance liquid chromatography
HRESIMS	High resolution Electron Spray Ionization Mass spectrometry
HSQC	Heteronuclear Single Quantum Coherence
IFN- γ	Interferon gamma
IL	Interleukin
<i>i</i> NOS	inducible nitric oxide synthase
LC-MS	Liquid Chromatography Mass Spectrometry
LPS	Lipopolysaccharide
MeOH	Methanol
MS	Mass Spectrometry

NF- κ B	Nuclear Factor kappa-light-chain-enhancer of activated B cells.
NMR	Nuclear Magnetic Resonance
NO	Nitric oxide
NOESY	Nuclear Overhauser and Exchange Spectroscopy
NSAIDs	Nonsteroidal Anti-inflammatory Drugs
PG	Prostaglandin
PMBCs	Peripheral blood mononuclear cells
Prep.-HPLC	Preparative High-performance liquid chromatography
RP	Reverse Phase
TLC	Thin Layer Chromatography
TNF- α	Tumor necrosis factor alpha
UV	Ultra Violet
WHO	World Health Organization
μ g	Microgramme
μ L	Microlitre
<i>d</i>	doublet
<i>dd</i>	doublet of doublet
<i>g</i>	Gramme
Hz	Hertz
<i>J</i>	Coupling constant
kg	Kilogramme
<i>m</i>	Multiplet
<i>m/z</i>	Mass to charge ratio
<i>mg</i>	Milligramme
MHz	Mega Hertz

min	Minute
<i>mL</i>	Millilitre
ppm	Parts per million
<i>s</i>	Singlet
<i>t</i>	Triplet
δ	Chemical shift

CHAPTER 1: INTRODUCTION

1.1: Background


Medicinal plants have played a vital role since antiquity in the management and prevention of different illnesses (Hafidh *et al.*, 2009; Biljana, 2012; Sofowora *et al.*, 2013) as well as to relieve pain (Sayhan *et al.*, 2017). Medicinal plants play a crucial role in rural communities in developing countries where the healthcare systems are poorly developed (Strasser, 2003; WHO, 2008; Auditeau *et al.*, 2019; Mintah *et al.*, 2019). Thus, they are still of great value and part of the customs of many communities (Kokwaro, 2009; Mahomoodally, 2013) where they are administered in forms of decoctions and concoctions for oral administration or as a paste for skin surface applications (Tabuti *et al.*, 2003; Malik *et al.*, 2019).

Plants biosynthesize a large variety of compounds which are often referred to as natural products or sometimes as phytochemicals (Dewick, 2002; Yang *et al.*, 2018). These phytochemicals belong to different classes of compounds mainly; phenylpropanoids (flavonoids, coumarins, and lignans), alkaloids, terpenoids, and polyketides (Wink, 2015; Che *et al.*, 2017; Thirumurugan *et al.*, 2018). These compounds are used by the plants for defensive purposes, as attractants to pollinators and seed-dispersing agents. They also act as allelochemicals to suppress competing neighbouring plants (Dewick, 2002; Osbourn and Lanzotti, 2009). Throughout history, some phytochemicals have been used to make valuable products such as flavouring agents, fragrances, preservatives, repellents and drugs (Beattie, 2009; Osbourn and Lanzotti, 2009).


Compounds isolated from medicinal plants have either served as a source of new drugs or as templates for the development of new drugs against several diseases including inflammation and inflammatory-related diseases (Harvey, 2008; Cragg and Newman, 2013). For example, salicylic acid (**58**), obtained from the bark of *Salix alba* (Jones, 2011; Desborough and Keeling,

2017), served as a template for aspirin (**59**) which was the first non-steroidal anti-inflammatory drug (NSAID) (Rainsford, 1984; Mahdi *et al.*, 2006).

Inflammation is a two-phased (acute and chronic) reaction involving a variety of inflammatory cells that secrete mediators (vasoactive amines, eicosanoids and cytokines) (Abdulkhaleq *et al.*, 2018; Poluha and Grossmann, 2018). Acute inflammation is triggered by the presence of harmful stimuli or injury (Chen *et al.*, 2017). This phase involves recruitment of blood plasma and leukocytes (neutrophils and macrophages) into the inflamed tissue (de Oliveira *et al.*, 2016). Generally, acute inflammation proceeds to chronic inflammation if the response is inefficient in clearing the stimuli or healing the damaged tissue (Beattie, 2009). However, chronic inflammation always happens in cohorts with chronic diseases (Yiu *et al.*, 2018). Current anti-inflammatory drugs used to manage inflammation and related diseases target enzymes involved in the biosynthesis of eicosanoids particularly phospholipase A₂ and cyclooxygenase in the arachidonic acid metabolism (Dhikav *et al.*, 2003; Dinarello, 2010). However, these drugs are associated with adverse effects like gastrointestinal bleeding and peptic ulcer (Lichtenstein *et al.*, 1995; Drini, 2017; Wong, 2019). Anti-inflammatory drugs targeting the suppression of cytokine have been pursued as alternatives in the treatment of inflammation and its associated diseases (Aggarwal *et al.*, 2009; Leyva-López *et al.*, 2016). Therefore, there is an effort to discover anti-inflammatory drugs which target cytokine production.



Flavonoids, secondary metabolites that occur in a wide range of plants have exhibited anti-inflammatory activities (Abdallah *et al.*, 2015; Leyva-López *et al.*, 2016). For instance, the isoflavone genistein (**55**) reduces pro-inflammatory cytokine over-activation (Valsecchi *et al.*, 2008) while the flavanone naringenin (**52**) decreases the release of cytokines (Tsai *et al.*, 2012). Chrysin (**60**), kaempferol (**61**) and quercetin (**62**) exhibit anti-inflammatory properties by decreasing the production of inflammatory mediators (Ginwala *et al.*, 2019). There is an increasing amount of effort focused on flavonoids as potential anti-inflammatory agents targeting cytokines.



Since plants from the genus *Tephrosia* Pers. (Fabaceae) elaborate flavonoids (Touqeer *et al.*, 2013; Chen *et al.*, 2014), in this study, five *Tephrosia* species (*T. linearis*, *T. hildebrandtii*, *T. rhodesica*, *T. vogelii*, and *T. elata*) were phytochemically studied to identify flavonoids with anti-inflammatory properties.

1.2: Statement of the Problem

Prolonged use of the current anti-inflammatory drugs such as aspirin and ibuprofen for management of inflammation and associated chronic diseases (Dinarello, 2010; Durgaprasad *et al.*, 2013) has been linked to severe side effects most commonly gastrointestinal bleeding and peptic ulcer (Lichtenstein *et al.*, 1995; Dhikav *et al.*, 2003; Zarghi and Arfaei, 2011; Goldstein and Cryer, 2015; Wong, 2019). Therefore, there is a need to develop new anti-inflammatory drugs that are safe and effective. Plant secondary metabolites are increasingly being recognized as effective and safer alternatives to the current available anti-inflammatory

drugs. In this study, the potential of flavonoids from *Tephrosia* species was assessed for their anti-inflammatory effects.

1.3: Objectives

1.3.1: General Objective

The main objective of this study was to identify anti-inflammatory principles from *Tephrosia* species.

1.3.2: Specific Objectives

The study was structured based on the following specific objectives:

- i. To characterize isolated compounds from *T. linearis*, *T. hildebrandtii*, *T. rhodesica*, *T. vogelii* and *T. elata*.
- ii. To determine the anti-inflammatory effects of the crude plant extracts, the isolated compounds and their derivatives.
- iii. To determine the anti-inflammatory synergetic effects of the isolated compounds.

1.4: Justification and Significance

Although inflammation is a vital immune process in the restoration of tissue homeostasis, its dysregulation is linked to the pathogenesis of chronic diseases including cancer, respiratory and neurological diseases (Chen *et al.*, 2017; Yiu *et al.*, 2018). Sufficient evidence exists for the use of anti-inflammatory drugs for the treatment of chronic diseases but these drugs have adverse side effects (Lichtenstein *et al.*, 1995; Drini, 2017). Flavonoids have been attributed to possess anti-inflammatory properties with diverse modes of action (García-Lafuente *et al.*, 2009; Funakoshi-Tago *et al.*, 2011; Abdallah *et al.*, 2015; Leyva-López *et al.*, 2016; Chen *et al.*, 2019). Among these include the regulation of pro-inflammatory cytokines which have become an attractive therapeutic target for the management of inflammation (Leyva-López *et*

al., 2016). Plants from the genus *Tephrosia* Pers. (Fabaceae) are known to elaborate several classes of flavonoids (Chen *et al.*, 2014; Muiva-Mutisya *et al.*, 2014; Atilaw *et al.*, 2017a; Atilaw *et al.*, 2017b; Muiva-Mutisya *et al.*, 2018). Moreover, crude extract of some *Tephrosia* species (*T. purpurea*, *T. maxima*, *T. vogelii* and *T. sinapou*) have shown anti-inflammatory activities (Auda *et al.*, 2009; Sandhya *et al.*, 2010; Valli *et al.*, 2011). But the phytochemicals responsible for the activities are yet to be identified. Therefore, in this study, the crude extracts, as well as flavonoids isolated from selected *Tephrosia* species, were evaluated to determine their anti-inflammatory activity and their potential for the development of anti-inflammatory drugs.

CHAPTER 2: LITERATURE REVIEW

2.1: Inflammation

Inflammation is an immune process triggered by the presence of pathogens in the body or tissue damage (Beattie, 2009; Chen *et al.*, 2017; Pahwa and Jialal, 2019). The inflammatory response involves the recruitment of blood plasma, platelets and leukocytes (neutrophils, mast cells and macrophages) into the inflamed tissue (Raghavendra *et al.*, 2015). In the acute phase, this process is manifested in form of swelling, pain, heat and loss of organ function (Sherwood and Toliver-Kinsky, 2004; Chen *et al.*, 2017). The inflammatory cells in this phase secrete short-lived mediators like histamine and prostaglandins (Abdulkhaleq *et al.*, 2018). However, if inflammation lingers for a long time, it becomes chronic (Pahwa and Jialal, 2019). Macrophages, neutrophils and lymphocytes in chronic inflammation are capable of sustaining the production of eicosanoids and cytokines for a long period (Selders *et al.*, 2017; Qu *et al.*, 2018).

The eicosanoids and cytokines initiate and regulate the inflammatory response and also contribute to its pathological manifestation (Voronov *et al.*, 1999; Sugimoto *et al.*, 2016). Their secretion from inflammatory cells (lymphocytes, neutrophils, mast cells, and macrophages) are triggered by pathogens, damaged tissue or biochemical imbalances (Parisi *et al.*, 2018; Yiu *et al.*, 2018). Eicosanoids are biosynthesized through the arachidonic acid pathway while cytokines through the nuclear factor κ B signaling pathway (Noverr *et al.*, 2003; Traish *et al.*, 2018).

2.1.1: Biosynthesis of Eicosanoids

Eicosanoids are oxylipins metabolized from arachidonic acid (Serhan *et al.*, 2010) and they are subdivided into prostanoids and leukotrienes based on the enzymes that mediate their biosynthesis (Goodman, 1996). The prostanoids, which are principally prostaglandins and

thromboxane are biosynthesized by cyclooxygenase (COX) while leukotrienes are products of lipoxygenase (LOX) (Ding *et al.*, 2003; Noverr *et al.*, 2003; Smyth and FitzGerald, 2010; Hanna and Hafez, 2018). Eicosanoids are only biosynthesized when required and their production depends on the availability of arachidonic acid (Goodman, 1996). When there is an infection or injury, arachidonic is released from phospholipids by phospholipase A₂ (PLA₂) and metabolized to eicosanoids (Katayama and Lee, 2003; Norris and Carr, 2013; Weinberger *et al.*, 2015).

Prostaglandins (E₂, I₂, D₂ and F₂) are the most important mediators and they are biosynthesized from the oxidation of arachidonic acid by the action of cyclooxygenase enzymes (COX-1 and COX-2) (Willoughby *et al.*, 2000; Ding *et al.*, 2003; Botting and Ayoub, 2005; Monitto *et al.*, 2011). COX-1 is present in the majority of cells and is involved in the normal homeostatic system while COX-2 is expressed only during inflammation (Lone and Taskén, 2013). Consequently, COX-2 is used as a therapeutic target for the management of inflammation (Samad *et al.*, 2002; Turman and Marnett, 2010; Norris and Carr, 2013). Prostaglandins act on many cells and are responsible for the manifestation of hyperalgesia during inflammation (Pettipher, 1998; Ricciotti and FitzGerald, 2011). Incidentally, elevated levels of prostaglandins have been found in patients with asthma, arthritis and cancer (Steele *et al.*, 1999; Ricciotti and FitzGerald, 2011; Gomes *et al.*, 2018; Jo-Watanabe *et al.*, 2019; Rittchen and Heinemann, 2019).

2.1.2: Biosynthesis of Cytokines

Cytokines are proteins that mediate inflammation and the most important ones are tumor necrosis factor-*alpha* (TNF- α), interferons *gamma* (IFN- γ), interleukins (IL) and colony-stimulating factors (CSF) (Chen *et al.*, 2017; Ferreira *et al.*, 2018). They are secreted by a variety of cells (macrophages, lymphocytes, mast cells and endothelial cells) (Thèze, 1998;

Duque and Descoteaux, 2014; Turner *et al.*, 2014). Their biosynthesis during inflammation is initiated when normal tissue homeostasis is disturbed by either infection, injury or imbalance in biochemical composition in the body (Traish *et al.*, 2018). When such happen, the macrophages and lymphocytes detect the pathogens or tissue damage through pattern-recognition receptors for instance toll-like receptors (TLRs) present on their surface (Mogensen, 2009; Jang *et al.*, 2015; Kim *et al.*, 2016).

As illustrated in Figure 2.1, the TLRs recognize the pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS) of Gram-negative bacteria (Mogensen, 2009). Stimulated TLRs lead to downstream activation of transcription factor NF- κ B through several adaptor molecules (Agbeko and Peters, 2011; Oviedo-Boyso *et al.*, 2014). The activated NF- κ B translocates to the nucleus and binds with DNA to stimulate the production of the cytokines (Liu *et al.*, 2017). Further, pro-inflammatory cytokines have been shown to induce the production of cyclooxygenase enzyme and therefore, elevate the production of prostaglandins through “crosstalk” (LaPointe and Isenović, 1999; Yao and Narumiya, 2019). Likewise, prostaglandins influence cytokine secretion via prostaglandin E receptors (EP) which triggers downstream expression of cytokines.

Generally, cytokines upregulate inflammatory response intensifying widespread pain as well as prompting a sickness syndrome such as fever, anorexia and altered mood (Luheshi and Rothwell, 1996; Conti *et al.*, 2004; Zhang and An, 2007). For instance, the upregulation of pro-inflammatory cytokines during menstruation account for dysmenorrhea (menstrual cramps) and endometriosis (Ma *et al.*, 2013). Besides, the intensive release of cytokines has been associated with the pathogenesis of many diseases (Torres *et al.*, 2019) as is the case in coronavirus disease 2019 (COVID-19) patients who experience a cytokine storm (Tang *et al.*, 2020).




Figure 2.1: Pathways for Biosynthesis of Prostaglandins and Cytokines

2.2: Anti-inflammatory Drugs

Anti-inflammatory drugs are essentially used to decrease inflammatory response compared to analgesics such as opioids that block pain signals to the brain (Maroon *et al.*, 2010; Slater *et al.*, 2010). The anti-inflammatory drugs target either the biosynthesis of eicosanoids or cytokines (Ricciotti and FitzGerald, 2011). Drugs that target arachidonic acid metabolism are either steroidal or nonsteroidal. The anti-cytokines are mainly monoclonal antibodies.

2.2.1: Steroidal Anti-inflammatory Drugs

These drugs inhibit the arachidonic acid release from phospholipids which is the initial step in prostaglandin biosynthesis (Malcher-Lopes *et al.*, 2008; Szeffel *et al.*, 2015). They are steroids and always are referred to as corticosteroids (or glucocorticoids) (Goppelt-Struebe *et al.*, 1989; Buttgerit *et al.*, 2013; de Kloet *et al.*, 2017). Prednisone (63), cortisone (64), hydrocortisone (65), dexamethasone (66) and methylprednisolone (67) are some of the typical examples

(Goppelt-Struebe *et al.*, 1989; Rainsford, 2007; Serhan *et al.*, 2010). Besides their use as anti-inflammatory drugs, they are also used to manage inflammatory-related diseases such as rheumatoid arthritis and asthma (Barnes, 1998). However, their drawbacks are in their side effects such as high blood pressure, ulcers, cataracts, menstrual irregularity and obesity (Bond, 1977; Schäcke *et al.*, 2002; Brown, 2009; Saag and Furst, 2013; Oray *et al.*, 2016).


2.2.2: Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

These drugs exhibit their therapeutic anti-inflammatory effects by inhibition of COX (Drini, 2017). They include aspirin (**59**), ibuprofen (**68**), diclofenac (**69**), naproxen (**70**) and Indocin (**71**) (Serhan *et al.*, 2010).


Prolonged use of NSAIDs has been associated with gastrointestinal injury and the toxicities are related to their inhibition of the COX-1 (Goldstein and Cryer, 2015). COX-2 selective drugs such as celecoxib (**72**) and rofecoxib (**73**) have been developed (Zarghi and Arfaei, 2011). However, they have been withdrawn because of their associated health risks such as stroke and thrombosis (Grosser *et al.*, 2006).

2.2.3: Anti-cytokine Drugs


Some drugs that prevent the expression and secretion of pro-inflammatory cytokines have been developed (Leyva-López *et al.*, 2016). They are mainly monoclonal antibodies such as adalimumab, etanercept and infliximab which are TNF- α inhibitors (Lis *et al.*, 2014; Menegatti *et al.*, 2019) and tocilizumab which is an IL-6 inhibitor (Venkiteshwaran, 2009). These drugs are also used to treat inflammatory-related diseases such as arthritis, Crohn's disease and depression (Oldfield *et al.*, 2009). There is an effort to discover anti-inflammatory drugs that target cytokines especially from natural products like flavonoids that have shown some anti-inflammatory properties (Aggarwal *et al.*, 2009; Leyva-López *et al.*, 2016).




63




64




65




66




67




68




69




70



71



72



73

2.3: Anti-inflammatory Flavonoids

Flavonoids are common in many plants especially as prominent constituents in fruits, vegetables, flowers and legumes (García-Lafuente *et al.*, 2009; Kumar and Pandey, 2013b; Panche *et al.*, 2016). Flavonoids are classified as chalcones, flavanones, flavanols, flavones,

isoflavones, pterocarpan and rotenoids (Agrawal, 1989). Several biological activities have been ascribed to flavonoids including anti-inflammatory properties (Kumar and Pandey, 2013a; Panche *et al.*, 2016; Ruiz-Cruz *et al.*, 2017). Some flavonoids have been shown to exhibit their anti-inflammatory effects by attenuating the cytokines release in either *in vitro* or *in vivo* in animal models as shown in Table 2.1 (Attiq *et al.*, 2018; Tungmunnithum *et al.*, 2018).





Specifically, a biflavonoid isolated from *Sellaginella tamariscina* suppressed the NF- κ B signalling pathway and downregulated the COX-2 production in TNF- α -activated A549 cells (Banerjee *et al.*, 2002). Flavonoids from *Chrozophora tinctoria* showed significant suppression of IL-1 β and IL-6 release from the phytohemagglutinin (PHA)-stimulated PMBCs (Abdallah *et al.*, 2015). *Broussonetia* flavonoids also showed anti-inflammatory properties by reducing the production of TNF- α and IL-6 from LPS-induced RAW 264.7 cells (Ryu *et al.*, 2019). Similarly, glycoside flavonoids from *Smilax glabra* exhibit anti-inflammatory effects by suppressing NF- κ B production (Shu *et al.*, 2018), while C-Geranyl flavonoids from *Palownia fortunei* showed anti-inflammatory activities by decreasing IL-6 and TNF- α release from LPS-treated cardiomyocytes (Zhang *et al.*, 2019a).

Although, little is known about the anti-inflammatory properties of the genus *Tephrosia*, some of the flavonoids such as apigenin (**12**) (Plioukas *et al.*, 2016), rutin (**76**) (Jain *et al.*, 2009) and quercetin (**76**) (Gómez-Garibay *et al.*, 2002) that have been isolated in the genus show anti-inflammatory activities.


Table 2.1: Anti-inflammatory Effects of flavonoids

No.	Flavonoid	Molecular target	Anti-inflammatory Effect	Reference
74	Amentoflavone	TNF- α -activated A549 cells.	Reduced COX-2 release by inhibiting NF- κ B.	(Banerjee <i>et al.</i> , 2002)




No.	Flavonoid	Molecular target	Anti-inflammatory Effect	Reference
		Phytohemagglutinin-stimulated PBMCs.	Suppressed the release of IL-1 β , IL-6, and PGE ₂ .	(Abdallah <i>et al.</i> , 2015)
75	Apigenin-7- <i>O</i> - β -D-glucopyranoside	LPS-RAW264.7 cells.	Decreased release of NO, <i>i</i> NOS, TNF- α , and IL-6.	(Ryu <i>et al.</i> , 2019)
76	Rutin			
77	Ochnaflavone	Rat platelets.	Inhibited phospholipase A ₂ (PLA ₂).	(Chang <i>et al.</i> , 1994)
12	Apigenin	LPS-stimulated RAW 264.5 cells.	Inhibited the production of NO and <i>i</i> NOS.	(Hu <i>et al.</i> , 2017)
13	Luteolin			
78	Quercetin			
79	Acacetin			
80	Diosmetin			
81	Bonanzin			
82	Artemetin			
83	Brousochalcone C	LPS-stimulated RAW 264.7 cells	Inhibited the release of TNF- α and IL-6.	(Ryu <i>et al.</i> , 2019)
84	Brousoflavanonol A			
85	Brousoflavonol B			
86	5-hydroxy-6,8-dimethoxyflavone-7- <i>O</i> - β -D-glucopyranosyl-(1 \rightarrow 6)- <i>O</i> - β -D-glucopyranoside	TNF- α stimulated J-170 cells	Inhibited NF- κ B production	(Shu <i>et al.</i> , 2018)
87	5-Hydroxy-3,8-dimethoxyflavone-7- <i>O</i> - β -D-glucopyranosyl-(1 \rightarrow 6)- <i>O</i> - β -D-glucopyranoside	TNF- α stimulated J-170 cells	Inhibited NF- κ B production	(Shu <i>et al.</i> , 2018)
88	3,7-Dihydroxy-8-methoxyflavone-6- <i>O</i> - β -D-glucopyranosyl-(1 \rightarrow 6)- <i>O</i> - β -D-glucopyranoside	TNF- α stimulated J-170 cells	Inhibited NF- κ B production	(Shu <i>et al.</i> , 2018)
89	Paulownione D	LPS treated cardiomyocytes	Suppressed the production of IL-6 and TNF- α	(Zhang <i>et al.</i> , 2019a).
90	Paulownione E			
91	Paulownione F			
92	Paulownione G			



- 75** $R_1 = \text{Glc}; R_2 = \text{H}; R_3 = \text{H}$
12 $R_1 = \text{H}; R_2 = \text{H}; R_3 = \text{H}$
79 $R_1 = \text{H}; R_2 = \text{H}; R_3 = \text{Me}$
13 $R_1 = \text{H}; R_2 = \text{OH}; R_3 = \text{H}$
80 $R_1 = \text{H}; R_2 = \text{OH}; R_3 = \text{Me}$



- 76** $R_1 = R_2 = R_3 = R_7 = \text{H}, R_4 = (\text{Glc})_2, R_5 = R_6 = \text{OH}$
78 $R_1 = R_2 = R_3 = R_4 = R_7 = \text{H}, R_5 = R_6 = \text{OH}$
81 $R_1 = R_2 = R_7 = \text{H}, R_3 = R_5 = R_6 = \text{OMe}, R_4 = \text{Me}$
82 $R_1 = R_7 = \text{H}, R_2 = R_4 = \text{Me}, R_3 = R_5 = R_6 = \text{OMe}$
85 $R_1 = R_3 = \text{A}, R_2 = R_7 = \text{H}, R_4 = \text{Me}, R_5 = R_6 = \text{OH}$
87 $R_1 = \text{OMe}, R_2 = (\text{Glc})_2, R_3 = R_5 = R_6 = R_7 = \text{H}, R_4 = \text{Me}$
88 $R_1 = R_3 = \text{H}, R_2 = \text{Glc}, R_4 = \text{Me}, R_5 = R_7 = \text{OMe}, R_6 = \text{OH}$
90 $R_1 = R_2 = R_4 = R_7 = \text{H}, R_3 = \text{B}, R_5 = R_6 = \text{OH}$



- 86** $R_1 = R_3 = R_4 = R_5 = \text{H}, R_2 = (\text{Glc})_2$
89 $R_1 = \text{A}, R_2 = R_3 = R_4 = \text{H}, R_5 = \text{OH}$
91 $R_1 = R_2 = \text{H}, R_3 = \text{B}, R_4 = \text{OMe}, R_5 = \text{OH}$
92 $R_1 = R_2 = \text{H}, R_3 = \text{C}, R_4 = R_5 = \text{OH}$

2.4: Botany of the Genus *Tephrosia*

The genus *Tephrosia* Pers. belongs to the subfamily Papilionoideae that is distinguished from other subfamilies in the family Fabaceae by the zygomorphic papilionoid (butterfly-like) flower (Taylor *et al.*, 2009). The genus is mainly distributed in the tropics and subtropics (Pedley, 2014). Plants in this genus are either annual/perennial herbs or soft woody shrubs (Agnew, 2013; Al-Ghamdi, 2013). It contains over 353 species all over the world with over 30 species occurring in Kenya (Atilaw *et al.*, 2017a). *T. linearis*, *T. hildebrandtii*, *T. vogelii*, *T. elata*, and *T. rhodesica* are the species under investigation and found in Kenya.

2.4.1: *Tephrosia linearis*

Tephrosia linearis (Willd.) Pers. (Figure 2.2) is a short-lived perennial plant that is commonly found growing in grassland and rocky bushy slopes mainly in areas with higher rainfall (Agnew, 2013).




Figure 2.2: Photograph of *Tephrosia linearis*

T. linearis is an erect herb that grows up to 130 cm tall with a densely pubescent stem. Its leaves are pinnated with 5-15 leaflets, the flowers are either pink or orange in a terminal and axillary stiff pedunculated pseudo-raceme of 6-10 nodes. The pods are pubescent and about 5 cm long

x 3 mm wide with 9-12 seeds (Gillett *et al.*, 1971). The plant is native to tropical and austral Africa and Madagascar. In Kenya, it is found in the highlands, western, central and coast regions (Agnew, 2013).

2.4.2: *Tephrosia hildebrandtii*

Tephrosia hildebrandtii Vatke Pers. (Figure 2.3) is a short-lived perennial plant that is commonly found growing in upland grassland and semi-evergreen bushland at altitudes of 1100-1900 m (Agnew, 2013).



Figure 2.3: Photograph of *Tephrosia hildebrandtii*

T. hildebrandtii is an erect herb that can grow up to a height of 100 cm (Lwande *et al.*, 1986b). Its stem is rather sparsely pubescent, appressed or spreading while the leaves are unifoliate. The flowers are reddish-purple born at the upper leaf axils and also terminal pseudo-racemes. Its pods are about 6 cm long x 4 mm wide with approximately 8 seeds (Gillett *et al.*, 1971). It

is native to Ethiopia, Kenya and Tanzania. In Kenya, it is found in the highland areas like Rift valley, Machakos, Nairobi and Kajiado (Agnew, 2013).

2.4.3: *Tephrosia vogelii*

Tephrosia vogelii Hook. f. Pers. (Figure 2.4) commonly called fish bean or fish-poison bean is native to tropical Africa and grows in a variety of habitats including savanna-like vegetation, grasslands, forest margins, wasteland and formerly cultivated fields (Mwaura *et al.*, 2013). It is a soft woody perennial plant with dense foliage and can grow up to 4 m tall (Agnew, 2013). Its stem is hairy while the leaves are arranged spirally with lateral leaflets (12-29) tomentose above and more densely beneath (Mwaura *et al.*, 2013). The flowers are white or pale violet borne at the terminal or axillary pseudo-racemes and fragrant when fresh. Its pods are about 110 x 13 x 4 mm with approximately 12-16 seeds (Gillett *et al.*, 1971). In Kenya, it is found in areas like Mt. Elgon, Trans Nzoia, Nakuru-Kisumu region, Kitale and Embu (Agnew, 2013).



Figure 2.4: Photograph of *Tephrosia vogelii*

Tephrosia elata

Tephrosia elata Deflers Pers. (Figure 2.5) is a short-lived bushy perennial plant that is commonly found growing in grasslands, formerly cultivated land fields, and thicket margins (Agnew, 2013). It is either an erect herb or soft woody shrub that can grow to the height of 150 cm. The stems are usually ridged and appressed strigose (Gillett *et al.*, 1971). Its leaves are pinnated with 15-21 leaflets, the flowers are either pink or purple in rather dense terminal racemes that are longer than their stalks (Gillett *et al.*, 1971). The pods are about 55x5mm which may be erect or bent upwards (Agnew, 2013). The plant is native to Ethiopia, Sudan, Kenya, Tanzania, Uganda, Zimbabwe, and the Arabian Peninsula. In Kenya, it is cosmopolitan and can be found in the western, central and coast regions (Agnew, 2013).



Figure 2.5: Photograph of *Tephrosia elata*

Tephrosia rhodesica

Tephrosia rhodesica Baker f. Pers. (Figure 2.6) is a short-lived perennial plant that is commonly found growing in grassland and rocky bushy slopes mainly in areas with higher rainfall (Agnew, 2013). The plant is a branching erect shrub and can grow to the height of 150 cm. The leaves are pinnate with 6-9 leaflets and the flowers are purple in terminal racemes. Its pods are

flat and bend upwards (Gillett *et al.*, 1971). The plant is native to tropical Africa including East Africa, Malawi, Zambia and South Africa. In Kenya, it is found in the Coast, Machakos, Magadi and Narok (Agnew, 2013).



Figure 2.6: Photograph of *Tephrosia rhodesica*

2.5: Traditional Uses of the Genus *Tephrosia*

Many *Tephrosia* species have been used traditionally in disease management and agricultural practices (Gachene and Wortmann, 2004). Their use varies from country to country and species to species. Notably, *T. linearis* leaf juice is traditionally used in Kenya to manage a broad spectrum of ailments in infants (Kokwaro, 1976; Kokwaro, 2009). In Uganda, the plant is used for treating swollen body parts (Oryema *et al.*, 2010) and managing premature ejaculation (Tabuti *et al.*, 2003). In Tanzania, *T. linearis* is used for treating cardiac palpitations (Chhabra and Mahunnah, 1994).

T. vogelii has multiple applications in ethnomedicine across East Africa. Its aqueous leaf extract is used to control ticks, lice and worms in livestock (Mwaura *et al.*, 2013; Dharani *et al.*, 2015).

The water extract of the plant is also used as an insecticide to control insect pests, mites and a rodenticide for mole-rats (Mwine *et al.*, 2011; Kisangau and Amri, 2012; Mkindi *et al.*, 2019). A hot water decoction of the leaf, stem bark and unripe fruit of *T. vogelii* is used to induce abortion (Dzenda *et al.*, 2007), while its macerated leaf is used as a purgative and emetic (Dafam *et al.*, 2014). The leaves of *T. vogelii* are also used as a fish poison for fishing (Tabuti *et al.*, 2003; Kerebba *et al.*, 2019).

T. purpurea has diverse applications in ethnomedicine. It is used as a fish poison for fishing and an antidote for snakebite (Heuzé *et al.*, 2018). It is also traditionally used for wound and ulcer treatment (Chinniah *et al.*, 2009). It is used as a purgative and medicine for stomach pains (Kokwaro, 2009)

The other *Tephrosia* species of relevant ethnomedical uses include *T. nana* which is used for the treatment of tuberculosis (Hamill *et al.*, 2003), *T. uniflora* used to manage snake bites (Abreu and Luis, 1996), *T. aequilata* is used to relieve abdominal pain, *T. bracteolata* used to treat syphilis in pregnant women (Williams, 2012), *T. noctiflora* used as a cough remedy and *T. villosa* used for liver and spleen pain management (Kokwaro, 2009).


2.6: Phytochemistry of the Genus *Tephrosia*

Over the years, efforts have been made to isolate and identify bioactive compounds of the plants of this genus. Several compounds have been isolated and characterized from the genus. The compounds are mainly flavonoids in the sub-classes: chalconoids, flavans, flavanones, flavones, flavonols and isoflavonoids (isoflavones, pterocarpan, coumestans, and rotenoids) (Touqueer *et al.*, 2013; Chen *et al.*, 2014).

2.6.1: Chalconoids from the Genus *Tephrosia*

A chalconoid is a flavonoid with a 1,3-diphenylpropane skeleton that may have an olefinic bond, keto, or hydroxyl group (Agrawal, 1989; Dewick, 2002; Rauter *et al.*, 2018). They are

subclassified as chalcanses, α -chalcanols, β -chalcanols, chalcenes, β -chalcanones (dihydrochalcones), α -chalcanones, chalcones, β -chalconols and chalcans-1,3-diones as shown in Scheme 2.1 depending on the substitution pattern in the propane moiety.



Scheme 2.1: Basic Skeletons of Subclasses of Chalconoids


As shown in Table 2.2, over twenty chalconoids in the subclasses of chalcones, β -chalcanones, and β -chalconols have been reported in the genus *Tephrosia*.

Table 2.2: Chalconoids from the Genus *Tephrosia*


No.	Chalconoid	Plant species (part)	References
93	Isoliquiritigenin	<i>T. toxicaria</i> (ST)	(Jang <i>et al.</i> , 2003)
94	Tephron	<i>T. candida</i> (SD)	(Chibber and Dutt, 1982)
95	Ovalichacone	<i>T. candida</i> (SD)	(Roy <i>et al.</i> , 1986)
96	Spinochalcone A	<i>T. spinosa</i> (RT)	(Rao and Prasad, 1992b)
97	Candidachalcone	<i>T. candida</i> (AP)	(Hegazy <i>et al.</i> , 2011)
98	(+)-Tephrosone	<i>T. purpurea</i> (AP)	(Chang <i>et al.</i> , 2000)
99	(+)-Tepropurpurin	<i>T. purpurea</i> (AP)	(Chang <i>et al.</i> , 1997)
100	Obovatachalcone	<i>T. obovata</i> (WP)	(Chen <i>et al.</i> , 1978)
101	Spinochalcone C	<i>T. spinosa</i> (RT)	(Rao and Prasad, 1992a)
102	Spinochalcone B	<i>T. spinosa</i> (RT)	(Rao and Prasad, 1992b)
103	2',6'-Dihydroxy -3'-prenyl-4'-methoxy- β -chalcone	<i>T. major</i> (RT, AP)	(Gómez-Garibay <i>et al.</i> , 2002)
104	Purpurenone	<i>T. purpurea</i> (RT)	(Rao and Raju, 1984)
105	Praecansone A	<i>T. praecans</i> (SD)	(Camele <i>et al.</i> , 1980)

No.	Chalconoid	Plant species (part)	References
106	Praecansone B	<i>T. praecans</i> (SD)	(Camele <i>et al.</i> , 1980)
107	Demethylpraecansone B	<i>T. aequilata</i> (RT)	(Tarus <i>et al.</i> , 2002)
108	Aequichalcone C	<i>T. aequilata</i> (RT)	(Atilaw <i>et al.</i> , 2017a)
109	Pongamol	<i>T. purpurea</i> (SD)	(Chang <i>et al.</i> , 1997)
110	<i>O</i> -Methylpongamol	<i>T. purpurea</i> (RT)	(Pelter <i>et al.</i> , 1981)
111	Elatadihydrochalcone	<i>T. elata</i> (SD)	(Muiva <i>et al.</i> , 2009)
112	Aequichalcone A	<i>T. aequilata</i> (RT)	(Atilaw <i>et al.</i> , 2017a)
113	Aequichalcone B	<i>T. aequilata</i> (RT)	(Atilaw <i>et al.</i> , 2017a)
114	Tunicatachalcone	<i>T. tunicata</i> (RT)	(Andrei <i>et al.</i> , 2000)
234	2',6'-Dimethoxy-4',5'-(2'',2''-dimethyl)-pyranochalcone	<i>T. pulcherrima</i> (RT)	(Ganapaty <i>et al.</i> , 2008b)
273	Tephronone	<i>T. candida</i> (SD)	(Chibber and Dutt, 1982)


Key: RT – roots, SD – seeds/seedpods, FL – flowers, AP – aerial parts, WP – whole plant




- 93 $R_1 = R_2 = R_4 = R_7 = H, R_3 = R_5 = R_6 = OH$
 94 $R_1 = OH, R_2 = R_4 = H, R_3 = R_5 = OMe, R_6 = R_7 = OCH_2O$
 95 $R_1 = OH, R_2 = A, R_3 = R_5 = OMe, R_4 = R_6 = R_7 = H$
 96 $R_1 = R_6 = R_7 = H, R_2 = R_4 = A, R_3 = R_5 = OH$
 97 $R_1 = OMe, R_2 = R_7 = OH, R_3 = R_5 = R_6 = OH, R_4 = B$
 273 $R_1 = OH, R_2 = R_4 = H, R_3 = R_5 = OMe, R_6 = R_7 = OCH_2O$




- 100 $R_1 = OH, R_2 = OMe, R_3 = H$
 101 $R_1 = OH, R_2 = R_3 = H$
 104 $R_1 = OMe, R_2 = R_3 = OH$
 105 $R_1 = R_2 = OMe, R_3 = OMe$
 106 $R_1 = R_2 = OMe, R_3 = OH$
 107 $R_1 = OH, R_2 = OMe, R_3 = OH$
 234 $R_1 = R_2 = OMe, R_3 = H$




- 98 $R_1 = H, R_2 = OH$
 99 $R_1 = OMe, R_2 = OAc$



108




- 109 $R = H$
 110 $R = Me$



2.6.2: Flavans of the Genus *Tephrosia*

Flavans are 2-phenylchromane derivatives and they are subdivided into flavans, flavan-3-ols, flavan-4-ols and flavan-3,4-diols as shown in Scheme 2.2 (Agrawal, 1989; Dewick, 2002; Rauter *et al.*, 2018). A few of these classes of flavonoids have been reported in the genus *Tephrosia* as listed in Table 2.3.




Scheme 2.2: Basic Skeletons of Subclasses of Flavans

Table 2.3: Flavans of the Genus *Tephrosia*

No.	Flavan	Plant source (part)	Reference
115	Tephrowatsin E	<i>T. watsoniana</i> (ST)	(Gómez <i>et al.</i> , 1985b)
116	5,7-Dimethoxy-8-prenylflavan	<i>T. madrensis</i> (LF & FL)	(Gómez <i>et al.</i> , 1983)
117	5-Hydroxy-7-methoxy-8-prenylflavan	<i>T. madrensis</i> (LF & FL)	(Gómez <i>et al.</i> , 1983)
118	Tephrowatsin D	<i>T. watsoniana</i> (ST)	(Gómez <i>et al.</i> , 1985b)
119	Tephrowatsin A	<i>T. watsoniana</i> (ST)	(Gómez <i>et al.</i> , 1985b)
120	Quercetol B	<i>T. quercetorum</i> (RT)	(Gomez-Garibay <i>et al.</i> , 1988)
121	Nitenin	<i>T. nitens</i>	(Gomez <i>et al.</i> , 1984)
122	Methylhildgardtol A	<i>T. hildbrandtii</i> (RT)	(Monache <i>et al.</i> , 1986)
123	Hildgardtol A	<i>T. hildbrandtii</i> (RT)	(Monache <i>et al.</i> , 1986)
124	Hildgardtol B	<i>T. hildbrandtii</i> (RT)	(Monache <i>et al.</i> , 1986)
125	Methylhildgardtol B	<i>T. hildbrandtii</i> (RT)	(Monache <i>et al.</i> , 1986)
126	Quercetol A	<i>T. quercetorum</i> (RT)	(Gomez-Garibay <i>et al.</i> , 1988)
127	Tephrowatsin B	<i>T. watsoniana</i> (ST)	(Gómez <i>et al.</i> , 1985b)
128	Hildgardtene	<i>T. hildbrandtii</i> (RT)	(Monache <i>et al.</i> , 1986)
129	Tepicanol A	<i>T. tepicana</i> (RT & AP)	(Gómez-Garibay <i>et al.</i> , 1997)
271	Rhodiflavan A	<i>T. rhodesica</i> (RT)	(Atilaw <i>et al.</i> , 2020)
272	Rhodiflavan B	<i>T. rhodesica</i> (RT)	(Atilaw <i>et al.</i> , 2020)

Key: RT – roots, SD – seeds or seedpods, FL–flowers, AP – aerial parts, WP – whole plant



115 R₁ = R₄ = R₅ = H, R₂ = R₃ = OMe

116 R₁ = A, R₂ = R₃ = OMe, R₄ = R₅ = H


117 R₁ = A, R₂ = OMe, R₃ = OH, R₄ = R₅ = H

118 R₁ = A, R₂ = R₃ = R₅ = OMe, R₄ = H

119 R₁ = A, R₂ = R₃ = OMe, R₄ = OH, R₅ = H

120 R₁ = A, R₂ = R₃ = R₄ = OMe, R₅ = H


121 R₁ = B, R₂ = R₃ = OMe, R₄ = R₅ = H



124 R₁ = OMe = R₂ = OH, R₃ = H


125 R₁ = R₂ = OMe, R₃ = H

126 R₁ = OMe, R₂ = R₃ = OH




122 R₁ = R₂ = OMe

123 R₁ = OMe, R₂ = OH



2.6.3: Flavanones

Flavanones have a 2-phenylchroman-4-one skeleton and some may possess a 3-hydroxy group (Agrawal, 1989; Dewick, 2002; Rauter *et al.*, 2018) as shown in Scheme 2.3. There are a number of this group of flavonoids that have been reported in *Tephrosia* species as listed in Table 2.4. The majority of these compounds have no substitution in ring B except a few like lupinifolin (**148**), lupinifolinol (**150**), tephrocandidins B (**140**) and 5-methyl ether citflavanone (**157**). Almost all flavanones reported in the genus are prenylated with prenylation occurring at either C-6 or C-8.




Scheme 2.3: Basic Skeleton of Subclasses of flavanones

Table 2.4: Flavanones of the Genus *Tephrosia*


NO	Flavanone	Plant source (part)	Reference
49	Glabranin	<i>T. major</i> (RT & AP)	(Gómez-Garibay <i>et al.</i> , 2002)
50	7-Methylglabranin	<i>T. villosa</i> (RT)	(Jayaraman <i>et al.</i> , 1980)
130	Candidone	<i>T. candida</i> (ST, LF)	(Roy <i>et al.</i> , 1986)
131	7-Hydroxy-5-methoxy-8-prenylflavanone	<i>T. vogelii</i> (LF)	(Stevenson <i>et al.</i> , 2012)
132	Epoxy candidone	<i>T. hamiltonii</i> (WP)	(Falak and Shoeb, 1987)
133	Tephroleocarpin A	<i>T. leiocarpa</i> (RT)	(Go' mez-Garibay <i>et al.</i> , 1991)
134	Falciformin	<i>T. falciformis</i> (SD)	(Khan <i>et al.</i> , 1986)
135	Tephrowatsin C	<i>T. watsoniana</i> (ST)	(Gómez <i>et al.</i> , 1985b)
136	Quercetol C	<i>T. quercetorum</i> (RT)	(Gomez-Garibay <i>et al.</i> , 1988)
137	Z-Quercetol C	<i>T. vogelii</i> (LF)	(Stevenson <i>et al.</i> , 2012)
138	Tephrocandidins A	<i>T. candida</i> (AP)	(Hegazy <i>et al.</i> , 2011)
139	Tephrocandidins B	<i>T. candida</i> (AP)	(Hegazy <i>et al.</i> , 2011)
140	Tephroleocarpin B	<i>T. leiocarpa</i> (RT)	(Go' mez-Garibay <i>et al.</i> , 1991)
141	5-Methyl ether tephroleocarpin B	<i>T. vogelii</i> (LF)	(Stevenson <i>et al.</i> , 2012)
142	Dehydroisoderricin	<i>T. purpurea</i> (RT)	(Rao and Raju, 1984)
143	5-Hydroxy-7-methoxy-8-[(<i>E</i>)-3-oxo-1-butenyl]flavanone	<i>T. toxicaria</i> (ST)	(Jang <i>et al.</i> , 2003)
144	Spinoflavanone B	<i>T. spinosa</i> (RT)	(Rao and Prasad, 1992a)
145	Tephrorins A	<i>T. purpurea</i> (AP)	(Chang <i>et al.</i> , 2000)
146	Tephrorins B	<i>T. purpurea</i> (AP)	(Chang <i>et al.</i> , 2000)
147	Fulvinervin A	<i>T. fulvinervis</i> (SD)	(Venkata Rao <i>et al.</i> , 1985)
148	Lupinifolin	<i>T. lupinifolia</i> (RT)	(Smalberger <i>et al.</i> , 1974)
149	Mundulinol	<i>T. subtriflora</i> (AP)	(Muiva-Mutisya <i>et al.</i> , 2018)
150	Lupinifolinol	<i>T. lupinifolia</i> (RT)	(Smalberger <i>et al.</i> , 1974)
151	Fulvinervin B	<i>T. fulvinervis</i> (SD)	(Venkata Rao <i>et al.</i> , 1985)
152	Isolonchocarpin	<i>T. purpurea</i> (SD)	(Gupta <i>et al.</i> , 1980)
153	5-Methoxyisolonchocarpin	<i>T. emoroides</i> (RT)	(Machocho <i>et al.</i> , 1995)
154	Spinoflavanone A	<i>T. spinosa</i> (RT)	(Rao and Prasad, 1992a)
155	Obovatin	<i>T. obovata</i> (WP)	(Chen <i>et al.</i> , 1978)
156	Obovatin methylester	<i>T. obovata</i> (WP)	(Chen <i>et al.</i> , 1978)
157	5-Methyl ether citflavanone	<i>T. vogelii</i> (LF)	(Stevenson <i>et al.</i> , 2012)
158	3-Hydroxy-5-methoxy-6",6"-dimethylpyrano-[2",3":7,8]-flavanone	<i>T. vogelii</i> (LF)	(Stevenson <i>et al.</i> , 2012)
159	Lanceolatin B	<i>T. purpurea</i> (SD)	(Gupta <i>et al.</i> , 1980)
160	Rhodimer	<i>T. rhodesica</i> (RT)	(Atilaw <i>et al.</i> , 2020)


NO	Flavanone	Plant source (part)	Reference
161	5-Methoxy-6",6"-dimethyl-4",5"-dihydrocyclopropa-furano-[2",3":7,8]-flavanone	<i>T. vogelii</i> (LF)	(Stevenson <i>et al.</i> , 2012)
162	Subtruf flavanonol	<i>T. subtriflora</i> (AP)	(Muiva-Mutisya <i>et al.</i> , 2018)
163	MS-II	<i>T. subtriflora</i> (AP)	(Muiva-Mutisya <i>et al.</i> , 2018)
164	(-)-Purpurin	<i>T. purpurea</i> (SD)	(Gupta <i>et al.</i> , 1980)
165	(+)-Purpurin	<i>T. purpurea</i> (RT)	(Rao and Raju, 1984)
166	Maximaflavanone A	<i>T. maxima</i> (RT)	(Venkata Rao <i>et al.</i> , 1994)
167	Isoglabratephrin B	<i>T. purpurea</i> (ST)	(Chen <i>et al.</i> , 2015)
168	5,4'-Dihydroxy-7-O-[(<i>E</i>)-3,7-dimethyl-2,6-octadienyl]-flavanone	<i>T. villosa</i> (RT)	(Madhusudhana <i>et al.</i> , 2010)
169	5,4'-Dihydroxy-7-O-[(<i>E</i>)-3,7-dimethyl-2,6-octadienyl]-8- <i>C</i> -[(<i>E</i>)-3,7-dimethyl-2,6-octadienyl]-flavanone	<i>T. villosa</i> (RT)	(Madhusudhana <i>et al.</i> , 2010)

Key: RT – roots, SD – seeds/seedpods, FL – flowers, AP – aerial parts, WP – whole plant



- 49 R₁ = A, R₂ = R₄ = OH, R₃ = R₅ = H
 50 R₁ = A, R₂ = OMe, R₃ = R₅ = H, R₄ = OH
 130 R₁ = A, R₂ = R₄ = OMe, R₃ = R₅ = H
 131 R₁ = A, R₂ = OH, R₃ = R₅ = H, R₄ = OMe
 132 R₁ = B, R₂ = R₄ = OMe, R₃ = R₅ = H
 133 R₁ = C, R₂ = OMe, R₄ = OH, R₃ = R₅ = H
 134 R₁ = C, R₂ = OMe, R₃ = R₄ = R₅ = H
 135 R₁ = D, R₂ = R₄ = OMe, R₃ = R₅ = H
 136 R₁ = C, R₂ = R₄ = OMe, R₃ = R₅ = H
 137 R₁ = E, R₂ = R₄ = OMe, R₃ = R₅ = H
 138 R₁ = E, R₂ = OH, R₄ = OMe, R₃ = R₅ = H
 139 R₁ = E, R₂ = R₅ = OH, R₃ = H, R₄ = OMe
 140 R₁ = F, R₂ = OMe, R₄ = OH, R₃ = R₅ = H
 141 R₁ = F, R₂ = R₄ = OMe, R₃ = R₅ = H
 142 R₁ = F, R₂ = OMe, R₃ = R₄ = R₅ = H
 143 R₁ = G, R₂ = OMe, R₄ = OH, R₃ = R₅ = H
 144 R₁ = R₃ = A, R₂ = R₄ = OH, R₅ = H
 145 R₁ = I, R₂ = OMe, R₃ = R₄ = R₅ = H
 146 R₁ = J, R₂ = OH, R₃ = R₄ = R₅ = H
 168 R₁ = R₃ = H, R₂ = L, R₄ = R₅ = OH
 169 R₁ = K, R₂ = L, R₃ = H, R₄ = R₅ = OH






147 R₁ = A, R₂ = OH, R₃ = R₄ = H

148 R₁ = A, R₂ = R₄ = OH, R₃ = H

149 R₁ = A, R₂ = R₃ = OH, R₄ = H

150 R₁ = A, R₂ = R₃ = R₄ = OH



151 R₁ = A, R₂ = OH, R₃ = R₄ = H

152 R₁ = R₂ = R₃ = R₄ = H

153 R₁ = R₃ = R₄ = H, R₂ = R₃ = OMe

154 R₁ = A, R₂ = OH, R₃ = R₄ = H


155 R₁ = H, R₂ = OH, R₃ = R₄ = H

156 R₁ = H, R₂ = OMe, R₃ = R₄ = H


157 R₁ = H, R₂ = OMe, R₃ = OH, R₄ = H

158 R₁ = H, R₂ = OMe, R₃ = H, R₄ = OH


166 R₁ = A, R₂ = R₃ = R₄ = H




159



160




161




162 R = OH


163 R = H



164




165



167

2.6.4: Flavones and Flavonols of the Genus *Tephrosia*

Flavones are 2-phenylchromen-4-one derivatives while flavonols are 3-hydroxyflavones (Agrawal, 1989; Dewick, 2002; Rauter *et al.*, 2018) as shown in Scheme 2.4. Many flavones and few flavonols that have been reported from the genus *Tephrosia* are listed in Table 2.5. Substitution in ring B is very rare except oxygenation at C-3 and C-4 in very few compounds like quercetin (**170**), methyl quercetin (**171**), chrysoeriol (**172**) and glucosides (**186** – **189**).




Scheme 2.4: Basic Skeletons of Flavones and Flavonols

Table 2.5: Flavones and Flavonols of the Genus *Tephrosia*

















No.	Flavone	Plant source (part)	Reference
38	Isopongaflavone	<i>T. bracteolata</i> (SD)	(Khalid and Waterman, 1981)
170	Kaempferitrin	<i>T. purpurea</i> (ST)	(Gómez-Garibay <i>et al.</i> , 2002; Atilaw <i>et al.</i> , 2017b)
171	Methyl quercetin	<i>T. watsoniana</i> (ST)	(Gómez <i>et al.</i> , 1985b)
172	Chrysoeriol	<i>T. toxicaria</i> (ST)	(Jang <i>et al.</i> , 2003)
173	<i>trans</i> -Tephrostachin	<i>T. bracteolata</i> (SD)	(Khalid and Waterman, 1981)
174	Emoroidone	<i>T. emoroides</i> (RT)	(Machocho <i>et al.</i> , 1995)
175	(<i>E</i>)-5-Hydroxytephrostachin	<i>T. purpurea</i> (ST)	(Atilaw <i>et al.</i> , 2017b)
176	Lanceolatin A	<i>T. apollinea</i> (AP)	(Nenaah, 2014)
177	<i>Z</i> -Tephrostachin	<i>T. vogelii</i> (LF)	(Stevenson <i>et al.</i> , 2012)
178	(<i>E</i>)-5-Hydroxyanhydrotephrostachin	<i>T. purpurea</i> (ST)	(Atilaw <i>et al.</i> , 2017b)
179	<i>trans</i> -Anhydrotephrostachin	<i>T. bracteolata</i> (SD)	(Khalid and Waterman, 1981)
180	Purleptone	<i>T. purpurea</i> (ST)	(Atilaw <i>et al.</i> , 2017b)
185	Terpurinflavone	<i>T. purpurea</i> (ST)	(Juma <i>et al.</i> , 2011)
181	Apollinine	<i>T. apollinea</i> (SD)	(Waterman and Khalid, 1980)
182	Tephroglabrin	<i>T. purpurea</i> (RT)	(Pelter <i>et al.</i> , 1981)
183	Hookerianin	<i>T. hookeriana</i> (SD)	(Prabhakar <i>et al.</i> , 1996)
184	Tepurindiol	<i>T. purpurea</i> (RT)	(Pelter <i>et al.</i> , 1981)
186	6-Hydroxykaempferol-6-methyl ether-3- <i>O</i> - α -rhamnopyranosyl(1 \rightarrow 2)[α -rhamnopyranosyl(1 \rightarrow 6)]- β -galactopyranoside-7- <i>O</i> - α -rhamnopyranoside - 27	<i>T. candida</i> (LF)	(Stevenson <i>et al.</i> , 2012)
187	6-Hydroxykaempferol-6-methyl ether-3- <i>O</i> - α -rhamnopyranosyl(1 \rightarrow 6)- β -galactopyranoside-7- <i>O</i> - α -rhamnopyranoside - 28	<i>T. candida</i> (LF)	(Stevenson <i>et al.</i> , 2012)





No.	Flavone	Plant source (part)	Reference
188	6-Hydroxykaempferol-6-methyl ether 3-O- α -rhamnopyranosyl(1 \rightarrow 2)[α -rhamnopyranosyl(1 \rightarrow 6)]- β -galactopyranoside -33	<i>T. candida</i> (LF)	(Stevenson <i>et al.</i> , 2012)
189	6-Hydroxykaempferol-6-methyl ether-3-O- α -rhamnopyranosyl(1 \rightarrow 2)](3-O- <i>E</i> -feruloyl)- α -rhamnopyranosyl(1 \rightarrow 6)]- β -galactopyranoside -60	<i>T. candida</i> (LF)	(Stevenson <i>et al.</i> , 2012)
190	Fulvinervin B	<i>T. fulvinervis</i> (SD)	(Venkata Rao <i>et al.</i> , 1985)
191	Fulvinervin C	<i>T. fulvinervis</i> (SD)	(Venkataratnam <i>et al.</i> , 1986)
192	Pseudosemiglabrin	<i>T. apollinea</i> (WP)	(Ahmad, 1986)
193	Pseudosemiglabrinol	<i>T. apollinea</i> (WP)	(Ahmad, 1986)
194	(-)-Semiglabrin	<i>T. semiglabrin</i> (AP, RT)	(Smalberger <i>et al.</i> , 1973)
195	(-)-Semiglabrinol	<i>T. semiglabrin</i> (AP, RT)	(Smalberger <i>et al.</i> , 1973)
196	Glabratephrin	<i>T. semiglabrin</i> (AP)	(Vleggaar <i>et al.</i> , 1978)
197	Isoglabratephrin	<i>T. purpurea</i> (AP)	(Hegazy <i>et al.</i> , 2009)
198	Glabratephrinol	<i>T. semiglabrin</i> (SD)	(Vleggaar <i>et al.</i> , 1978)
199	Kanjone	<i>T. purpurea</i> (SD)	(Gupta <i>et al.</i> , 1980)
200	Tephropurpulin	<i>T. purpurea</i> (AP)	(Hegazy <i>et al.</i> , 2009)
201	Tephroodin	<i>T. purpurea</i> (ST)	(Muiva-Mutisya <i>et al.</i> , 2014)
235	Kaempferol-3-O- β -D-glucopyranoside	<i>T. calophylla</i> (RT)	(Kishore <i>et al.</i> , 2003)
268	Terpurleflavone	<i>T. purpurea</i> (ST)	(Atilaw <i>et al.</i> , 2017b)
269	Tachrosin	<i>T. purpurea</i> (ST)	(Atilaw <i>et al.</i> , 2017b)

Key: RT–roots, SD–seeds/seedpods, FL–flowers, AP–aerial parts, ST– the stem, WP–whole plant



- 170** $R_1 = R_3 = R_6 = H, R_2 = R_5 = J, R_4 = R_7 = OH$
171 $R_1 = R_3 = H, R_2 = R_5 = R_6 = R_7 = OH, R_4 = OMe$
172 $R_1 = R_3 = R_5 = H, R_2 = R_4 = R_5 = R_7 = OH, R_6 = OMe$
173 $R_1 = A, R_2 = R_4 = OMe, R_3 = R_5 = R_6 = R_7 = H$
174 $R_1 = A, R_2 = OH, R_4 = OMe, R_3 = R_5 = R_6 = R_7 = H$
175 $R_1 = A, R_2 = OMe, R_4 = OH, R_3 = R_5 = R_6 = R_7 = H$
176 $R_1 = A, R_2 = OMe, R_3 = R_4 = R_5 = R_6 = R_7 = H$
177 $R_1 = B, R_2 = OH, R_4 = OMe, R_3 = R_5 = R_6 = R_7 = H$
178 $R_1 = C, R_2 = OMe, R_4 = OH, R_3 = R_5 = R_6 = R_7 = H$
179 $R_1 = C, R_2 = R_4 = OMe, R_3 = R_5 = R_6 = R_7 = H$
180 $R_1 = D, R_2 = OMe, R_4 = OH, R_3 = R_5 = R_6 = R_7 = H$
181 $R_1 = E, R_2 = OMe, R_3 = R_4 = R_5 = R_6 = R_7 = H$
182 $R_1 = F, R_2 = OMe, R_3 = R_4 = R_5 = R_6 = R_7 = H$
183 $R_1 = E, R_2 = R_4 = OMe, R_3 = R_5 = R_6 = R_7 = H$
184 $R_1 = G, R_2 = OMe, R_3 = R_4 = R_5 = R_6 = R_7 = H$
185 $R_1 = I, R_2 = OAc, R_3 = R_4 = R_5 = R_6 = R_7 = H$
186 $R_1 = R_6 = H, R_2 = J, R_3 = OMe, R_4 = R_7 = OH = R_5 = L$
187 $R_1 = R_6 = H, R_2 = J, R_3 = OMe, R_4 = R_7 = OH = R_5 = K$
188 $R_1 = R_6 = H, R_2 = R_4 = R_7 = OH, R_3 = OMe, R_5 = L$
189 $R_1 = R_6 = H, R_2 = R_4 = R_7 = OH, R_3 = OMe, R_5 = M$
235 $R_1 = R_3 = R_6 = H, R_2 = R_4 = R_7 = OH, R_5 = N$
269 $R_1 = F, R_2 = R_4 = OMe, R_3 = R_5 = R_6 = R_7 = H$






2.6.5: Isoflavonoids of the Genus *Tephrosia*

Isoflavonoids are commonly subclassified into isoflavones, isoflavans, isoflav-3-enes, coumestans, coumaronochromones, pterocarpanes and rotenoids based on their structural skeleton as illustrated in Scheme 2.5 (Whitten *et al.*, 1997; Rauter *et al.*, 2018). The isoflavones that have been reported in several species of *Tephrosia* are listed in Table 2.6. The majority of the reported isoflavones lack C-5 oxygenation but *O*-prenylation is common. Very few coumestans have been reported from the genus as listed in Table 2.7. Pterocarpanes especially those having a 6a,11a-dihydrobenzofurobenzopyran ring are common in the genus *Tephrosia* as listed in Table 2.8.

Rotenoids are isoflavonoids having an extra carbon in form of a methylene which bridges C-2-C-2' of an isoflavone skeleton via an epoxy residue (Abidi, 1987; Agrawal, 1989; Whitten *et al.*, 1997). Rotenoids are considered as 2-methylene-2'-epoxyisoflavonoids with a *cis*-configuration at the fusion between *B/C* rings (Abidi, 1987). Several rotenoids have been reported in the genus as listed in Table 2.9.






Scheme 2.5: Basic Skeletons of Isoflavonoids

Table 2.6: Isoflavones Reported from the *Tephrosia* species

No.	Isoflavone	Plant species (part)	References
46	Calopogoniumisoflavone B	<i>T. maxima</i> (RT)	(Murthy and Rao, 1985)
55	Genistein	<i>T. toxicaria</i> (ST)	(Jang <i>et al.</i> , 2003)
202	Maximaisoflavone J	<i>T. maxima</i> (RT)	(Murthy and Rao, 1985)
203	Viridiflorin	<i>T. viridiflora</i> (RT & AP)	(Gómez <i>et al.</i> , 1985a)
204	Maximaisoflavone H	<i>T. maxima</i> (RT)	(Rao and Murthy, 1985)
205	Maximaisoflavone C	<i>T. maxima</i> (AP)	(Rao <i>et al.</i> , 1984)
206	Maximaisoflavone E	<i>T. maxima</i> (AP, RT)	(Rao <i>et al.</i> , 1984)
207	Maximaisoflavone D	<i>T. maxima</i> (AP, RT)	(Rao <i>et al.</i> , 1984)
208	Maximaisoflavone F	<i>T. maxima</i> (AP, RT)	(Rao <i>et al.</i> , 1984)
209	7,8,6'-Trimethoxy-3',4'-methylenedioxyisoflavone	<i>T. maxima</i> (AP)	(Rao <i>et al.</i> , 1984)
210	Maximaisoflavone G	<i>T. maxima</i> (AP, RT)	(Rao <i>et al.</i> , 1984)
211	6-Methoxy-7-hydroxy-3',4'-methylenedioxyisoflavone	<i>T. maxima</i> (AP)	(Rao <i>et al.</i> , 1984)
212	7,6'-Trimethoxy-3',4'-methylenedioxyisoflavone	<i>T. maxima</i> (AP)	(Rao <i>et al.</i> , 1984)
213	Maximaisoflavone B	<i>T. maxima</i> (RT)	(Rao and Murthy, 1985)
214	Maximaisoflavone A	<i>T. maxima</i> (AP)	(Rao <i>et al.</i> , 1984)
215	Pumilaisoflavone C	<i>T. pumila</i> (SD)	(Yenesew <i>et al.</i> , 1989)
216	Pumilaisoflavone B	<i>T. pumila</i> (SD)	(Dagne <i>et al.</i> , 1988)
217	Derrone	<i>T. purpurea</i> (ST)	(Atilaw <i>et al.</i> , 2017b)
218	5,7-Di- <i>O</i> -prenylbiochanin A	<i>T. tinctoria</i> (ST)	(Khalivulla <i>et al.</i> , 2008)
219	Pumilaisoflavone A	<i>T. pumila</i> (SD)	(Dagne <i>et al.</i> , 1988)
220	Warangalone	<i>T. elata</i> (RT)	(Lwande <i>et al.</i> , 1985a)
221	Pumilaisoflavone D	<i>T. pumila</i> (SD)	(Yenesew <i>et al.</i> , 1989)
222	Elongatin	<i>T. viridiflora</i> (RT & AP)	(Smalberger <i>et al.</i> , 1975)
223	Auriculatin	<i>T. calophylla</i> (RT)	(Ganapaty <i>et al.</i> , 2014)
224	Auriculasin	<i>T. calophylla</i> (RT)	(Ganapaty <i>et al.</i> , 2014)
225	Isoauriculatin	<i>T. calophylla</i> (RT)	(Ganapaty <i>et al.</i> , 2014)
226	Isoauriculasin	<i>T. calophylla</i> (RT)	(Ganapaty <i>et al.</i> , 2014)
227	Pumilanol	<i>T. pumila</i> (RT)	(Ganapaty <i>et al.</i> , 2008a)


No.	Isoflavone	Plant species (part)	References
237	7,4'-Dihydroxy-3',5'-dimethoxyisoflavone	<i>T. purpurea</i> (WP)	(Chang <i>et al.</i> , 2000)
238	3'-Methoxydaidzein	<i>T. purpurea</i> (WP)	(Chang <i>et al.</i> , 2000)

Key: RT – roots, SD – seeds/seedpods, AP – aerial parts, ST – stem




- 55 R₁ = R₃ = R₅ = R₆ = R₈ = R₉ = H, R₂ = R₄ = R₇ = OH
 202 R₂ = A, R₁ = R₃ = R₄ = R₅ = R₆ = R₈ = R₉ = H, R₇ = OMe
 203 R₁ = R₆ = R₉ = H, R₂ = R₄ = R₇ = OH, R₃ = B, R₅ = R₈ = OMe
 204 R₁ = R₂ = OCH₂O, R₃ = R₄ = R₅ = R₆ = R₈ = R₉ = H, R₇ = OMe
 205 R₁ = R₃ = R₄ = R₆ = R₉ = H, R₂ = A, R₇ = R₈ = OCH₂O
 206 R₁ = OMe, R₂ = OH, R₃ = R₄ = R₅ = R₈ = R₉ = H, R₆ = R₇ = OCH₂O
 207 R₁ = R₂ = OCH₂O, R₃ = R₄ = R₅ = R₈ = R₉ = H, R₆ = R₇ = OMe
 208 R₁ = R₉ = OMe, R₂ = OH, R₃ = R₄ = R₅ = R₈ = H, R₆ = R₇ = OCH₂O
 209 R₁ = R₂ = R₉ = OMe, R₃ = R₄ = R₅ = R₈ = H, R₆ = R₇ = OCH₂O
 210 R₁ = R₃ = R₄ = R₅ = R₈ = H, R₃ = OH, R₆ = R₇ = OCH₂O, R₉ = OMe
 211 R₁ = R₄ = R₅ = R₈ = R₉ = H, R₂ = OH, R₃ = OMe, R₆ = R₇ = OCH₂O
 212 R₁ = R₃ = R₄ = R₅ = R₈ = H, R₂ = R₉ = OMe, R₆ = R₇ = OCH₂O
 213 R₂ = A, R₁ = R₃ = R₄ = R₅ = R₈ = R₉ = H, R₆ = R₇ = OCH₂O
 214 R₁ = R₂ = OCH₂O, R₃ = R₄ = R₅ = R₈ = R₉ = H, R₆ = R₇ = OCH₂O
 215 R₁ = R₉ = H, R₂ = R₄ = R₇ = OH, R₃ = R₅ = B, R₆ = R₈ = OMe
 237 R₁ = R₃ = R₄ = R₅ = R₉ = H, R₂ = R₇ = OH, R₆ = R₈ = OMe
 238 R₁ = R₃ = R₄ = R₅ = R₈ = R₉ = H, R₂ = R₇ = OH, R₆ = OMe


- 219 R₁ = R₃ = H, R₂ = OH, R₄ = R₆ = OMe, R₅ = C
 220 R₁ = B, R₂ = R₅ = OH, R₃ = R₄ = R₅ = R₆ = H
 221 R₁ = R₃ = H, R₂ = R₅ = OH, R₄ = R₆ = OMe
 222 R₁ = R₄ = H, R₂ = R₅ = OH, R₃ = R₆ = OMe
 223 R₁ = B, R₂ = R₃ = R₅ = OH, R₄ = R₆ = H
 224 R₁ = B, R₂ = R₄ = R₅ = OH, R₃ = R₆ = H
 225 R₁ = R₄ = R₆ = H, R₂ = R₃ = OH, R₅ = D
 226 R₁ = R₃ = R₆ = H, R₂ = R₄ = OH, R₅ = D



- 46 R₁ = H, R₂ = R₃ = OCH₂O
 217 R₁ = R₃ = OH, R₂ = H



216




218

Table 2.7: Coumestans Reported from the Genus *Tephrosia*

No.	Coumestan	Plant species (part)	References
227	2-Methoxy-3,9-dihydroxycoumestone	<i>T. hamiltonii</i> (RT)	(Rajani and Sarma, 1988)
228	Flemichaparin C	<i>T. hamiltonii</i> (RT)	(Rajani and Sarma, 1988)
229	Tephrosol	<i>T. villosa</i> (RT)	(Rao and Srimannarayana, 1980)
230	Tephcalostan D	<i>T. calophylla</i> (RT)	(Ganapaty <i>et al.</i> , 2009)
231	Tephcalostan C	<i>T. calophylla</i> (RT)	(Ganapaty <i>et al.</i> , 2009)
232	Tephcalostan B	<i>T. calophylla</i> (RT)	(Ganapaty <i>et al.</i> , 2009)
232	Tephcalostan	<i>T. calophylla</i> (WP)	(Kishore <i>et al.</i> , 2003)
239	3,9-Dihydroxy-8-methoxycoumestan	<i>T. purpurea</i> (WP)	(Chang <i>et al.</i> , 1997)

Key: RT – Roots, WP – whole plant




227 R₁ = R₃ = OH, R₂ = OMe, R₄ = H


228 R₁ = OMe, R₂ = H, R₃ = R₄ = OCH₂O

229 R₁ = OH, R₂ = OMe, R₃ = R₄ = OCH₂O


239 R₁ = R₃ = OH, R₂ = H, R₄ = OMe




230



231



232





233

Table 2.8: Pterocarpan Reported from the Genus *Tephrosia*

No.	Pterocarpan	Plant species (Part)	Reference
24	Maackiain	<i>T. purpurea</i> (WP)	(Chang <i>et al.</i> , 1997)
30	Pisatin	<i>T. bidwilli</i> (SD)	(Ingham and Markham, 1980)
240	3-Hydroxy-4-methoxy-8,9-methylenedioxypterocarpan	<i>T. purpurea</i> (WP)	(Chang <i>et al.</i> , 1997)
241	Medicarpin	<i>T. purpurea</i> (WP)	(Chang <i>et al.</i> , 1997)
242	Methoxymaackiain	<i>T. bidwilli</i> (SD)	(Ingham and Markham, 1980)
243	Tephrocarpin	<i>T. bidwilli</i> (SD)	(Ingham and Markham, 1980)
244	Acanthocarpan	<i>T. bidwilli</i> (SD)	(Ingham and Markham, 1980)
245	3,4-Dimethylenedioxypterocarpan	<i>T. aequilata</i> (RT)	(Tarus <i>et al.</i> , 2002)
246	Hildecarpin	<i>T. hildebrandtii</i> (RT)	(Lwande <i>et al.</i> , 1986a)
247	Emoroidocarpan	<i>T. emoroides</i> (RT)	(Machocho <i>et al.</i> , 1995)

No.	Pterocarpan	Plant species (Part)	Reference
248	4'-Hydroxyemeroidocarpan	<i>T. purpurea</i> (ST)	(Li <i>et al.</i> , 2011)
249	Hildecarpidin	<i>T. hildebrandtii</i> (RT)	(Lwande <i>et al.</i> , 1987)
250	Flemichaparin B	<i>T. hamiltonii</i> (RT)	(Rajani and Sarma, 1988)
251	3,4:8,9-Dimethylenedioxy-6a,11a-pterocarpene	<i>T. aequilata</i> (RT)	(Atilaw <i>et al.</i> , 2017a)
262	Rhodacarpin	<i>T. rhodesica</i> (RT)	(Atilaw <i>et al.</i> , 2020)

KEY: ST – stems, WP – whole plant, SD – seeds/seedpods, RT - roots




272

Table 2.9: Rotenoids Reported in the Genus *Tephrosia*.

No.	Rotenoid	Plant source (part)	Reference
18	Munduserone	<i>T. fulvinervis</i> (RT) <i>T. pentaphylla</i> (LV)	(Dagne <i>et al.</i> , 1989)
20	Rotenone	<i>T. pentaphylla</i> (RT)	(Dagne <i>et al.</i> , 1989)
22	Deguelin	<i>T. fulvinervis</i> (RT)	(Dagne <i>et al.</i> , 1989)
23	Tephrosin	<i>T. obovata</i> (WP)	(Chen <i>et al.</i> , 1958)
19	<i>cis</i> -12a-Hydroxymunduserone	<i>T. fulvinervis</i> (RT)	(Dagne <i>et al.</i> , 1989)
42	Dehydrorotenone	<i>T. villosa</i> (SD)	(Krupadanam <i>et al.</i> , 1977a)
252	Sumatrol	<i>T. pentaphylla</i> (RT)	(Dagne <i>et al.</i> , 1989)
21	<i>cis</i> -12a-Hydroxyrotenone	<i>T. pentaphylla</i> (RT)	(Dagne <i>et al.</i> , 1989)

No.	Rotenoid	Plant source (part)	Reference
254	6a-Hydroxyrotenone	<i>T. pentaphylla</i> (RT)	(Dagne <i>et al.</i> , 1989)
255	Villol	<i>T. villosa</i> (SD)	(Krupadanam <i>et al.</i> , 1977a)
256	Villosin	<i>T. villosa</i> (SD)	(Krupadanam <i>et al.</i> , 1977a)
257	6-Acetoxydihydrostemonal	<i>T. pentaphylla</i> (RT, LV)	(Dagne <i>et al.</i> , 1989)
258	Dihydrostemonal	<i>T. pentaphylla</i> (RT, LV)	(Dagne <i>et al.</i> , 1989)
259	9-Demethyldihydrostemonal	<i>T. pentaphylla</i> (SD)	(Dagne <i>et al.</i> , 1989)
260	6-Hydroxy- α -toxicarol	<i>T. villosa</i> (RT)	(Muiva-Mutisya <i>et al.</i> , 2014)
261	4',5'-Dihydro-5',11-dihydroxy-4'-methoxytephrosin	<i>T. toxicaria</i> (ST)	(Jang <i>et al.</i> , 2003)
262	α -toxicarol	<i>T. pentaphylla</i> (LV) <i>T. fulvinervis</i> (RT)	(Dagne <i>et al.</i> , 1989)
263	Villosol	<i>T. villosa</i> (SD)	(Krupadanam <i>et al.</i> , 1977a)
264	Villosinol	<i>T. villosa</i> (SD)	(Krupadanam <i>et al.</i> , 1977a)
265	Villinol	<i>T. villosa</i> (SD)	(Krupadanam <i>et al.</i> , 1977a)
266	Villosone	<i>T. villosa</i> (SD)	(Krupadanam <i>et al.</i> , 1977a)
267	Rotenonone	<i>T. villosa</i> (SD)	(Krupadanam <i>et al.</i> , 1977a)

Key: RT – roots, SD – seeds/seedpods, LV – leaves, ST – the stem, WP – whole plant



20 R₁ = R₂ = R₃ = H


252 R₁ = OH, R₂ = R₃ = H

253 R₁ = R₃ = H, R₂ = OH

254 R₁ = R₂ = H, R₃ = OH

255 R₁ = R₂ = R₃ = OH

256 R₁ = R₃ = OH, R₂ = H




18 R₁ = Me, R₂ = R₃ = R₄ = H

19 R₁ = Me, R₂ = R₄ = H, R₃ = OH

257 R₁ = Me, R₂ = R₃ = H, R₄ = OH

258 R₁ = Me, R₂ = R₄ = OH, R₃ = H

259 R₁ = R₃ = H, R₂ = R₄ = OH





22 R₁ = R₂ = R₃ = H

23 R₁ = R₃ = H, R₂ = OH

260 R₁ = R₃ = OH, R₂ = H

262 R₁ = OH, R₂ = R₃ = H



- 42 R₁ = R₂ = H
 263 R₁ = OH, R₂ = H
 264 R₁ = R₂ = OH
 265 R₁ = OH, R₂ = OMe
 266 R₁ = OH, R₂ = O
 267 R₁ = H, R₂ = O

2.7: Biological Activities of Compounds Isolated from the Genus *Tephrosia*

Numerous flavonoids have been reported from the genus *Tephrosia* (Touqueer *et al.*, 2013; Chen *et al.*, 2014; Samuel *et al.*, 2019). However, just a few of the isolated compounds have been evaluated for their biological activities including anticancer, anti-plasmodial, anti-protozoal, anti-microbial and insecticidal (Table 2.10). Despite the reports that some of the crude extracts exhibited anti-inflammatory activities (Auda *et al.*, 2009; Sandhya *et al.*, 2010; Valli *et al.*, 2011), compounds isolated from this genus have not been assessed for their anti-inflammatory effects. However, compounds such as genistein (**55**) (Hämäläinen *et al.*, 2007), isoliquiritigenin (**93**) (Lee *et al.*, 2009), and chrysoeriol (**172**) (Wu *et al.*, 2020) isolated from other sources have shown significant anti-inflammatory activities.

Table 2.10: Biological Activities of Compounds Isolated from the Genus *Tephrosia*

No	Compound	Plant source	Activity	Reference
20	Rotenone	<i>T. elata</i>	antifeedant	(Bentley <i>et al.</i> , 1987)
22	Deguelin	<i>T. elata</i>	Antiplasmodial	(Muiva <i>et al.</i> , 2009)
23	Tephrosin	<i>T. elata</i>	Antifeedant	(Bentley <i>et al.</i> , 1987)
24	Maackiain	<i>T. purpurea</i>	Cancer chemopreventive	(Chang <i>et al.</i> , 2000)
29	Hildecarpin	<i>T. hildebrandtii</i>	Antifeedant Antifungal	(Lwande <i>et al.</i> , 1986a)
31	Pongachin	<i>T. pulcherrima</i>	Antimicrobial	(Ganapaty <i>et al.</i> , 2008b)

No	Compound	Plant source	Activity	Reference
32	Emoroidenone	<i>T. emoroides</i>	Antifeedant	(Machocho <i>et al.</i> , 1995)
38	Isopongaflavone	<i>T. elata</i>	Antifeedant,	(Bentley <i>et al.</i> , 1987)
		<i>T. aquilata</i>	Antiplasmodial	(Atilaw <i>et al.</i> , 2017a)
53	Rhodiflavan C	<i>T. rhodesica</i>	Antiplasmodial	(Atilaw <i>et al.</i> , 2020)
55	Genistein	<i>T. toxicaria</i>	Cancer chemopreventive	(Jang <i>et al.</i> , 2003)
93	Isoliquiritigenin	<i>T. toxicaria</i>	Cancer chemopreventive	(Jang <i>et al.</i> , 2003)
97	Candidachalcone	<i>T. candida</i>	Estrogenic	(Hegazy <i>et al.</i> , 2011)
98	Tephrosone	<i>T. purpurea</i>	Cancer chemopreventive	(Chang <i>et al.</i> , 2000)
99	Tephropurpurin	<i>T. purpurea</i>	Cancer chemopreventive	(Chang <i>et al.</i> , 2000)
100	Obovatachalcone	<i>T. aquilata</i>	Antiplasmodial	(Atilaw <i>et al.</i> , 2017a)
105	Praecansone A	<i>T. praecans</i> <i>T. aquilata</i>	Antibacterial Antiplasmodial	(Tarus <i>et al.</i> , 2002) (Atilaw <i>et al.</i> , 2017a)
106	Praecansone B	<i>T. praecans</i> , <i>T. aquilata</i>	Antibacterial Antiplasmodial	(Tarus <i>et al.</i> , 2002) (Atilaw <i>et al.</i> , 2017a)
107	Demethylpraecansone B	<i>T. aequilata</i>	Antibacterial	(Tarus <i>et al.</i> , 2002)
108	Aequichalcone C	<i>T. aequilata</i>	Antiplasmodial	(Atilaw <i>et al.</i> , 2017a)
109	Pongamol	<i>T. purpurea</i>	Cancer chemopreventive	(Chang <i>et al.</i> , 2000)
111	Elatadihydrochalcone	<i>T. elata</i>	Antiplasmodial	(Muiva <i>et al.</i> , 2009)

No	Compound	Plant source	Activity	Reference
112	Aequichalcone A	<i>T. aequilata</i>	Antiplasmodial	(Atilaw <i>et al.</i> , 2017a)
113	Aequichalcone B	<i>T. aequilata</i>	Antiplasmodial	(Atilaw <i>et al.</i> , 2017a)
119	Tephrowatsin A	<i>T. rhodesica</i>	Antiplasmodial	(Atilaw <i>et al.</i> , 2020)
120	Quercetol B (9)	<i>T. rhodesica</i>	Antiplasmodial	(Atilaw <i>et al.</i> , 2020)
128	Hildgardtene	<i>T. emoriodes</i>	antifeedant	(Machochi <i>et al.</i> , 1995)
138	Tephrocandidins A	<i>T. candida</i>	Estrogenic	(Hegazy <i>et al.</i> , 2011)
139	Tephrocandidins B	<i>T. candida</i>	Estrogenic	(Hegazy <i>et al.</i> , 2011)
144	Spinoflavanone B	<i>T. subtriflora</i>	Antiplasmodial	(Muiva-Mutisya <i>et al.</i> , 2018)
149	Mundulinol	<i>T. subtriflora</i>	Antiplasmodial	(Muiva-Mutisya <i>et al.</i> , 2018)
156	Obovatin methyl ether	<i>T. elata</i>	Antiplasmodial Piscicidal	(Muiva <i>et al.</i> , 2009) (Chen <i>et al.</i> , 1978)
159	Lanceolatin B	<i>T. purpurea</i>	Cancer chemopreventive	(Chang <i>et al.</i> , 2000)
162	Subtrufavanonol	<i>T. subtriflora</i>	Antiplasmodial	(Muiva-Mutisya <i>et al.</i> , 2018)
163	MS-II	<i>T. subtriflora</i>	Antiplasmodial	(Muiva-Mutisya <i>et al.</i> , 2018)
168	Purpurin	<i>T. purpurea</i>	Cancer chemopreventive	(Chang <i>et al.</i> , 2000)
172	Chrysoeriol	<i>T. toxicaria</i>	Cancer chemopreventive	(Jang <i>et al.</i> , 2003)
174	Emoroidone	<i>T. emoroides</i>	Antifeedant	(Machochi <i>et al.</i> , 1995)
180	Purleptone	<i>T. purpurea</i>	Cytotoxicity	Atilaw <i>et al.</i> , 2017
185	Terpurinflavone	<i>T. purpurea</i>	Antiplasmodial	Juma <i>et al.</i> , 2011

No	Compound	Plant source	Activity	Reference
201	Tephrodin	<i>T. purpurea</i>	Antiplasmodial	(Muiva-Mutisya et al., 2014)
227	Pumilanol	<i>T. pumila</i>	Antiprotozoal	(Ganapaty et al., 2008a)
237	7,4'-Dihydroxy-3',5'-dimethoxyisoflavone	<i>T. purpurea</i>	Cancer chemopreventive	(Chang et al., 2000)
240	(-)-3-Hydroxy-4-methoxy-8,9-methylenedioxypterocarpan	<i>T. purpurea</i>	Cancer chemopreventive	(Chang et al., 2000)
241	Medicarpin	<i>T. purpurea</i>	Cancer chemopreventive	(Chang et al., 2000)
245	3,4-Dimethylenedioxypterocarpan	<i>T. aequilata</i>	Antifeedant	(Tarus et al., 2002)
247	Emoroidocarpan	<i>T. emoroides</i>	Antifeedant	(Machocho et al., 1995)
251	3,4:8,9-Dimethylenedioxy-6a,11a-pterocarpene	<i>T. aequilata</i>	Antiplasmodial	(Atilaw et al., 2017a)
260	6-Hydroxyrotenone	<i>T. rhodesica</i>	Antiplasmodial	(Atilaw et al., 2020)
262	α -Toxicarol	<i>T. toxicaria</i>	Larvicidal	(Vasconcelos et al., 2009)
268	Terpurlepflavone	<i>T. purpurea</i>	Antiplasmodial Cytotoxicity	(Atilaw et al., 2017b)
269	Tachrosin	<i>T. purpurea</i>	Antiplasmodial Cytotoxicity	(Atilaw et al., 2017b)
270	Rhodiflavan A	<i>T. rhodesica</i>	Antiplasmodial	(Atilaw et al., 2020)
271	Rhodiflavan B	<i>T. rhodesica</i>	Antiplasmodial	(Atilaw et al., 2020)
272	Rhodacarpin	<i>T. rhodesica</i>	Antiplasmodial	(Atilaw et al., 2020)

CHAPTER 3: MATERIALS AND METHODS

3.1 Column Chromatography

Column chromatography was performed using Merck silica gel 60 (70-230 mesh) as a stationary phase and *n*-hexane or cyclohexane/ethyl acetate as a mobile phase while gel filtration chromatography was done using Sephadex LH-20 with dichloromethane/methanol (1:1) as mobile phase. TLC was carried out on pre-coated silica gel 60 PF₂₅₄₊₃₆₅ plates. Chromatotron 7924T (USA) was used for purification. Chromatographic spots were detected under a UV lamp (254 and 365 nm) or sprayed with 5% sulphuric acid in methanol.

3.2 Preparative High-Performance Liquid Chromatography

Preparative HPLC was performed on a Shimadzu LC-20AP system equipped with a DGU-20A5R degassing unit, SPD-M20A detector and SIL-20AUCHT autosampler. A C18 column (Nucleodur Polartec 5 μ m, 10 x 125 mm or Phenomenex 10 μ m, 10 x 250 mm) was used for reverse-phase separation. Methanol/water in 0.1% formic acid was used as the mobile phase. The fractions were loaded in the range of 50-200 μ L as injection volume with a flow rate of 4 mL/min and the temperature was maintained at 25°C. The HPLC was operated using the LabSolution software system. The fractions were concentrated under reduced pressure on a rotary evaporator and appropriately combined after verification by LC-MS.

3.3 High-Resolution Electron Spray Ionization Mass Spectrometry

The HPLC–HRMSⁿ experiments were carried out on an LTQ Orbitrap spectrometer (Thermo Scientific, USA) equipped with a HESI-II source. The spectrometer was operated in positive mode with a nominal mass resolving power of 60,000 at *m/z* 400 with a scan rate of 1 Hz under the following parameters: spray voltage 6 kV, capillary temperature 300°C and tube lens 100 V. Argon served as collision gas and nitrogen was used as sheath gas (66 arbitrary units) and auxiliary gas (8 arbitrary units). All MSⁿ experiments were performed with collision-induced dissociation at 35 eV. The spectrometer was equipped with an Agilent 1200 HPLC system

(Santa Clara, USA) including a pump, PDA detector, column oven (30 °C) and auto-sampler (injection volume: 5 μ L for Full scan, 7 μ L for MSⁿ). The HPLC analyses were performed with a Luna C18 column (60 \times 3 mm, 3 μ m particle size) from Phenomenex (Torrance, USA) with a water (+0.1% formic acid) (A) and methanol (+0.1% formic acid) (B) gradient (flow rate 360 μ L/min). The gradient was set as follows: linear gradient from 95% A to 100% B over 24 min, 100% B isocratic for 5 min, the system returned within 1 min to initial conditions of 95% A and was equilibrated for 5 min. All the samples were dissolved in methanol.

3.4 Nuclear Magnetic Resonance Spectroscopy

NMR spectra were recorded on a Bruker Advance III 600 MHz spectrometer equipped with a cryoprobe unit using standard pulse sequences and referenced with the TMS. The chemical shifts (δ) are expressed in parts per million (ppm) and coupling constants (J) in Hertz (Hz). COSY, NOESY, HSQC and HMBC experiments were acquired using the standard Bruker programs. All the experiments were performed in deuterated solvents and chemical shifts were calibrated relative to the solvent peaks.

3.5 Optical Rotation and Circular Dichroism

Optical rotation was determined using an Autopol IV automatic polarimeter. CD measurements were done on a Jasco J-715 spectrometer.

3.6: Plant Materials

Detailed information regarding the collection of *Tephrosia* species used in this study is presented in Table 3.1. The plants were authenticated by Mr. Patrick Mutiso of the University Herbarium, School of Biological Sciences, the University of Nairobi, where voucher specimens were deposited.

Table 3.1: Plant collection and voucher details

<i>Tephrosia</i> species	Plant part	Locality	Collection date	Voucher number
<i>T. vogelii</i>	Seedpods	Tororo, Uganda N0°39'37.2" E034°12'5.6"	04.08.2016	ORO-2016/04
<i>T. hildebrandtii</i>	Aerial parts	Thika, Kenya S01°03'19.2" E037°14'10.4"	23.02.2017	ORO-2017/07
<i>T. elata</i>	Aerial parts	Thika, Kenya S01°03'20.5" E037°14'12.4"	23.02.2017	ORO-2017/08
<i>T. rhodesica</i>	Stems	Dzombo hills, Kwale county, Kenya S04°29'28.9" E039°15'16.3"	27.03.2018	ORO-2018/09
<i>T. linearis</i>	Aerial parts	Gongoni, Kwale county, Kenya S04°23'57.3" E039°27'17.4"	28.03.2018	ORO-2018/11

3.7: Extraction and Isolation

3.7.1: The Aerial Parts of *Tephrosia linearis*

The powder of *T. linearis* aerial parts (890 g) was extracted using dichloromethane/methanol (1:1). The concentrated extract (72.5 g) was partitioned between water and *n*-hexane to remove fats. The aqueous layer was further partitioned in ethyl acetate (EtOAc). The ethyl acetate portion was concentrated to provide a brown paste (18.4 g) that was then fractionated on silica gel using cyclohexane/ethyl acetate (EtOAc) in increasing polarity. The fraction that eluted at 5% EtOAc in cyclohexane was purified on Sephadex LH-20 using dichloromethane/methanol (1:1) followed by preparative HPLC (20:80, MeOH/H₂O-100% MeOH gradient elution for 50 min at a flow rate of 4 mL/min) yielding lineaflavone C (**3**) (1.1 mg). Similarly, the 10% EtOAc in cyclohexane fraction was purified using Sephadex LH-20 followed by preparative HPLC to give acetylobovatin (**6**) (1.0 mg). The 20% EtOAc in cyclohexane fraction was purified in a similar way to give maackiain (**24**) (11.5 mg), tephrosin (**23**) (5.3 mg), rotenone (**20**) (3.7 mg), deguelin (**22**) (6.3 mg) and 6-*C*-prenylapigenin (**10**) (18.2 mg). Fractions from 30% EtOAc in

cyclohexane were also purified on Sephadex LH-20 followed by preparative HPLC to give lineaflavone A (**1**) (24.3 mg), lineaflavone B (**2**) (5.3 mg), lineaflavone D (**4**) (1.9 mg), 6-methoxygeraldone (**5**) (1.0 mg), 5-hydroxy-7-methoxysaniculamin A (**7**) (1.0 mg), 7-*O*-methyl-6-prenylnaringenin (**8**) (2.3 mg), erylivingstone I (**9**) (1.5 mg), 5,7,4',2''-tetrahydroxy-6-[3''-methyl-3''-butenyl]-flavone (**11**) (8.8 mg), apigenin (**12**) (1.2 mg), atalantoflavone (**15**) (4.9 mg), geraldone (**14**) (1.0 mg), munduserone (**18**) (1.0 mg), *cis*-12a-hydroxymunduserone (**19**) (1.0 mg) and 12a-hydroxyrotenone (**21**) (3.3 mg). Purification of the 100% EtOAc fractions by preparative HPLC gave luteolin (**13**) (3.3 mg), patuletin 3-*O*-rhamnoside (**16**) (1.0 mg) and eupatolitin 3-*O*-rhamnoside (**17**) (16.5 mg).

3.7.2: *The Aerial Parts of Tephrosia hildebrandtii*

The powder of *T. hildebrandtii* aerial part (1.0 kg) was extracted using dichloromethane-methanol (1:1) to provide a dark brown paste (82.4 g). The crude extract (42.9 g) was fractionated on silica gel using cyclohexane-EtOAc in increasing polarity. The fraction that eluted with 30% EtOAc in cyclohexane was purified on Sephadex LH-20 using dichloromethane-methanol, (1:1) followed by Prep.-HPLC (20:80, MeOH/H₂O-100% MeOH gradient elution for 50 min with flow rate of 4 mL/min) to give 5,7,3'-trihydroxy-4-methoxy-8-prenylisoflavone (**26**) (1.0 mg), 5,3'-dihydroxy-4'-methoxy-2'',2''-dimethylpyrano[5'',6'':8,7]isoflavone (**27**) (1.1 mg), 4-hydroxyemoroidocarpan (**28**) (1.0 mg), pongachin (**31**) (1.6 mg), emoroidenone (**32**) (2.0 mg) and tephrosin (**22**) (1.8 mg). Similarly, the 50% EtOAc in cyclohexane fraction was purified using Sephadex LH-20 followed by Prep.-HPLC to give hildaflavone (**25**) (1.0 mg), desmoxyphyllin A (**33**) (1.0 mg), hildecarpin (**29**) (1.7 mg), pisatin (**30**) (1.6 mg) and pinoresinol (**34**) (1.2 mg).

3.7.3: *The Seedpods of Tephrosia vogelii*

The seedpods powder of *T. vogelii* (4.0 kg) was extracted using dichloromethane/methanol (1:1) to provide a dark brown paste (427.1 g). The concentrated extract was partitioned between water and *n*-hexane to remove fats. The aqueous layer was further partitioned in ethyl acetate (EtOAc). The ethyl acetate portion was concentrated to provide a brown paste (122.5 g) that was then fractionated on silica gel using *n*-hexane/EtOAc in increasing polarity. The fractions that eluted with 5-10% EtOAc in *n*-hexane were combined together and purified on Sephadex LH-20 using dichloromethane/methanol (1:1) followed by chromatotron (20:80, EtOAc/*n*-hexane-100% EtOAc gradient elution) to give isopongaflavone (**38**) (54.7 mg), 6a,12a-dehydro- α -toxicarol (**43**) (2.4 mg) and dehydrorotenone (**42**) (20.1 mg). 15% EtOAc in *n*-hexane fraction was purified on Prep.-HPLC (20:80, MeOH/H₂O-100% MeOH gradient elution for 35 min) to give vogelisoflavone A (**35**) (3.3 mg), onogenin (**37**) (1.7 mg) and tephrosin (**23**) (1.5 mg). The fraction eluted at 20% was purified on Prep.-HPLC (75:25, MeOH/H₂O isocratic elution for 20 min) to give luteolin (**13**) (1.3 mg). 70% EtOAc in *n*-hexane fraction was purified on Prep.-HPLC (5:80, MeOH/H₂O-100% MeOH gradient elution for 50 min) to give vogelisoflavone B (**36**) (2.3 mg), 4',7-dihydroxy-3'-methoxyflavanone (**39**) (1.2 mg), *trans-p*-hydroxycinnamic acid (**40**) (2.6 mg), 2-methoxyglyricidol (**41**) (1.1 mg) and pinoresinol (**34**) (1.2 mg).

3.7.4: *The Stems of Tephrosia elata*

The powdered stem of *T. elata* (1.5 kg) was extracted using dichloromethane/methanol (1:1) to provide a dark brown paste (63.5 g). A portion (25.0 g) of the concentrated extract was partitioned between water and *n*-hexane to remove fats. The aqueous layer was further partitioned in EtOAc. The ethyl acetate portion was concentrated to provide a brown paste (10.1 g). It was then fractionated on silica gel using *n*-hexane/EtOAc/MeOH (6:3:1) and two major fractions were obtained. The second fraction was purified on Prep.-HPLC (35:80,


MeOH/H₂O-100% MeOH gradient elution for 50 min) to give elatisoflavone (**44**) (1.0 mg), barbigerone (**45**) (3.2 mg), calopogoniumisoflavone B (**46**) (1.0 mg) and jamaicin (**47**) (1.0 mg).

3.7.5: The Stems of *Tephrosia rhodesica*

The powdered stems of *T. rhodesica* (889 g) was extracted using dichloromethane/fractionated on silica gel using cyclohexane/EtOAc in increasing polarity. The fractions that eluted with 10% EtOAc in cyclohexane was purified on Sephadex LH-20 using dichloromethane/methanol (1:1) followed by Prep.-HPLC (20:80, MeOH/H₂O-100% MeOH gradient elution for 45 min) to give glabranin (**49**) (1.0 mg) and edunol (**56**) (2.8 mg). The 20% EtOAc in cyclohexane fraction was purified on Prep.-HPLC (20:80, MeOH/H₂O-100% MeOH gradient elution for 35 min) to give 3-methoxycoumestrol (**48**) (1.0 mg). The fraction eluted at 30% EtOAc in cyclohexane was purified on Prep.-HPLC (20:85, MeOH/H₂O -100% MeOH gradient elution for 50 min) to give rhodiflavan C (**53**) (1.0 mg), liquiritigenin (**51**) (1.0 mg), naringenin (**52**) (1.0 mg), 3'-*O*-methylrobohol (**54**) (1.1 mg), genistein (**55**) (1.0 mg), 7-*O*-methylglabranin (**50**) (1.0 mg), tephrosin (**23**) (1.0 mg) and 12a-hydroxyrotenone (**21**) (1.2 mg).

3.8: Synthesis of the Pyrazoline Derivative of Isopongaflavone

Isopongaflavone, **38** (10 mg) was dissolved in ethanol (5 mL) and hydrazine monohydrate (0.5 mL) was added dropwise. The mixture was refluxed at 85°C for 10 hours with the progress of the reaction being monitored using LC-MS. The reaction mixture was concentrated *in vacuo*, diluted with water (100 mL) and extracted with dichloromethane (3 x 15 mL). The dichloromethane extract was purified using prep.-HPLC (20:85, MeOH/H₂O-100% MeOH gradient elution for 45 min) to give a pyrazole isopongaflavone derivative, pyrazoisopongaflavone (**57**) (6.98 mg, 67% yield).



3.9: Anti-inflammatory Assay

The anti-inflammatory assays were done in Pharmacelsus, Saarbrücken, Germany. They were conducted using peripheral blood mononuclear cells obtained from Immunospot (ePBMC®-Uncharacterized Cryopreserved Human PBMC) purchased from Cellular Technologies Limited [C.T.L., Ohio, USA, Appendix B2, (<http://www.immunospot.com/CatalogueRetrieve.aspx?ProductID=10537096&A=SearchResult&SearchID=10324581&ObjectID=10537096&ObjectType=27>)]. The pure compounds were dissolved in dimethyl sulfoxide (DMSO) to obtain 20 mM stock solutions while the crude plant extract was made as a 20 mg/mL stock solution. Ibuprofen was prepared as a stock solution of 20 mM in DMSO and was used as a positive control. Lipopolysaccharide (LPS) was dissolved in a cell culture medium at a concentration of 1 mg/mL. Pure compounds were tested at a concentration of 100 μM, while the crude plant extract was used at a concentration of 100 μg/mL. The final DMSO concentration was 0.5% in all the samples. The positive control, ibuprofen, was also used at 100 μM and all samples were co-incubated with 10 μg/mL LPS. PBMCs were the main source of cytokines [interleukins (IL-1β, IL-2, IL-6), interferon-*gamma* (IFN-γ), granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-*alpha* (TNF-α)] within the circulating blood. Due to the small amounts of cytokines released by PBMCs into the supernatant, a bead-based assay (ProcartaPlex, Luminex) was used to quantify the six cytokines in parallel within a 50 μL sample using appropriate calibration standards. Human cryopreserved PBMCs were thawed according to the manufacturer's instructions. Three vials of cells from different donors were pooled. Cells were

washed, resuspended in RPMI 1640 containing 10% FBS, plated in 96-well round-bottom plates at 100,000 PBMCs/well and exposed to the test items at the concentrations stated above. Therefore, subsequent dilutions of stock solutions of the test items were prepared in a 96-well plate and transferred to the PBMCs containing wells. The cells were incubated for 24 hours at 37°C and 5% CO₂. The plates were then centrifuged for 3 min at 350 g and the cell-free supernatant was collected and subjected to cytokine bead-array assay. The cytokine bead-array assay was conducted according to the manufacturer's instructions and read on a MagPix reader. For the dose-response relationship, absolute concentrations were calculated by the MagPix software using two separate calibration series as provided by the manufacturer. For negative control, cells were incubated only with a cell culture medium. As a positive control for inflammation, cells were incubated with 10 µg/mL LPS, while as a positive control for anti-inflammation, cells were co-incubated with 10 µg/mL LPS and 100 µM ibuprofen.

CHAPTER 4: RESULTS AND DISCUSSION

In this study, five *Tephrosia* species (*T. linearis*, *T. hildebrandtii*, *T. vogelii*, *T. elata* and *T. rhodesica*) were phytochemically studied to identify secondary metabolites with anti-inflammatory properties. Their crude extracts were subjected to chromatographic separations leading to the identification of fifty-six compounds. Their characterizations were based on UV, NMR and MS spectroscopic data. The structural elucidation and anti-inflammatory activities of the compounds from these five *Tephrosia* species are discussed in the following sections.


4.1: Characterization of Compounds Isolated from *Tephrosia linearis*

The following compounds were isolated from the aerial parts of *T. linearis*: seven new compounds; lineaflavone A (**1**), lineaflavone B (**2**), lineaflavone C (**3**), lineaflavone D (**4**), 6-methoxygeraldone (**5**), acetylobovatin (**6**) and 5-hydroxy-7-methoxysaniculamin A (**7**), together with eighteen other known compounds identified as 7-*O*-methyl-6-prenylnaringenin (**8**), erylivingstone I (**9**), 6-*C*-prenylapigenin (**10**), 5,7,4',2''-tetrahydroxy-6-[3''-methyl-3''-butenyl]-flavone (**11**), apigenin (**12**), luteolin (**13**), geraldone (**14**), atalantoflavone (**15**), patuletin 3-*O*-rhamnoside (**16**), eupatolitin 3-*O*-rhamnoside (**17**), munduserone (**18**), *cis*-12a-hydroxymunduserone (**19**), rotenone (**20**), 12a-hydroxyrotenone (**21**), deguelin (**22**), tephrosin (**23**) and (-)-maackianin (**24**).

4.1.1: Lineaflavone A (**1**)

Compound **1** was isolated as a pale-yellow paste. Its molecular formula was deduced as C₂₇H₂₈O₅ based on the HRESIMS molecular ion [M+H]⁺ at *m/z* 433.2011 (calcd for C₂₇H₂₉O₅, 433.2010) and [M+Na]⁺ at *m/z* 455.1828 (calcd for C₂₇H₂₈O₅Na 455.1829) together with ¹³C NMR data (Table 4.1 and Appendix A1). A flavone skeleton was evident from the UV (λ_{\max} 252, 300, and 336 nm) and NMR data [δ_{H} 6.69 (H-3); δ_{C} 161.4 (C-2), 109.0 (C-3), and 176.6 (C-4)] (Table 4.1 and Appendix A1) (Mabry *et al.*, 1970; Agrawal, 1989). The ¹H NMR data

also exhibited signals for a methoxy group (δ_{H} 3.87, δ_{C} 62.9), a dimethylpyran ring [(*cis*-olefinic protons at δ_{H} 5.93, 6.77 (d, $J = 10.1$ Hz) and methyl protons at δ_{H} 1.42 (s, 6H)] and a *trans*-olefinic 3-methoxy-3-methylbut-1-enyl group [olefinic protons at δ_{H} 6.86, 6.63 (d, $J = 16.7$ Hz)] (Atilaw *et al.*, 2017b)]. The ^1H NMR further revealed signals for sets of mutually coupled protons resonating at δ_{H} 8.05 (2H, m), 7.60 (2H, m) and 7.61 (1H, m) assigned to ring B (Prabhakar *et al.*, 1996; Atilaw *et al.*, 2017b). The MS data (Scheme 4.1 and Appendix A1) of **1** showed fragments of 64 Da ($2 \times \text{CH}_3\text{OH}$) in the positive-ion mode confirming the occurrence of two methoxy groups in the compound. Further, loss of 42 Da (C_3H_6), 54 Da (C_4H_6), and 66 Da (C_5H_6) from $[\text{M}+\text{H}-64]^+$ ion in the MS^3 spectrum was ascribed to the prenyl and dimethylpyran moieties (Xu *et al.*, 2012). The absence of substitution in ring B was further evident from the retro-Diels Alder MS fragmentations of the C-ring (Ma *et al.*, 1997) yielding m/z 249 indicating a loss of C_8H_6 and also m/z 233 for loss of $\text{C}_9\text{H}_6\text{O}_2$. This implied that ring A was completely substituted. The HMBC correlations of the proton at δ_{H} 6.77 (H-4'') with C-5 and C-7 and δ_{H} 5.93 (H-5'') with C-6 allowed the placement of the 2,2-dimethylpyran ring at C-6/7. HMBC correlations of δ_{H} 6.86 (H-1''') with C-7 and C-9 supported the placement of the *trans*-olefinic 3-methoxy-3-methylbut-1-enyl substituent at C-8. The placement of the methoxy group (δ_{H} 3.87) at C-5 was established based on its HMBC correlation. Therefore, compound **1** was characterized as 5-methoxy-2'',2''-dimethylpyrano[5'',6'':6,7]-8-(*E*-3-methoxy-3-methylbut-1-enyl)flavone. This is a new compound and was given the trivial name lineaflavone A.



hydroxy-3-methylbut-1-enyl)flavone. This new compound was given the trivial name lineaflavone B.





Table 4.1: NMR Data for Compounds 1 and 2 in Acetone-d₆ (600 MHz)

1				2		
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
2	161.4			161.2		
3	109.0	6.69, s	C-2, C-4, C-10, C-1'	100.4	6.67, s	C-2, C-4, C-10, C-1'
4	176.6			176.9		
5	154.7			154.6		
6	113.7			113.0		
7	156.1			155.0		
8	111.4			113.2		
9	156.4			156.3		
10	113.3			112.9		
1'	132.8			132.6		
2'/6'	127.0	8.05, m	C-2, C-2'/6', C-4'	127.0	8.06, m	C-2'/6', C-4', C-2
3'/5'	130.0	7.60, m	C-1', C-3'/5'	129.8	7.56, m	C-1', C-3'/5'
4'	132.2	7.61, m	C-2'/6'	132.1	7.57, m	C-2'/6'
2''	78.8			78.7		
3''	131.7	5.93, d (10.1)	C-6, C-2'', C-2''-Me ₂	131.6	5.87, d (10.1)	C-6, C-2'', C-2''-Me ₂
4''	116.9	6.77, d (10.1)	C-5, C-6, C-7, C-2''	116.9	6.75, d (10.1)	C-5, C-6, C-7, C-2''
2''-Me ₂	28.4	1.53, s	C-2'', C-3'', C-2''-Me	28.7	1.49, s	C-2'', C-3'', C-2''-Me
1'''	118.1	6.86, d (16.7)	C-8, C-7, C-9, C-2''', C-3'''	116.0	6.13, d (12.1)	C-8, C-7, C-9, C-2''', C-3'''
2'''	142.1	6.63, d (16.7)	C-8, C-3''', C-3'''-Me ₂	144.6	6.09, d (12.1)	C-8, C-3''', C-3'''-Me ₂
3'''	76.0			71.8		
3'''-Me ₂	26.4	1.42, s	C-2''', C-3''', C-3'''-Me	30.2	1.21, s	C-2''', C-3''', C-3'''-Me
5-OMe	62.9	3.87, s	C-5	62.8	3.86, s	C-5
3'''-OMe	50.6	3.26, s	C-3'''			

4.1.3: Lineaflavone C (3)

Compound **3** was obtained as a yellow paste. Its molecular formula, C₂₅H₂₂O₄, was established from its HRESIMS [molecular ion [M+H]⁺ at *m/z* 387.1591 (calcd for C₂₅H₂₃O₄, 387.1591) and the [M+Na]⁺ peak at *m/z* 409.1408 (calcd for C₂₅H₂₂O₄Na 409.1410)] and NMR data (Table 4.2 and Appendix 3). A 5-hydroxyflavone derivative was evident from the UV (λ_{\max} 230 and 280 nm) and NMR [δ_{H} 6.89 (H-3) and 13.55 (5-OH); δ_{C} 164.1 (C-2), 106.4 (C-3) and 183.8 (C-4)] (Mabry *et al.*, 1970). The NMR data of **3** showed close relation with those of **1**. The notable differences were the occurrence of a hydroxy group at C-5 in **3** rather than a methoxy group in **1** and the nature of the prenyl residue at C-8. The prenyl group in compound **3** had olefinic methylene (δ_{H} 5.13, 5.14 (brs), δ_{C} 117.3) instead of a methoxy group at C-3''' in **1**. The MS² of the compound in the positive-ion mode was dominated by neutral losses of 42 Da (C₃H₆), 54 Da (C₄H₆) and 70 Da (C₃H₆+CO). This confirmed the presence of prenyl and dimethylpyran substituents (Xu *et al.*, 2012). Thus, compound **3** was characterized as 5-hydroxy-2'',2''-dimethylpyrano[5'',6'':6,7]-8-(*E*-3-methylbuta-1,3-dienyl)flavone. This is a new compound that was given the trivial name lineaflavone C.



4.1.4: Lineaflavone D (4)

Compound **4** was obtained as a yellow paste. The HRESIMS [molecular ion [M+H]⁺ at *m/z* 401.1747 (calcd. for C₂₆H₂₅O₄, 401.1747) and [M+Na]⁺ at *m/z* 423.1567 (calcd. C₂₆H₂₄O₄Na, 423.1567)] was consistent with a molecular formula of C₂₆H₂₄O₄. The UV (λ_{\max} at 232, 284

and 342 nm) and NMR data (Table 4.2 and Appendix A4) showed that the compound is a flavone derivative (Agrawal, 1989). The ^1H , ^{13}C NMR and MS data of **4** are closely related to compound **3**; the difference was in the presence of a methoxy group (δ_{H} 3.88 and δ_{C} 62.9) at C-5 in this compound rather than the hydroxy group in **3**. Its MS² in positive ion mode was dominated by neutral losses of 32 Da (CH_3OH) confirming the presence of a methoxy group. Therefore, compound **4**, was characterized as 5-methoxy-2'',2''-dimethylpyrano[5'',6'':6,7]-8-(*E*-3-methylbuta-1,3-dienyl)flavone, a new compound given the trivial name lineaflavone D.




Table 4.2: NMR Data for Compounds 3 and 4 in Acetone-d₆ (600 MHz)

3				4		
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
2	164.1			161.5		
3	106.4	6.89, s	C-2, C-4, C-10, C-1'	109.0	6.70, s	C-2, C-4, C-10, C-1'
4	183.8			176.7		
5	156.3			154.7		
6	106.2			113.7		
7	158.0			156.3		
8	106.3			111.5		
9	155.1			156.5		
10	106.1			113.4		
1'	132.4			132.7		
2'/6'	127.4	8.11, m	C-2, C-2'/6', C-4'	127.0	8.05, m	C-2, C-2'/6', C-4'
3'/5'	130.1	7.65, m	C-1', C-3'/5'	130.0	7.61, m	C-1', C-3'/5'
4'	132.9	7.64, m	C-2'/6'	132.3	7.60, m	C-2'/6'
2''	79.5			79.0		
3''	129.3	5.84, d (10.1)	C-6, C-2'', C-2''-Me ₂	131.7	5.94, d (10.1)	C-6, C-2'', C-2''-Me ₂
4''	115.9	6.72, d (10.0)	C-5, C-6, C-7, C-2''	116.8	6.77, d (10.1)	C-5, C-6, C-7, C-2''
2''-Me ₂	28.5	1.56, s	C-2'', C-3'', C-2''-Me	28.4	1.55, s	C-2'', C-3'', C-2''-Me
1'''	118.2	6.93, d (16.5)	C-7, C-8, C-9, C-2''', C-3'''	118.5	6.99, d (16.5)	C-7, C-8, C-9, C-2''', C-3'''
2'''	136.0	7.45, d (16.5)	C-8, C-3''', C-4''', C-5'''	136.8	7.49, d (16.5)	C-8, C-3''', C-4''', C-5'''
3'''	143.9			143.9		
4'''	117.3	5.14, br s	C-2''', C-5'''	118.0	5.17, br s	C-2''', C-5'''
5'''	18.3	2.07, s	C-2''', C-3''', C-4'''	18.3	2.07	C-2''', C-3''', C-4'''
5-OH		13.55, s	C-5, C-6, C-10			
5-OMe				62.9	3.88, s	C-5

4.1.5: 6-Methoxygeraldone (5)

This was isolated as a yellow paste. Its molecular formula was deduced as C₁₇H₁₄O₆, based on the HRESIMS [molecular ion [M+H]⁺ at *m/z* 315.0863 (calcd for C₁₇H₁₅O₆, 315.0863) and the [M+Na]⁺ peak at *m/z* 337.0684 (calcd for C₁₇H₁₄O₆Na, 337.0683)] and NMR data (Table 4.3 and Appendix A5). The UV data (λ_{\max} 218, 224 and 342 nm) and NMR data [δ_{H} 6.66 (s, H-3); δ_{C} 163.4 (C-2), 105.6 (C-3) and 177.0 (C-4)] were typical of a flavone (Table 4.3 and Appendix A5) (Mabry *et al.*, 1970; Agrawal, 1989). Further, the NMR data exhibited the presence of two methoxy groups (δ_{H} 3.97, δ_{C} 56.5 and δ_{H} 4.00, δ_{C} 56.5). The MS³ spectrum of the compound was dominated by losses of 15 Da (CH₃), thus supporting the presence of methoxy groups. The ¹H NMR disclosed signals for two aromatic singlets at δ_{H} 7.46 and 7.11 and a set of ABX coupled protons [δ_{H} 7.00 (d, *J* = 8.3 Hz), 7.58 (dd, *J* = 8.3, 2.1 Hz and 7.62 (d, *J* = 2.1 Hz)]. HMBC correlations of the proton at δ_{H} 7.46 with C-7, C-9 and C-4 placed it at C-5. Further, this proton (δ_{H} 7.46) showed a NOESY correlation with the methoxy proton at δ_{H} 3.97 that allowed the placement of the methoxy group at C-6. This implied the other singlet proton at δ_{H} 7.11 could only be at C-8 and the ABX system was in ring B. Two ABX protons at δ_{H} 7.58 (dd, *J* = 8.3, 2.1 Hz) and 7.62 (d, *J* = 2.1 Hz) showed HMBC correlation with C-2 which placed them at C-6' and C-2', respectively, and their coupling partner (δ_{H} 7.00) at C-5'. The hydroxy group proton at δ_{H} 8.38 showed HMBC correlation with C-5', C-4' and C-3' which allowed for the placement of the hydroxy group at C-4' and the methoxy group (δ_{H} 4.00) at C-3'. This was supported by the NOESY correlation of H-2' (δ_{H} 7.62) with the methoxy protons (δ_{H} 4.00). Thus, compound **5** was characterized as 7,4'-dihydroxy-6,3'-dimethoxyflavone. This is a new compound and was given the trivial name 6-methoxygeraldone by comparison with geraldone (**14**) (Lopes *et al.*, 1979).




Table 4.3: NMR Data for Compound 5 in Acetone-d₆ (600 MHz)

5			
Position	δ_C	δ_H, mult. (<i>J</i> in Hz)	HMBC
2	163.4		
3	105.6	6.66, s	C-2, C-4, C-10, C-1'
4	177.0		
5	105.3	7.46, s	C-4, C-6, C-7, C-9
6	147.3		
7	153.1		
8	104.1	7.11, s	C-6, C-7, C-10
9	153.3		
10	117.7		
1'	124.4		
2'	110.2	7.62, d (2.1)	C-2, C-4', C-3', C-6'
3'	148.8		
4'	150.8		
5'	116.3	7.00, d (8.3)	C-1', C-3'
6'	120.8	7.58, dd (8.3, 2.1)	C-2, C-2', C-4'
6-OMe	56.5	3.97, s	C-6
3'-OMe	56.5	4.00, s	C-3'
4'-OH		8.38	C-3', C-4', C-5'

4.1.6: *Acetylobovatin* (6)

Compound **6** was isolated as an off-white paste. The molecular formula was deduced as C₂₂H₂₀O₆ from the HRESIMS [molecular ion [M+H]⁺ at *m/z* 381.1333 (calcd for C₂₂H₂₁O₆, 381.1333) and a[M+Na]⁺ peak at *m/z* 403.1161 (calcd for C₂₂H₂₀O₆Na, 403.1152)] and ¹³C NMR data (Table 4.4 and Appendix A6). The UV (λ_{max} 224, 272, 296 and 358 nm) and NMR data [δ_H 5.68 (dd, *J* = 12.7, 3.1 Hz, H-2), 2.90 (dd, *J* = 17.1, 3.2 Hz, H-3_{eq}), 3.22 (dd, *J* = 17.1, 12.7 Hz, H-3_{ax}) and 12.24 (OH-5); δ_C 80.2 (C-2), 43.4 (C-3) and 197.4 (C-4)] showed the presence of a 5-hydroxyflavanone skeleton (Agrawal, 1989). A modified 2,2-dimethylpyran ring was evident in the NMR spectra [*cis*-olefinic protons at δ_H 6.68, 5.58 (d, *J* = 10.2 Hz, 1H),

a methyl group δ_{H} 1.45 (s, 3H), oxymethylene protons δ_{H} 4.09, 4.25 (d, $J = 11.7$ Hz, 2H) and an acetyl group [δ_{H} 1.97 (s, 3H), δ_{C} 20.6, 170.6 (C=O)]. HMBC correlation of the oxymethylene protons at δ_{H} 4.09 with C-2'', C-3'', 2''-CH₃ and C=O allowed the placement of the acetyl group at 2''-CH₂. The presence of the acetyl group and the pyran ring was further supported by MS³ data that showed fragments of 18 Da (H₂O), 28 Da, (CO), 60 Da (CH₃COOH), 70 Da (C₃H₆, CO) and 104 Da (C₈H₈) (Xu *et al.*, 2012). The NMR data showed signals for an unsubstituted ring B [(δ_{H} 7.60 (H-2'/6'), 7.47 (H-3'/5') and 7.42 (H-4'))] and a singlet at δ_{H} 5.91 that was assigned to ring A. HMBC correlation between the hydroxy proton at δ_{H} 12.24 (OH-5) with δ_{C} 97.6 (C-6, δ_{H} 5.91) allowed the placement of the modified 2'',2''-dimethylpyran ring at C-7/8. A (2*S*)-configuration was established from the ECD spectrum of **6** (Figure 4.1) that showed positive and negative Cotton effects at 317 and 295 nm (Stevenson *et al.*, 2012). However, the configuration at 2''-CH₂ remains undetermined. Therefore, compound **6** was characterized as (2*S*)-5-hydroxy-2''-methyl-2''-acetoxymethylpyrano[5'',6'':7,8]flavanone. It is a new compound that was given the trivial name acetylobovatin because of its close similarity with obovatin (Andrei *et al.*, 2000).





Figure 4.1: ECD spectrum of compound 6



4.1.7: 5-Hydroxy-7-methoxysaniculamin A (7)

Compound **7** was isolated as an off-white paste. Its molecular formula was deduced as $C_{21}H_{22}O_6$ based on the HRESIMS [molecular ion $[M+H]^+$ at m/z 371.1488 (calcd for $C_{21}H_{23}O_6$, 371.1489) and the $[M+Na]^+$ peak at m/z 393.1309 (calcd for $C_{21}H_{22}O_6Na$, 393.1309)] and NMR (Table 4.4 and Appendix A7). In the NMR, the AMX spin system at δ_H 5.47 (dd, $J = 13.2, 2.5$ Hz, H-2), 2.73 (m, H-3_{eq}) and signals at 3.22 (dd, $J = 17.2, 13.0$ Hz, H-3_{ax}), 12.35 (OH-5); δ_C 79.3 (C-2), 42.7 (C-3) and 196.9 (C-4)] (Xu *et al.*, 2016) and UV (λ_{max} 224, 230, 292 and 336 nm) data (Mabry *et al.*, 1970) indicated that compound **7** has a 5-hydroxyflavanone skeleton. Further, the NMR spectra exhibited signals for a methoxy group (δ_H 3.88, δ_C 55.5) and a 2''-hydroxy-3''-methylbut-3''-enyl [δ_H 2.86, 2.77 (m) for H-1'', 4.29 (dd, $J = 7.0, 3.8$ Hz) for H-2'', 4.69 and 4.63 (brs) for H-4'' and 1.79 (s) for H-5''] group. The MS data was dominated by losses of 72 Da (C_4H_8O) and 18 Da (H_2O), supporting the existence of a hydroxy-3-methylbut-3-enyl group (Xu *et al.*, 2012). The 1H NMR spectrum further showed an AA'XX' spin system at δ_H 7.41 and 6.91 ($J = 8.5$ Hz, d, 2H) assigned to a 4'-substituted ring B. HMBC correlations of H-1'' (δ_H 4.25, 4.09) with C-7 (δ_C 166.1) and C-5 (δ_C 160.9) allowed placement of the 2-hydroxy-3-methylbut-3-enyl group at C-6 (δ_C 106.8). A (2*S*)-configuration was established from the ECD spectrum of **7** (Figure 4.2) that showed positive and negative Cotton effects at 335 and 291 nm (Bedane *et al.*, 2016). However, the configuration at 2'' remains undetermined. Therefore, compound **7** was characterized as (2*S*)-5,4',dihydroxy-7-methoxy-6-(2-hydroxy-3-

methylbut-3-enyl)flavanone, it is a new compound given the trivial name 5-hydroxy-7-methoxysaniculamin A, by comparison with saniculamin A (Xu *et al.*, 2016).





Figure 4.2: ECD spectrum of compound 7




7

Table 4.4: NMR Data for Compounds 6 and 7 in Acetone-d₆ (600 MHz)

6				7		
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
2	80.2	5.68, dd (12.7, 3.1)	C-4, C-1', C-2'/6'	79.3	5.47, dd (13.2, 2.5)	C-4, C-1', C-2'/6'
3	43.4	2.90, dd (17.1, 3.2 H _{eq}) 3.22, dd (17.1, 12.7 H _{ax})	C-2, C-4, C-10, C-1'	42.7	2.73, m (H _{eq}) 3.22, dd (17.2, 13.0 H _{ax})	C-2, C-4, C-10, C-1'
4	197.4			196.9		
5	164.8			160.9		
6	97.6	5.91, s	C-5, C-7, C-8, C-10	106.8		
7	162.4			166.1		
8	102.3			90.9	6.15, s	C-6, C-7, C-9, C-10
9	157.9			162.1		
10	103.8			102.5		
1'	139.8			129.9		
2'/6'	127.2	7.60, m	C-2, C-2'/6', C-4'	128.1	7.41, d (8.5)	C-2, C-2'/6', C-4'
3'/5'	129.5	7.47, m	C-1', C-4', C-3'/5'	115.2	6.91, d (8.5)	C-1', C-3'/5', C-4'
4'	129.6	7.42, m	C-2'/6', C-3'/5'	157.9		
1''				28.6	2.76, m 2.86, m	C-5, C-6, C-7, C-2''
2''	80.0			74.5	4.29, m	C-1'', C-4'', C-5''
3''	123.1	5.58, d (10.1)	C-8, C-4'', 2''-CH ₃ , 2''-CH ₂	148.4		
4''	118.5	6.68, d (10.1)	C-7, C-8, C-9, C-2''	109.3	4.69 and 4.63, s(broad)	C-2'', C-3'', C-5''
5''				16.6	1.66, s	C-2'', C-3'', C-4''
2''-CH ₂	68.9	4.09, d (11.8) 4.25, d (11.7)	C-2'', C-3'', 2''-CH ₃ , C=O			
2''-CH ₃	23.9	1.45, s	C-2'', C-3'', 2''-CH ₂			
7-OMe				55.5	3.75, s	C-7
5-OH		12.24	C-5, C-6, C-10,		12.35	C-5, C-6, C-10
<u>C</u> (O)CH ₃	170.6					
<u>C</u> (O) <u>CH</u> ₃	20.6	1.97	C=O			

4.1.8: 7-O-Methyl-6-prenylnaringenin (8)

Compound **8** was isolated as an off-white paste. Its molecular formula was deduced as C₂₁H₂₂O₅ from its HRESIMS [molecular ion [M+H]⁺ at *m/z* 355.1537 (calcd for C₂₁H₂₃O₅, 355.1540)] and ¹³C NMR data (Table 4.5 and Appendix A8). A 5-hydroxyflavanone was evident from the UV (λ_{\max} 236 and 292 nm) and NMR [AMX system; δ_{H} 5.39 (1H, dd, *J* = 13.2, 2.9 Hz) for H-2, 3.04 (1H, dd, *J* = 16.8, 13.2 Hz) for H-3_{ax}, 2.75 (1H, dd, *J* = 16.8, 2.9 Hz) for H-3_{eq} and 12.27 for 5-OH] (Table 4.5 and Appendix A8) (Mabry *et al.*, 1970; Agrawal, 1989). Further, the NMR spectra exhibited signals for a methoxy group [δ_{H} 3.89 (δ_{C} 56.5)], prenyl group [δ_{H} 3.22, 2H (δ_{C} 21.6) for methylene group; 5.16, t, *J* = 7.3 Hz, 1H (δ_{C} 123.4) for olefinic protons, δ_{C} 131.4 for a quaternary carbon and δ_{H} 1.63 (s, 3H) and δ_{H} 1.74 (s, 3H) for methyl groups]. The NMR data also showed peaks for AA'XX'-coupled aromatic protons [δ_{H} 7.42 (δ_{C} 129.0) and 6.91 (δ_{C} 116.2) (2H, d, *J* = 8.7 Hz) to H-2'/6' and H-3'/5', respectively, assigned to ring B] and a singlet aromatic proton at δ_{H} 6.15. The attachment of the prenyl group to C-6 also followed HMBC correlations of H-1'' (δ_{H} 3.22) with C-6, C-5 and C-7, while the methoxy group was placed at C-7 based on the HMBC correlation of its protons with C-7. Thus, compound **8** was identified as 7-O-methyl-6-prenylnaringenin (Intekhab and Aslam, 2009; Zhang *et al.*, 2019b). 7-O-Methyl-6-prenylnaringenin (**8**) was previously isolated from *Feronia limonia* (Intekhab and Aslam, 2009) and *Mallotus conspurcatus* Croizat (Zhang *et al.*, 2019b). This is its first report in the genus *Tephrosia*.



8

4.1.9: Erylivingstone I (9)

Compound **9** was obtained as an off-white solid. The molecular formula of $C_{17}H_{16}O_6$ was established from the HRESIMS [molecular ion $[M+H]^+$ at m/z 317.1021 (calcd for $C_{17}H_{17}O_6$, 317.1020)]. Compound **9** was established as a flavanone from UV (λ_{max} 236 and 292 nm) and 1H NMR data (Table 4.5 and Appendix A9) (Mabry *et al.*, 1970; Agrawal, 1989). The NMR data exhibited signals of two methoxy groups [δ_H 3.85 (δ_C 56.5) and δ_H 3.87 (δ_C 56.3)]. Further, the NMR data revealed signals for an ABX spin system [δ_H 7.18 (1H, d, $J = 2.0$ Hz); 6.86 (1H, d, $J = 8.1$ Hz) and 6.99 (1H, dd, $J = 8.1, 2.0$ Hz)] and two aromatic singlet protons (δ_H 7.26 and 6.47). Placement of the singlet at δ_H 7.26 at C-5 followed its HMBC correlations with C-4, C-7 and C-9. The other singlet proton at δ_H 6.47 could only be at C-8 as evident from its HMBC correlations with C-6, C-7, C-9 and C-10. The HMBC correlation of the methoxy protons at δ_H 3.85 with C-6 placed the substituent at C-6. Two ABX protons at δ_H 7.18 (1H, d, $J = 2.0$ Hz) and 6.99 (1H, dd, $J = 8.1, 2.0$ Hz) showed HMBC correlations with C-2 that placed them at C-2' and C-6', respectively, and their coupling partner [6.86 (1H, d, $J = 8.1$ Hz)] at C-5'. HMBC correlations of H-5' and methoxy protons (δ_H 3.87) with C-3' place the methoxy group at C-3'. These spectral data of **9** were comparable to those described in the literature and thus compound **9** was identified as 7,4'-dihydroxy-6, 3'-dimethoxyflavanone (erylivingstone I) (Bedane *et al.*, 2016). Erylivingstone I (**9**) was previously isolated from *Erythrina livingstoniana* (Bedane *et al.*, 2016) and this is its first report in the genus *Tephrosia*.





Table 4.5: NMR Data for Compounds 8 and 9 in Acetone-d₆ (600 MHz)

8				9		
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
2	80.1	5.46, dd (13.0, 3.0)	C-2'/6', C-1', C-4	80.9	5.39, dd (13.2, 2.9)	C-2', C-6', C-1', C-4
3	43.6	2.75, dd (17.1, 3.1 H _{eq}) 3.19, m (H _{ax})	C-2, C-4, C-1', C-10	44.7	2.66, dd (16.8, 2.9 H _{eq}) 3.04, dd (16.8, 13.2 H _{ax})	C-4, C-1', C-10
4	197.7			190.5		
5	160.9			107.9	7.26, s	C-10, C-6, C-9, C-7, C-4
6	109.9			144.2		
7	166.3			159.0		
8	91.8	6.15, s	C-7, C-9, C-6, C-10	104.3	6.47, s	C-7, C-9, C-6, C-10
9	162.7			155.2		
10	103.5			113.9		
1'	130.8			131.9		
2'	129.0	7.42, d (8.5)	C-2, C-2'/6', C-4'	111.1	7.18, d (2.0)	C-2, C-6', C-4'
3'	116.2	6.91, d (8.5)	C-3'/5', C-1'	148.3		
4'	158.7			147.7		
5'	116.2	6.91, d (8.5)	C-3'/5', C-1'	115.6	6.86, d (8.1)	C-3', C-1'
6'	129.0	7.42, d (8.5)	C-2, C-2'/6', C-4'	120.4	6.99, dd (8.1, 2.0)	C-2, C-2', C-4'
1''	21.6	3.22, m	C-6, C-2'', C-5, C-7			
2''	123.4	5.16, t (7.3)	C-4'', C-5'', C-1''			
3''	131.3					
4''	25.9	1.63, s	C-5'', C-2'', C-3''			
5''	17.8	1.74, S	C-4'', C-2'', C-3''			
5-OH		12.27, s				
6-OMe				56.5	3.85, s	C-6
7-OMe	56.5	3.89, s	C-7			
3'-OMe				56.3	3.87, s	C-3'

4.1.10: 6-C-Prenylapigenin (10)

Compound **10** was isolated as a yellow paste. Its molecular formula was deduced as C₂₀H₁₈O₅ from the HRESIMS molecular ion [M+H]⁺ at *m/z* 339.1228 (calcd C₂₀H₁₉O₅, 339.1227) and ¹³C NMR data (Table 4.6 and Appendix A10). The presence of a 5-hydroxyflavone skeleton was evident from the UV (λ_{\max} 230, 274 and 332 nm) and NMR data (Mabry *et al.*, 1970; Agrawal, 1989). The NMR data exhibited signals for a prenyl group [δ_{H} 3.25, d, *J* = 7.2 Hz, 2H (δ_{C} 22.0) for a methylene group; δ_{H} 5.28, t, *J* = 7.5 Hz, 1H (δ_{C} 123.2) for an olefinic proton, δ_{C} 131.6 for a quaternary carbon and δ_{H} 1.65, s, 3H (δ_{C} 25.9) and δ_{H} 1.78, s, 3H (δ_{C} 17.9) for methyl groups] and downfield signals at δ_{H} 9.62 and 9.20 attributed to two hydroxy groups. Further, the NMR spectra exhibited signals for a singlet in the aromatic region [δ_{H} 6.61 (δ_{C} 94.1)] and AA'XX' coupled aromatic protons [δ_{H} 7.93 and 6.91 (2H, d, *J* = 8.8 Hz)] assigned to ring B. 5-Hydroxy proton (δ_{H} 13.30) and H-1'' (δ_{H} 3.25) showed HMBC correlations with C-6 that allowed for placement on the prenyl group at C-6. The HMBC correlations of the hydroxy proton at δ_{H} 9.20 with C-3'/5' and C-4' allowed for the placement of this group at C-4'. Thus, compound **10** was identified as 5,7,4'-trihydroxy-6-(3-methylbut-2-enyl)flavone (6-C-prenylapigenin) (Monache *et al.*, 1994; Chang *et al.*, 1995; Abegaz *et al.*, 1998). 6-C-Prenylapigenin was previously isolated from *Polygonum* and *Dorstenia* species (Abegaz *et al.*, 1998; Dzoyem *et al.*, 2017) and *Cudrania cochinchinensis* (Chang *et al.*, 1995). It is the first time it is being reported in the genus *Tephrosia*.



4.1.11: 5,7,4',2''-Tetrahydroxy-6-[3''-methylbut-3''-enyl]flavone (11)

Compound **11** was isolated as a yellow paste. Its molecular formula was deduced as C₂₀H₁₈O₆ from its HRESIMS molecular ion [M+H]⁺ at *m/z* 355.1176 (calcd for C₂₀H₁₉O₆, 355.1176) and ¹³C NMR data (Table 4.6 and Appendix A11). The presence of a 5-hydroxyflavone skeleton was evident from the UV (λ_{\max} 224, 274 and 334 nm) and NMR data (Mabry *et al.*, 1970; Agrawal, 1989). The NMR data showed very close similarity with compound **10**. The only difference was in the nature of the prenyl group. The prenyl substituent in **11** had a hydroxy group at C-2'' [δ_{H} 4.43 (dd, *J* = 7.9, 3.5 Hz), δ_{C} 76.5 for an oxymethine residue]. Based on this spectral data, compound **11** was identified as 5,7,4',2''-tetrahydroxy-6-[3''-methylbut-3''-enyl]flavone (Lee *et al.*, 1998) but C-2'' absolute configuration remains undetermined. This compound was previously isolated from *Maclura pomifera* (Lee *et al.*, 1998). This is its first report in the genus *Tephrosia*.





Table 4.6: NMR Data for Compounds 10 and 11 in Acetone-d₆ (600 MHz)

10				11		
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
2	164.8			165.0		
3	104.1	6.63, s	C-2, C-4, C-10, C-1'	104.0	6.64, s	C-2, C-4, C-10, C-1'
4	183.2			183.2		
5	160.2			160.7		
6	112.3			110.2		
7	162.4			164.1		
8	94.1	6.61, s	C-6, C-7, C-9, C-10	95.3	6.56, s	C-6, C-7, C-9, C-10
9	156.6			157.1		
10	105.2			105.0		
1'	123.4			123.4		
2'/6'	129.2	7.93, d (8.8)	C-2, C-2'/6', C-4'	129.3	7.95, d (8.8)	C-2, C-2'/6', C-4'
3'/5'	116.9	7.02, d (8.8)	C-1', C-3'/5', C-4'	116.8	7.03, d (8.8)	C-1', C-3'/5', C-4'
4'	161.8			161.8		
1''	22.0	3.35, d (7.2)	C-5, C-6, C-7, C-2'', C-3''	30.3	2.92, dd (14.5, 7.9) 3.07, dd (14.5, 3.5)	C-5, C-7, C-2''
2''	123.2	5.28, t (7.5)	C-1'', C-4'', C-5''	76.5	4.43, dd (7.9, 3.5)	C-1'', C-3'', C-4''
3''	131.6			148.2		
4''	25.9	1.65, s	C-2'', C-3'', C-5''	110.4	4.77, br s 4.94, br s	C-2'', C-5''
5''	17.9	1.78, s	C-2'', C-3'', C-4''	18.4	1.84, s	C-3, C-2'', C-4''
5-OH		13.30, s	C-5, C-6, C-10		13.51	C-5, C-6, C-10
7-OH		9.62, s	C-6, C-7			
4'-OH		9.20	C-3'/5', C-4'			

4.1.12: Apigenin (12)

Compound **12** was isolated as a yellow paste. Its molecular formula was deduced as C₁₅H₁₀O₅ from the HRESIMS [molecular ion [M+H]⁺ at *m/z* 271.0601 (calcd for C₁₅H₁₁O₅, 271.0601)] and ¹³C NMR data (Table 4.7 and Appendix A12). The presence of a 5-hydroxyflavone skeleton was evident from UV (λ_{max} 230, 266 and 336 nm) and NMR data (Mabry *et al.*, 1970; Agrawal, 1989). The NMR spectra showed the presence of two *meta*-coupled aromatic protons at δ_{H} 6.26, (d, *J* = 2.1 Hz) and 6.54, (d, *J* = 2.2 Hz) and an AA'XX' spin system [δ_{H} 7.95 and 7.03 (d, *J* = 8.8 Hz, 2H) assigned to ring B]. The HMBC correlations of the proton at δ_{H} 6.26 with C-8, C-5, C-10 and C-7 allowed its placement at C-6, while the proton at δ_{H} 6.54 was assigned to H-8 due to its HMBC correlations with C-6, C-9, C-10 and C-7. Thus, compound **12** was identified as 5,7,4'-trihydroxyflavone (apigenin). Apigenin was previously reported from *Tamarix dioica* (Parmar *et al.*, 1994) and *T. elata* (Atilaw, 2018) but this is its first report in the plant.



4.1.13: Luteolin (13)

Compound **13** was isolated as a yellow paste. Its molecular formula was deduced as C₁₅H₁₀O₆ on the basis of its HRESIMS [molecular ion [M+H]⁺ at *m/z* 287.0551 (calcd for C₁₅H₁₁O₆, 287.0550)] and ¹³C NMR data (Table 4.7 and Appendix A13). The presence of a 5-hydroxyflavone skeleton was evident from the UV (λ_{max} 264 and 350 nm) and NMR data (Table 4.7 and Appendix A13) (Mabry *et al.*, 1970; Agrawal, 1989). The NMR spectra exhibited

signals for *meta*-coupled aromatic protons [δ_{H} 6.25 and 6.52 (1H, d, $J = 2.0$ Hz) assigned to ring A with biogenetically expected oxygenation at C-7] and ABX-coupled aromatic protons [δ_{H} 7.50 (1H, d, $J = 2.2$ Hz), 7.47 (1H, dd, $J = 8.3, 2.2$ Hz) and 7.00 (1H, d, $J = 8.3$ Hz)] assigned to ring B. HMBC correlations of C-2 with the protons at δ_{H} 7.50 and 7.47 allowed the placement of an OH at C-3'. Based on these spectral data and comparison with literature (Lin *et al.*, 2015), compound **13** was identified as 5,7,3',4'-tetrahydroxyflavone (luteolin). Luteolin was previously isolated from *Dendranthema morifolium* (Lin *et al.*, 2015), but this is its first report in the genus *Tephrosia*.





Table 4.7: NMR Data for Compounds 12 and 13 in Acetone-d₆ (600 MHz)

12				13		
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
2	165.1			165.2		
3	104.1	6.64, s	C-2, C-4, C-10, C-1'	104.2	6.58, s	C-2, C-4, C-10, C-1'
4	183.1			183.0		
5	163.4			163.4		
6	99.7	6.26, d (2.1)	C-5, C-7, C-8, C-10	99.7	6.25, d (2.0)	C-5, C-7, C-8, C-10
7	164.8			164.9		
8	94.7	6.54, d (2.2)	C-6, C-7, C-9, C-10	94.7	6.52, d (2.0)	C-6, C-9, C-7, C-10
9	158.8			158.8		
10	105.4			105.3		
1'	123.3			123.6		
2'	129.3	7.95, d (8.8)	C-2, C-2'/6', C-4'	114.1	7.50, d (2.2)	C-2, C-6', C-4'
3'	116.9	7.03, d (8.8)	C-1', C-3'/5', C-4'	146.6		
4'	161.9			150.3		
5'	116.9	7.03, d (8.8)	C-1', C-3'/5', C-4'	116.7	7.00, d (8.3)	C-1', C-3', C-4'
6'	129.3	7.95, d (8.8)	C-2, C-2'/6', C-4'	120.1	7.47, d (8.3, 2.2)	C-2, C-2', C-4'
5-OH		13.02	C-5, C-6, C-10		13.04, s	C-5, C-6, C-10

4.1.14: Geraldone (14)

Compound **14** was obtained as a yellow paste. The ^{13}C NMR data and HRESIMS molecular ion $[\text{M}+\text{H}]^+$ at m/z 285.0758 (calcd for $\text{C}_{16}\text{H}_{13}\text{O}_5$, 285.0757) were consistent with the molecular formula $\text{C}_{16}\text{H}_{12}\text{O}_5$ (Table 4.8 and Appendix A14). The UV (λ_{max} 238 and 340 nm) and NMR data indicated that this compound is a flavone (Mabry *et al.*, 1970; Agrawal, 1989). Its NMR data showed the presence of a methoxy group (δ_{H} 4.00, δ_{C} 56.6). Further, the NMR spectra showed signals for two ABX spin systems [δ_{H} 7.96 (1H, d, $J = 8.7$ Hz), 7.97 (1H, dd, $J = 8.7$, 2.3 Hz) and 7.84 (1H, d, $J = 2.2$ Hz)] and [δ_{H} 7.62 (1H, d, $J = 2.1$ Hz), 7.59 (1H, dd, $J = 8.3$, 2.1 Hz) and 7.00 (1H, d, $J = 8.3$ Hz)]. The ABX-coupled aromatic proton at δ_{H} 7.96 showed HMBC correlations with C-9 (δ_{C} 163.2), C-7 (δ_{C} 158.8) and C-4 (δ_{C} 177.2) allowing for its placement at C-5 in ring A and thus, the other ABX system was assigned to ring B. The substitution pattern of ring B of **14** and **13** are identical. HMBC correlation of the *meta* proton (H-2') with C-3' which in turn with methoxy protons allowed for the placement of the methoxy group at C-3'. Thus, compound **14** was identified as 3'-methoxy-7,4'-dihydroxyflavone (geraldone) (Jung *et al.*, 2004). Geraldone (**14**) was previously isolated from *Sahertia concallariodora* (Lopes *et al.*, 1979) and *Albizia julibrissin* (Jung *et al.*, 2004). This is its first report in the genus *Tephrosia*.



14

Table 4.8: NMR Data for Compound 14 in Acetone-d₆ (600 MHz)

14			
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
2	163.6		
3	106.1	6.66, s	C-2, C-4, C-10, C-1'
4	177.2		
5	127.7	7.96, d (8.7)	C-4, C-7, C-9,
6	115.3	6.97, dd (8.7, 2.3)	C-8, C-10
7	158.8		
8	103.6	7.84, d (2.2)	C-6, C-7, C-10, C-9
9	163.2		
10	118.0		
1'	124.3		
2'	110.3	7.62, d (2.1)	C-2, C-3', C-4', C-6'
3'	148.8		
4'	150.9		
5'	116.3	7.00, d (8.3)	C-1', C-3', C-4'
6'	120.9	7.59, dd (8.3, 2.1)	C-2, C-4', C-3'
6-OMe			
3'-OMe	56.6	4.00, s	C-3'
4'-OH			

4.1.15: Atalantoflavone (15)

Compound **15** was isolated as a yellow paste. Its molecular formula was deduced as C₂₀H₁₆O₅ from the HRESIMS molecular ion [M+H]⁺ at *m/z* 337.1071 (calcd for C₂₀H₁₇O₅, 337.1071) and ¹³C NMR data (Table 4.9 and Appendix A15). The presence of a 5-hydroxyflavone skeleton was evident from UV (λ_{\max} 242, 306 and 354 nm) and NMR data (Table 4.9 and Appendix A15) (Mabry *et al.*, 1970; Agrawal, 1989). The ¹H and ¹³C NMR spectra exhibited signals for a 2,2-dimethylchromene moiety [δ_H 1.47, (s, 6H) for methyl groups and δ_H 5.76 (*J* = 10.0 Hz, 1H) for H-3" and 6.66 (*J* = 10.0 Hz, 1H) for H-4"]. Further, the NMR revealed the presence of an AA'XX' spin system [δ_H 7.96 (d, *J* = 8.9 Hz, 2H) for H-2'/6' and δ_H 7.03 (d, *J* = 8.8 Hz, 2H) for H-3'/5'] assigned to a *p*-substituted ring B and a singlet proton at δ_H 6.49 for a ring A proton. The placement of the proton at δ_H 6.49 to H-6 was based on its HMBC correlations with C-8, C-5, C-10 and C-7. The HMBC correlation of H-4" (δ_H 6.66) with C-8, C-7, C-9 and C-2" placed the 2,2-dimethylchromene moiety at C-7/8. The above spectral data of **15** were identical to those described in the literature (Banerji *et al.*, 1988; Chang, 1990) for 5,4'-dihydroxy-2",2"-

dimethylpyrano[5'',6'':7,8]flavone (atalantoflavone or limomianin). Atalantoflavone (**15**) was previously reported from *Atalantza racemosa* (Banerji *et al.*, 1988) and *Citrus limonia* (Chang, 1990). This is its first report in the genus *Tephrosia*.





Table 4.9: NMR Data for Compound 15 in Acetone-d₆ (600 MHz)

15			
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
2	165.2		
3	104.1	6.67 s	C-2, C-4, C-10, C-1'
4	183.3		
5	157.9		
6	95.7	6.49, s	C-5, C-7, C-8, C-10
7	160.1		
8	106.1		C-6, C-7, C-9, C-10
9	157.3		
10	105.9		
1'	123.2		
2'	129.3	7.96, d (8.9)	C-2, C-2'/6', C-4'
3'	116.9	7.03, d (8.8)	C-1', C-3'/5', C-4'
4'	162.0		
5'	116.9	7.03, d (8.8)	C-1', C-3'/5', C-4'
6'	129.3	7.96, d (8.9)	C-2, C-2'/6', C-4'
2''	78.8		
3''	129.3	5.76, d (10.0)	C-8, C-2'', 2''-Me ₂
4''	115.8	6.66, d (10.0)	C-7, C-8, C-9, C-2''
2''-Me ₂	28.4	1.47, s	
5-OH		13.31, s	C-6, C-10, C-5

4.1.16: Patuletin-3-O-rhamnoside (**16**)

Compound **16** was isolated as a yellow solid. Its molecular formula was deduced as C₂₂H₂₂O₁₂ on the basis of the HRESIMS [molecular ion [M+H]⁺ at *m/z* 479.1177 (calcd for C₂₂H₂₃O₁₂, 479.1184) with its sodiated ion [M+Na]⁺ at *m/z* 501.0996 (calcd for C₂₂H₂₂O₁₂Na, 501.1003)] and ¹³C NMR data (Table 4.10 and Appendix A16). The presence of a 5-hydroxyflavonol

skeleton was evident from the UV absorption (λ_{\max} 260 and 344 nm) and NMR data [δ_{H} 12.93 (5-OH); δ_{C} 158.5 (C-2), 135.4 (C-3) and 179.7 (C-4)] (Mabry *et al.*, 1970; Agrawal, 1989). The ^1H and ^{13}C NMR spectra exhibited signals for a methoxy [δ_{H} 3.88, 3H (δ_{C} 60.7)] and rhamnose [δ_{H} 5.53, 1H for an anomeric proton, H-2" (δ_{C} 102.7) and methyl protons for 6"-Me at δ_{H} 0.91 (d, $J = 6.1$ Hz) (δ_{C} 17.8)] (Nawwar *et al.*, 1984) moieties. Further, the NMR spectra revealed signals for an aromatic singlet proton at δ_{H} 6.55 and an ABX spin system [δ_{H} 6.99, d, $J = 8.3$ Hz, 1H for H-5'; δ_{H} 7.40, dd, $J = 8.3, 2.1$ Hz, 1H for H-6'; and 7.51 d, $J = 2.1$ Hz for H-2']. The HMBC correlations of the proton at δ_{H} 6.55 with C-6, C-9, C-10 and C-7 allowed for its placement at C-8 and thus, the ABX system was assigned to ring B. The HMBC correlations of the anomeric proton, H-2" (δ_{H} 5.53) with C-3 allowed the placement of the rhamnose moiety at C-3. HMBC correlations of the 5-OH with C-5 and C-6 which in turn correlates with the methoxy protons allowed for the placement of the methoxy group at C-6. The HMBC correlations of C-2 with the aromatic protons at δ_{H} 7.40 and 7.51 placed the hydroxy substituents at C-3' and C-4'. Thus, compound **16** was identified as patuletin 3-*O*- α -L-rhamnopyranoside (patuletin-3-*O*-rhamnoside) (Costa *et al.*, 1994). Patuletin-3-*O*-rhamnoside (**16**) was previously isolated from *Kalanchoe gracilis* (Liu *et al.*, 1989) and *Kalanchoe brasiliensis* (Costa *et al.*, 1994). This is its first report in the genus *Tephrosia*.



4.1.17: Eupatolitin-3-O-rhamnoside (17)

Compound **17** was isolated as a yellow solid. Its molecular formula was deduced as C₂₃H₂₄O₁₂ from the HRESIMS molecular ion [M+H]⁺ at *m/z* 493.1333 (calcd for C₂₃H₂₅O₁₂, 493.1341) with its sodiated ion [M+Na]⁺ at *m/z* 515.1153 (calcd for C₂₃H₂₄O₁₂Na, 515.1160) and NMR data (Table 4.10 and Appendix A17). The presence of a 5-hydroxyflavonol skeleton was evident from UV absorption (λ_{max} 266 and 348 nm) and NMR data (Mabry *et al.*, 1970; Agrawal, 1989). The NMR data showed very close similarity with compound **16**. The only difference between the two compounds was the presence of a methoxy group (δ_{H} 3.80, δ_{C} 60.6) in this compound at C-7 instead of a hydroxy group. Thus, compound **17** was identified as eupatolitin 3-*O*- α -L-rhamnopyranoside (eupatolitin-3-*O*-rhamnoside) (Quijano *et al.*, 1970). Eupatolitin-3-*O*-rhamnoside (**17**) was previously isolated from *Eupatorium ligustrinum* (Quijano *et al.*, 1970) and this is its first report in the genus *Tephrosia*.




Table 4.10: NMR Data for Compounds 16 and 17 in Acetone-d₆ (600 MHz)

16				17		
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
2	158.5			158.6		
3	135.4			135.7		
4	179.7			179.6		
5	153.7			153.6		
6	132.0			133.2		
7	153.2			160.2		
8	94.5	6.55, s	C-6, C-7, C-9, C-10	91.7	6.77, s	C-6, C-7, C-9, C-10
9	157.8			153.3		
10	106.2			106.9		
1'	122.9			122.9		
2'	116.8	7.51, d (2.1)	C-2, C-4', C-6'	116.7	7.52, d (2.1)	C-2, C-4', C-6'
3'	145.9			145.9		
4'	149.1			149.0		
5'	116.2	6.99, d (8.3)	C-1', C-3'	116.1	7.00, d (8.4)	C-1', C-3'
6'	122.6	7.40, dd (8.3, 2.1)	C-2, C-2', C-4'	122.6	7.42, dd (8.3, 2.1)	C-2, C-2', C-4'
2''	102.7	5.53, d (1.6)	C-3, C-3'', C-4'', C-6''	102.7	5.54, d (1.4)	C-3, C-3'', C-4'', C-6''
3''	71.5	4.21, dd (3.5, 1.6)	C-4'', C-5''	71.4	4.21, dd (3.5, 1.6)	C-2'', C-4'', C-5''
4''	72.1	3.73, dd (9.3, 3.4)	C-3'', C-5'', C-6''	72.1	3.71, dd (9.2, 3.4)	C-3'', C-5'', C-6''
5''	73.0	3.34, m	C-4'', 6''-Me	73.0	3.34, dd (9.4, 9.4)	C-4'', 6''-Me
6''	71.4	3.41, m	C-4''	71.4	3.40, m	C-4'', 2''-Me
6''-Me	17.8	0.91, d (6.1)	C-5'', C-6''	17.8	0.91, d (6.1)	C-3'', C-5''
6-OMe	60.7	3.88, s	C-6	56.8	3.98, s	C-6
7-OMe				60.6	3.80, s	C-7
5-OH		12.93, s	C-5, C-6, C-10		12.65	C-5, C-6, C-10

4.1.18: Munduserone (**18**)

Compound **18** was obtained as a white paste. Its molecular formula was deduced as C₁₉H₁₈O₆ from the HRESIMS [molecular ion [M+H]⁺ at *m/z* 343.1177 (calcd C₁₉H₁₉O₆, 343.1176), [M+Na]⁺ at *m/z* 365.0998 (calcd C₁₉H₁₈O₆Na, 365.0996)] and NMR data (Table 4.11 and Appendix A18). A rotenoid skeleton was evident from the UV (λ_{\max} 230 and 280 nm) and NMR data [δ_{H} 4.61, dd, *J* = 12.2, 2.9 Hz, and 4.30, dd, *J* = 12.2, 1.3 Hz for H-6 (δ_{C} 66.1); δ_{H} 5.12, ddd, *J* = 3.9, 3.0, 1.0 Hz for H-6a (δ_{C} 72.3); δ_{H} 3.91, d, *J* = 4.0 Hz for H-12a (δ_{C} 44.1) and δ_{C} 188.8 for C-12)] (Mabry *et al.*, 1970; Agrawal, 1989) (Table 4.11 and Appendix A18). The NMR data of **18** displayed signals for three methoxy groups [δ_{H} 3.65 (δ_{C} 56.0), 3.76 (δ_{C} 55.1) and 3.86 (δ_{C} 55.3)]. Further, ¹H NMR revealed signals for two singlet protons [δ_{H} 6.72 (δ_{C} 112.6) and 6.47 (δ_{C} 102.3)], and an ABX spin system [δ_{H} 7.82, d, *J* = 8.9 Hz (δ_{C} 128.8), 6.62, dd, *J* = 8.8, 2.3 Hz (δ_{C} 110.2) and 6.46, d, *J* = 2.4 Hz (δ_{C} 100.4)]. HMBC correlations of one of the ABX protons at δ_{H} 7.82 with C-7a, C-12 and C-9 allowed for its placement at C-11. This placed the singlet aromatic protons in ring B at H-1 and H-4. HMBC correlation of the proton at δ_{H} 6.47 with C-1a, C-2, C-4a and C-3 allowed for its placement at C-4, whereas the correlation of the other singlet proton at δ_{H} 6.72 with C-12a, C-1a, C-2, C-3 and C-4a allowed for its placement at C-1. The chemical shift value of H-1 can be used to determine whether the stereochemistry of the B/C ring junction is *cis* (δ 6.4-6.8) or *trans* (δ 7.7-8.3) (Yenesew *et al.*, 1998). Since H-1 resonated at δ_{H} 6.72, the stereochemistry of the B/C ring junction was determined to be *cis* in this compound. Thus, compound **18** was identified as munduserone (Dagne *et al.*, 1989). Munduserone (**18**) was previously isolated from *Tephrosia fulvinervis* (Dagne *et al.*, 1989). This is its first report in this species.




Table 4.11: NMR Data for Compound 18 in Acetone-d₆ (600 MHz)

18			
Position	δ_C	δ_H, mult. (<i>J</i> in Hz)	HMBC
1	111.6	6.72, s	C-1a, C-2, C-3, C-4a, C-12a
1a	105.2		
2	143.9		
3	150.2		
4	101.3	6.47, s	C-1a, C-2, C-3, C-4a
4a	148.1		
6	66.1	4.61, dd (12.2, 2.9) 4.30, dd (12.2, 1.3)	C-4a, C-6a, C-12, C-12a
6a	72.3	5.14, ddd (3.9, 3.0, 1.0)	C-4a, C-6a, C-12, C-12a
7a	162.9		
8	100.4	6.46, d (2.4)	C-7a, C-10, C-11a
9	166.4		
10	110.2	6.62, dd (8.8, 2.3)	C-8, C-11a
11	128.8	7.82, d (8.9)	C-7a, C-9, C-12
11a	112.8		
12	188.8		
12a	44.1	3.91, d (4.0)	C-1, C-1a, C-4a, C-12
2-OMe	56.0	3.65, s	C-2
3-OMe	55.1	3.76, s	C-3
9-OMe	55.3	3.86, s	C-9

4.1.19: *cis*-12a-Hydroxymunduserone (19)

Compound **19** was isolated as a white paste. The molecular formula was deduced as C₂₃H₂₂O₇ from its NMR data (Table 4.13 and Appendix A19). A 12a-hydroxyrottenoid skeleton was evident from the NMR data [δ_{H} 4.58, dd, $J = 12.2, 2.5$ Hz, and 4.47, dd, $J = 12.1, 1.1$ Hz for H-6 (δ_{C} 64.7); δ_{H} 4.69, dd, $J = 2.5, 1.1$ Hz for H-6a (δ_{C} 77.1); δ_{C} 68.5 for C-12a and δ_{C} 191.7 for C-12] (Mabry *et al.*, 1970; Agrawal, 1989). The NMR data of **19** was very similar to that of **18**. The key difference was the presence of the hydroxyl group at C-12a (δ_{C} 68.5) in

compound **19**. This was evident from the HMBC correlation of H-6 (δ_{H} 4.58 and 4.47 with C-12a and also the correlation of H-1 (δ_{H} 6.62) with C-12a. The NMR data was found to be similar to that of *cis*-12a-hydroxymunduserone (Dagne *et al.*, 1989). This compound was previously isolated from *T. fulvinervis* (Dagne *et al.*, 1989). This is the first report in this species.





Table 4.12: NMR Data for Compound 19 in Acetone- d_6 (600 MHz)

19			
Position	δ_{C}	δ_{H}, mult. (<i>J</i> in Hz)	HMBC
1	112.3	6.62, s	C-1a, C-2, C-3, C-4a, C-12a
1a	109.9		
2	144.7		
3	152.5		
4	102.0	6.49, s	C-1a, C-2, C-3, C-4a
4a	149.8		
6	64.7	4.58, dd (12.2, 2.5) 4.47, dd (12.1, 1.1)	C-4a, C-6a, C-12, C-12a
6a	77.1	4.69, dd (2.5, 1.1)	C-4a, C-6a, C-12, C-12a
7a	163.1		
8	101.3	6.42, d (2.3)	C-7a, C-10, C-11a
9	167.6		
10	111.5	6.62, dd (8.8, 2.3)	C-8, C-11a
11	129.7	7.79, d (8.8)	C-7a, C-9, C-12
11a	112.8		
12	191.7		
12a	68.5		
2-OMe	56.8	3.60, s	C-2
3-OMe	56.0	3.76, s	C-3
9-OMe	56.3	3.84, s	C-9

4.1.20: Rotenone (20)

Compound **20** was isolated as a white paste. The molecular formula was established as $\text{C}_{23}\text{H}_{22}\text{O}_6$ from the HRESIMS [molecular ion $[\text{M}+\text{H}]^+$ at m/z 395.1486 (calcd for $\text{C}_{23}\text{H}_{23}\text{O}_6$, 395.1489), $[\text{M}+\text{Na}]^+$ at m/z 417.1305 (calcd for $\text{C}_{23}\text{H}_{22}\text{O}_6\text{Na}$, 417.1309) and NMR data (Table

4.13 and Appendix A20). A rotenoid skeleton was evident from the UV (λ_{\max} 222 and 296 nm) and NMR data (Table 4.13 and Appendix A20) (Mabry *et al.*, 1970; Agrawal, 1989). The NMR data of **20** displayed signals for two methoxy groups [δ_{H} 3.65 (δ_{C} 56.9) and 3.77 (δ_{C} 56.0)] and 2-isopropenyltetrahydrofuran residues [δ_{H} 2.95 (1H, dd, $J = 15.7, 8.1$ Hz) and 3.30 (1H, dd, $J = 15.7, 9.8$ Hz) for methylene protons (δ_{C} 31.9), 5.35 (1H, t, $J = 8.9$ Hz) for methine protons (δ_{C} 88.9), 5.08, broad-s for olefinic methylene protons (δ_{C} 112.4), 1.77 (3H, s) for methyl protons (δ_{C} 17.2) and δ_{C} 144.4 for quaternary carbon]. Further, ^1H NMR revealed signals for two singlet protons [δ_{H} 6.72 and 6.46] and *ortho*-coupled aromatic protons [δ_{H} 6.51 (1H, d, $J = 8.6$ Hz) and 7.79 (1H, d, $J = 8.5$ Hz)]. The deshielded aromatic proton at δ_{H} 7.79 showed HMBC correlations with C-7a, C-12 and C-9 which allowed for its placement at C-11 and its coupling partner at C-10. HMBC correlations of the aromatic singlet protons at δ_{H} 6.46 and 6.72 with C-2 and C-3 placed the methoxy groups at C-2 and C-3. HMBC correlations of H-4' with C-8, C-7a and C-9 allowed for the placement of the 2-isopropenyltetrahydrofuran moiety at C-8/C-9. In the ^1H NMR, H-1 resonated at a shielded resonance of δ_{H} 6.72 indicating the *B/C* ring junction is *cis*. Thus, compound **20** was identified as rotenone (Carlson *et al.*, 1973). Rotenone (**20**) has been reported in several *Tephrosia* species including the root of this plant (Were *et al.*, 1990) but this is its first report from the aerial part.



4.1.21: 12a-Hydroxyrotenone (21)

Compound **21** was isolated as a white paste. The molecular formula was established as $C_{23}H_{22}O_7$ from its HRESIMS [molecular ion $[M+H]^+$ at m/z 411.1438 (calcd for $C_{23}H_{23}O_7$, 411.1438), $[M+Na]^+$ at m/z 433.1257 (calcd for $C_{23}H_{22}O_7Na$, 433.1258) and NMR data (Table 4.14 and Appendix A21). A 12a-hydroxyrotenoid skeleton was evident from (λ_{max} 226 and 298 nm) and NMR data (Table 4.14 and Appendix A21) (Mabry *et al.*, 1970; Agrawal, 1989). The NMR data of **21** displayed very close similarity with those of compound **20**. The notable difference was the presence of the hydroxyl group at C-12a (δ_C 68.5) in compound **21**. It was evident from HMBC correlations of H-6 (δ_H 4.59 and 4.48 with C-12a and also H-1 (δ_H 6.64) with C-12a. In the 1H NMR, H-1 resonated at a shielded resonance of δ_H 6.64 indicating that the *B/C* ring junction is *cis*. These spectral data were identical to those described in the literature for 12a-hydroxyrotenone (Carlson *et al.*, 1973; Oberholzer *et al.*, 1974). 12a-Hydroxyrotenone (**21**) was previously reported in the roots of this plant (Were *et al.*, 1990) but this is its first report from the aerial part.





Table 4.13: NMR Data for Compounds 20 and 21 in Acetone-d₆ (600 MHz)

20				21		
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
1	112.6	6.72, s	C-1a, C-2, C-3, C-4a, C-12a	112.5	6.64, s	C-1a, C-2, C-3, C-4a, C-12a
1a	106.2			109.2		
2	144.9			144.7		
3	151.1			152.5		
4	102.3	6.46, s	C-1a, C-2, C-3, C-4a	102.0	6.49, s	C-1a, C-2, C-3, C-4a
4a	149.0			149.8		
6	67.0	4.60, dd (12.3, 2.9) 4.29, dd (12.3, 1.4)	C-4a, C-6a, C-12, C-12a	64.6	4.59, dd (12.2, 2.5) 4.48, dd (12.2, 1.2)	C-4a, C-6a, C-12a
6a	73.2	5.13, ddd (4.0, 2.9, 1.1)	C-1a, C-6, C-7a, C-12	77.1	4.70, dd (2.4, 1.1)	C-1a, C-6, C-12
7a	158.9			168.2		
8	113.8			113.9		
9	167.9			158.3		
10	105.1	6.51, d (8.6)	C-8, C-9, C-11a	105.5	6.54, d (8.6)	C-8, C-9, C-11a
11	130.3	7.79, d (8.5)	C-7a, C-9, C-12	130.4	7.77, d (8.5)	C-7a, C-9, C-12
11a	114.4			113.6		
12	189.4			191.5		
12a	45.1	3.90, d (4.0)	C-1, C-1a, C-4a, C-11a, C-12	68.5		
4'	31.9	2.95, dd (15.7, 8.1) 3.30, dd (15.7, 9.8)	C-7a, C-8, C-9, C-5', C-6'	31.7	2.93, dd (15.8, 8.1) 3.27, dd (15.8, 9.8)	C-7a, C-8, C-9, C-5', C-6'
5'	88.4	5.35, t (8.9)	C- 4', C-7'	88.5	5.34, m	C-7', C- 4', C-6', C- 8'
6'	144.4			144.5		
7'	112.4	5.08, s 4.93, s	C- 5', C-6', C-8'	112.4	5.07, s 4.93, s	C- 5', C-6', C-8'
8'	17.2	1.77, s	C- 5', C-6', C-7'	17.2	1.76, s	C- 5', C-6', C-7'
2-OMe	56.9	3.65, s	2	56.9	3.61, s	2
3-OMe	56.0	3.77, s	3	56.0	3.77, s	3

4.1.22: Deguelin (22)

Compound **22** was isolated as a white paste. The molecular formula was established as $C_{23}H_{22}O_6$ from the HRESIMS [molecular ion $[M+H]^+$ at m/z 395.1495 (calcd for $C_{23}H_{23}O_6$, 395.1489), $[M+Na]^+$ at m/z 417.1304 (calcd for $C_{23}H_{22}O_6Na$, 417.1309) and NMR data (Table 4.14 and Appendix A22). A rotenoid skeleton was evident from the UV absorption (λ_{max} 234, 268 and 298 nm) and NMR data (Table 4.14 and Appendix A22) (Mabry *et al.*, 1970; Agrawal, 1989). The NMR data of **22** displayed very close similarity with those of rotenone (**20**). The notable difference was the presence of a 2,2-dimethylchromene moiety at C-8/C-9 in **22** rather than a 2-isopropenyltetrahydrofuran group in **20**. These spectral data were identical to those described in the literature for deguelin (Luyengi *et al.*, 1994). This compound was previously reported in the roots of this plant (Were *et al.*, 1990) but this is its first report from the aerial part.



4.1.23: Tephrosin (23)

Compound **23** was isolated as a white paste. The molecular formula was established as $C_{23}H_{22}O_7$ from its HRESIMS data [molecular ion $[M+H]^+$ at m/z 411.1430 (calcd for $C_{23}H_{23}O_7$, 411.1438), $[M+Na]^+$ at m/z 433.1238 (calcd for $C_{23}H_{22}O_7Na$, 433.1258) and NMR data (Table 4.14 and Appendix A23). A 12a-hydroxyrotenoid skeleton was evident from the UV absorption (λ_{max} 234, 270 and 316 nm) and NMR data (Table 4.14 and Appendix A23) (Mabry *et al.*, 1970; Agrawal, 1989). The NMR data of **23** displayed very close similarity with those of

compound **22**. The notable difference was the presence of the hydroxy group at C-12a (δ_c 77.1) in compound **23**. This was evident from HMBC correlation of H-6 (δ_H 4.65 and 4.49 with C-12a and also H-1 (δ_H 6.65) with C-12a. These spectral data were identical to those described in the literature for tephrosin (Luyengi *et al.*, 1994). This compound was previously reported in the roots of this plant (Were *et al.*, 1990) but this is its first report from the aerial part.




Table 4.14: NMR Data for Compounds 22 and 23 in Acetone-d₆ (600 MHz)


22				23		
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
1	112.5	6.73, s	C-2, C-3, C-4a, C-12a	112.3	6.65, s	C-2, C-3, C-4a, C-12a
1a	106.0			108.9		
2	144.8			144.7		
3	151.1			152.5		
4	102.3	6.45, s	C-1a, C-2, C-3, C-4a	102.0	6.46, s	C-1a, C-2, C-4a, C-3
4a	149.0			149.8		
6	67.0	4.30, m 4.66, dd (12.2, 2.9)	C-4a, C-6a, C-12, C-12a	64.6	4.49, dd (12.1, 1.1) 4.65, dd (12.1, 2.5)	C-4a, C-6a
6a	73.5	5.14, ddd (4.0, 2.9, 1.1)	C-1a, C-6, C-12, C-12a	77.3	4.71, dd (2.5, 1.1)	C-1a, C-6, C-12, C-12a
7a	160.4			157.1		
8	109.9			108.9		
9	157.8			160.7		
10	111.7	6.45, d (8.0)	C-8, C-11a	112.1	6.47, d (8.0)	C-8, C-11a
11	129.0	7.70, d (8.7)	C-7a, C-9, C-12	129.0	7.69, d (8.7)	C-7a, C-9, C-12
11a	113.8			112.5		
12	189.6			191.8		
12a	44.9	3.91, d (4.0)	C-1, C-1a, C-4a, C-11a, C-12	77.1		
4'	116.1	6.65, d (10.1)	C-7a, C-8, C-9, C-6'	115.9	6.61, d (10.1)	C-7a, C-8, C-9, C-6'
5'	130.0	5.73, d (10.1)	C-8, C-6', C-7', C-8'	130.0	5.73, d (10.1)	C-8, C-6', C-7', C-8'
6'	78.4			78.6		
7'	28.2*	1.36, s	C-5', C-6', C-8'	28.2*	1.35, s	C-5', C-6', C-8'
8'	28.6*	1.44, s	C-5', C-6', C-7'	28.6*	1.44, s	C-5', C-6', C-7'
2-OMe	56.8	3.64, s	2	56.8	3.61, s	2
3-OMe	56.0	3.74, s	3	56.0	3.76, s	3

*interchangeable positions

*interchangeable positions

4.1.24: *Maackiain* (24)

Compound **24** was isolated as a white paste. The molecular formula was established as C₁₆H₁₂O₅ from its HRESIMS [molecular ion [M+H]⁺ at *m/z* 285.0758 (calcd for C₁₆H₁₃O₅, 285.0757) and NMR data (Table 4.15 and Appendix A24). A pterocarpan skeleton was evident from the UV (λ_{\max} 228 and 310 nm) and NMR [δ_{H} 3.61, dd, *J* = 10.6, 10.2 Hz, and 4.27, dd, *J* = 10.7, 4.6 Hz for H-6 (δ_{C} 67.0); 3.56, ddd, *J* = 10.1, 7.0, 4.7 Hz for H-6a (δ_{C} 41.0); and 5.49, d, *J* = 7.0 Hz for H-11a (δ_{C} 79.4)] (Table 4.15 and Appendix A24) data (Mabry *et al.*, 1970; Agrawal, 1989). The NMR spectra displayed signals for a methylenedioxy group [two singlets at δ_{H} 5.93 and 5.90, 2H (δ_{C} 102.1)]. Further, the NMR data revealed signals for two singlet protons [δ_{H} 6.89 and 6.40] and an AMX spin system [δ_{H} 7.30, d, *J* = 8.3 Hz (δ_{C} 133.0), 6.55, dd, *J* = 8.4, 2.4 Hz (δ_{C} 110.4) and 6.35, d, *J* = 2.4 Hz (δ_{C} 103.9)]. HMBC correlation of one of the ABX system protons at δ_{H} 7.30 with C-11a, C-4a, C-3 and C-4 allowed for its placement at C-1 with its coupling partners at δ_{H} 6.55 (dd, *J* = 8.4, 2.4 Hz) and 6.35 (d, *J* = 2.4 Hz) at C-2 and C-4, respectively. HMBC correlation of the singlet proton at δ_{H} 6.89 with C-6a, C-9, C-10a, C-10 and C-8 allowed for its placement at C-7, whereas the correlation of the proton at δ_{H} 6.40 with C-6b, C-8, C-9 and C-10a allowed for its placement at C-10. The placement of the methylenedioxy group at C-8/C-9 was based on the HMBC correlation of its protons with C-8 and C-9. Therefore, compound **24** was identified as 3-hydroxy-8,9-methylenedioxypterocarpan (maackiain) (Abdel-Kader, 2001). Maackiain has previously been reported in several plants including *Ononis vaginalis* (Abdel-Kader, 2001) and *T. elata* (Atilaw, 2018), but this is its first report in this plant.



24

Table 4.15: NMR Data for Compound 24 in Acetone- d_6 (600 MHz)

24			
Position	δ_C	δ_H , mult. (J in Hz)	HMBC
1	133.0	7.30, d (8.3)	C-3, C-4, C-4a, C-11a
2	110.4	6.55, dd (8.4, 2.4)	C-3, C-4, C-11b
3	159.7		
4	103.9	6.35, d (2.4)	C-2, C-3, C-4a, C-11b
4a	157.7		
6	67.0	3.61, dd (10.6, 10.2) 4.27, dd (10.7, 4.6)	C-4a, C-6a, C-6b, C-11a
6a	41.0	3.56, ddd (10.1, 7.0, 4.7)	C-6, C-6b, C-10a
6b	119.5		
7	105.9	6.89, s	C-6a, C-8, C-9, C-10, C-10a
8	142.4		
9	148.9		
10	94.0	6.40, s	C-6b, C-8, C-9, C-10a
10a	155.3		
11a	79.4	5.49, d (7.0)	C-1, C-4a, C-6, C-6a, C-6b, C-11b
11b	112.8		
OCH ₂ O	102.1	5.93, s 5.90, s	C-8, C-9

4.2: Characterization of Compounds Isolated from *Tephrosia hildebrandtii*

An extract of the aerial parts of *T. hildebrandtii* was subjected through sets of chromatographic techniques to give a new flavone named hildeflavone (**25**) together with other ten known compounds identified as 5,7,3'-trihydroxy-4'-methoxy-8-prenylisoflavone (**26**), 5,3'-dihydroxy-4'-methoxy-2'',2''-dimethylpyrano[5'',6'':8,7]isoflavone (**27**), 4'-hydroxyemoroidocarpan (**28**), hildecarpin (**29**), pisatin (**30**), pongachin (**31**), emoroidenone (**32**), desmoxyphyllin A (**33**), pinoresinol (**34**) and tephrosin (**22**).

4.2.1: Hildeflavone (**25**)

Compound **25** was isolated as a yellow paste. The molecular formula was established as C₂₂H₂₂O₅ from the HRESIMS molecular ion [M+H]⁺ at m/z 367.1540 (calcd for C₂₂H₂₃O₅, 367.1540), [M+Na]⁺ at m/z 389.1361 (calcd for C₂₂H₂₂O₅Na, 389.1359) and ¹³C NMR data (Table 4.16 and Appendix A25). A 5-hydroxyflavone skeleton was evident from the UV (λ_{\max} 228 and 268 nm) and NMR data [δ_{H} 6.86 for H-3 and 13.26 for 5-OH; δ_{C} 165.2 (C-2), 105.6 (C-3), 183.8 (C-4)] (Table 4.16 and Appendix A25) (Mabry *et al.*, 1970; Agrawal, 1989). Further, the NMR spectra exhibited signals for a methoxy [δ_{H} 4.02 (δ_{C} 56.9)] and a *trans*-oriented-3''-methoxy-3''-methylbut-1''-enyl [δ_{H} 1.40, s, 6H (δ_{C} 26.5) for methyl groups, 6.80, d, 1H, $J = 16.7$ Hz (δ_{C} 118.1) for H-1'', 6.54, d, 1H, $J = 16.7$ Hz (δ_{C} 140.0) for H-2'' and 3.23, s, 3H (δ_{C} 50.52) for a methoxy substituent] groups (Khalid and Waterman, 1981; Atilaw *et al.*, 2017b). The NMR also exhibited signals for three sets of mutually coupled protons [δ_{H} 8.11, m, 2H (δ_{C} 127.5), 7.63, m, 2H (δ_{C} 130.0 and 7.65, m, 1H (δ_{C} 132.9)] typical of an unsubstituted flavone ring B and a singlet aromatic proton at δ_{H} 6.55 assigned to ring A. HMBC correlations of the proton at δ_{H} 6.55 with C-8, C-5, C-10 and C-7 allowed for its placement at C-6. The methoxy protons at δ_{H} 4.02 showed HMBC correlation with C-7 (δ_{C} 164.3) which allowed for the placement of this substituent at C-7. Placement of the prenyl group at C-8 was based on HMBC correlation of H-1'' with C-9 (δ_{C} 155.0), C-8 (δ_{C} 106.3) and C-7 (δ_{C} 164.3). Thus,

compound **25** was identified as 5-hydroxy-7-methoxy-8-(*E*-3-methoxy-3-methylbut-1-enyl)flavone. This is a new compound and was given the trivial name hildeflavone.





Table 4.16: NMR Data for Compound 25 in Acetone- d_6 (600 MHz)

25			
Position	δ_C	δ_H , m (J in Hz)	HMBC
2	165.2		
3	106.2	6.86, <i>s</i>	C-10, C-4, C-2, C-1'
4	183.8		
5	162.5		
6	96.2	6.55, <i>s</i>	C-5, C-8, C-7, C-10
7	164.3		
8	106.3		
9	155.0		
10	105.8		
1'	132.5		
2'/6'	127.5	8.11, <i>m</i>	C-2, C-2'/6', C-4'
3'/5'	130.0	7.63, <i>m</i>	C-3'/5', C-1'
4'	132.9	7.65, <i>m</i>	
1''	118.1	6.80, <i>d</i> (16.7)	C-3'', C-2'', C-7, C-9
2''	140.0	6.54, <i>d</i> (16.7)	C-3''-Me ₂ , C-8
3''	76.0		
3''-Me ₂	26.5	1.40, <i>s</i>	C-3''-Me, C-3'', C-2''
3''-OMe	50.5	3.23, <i>s</i>	C-3''
7-OMe	56.9	4.02, <i>s</i>	C-7
5-OH		13.26, <i>s</i>	

4.2.2: 5,7,3'-Trihydroxy-4'-methoxy-8-prenylisoflavone (26)

Compound **26** was isolated as a pale yellow paste. The molecular formula was established as C₂₁H₂₀O₆ from the HRESIMS molecular ion [M+H]⁺ at *m/z* 369.1349 (calcd for C₂₁H₂₁O₆, 369.1333) together with NMR data (Table 4.17 and Appendix A26). A 5-hydroxyisoflavone

skeleton was evident from the UV (λ_{\max} 230, 274 and 332 nm) and NMR data [δ_{H} 8.30 for H-2 and 12.99 for 5-OH; δ_{C} 154.6 for C-2, 123.7 for C-3 and 181.9 for C-4] (Mabry *et al.*, 1970; Agrawal, 1989). The NMR data exhibited signals for a prenyl and a methoxy group. Further, the NMR spectra showed signals for a singlet aromatic proton at δ_{H} 6.37 and an ABX spin system [δ_{H} 6.89, d, $J = 8.1$ Hz (δ_{C} 115.6), 7.10, dd, $J = 8.2, 2.0$ Hz (δ_{C} 122.8) and 7.27, d, $J = 2.0$ Hz (δ_{C} 113.7)]. The proton at δ_{H} 6.37 was placed at C-6 based on its HMBC correlation with C-5 and C-8. Two of the AXY system protons (δ_{H} 6.81 and 7.10) showed HMBC correlation with C-4'. Further correlation with the methoxy protons allowed the placement of this substituent at C-4'. HMBC correlation of H-1" (δ_{H} 3.45) with C-8, C-9 and C-7 placed the prenyl at C-8. Thus, compound **26** was identified as 5,7,3'-trihydroxy-4'-methoxy-8-prenylisoflavone (Souza *et al.*, 2017). This compound was previously reported in *Vatairea guianensis* by Souza *et al.*, (2017). However, this is its first report in this plant.



4.2.3: 5,3'-Dihydroxy-4'-methoxy-2'',2''-dimethylpyrano[5'',6'':8,7]isoflavone (27)

Compound **27** was isolated as a pale yellow paste. The molecular formula was deduced as $\text{C}_{21}\text{H}_{18}\text{O}_6$ from the HRESIMS [molecular ion $[\text{M}+\text{H}]^+$ at m/z 367.1198 (calcd for $\text{C}_{21}\text{H}_{19}\text{O}_6$, 367.1176)] and NMR data (Table 4.17 and Appendix A27). Both the 1D- and 2D-NMR data of **27** showed very close similarity with those of compound **26**. The only notable difference was the presence of a 2,2-dimethylchromene moiety in compound **27** instead of a 3-methylbut-2-enyl group in **26**. Therefore, compound **27** was identified as 5,3'-dihydroxy-4'-methoxy-2'',2''-

dimethylpyrano[5'',6'':8,7]isoflavone (Souza *et al.*, 2013). This compound was previously reported in *Vatairea guianensis* by Souza *et al.*, (2013), but this is its first report in the genus *Tephrosia*.





Table 4.17: NMR Data for Compounds 26 and 27 in Acetone-d₆ (600 MHz)

26				27		
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
2	154.6	8.30, s	C-3, C-4, C-9	154.6	8.30, s	C-3, C-4, C-9
3	123.7			123.5		
4	181.9			182.6		
5	161.5			160.2		
6	99.5	6.37, s	C-5, C-8	100.4	6.21, s	C-5, C-8
7	161.2			163.3		
8	107.2			100.9		
9	156.2			152.9		
10	107.2			100.4		
1'	123.6			123.3		
2'	113.7	7.27, d (2.0)	C-3, C-4', C-6'	113.7	7.26, d (2.0)	C-3, C-4', C-6'
3'	147.6			147.7		
4'	148.0			148.0		
5'	115.6	6.89, d (8.2)	C-1', C-3', C-4'	115.7	6.90, d (8.1)	C-1', C-3', C-4'
6'	122.8	7.10 dd (8.1, 2.0)	C-3, C-1', C-2', C-4'	122.8	7.09 dd (8.1, 2.0)	C-2', C-4'
1''	22.0	3.45, d (7.3)	C-8, C-9, C-3''			
2''	123.1	5.25, t (7.2)		79.0		
3''	132.0			128.7	5.76, d (10.0)	C-2'', 2''-Me ₂
4''	17.9*	1.81	C-2'', C-3'', C-5''	115.0	6.73, d (9.9)	C-7, C-2''
5''	25.9*	1.66	C-2'', C-3'', C-4''			
6''						
2''-Me ₂				28.3	1.48, s	C-2'', C-3'', 2''-Me
5-OH		12.99, s			13.14 s	
4'-OMe	56.4	3.89, s	C-4'	56.4	3.89, s	C-4'

*interchangeable

4.2.4: 4'-Hydroxyemoroidocarpan (28)

Compound **28** was isolated as a white paste. The molecular formula was established as C₂₁H₁₈O₆ from the HRESIMS [molecular ion [M+H]⁺ at *m/z* 367.1193 (calcd for C₂₁H₁₉O₆, 367.1176)] and NMR data (Table 4.18 and Appendix A28). A pterocarpan skeleton was evident from NMR data [δ_{H} 3.62, dd, *J* = 11.7, 10.1 Hz, and 5.28, dd, *J* = 10.5, 4.4 Hz for H-6 (δ_{C} 67.2); 3.57, ddd, *J* = 9.9, 7.1, 4.5 Hz for H-6a (δ_{C} 41.0) and 5.50, d, *J* = 7.1 Hz for H-11a (δ_{C} 79.7)] (Mabry *et al.*, 1970; Agrawal, 1989). The NMR spectra displayed signals for a methylenedioxy [δ_{H} 5.93 and 5.91, 2H (δ_{C} 102.1)] and 2-(3-hydroxy-isopropenyl)-tetrahydrofuran [δ_{H} 3.10, dd, *J* = 15.3, 7.9 Hz and 3.39, dd, *J* = 15.5, 9.7 Hz for H-4' (δ_{C} 35.0); 5.35, t, *J* = 8.6 Hz for H-5' (δ_{C} 85.0); 4.18, s for H-8' (δ_{C} 62.3); 5.18 and 5.20, broad-s for H-7' (δ_{C} 109.9); and δ_{C} 150.0 for C-6'] groups. Further, the NMR data revealed the presence of four singlet aromatic protons [δ_{H} 7.25, 6.28, 6.90 and 6.39]. HMBC correlation of the aromatic singlet proton at δ_{H} 7.25 with C-11a, C-4a and C-3 allowed for its placement at C-1, whereas the correlation of the proton at δ_{H} 6.28 with C-2 and C-11b allowed for its placement at C-4. HMBC correlation of the proton at δ_{H} 6.90 with C-6a, C-8, C-9 and C-10a allowed for its placement at C-7. HMBC correlation of methylenedioxy protons with C-8/C-9 placed this group at these carbons. The placement of the 2-(3-hydroxy-isopropenyl)-tetrahydrofuran group at C-2/C-3 was from the HMBC correlations of H-4' (δ_{H} 3.10 and 3.39) with C-5', C-1, C-6' and C-3. Thus, compound **28** was identified as 4'-hydroxyemoroidocarpan (Harinantenaina *et al.*, 2010). This compound was previously reported from the roots of the endemic Malagasy *Pongamiopsis pervilleana* by Harinantenaina *et al.*, (2010), but it is the first report in this plant.



28


Table 4.18: NMR Data for Compound 28 in Acetone-d₆ (600 MHz)

28			
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
1	127.8	7.25, s	C-3, C-4a, C-11a, C-4'
2	113.5		
3	161.8		
4	98.4	6.28, s	C-2, C-3, C-4a, C-11b
4a	157.1		
6	67.2	3.62, dd (11.7, 10.1) 5.28, dd (10.5, 4.4)	C-4a, C-6a, C-6b, C-5'
6a	41.0	3.57, dd (9.9, 7.1, 4.5)	C-6, C-6b, C-10a
6b	119.5		
7	105.9	6.90, s	C-6a, C-8, C-9, C-10a
8	142.5		
9	148.9		
10	93.9	6.39, s	C-6b, C-8, C-9, C-10a
10a	155.3		
11a	79.7	5.50, d (7.1)	C-1, C-2, C-4a, C-6
11b	121.6		
4'	35.0	3.10, dd (15.3, 7.9) 3.39, dd (15.5, 9.7)	C-1, C-3, C-5', C-6'
5'	85.0	5.35, t (8.6)	C-4', C-6', C-7'
6'	150.0		
7'	109.9	5.18, s 5.20, s	C-5', C-6', C-8'
8'	62.3	4.18, s	
OCH ₂ O	102.1	5.91, s 5.93, s	C-8, C-9

4.2.5: Hildecarpin (29)

Compound **29** was isolated as a white paste. Its molecular formula was deduced as C₁₇H₁₄O₇ from HRESIMS molecular ion peak [M+H]⁺ at *m/z* 381.0814 (calcd for C₁₇H₁₅O₇, 381.0812) and NMR data (Table 4.19 and Appendix A29). A 6a-hydroxypterocarpan skeleton was evident from the NMR data [δ_H 4.00, d, *J* = 11.3 Hz, 4.08, d, *J* = 11.4 Hz for H-6; 5.25, s for H-11a and 4.98, s for 6a-OH] (Table 4.19 and Appendix A29) (Mabry *et al.*, 1970; Agrawal, 1989). The

NMR spectra showed signals for a methylenedioxy and methoxy group. Additionally, the NMR data exhibited signals for four singlet aromatic protons (δ_{H} 6.99, 6.89, 6.35 and 6.36). A hydroxy proton at δ_{H} 7.86 showed HMBC correlation with C-2, C-3 and C-4 allowing for its placement at C-3 and methoxy group at C-2, while the singlet aromatic proton (δ_{H} 6.89) was placed at C-4. HMBC correlation of the methylenedioxy protons (δ_{H} 5.92 and 5.95) with C-8 and C-9 supported its placement at C-8/C-9. Thus, compound **29** was identified as hildecarpin (Lwande *et al.*, 1985b). Hildecarpin was previously reported from the root of this plant (Lwande *et al.*, 1985b). But this is the first report of hildecarpin in the aerial parts of *T. hildebrandtii*.



4.2.6: Pisatin (30)

Compound **30** was isolated as a white paste. The molecular formula was deduced as $\text{C}_{17}\text{H}_{14}\text{O}_6$ from its HRESIMS $[\text{M}-\text{H}_2\text{O}]^+$ at m/z 297.0756 (calcd for $\text{C}_{17}\text{H}_{15}\text{O}_6$, 315.0863) and NMR data (Table 4.19 and Appendix A30). A 6a-hydroxypterocarpan skeleton was evident from the NMR data [δ_{H} 4.10, d, $J = 11.4$ Hz, 4.14, d, $J = 11.4$ Hz for H-6; 5.29, s for H-11a and 5.03, s for 6a-OH] (Table 4.19 and Appendix A30) (Mabry *et al.*, 1970; Agrawal, 1989). The NMR spectra showed signals for a methylenedioxy and a methoxy substituent (Table 4.19 and Appendix A30). Further, the NMR exhibited signals for two singlet aromatic protons (δ_{H} 6.90 and δ_{H} 6.36) and an ABX spin system [δ_{H} 7.37, d, $J = 8.5$ Hz, 6.63, dd, $J = 8.6, 2.6$ Hz and 6.40, d, $J = 2.5$ Hz]. HMBC correlations of the proton at δ_{H} 7.37 with C-11a, C-4a and C-3 allowed for its placement at C-1 with its coupling partners δ_{H} 6.63 and 6.40 at C-2 and C-4, respectively. Placement of the methylenedioxy group at C-8/9 was based on the HMBC correlations of its

protons with C-8 and C-9. HMBC correlation of the methoxy protons with C-3 allowed for its placement at C-3. Thus, compound **30** was identified as pisatin (Ingham and Markham, 1980). Pisatin was previously isolated from the seeds of *Tephrosia bidwilli* by Ingham and Markham, (1980) but it is the first report in this plant.





Table 4.19: NMR data for Compounds 29 and 30 in Acetone-d₆ (600 MHz)

29				30		
Position	δ_C	δ_H , mult. (J in Hz)	HMBC	δ_C	δ_H , mult. (J in Hz)	HMBC
1	113.3	6.99, s	C-2, C-3, C-4a, C-11a, C-11b	132.1	7.37, d (8.5)	C-3, C-4a, C-11a
2	148.2			109.0	6.63, dd (8.6, 2.6)	C-3, C-4, C-11b
3	143.1			161.0		
4	103.4	6.89, s	C-2, C-3, C-4a, C-11b	101.1	6.40, d (2.5)	C-2, C-3, C-4a, C-11b
4a	149.7			156.2		
6	69.6	4.00, d (11.3) 4.08, d (11.4)	C-4a, C-6a, C-6b, C-11a,	69.4	4.10, d (11.4) 4.14, d (11.4)	C-4a, C-6a, C-6b, C-11a
6a	76.5			76.4		
6b	120.8			120.6		
7	103.5	6.35, s	C-6a, C-8, C-9, C-10, C-10a	103.5	6.90, s	C-6a, C-8, C-9, C-10, C-10a
8	142.0			142.0		
9	149.3			149.4		
10	93.2	6.36, s	C-6b, C-8, C-9, C-10a	93.3	6.36, s	C-6b, C-7, C-8, C-9, C-10a
10a	154.6			154.6		
11a	85.4	5.25, s	C-1, C-4a, C-6a, C-10a, C-11b	85.0	5.29, s	C-1, C-4a, C-6, C-6a, C-6b, C-11b
11b	111.2			113.3		
2-OMe	55.9	3.84, s	C-2			
3-OMe				54.7	3.77, s	C-3
3-OH		7.86, s	C-2, C-3, C-4			
6a-OH		4.98, s	C-6, C-6a, C-6b, C-11b		5.03, s	C-6, C-6a, C-6b, C-11b
OCH ₂ O	101.4	5.92, s	C-8, C-9	101.4	5.92, s	C-8, C-9
		5.95, s			5.96, s	

4.2.7: Pongachin (31)

Compound **31** was obtained as an off-white solid. The molecular formula was established as $C_{21}H_{20}O_4$ from the HRESIMS [molecular ion $[M+H]^+$ at m/z 337.1427 (calcd for $C_{21}H_{21}O_4$, 337.1431, $[M+Na]^+$ at m/z 359.1243 (calcd for $C_{21}H_{20}O_4Na$, 359.1254)] and ^{13}C NMR data (Table 4.20 and Appendix A31). A flavanone skeleton was evident from the UV (λ_{max} 268 and 293 nm) and NMR data [AMX spin system of δ_H 5.55, dd, $J = 12.7, 3.1$ Hz for H-2 (δ_C 79.8), 2.71, dd, $J = 16.3, 3.0$ Hz for H-3eq and 2.97, dd, $J = 16.3, 12.7$ Hz for H-3ax (δ_C 46.2); δ_C 187.8 for C-4] (Table 4.20 and Appendix A31) (Mabry *et al.*, 1970; Agrawal, 1989). The NMR showed signals of a methoxy and 2,2-dimethylchromene moiety [δ_H 6.58 (1H, d, $J = 10.0$ Hz) for H-4", 5.79 (1H, d, $J = 10.0$ Hz) for H-5", 1.42 (3H, s) for H-7" and 1.44 (3H, s) for H-8"] groups. The NMR spectra revealed the presence of three sets of mutually coupled protons [δ_H 7.57, m, 2H (δ_C 127.0), 7.45, m, 2H (δ_C 129.5 and 7.39, m, 1H (δ_C 129.2)] assigned to an unsubstituted ring B and a singlet proton at δ_H 6.11 (δ_C 94.5) assigned to ring A. HMBC correlations of the singlet proton at δ_H 6.11 with C-8, C-5, C-10 and C-7 allowed for its placement at C-6. The methoxy group at δ_H 3.82 (δ_C 56.2) showed HMBC correlations with C-5 allowing its placement at this position. HMBC correlations of H-4" (δ_H 6.58) with C-8, C-9 and C-7 placed the 2,2-dimethylchromene moiety at C-7/8. Thus, compound **31** was identified as 5-methoxy-6",6"-dimethylpyrano[2",3":6,7]flavanone (pongachin) (Andrei *et al.*, 2000). Pongachin was previously reported from the roots of *Tephrosia tunicata* (Andrei *et al.*, 2000) but, this is its first report from this plant.



31

4.2.8: Emoroidenone (32)

Compound **32** was obtained as an off-white solid. Its molecular formula was deduced as $C_{21}H_{20}O_4$ from the HRESIMS [molecular ion $[M+H]^+$ at m/z 337.1433 (calcd for $C_{21}H_{21}O_4$, 337.1431, $[M+Na]^+$ at m/z 359.1251 (calcd for $C_{21}H_{20}O_4Na$, 359.1254)] and ^{13}C NMR data (Table 4.20 and Appendix A32). A flavanone skeleton was apparent from the UV (λ_{max} 215 and 290 nm) and NMR data [AMX spin system of δ_H 5.54 (1H, dd, $J = 12.5, 3.0$ Hz for H-2), 2.70 (1H, dd, $J = 16.2, 3.1$ Hz for H-3eq) and 2.95 (1H, dd, $J = 16.2, 12.5$ Hz, H-3ax) and δ_C 186.4 for C-4] (Mabry *et al.*, 1970; Agrawal, 1989). The NMR data of **32** had close similarity to those of compound **31**. The difference was the presence of an 2-isopropenyltetrahydrofuryl group [δ_H 2.90 (dd, $J = 15.1, 7.8$ Hz) and 3.34, m for H-4" (δ_C 31.1); 5.35, m for H-5" (δ_C 87.4); 1.76, s for H-8' (δ_C 16.4); 4.91 and 5.08, broad-s for H-7' (δ_C 111.4); and δ_C 143.9 for C-6"] in compound **32** instead of a 2,2-dimethylchromene moiety in **31**. Based on these spectral data, compound **32** was identified as 4",5"-dihydro-5-methoxy-5"-isopropenylfuran(2",3":7,8)-flavanone (emoroidenone). Emoroidenone was previously reported from the roots of *Tephrosia emoroides* (Machocho *et al.*, 1995) but this is its first report in this plant.





Table 4.20: NMR Data for Compounds 31 and 32 in Acetone-d₆ (600 MHz)

31				32		
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
2	79.8	5.55, dd (12.7, 3.1)	C-2'/6', C-1', C-4	78.7	5.54, dd, (12.5, 3.0)	C-2'/6', C-1', C-4
3	46.2	2.71, dd (16.3, 3.0) 2.97, dd (16.3, 12.7)	C-2, C-10, C-1, C-4	45.6	2.70, dd (16.2, 3.1) 2.95, dd (16.2, 12.5)	C-2, C-10, C-1, C-4
4	187.8			186.4		
5	159.4			163.3		
6	94.5	6.11, s	C-8, C-10, C-7, C-9, C-4	87.4	6.21, s	C-8, C-10, C-7, C-9, C-4
7	160.3			166.2		
8	103.4			104.8		
9	163.0			159.1		
10	106.5			105.7		
1'	140.5			139.7		
2'/6'	127.0	7.57, m	C-2, C-2'/6', C-4'	126.2	7.56, m	C-2, C-2'/6', C-4'
3'/5'	129.5	7.45, m	C-3'/5', C-1'	128.5	7.44, m	C-3'/5', C-1'
4'	129.2	7.39, m	C-2'/6'	128.3	7.38, m	C-2'/6'
4''	116.6	6.58, d (10.0)	C-6'', C-8, C-9, C-7	31.1	2.90, dd (15.1, 7.9) 3.34, m	C-6'', C-8, C-9, C-7
5''	127.3	5.59, d (10.0)	C-7'', C-8'', C-6'', C-8	87.8	5.35, m	C-7'', C-8'', C-6'', C-8
6''	78.5			143.9		
7''	28.3*	1.42, s	C-8'', C-6'', C-5''	111.2	4.91, s 5.08, s	C-8'', C-6'', C-5''
8''	28.6*	1.44, s	C-7'', C-6'', C-5''	16.4	1.76, s	C-7'', C-6'', C-5''
5-OMe	56.2	3.82, s	C-5	55.5	3.82, s	C-5

*interchangeable

4.2.9: Desmoxyphyllin A (33)

Compound **33** was isolated as a yellow paste. Its molecular formula was deduced as C₂₁H₂₀O₄ from the HRESIMS [molecular ion [M+H]⁺ at *m/z* 315.0499 (calcd for C₂₁H₂₁O₄, 315.0499)] and ¹³C NMR data (Table 4.21 and Appendix A33). The presence of a 5-hydroxycoumaronochromone skeleton was evident from the UV (λ_{\max} 258, 284 and 336 nm) and NMR data [δ_{H} 13.00 for 5-OH; δ_{C} 165.5 (C-2), δ_{C} 98.7 (C-3) and δ_{C} 179.6 (C-4)] (Mabry *et al.*, 1970; Agrawal, 1989). The NMR spectra showed a signal for a methoxy group [δ_{H} 4.00, s, 3H (δ_{C} 56.9)]. Further, the NMR exhibited a set of *meta*-coupled protons [δ_{H} 6.39 and 6.62 (1H, d, *J* = 2.2 Hz)] and two singlet aromatic protons (δ_{H} 7.20 and 7.51). HMBC correlations of the proton at δ_{H} 6.39 with C-7, C-8 and C-10 allowed for its placement at C-6 while its coupling partner at C-8. ³J HMBC correlations of the proton at δ_{H} 7.20 with C-5' which in turn correlates with the methoxy protons allowed for the placement of this substituent at C-5'. Thus, compound (**33**) was identified as 7,4'-dihydroxy-5'-methoxycoumaronochromone (desmoxyphyllin A) (Mizuno *et al.*, 1992). Desmoxyphyllin A was previously isolated from the leaves of *Desmodium oxyphyllum* (Mizuno *et al.*, 1992). This is its first report in the genus *Tephrosia*.



4.2.10: Pinoresinol (34)

Compound **34** was isolated as a white paste. Its molecular formula was deduced as C₂₀H₂₂O₆ from the HRESIMS [molecular ion [M₂+H]⁺ at *m/z* 717.2900 (calcd for C₂₀H₂₃O₆, 717.2900)] and ¹³C NMR data (Table 4.21 and Appendix A34) representing an index of hydrogen deficiency of 10. The NMR showed signals for a methoxy

group [δ_{H} 3.86, (δ_{C} 56.4)]. The ^1H NMR spectra showed signals for an ABX spin system [δ_{H} 6.77 (1H, d, $J = 8.1$ Hz), 6.82 (1H, dd, $J = 8.1, 2.0$ Hz) and 6.95 (1H, d, $J = 1.9$ Hz) attributed to a trisubstituted benzene ring]. The NMR further displayed resonance for four mutually coupled aliphatic protons [δ_{H} 4.77 (1H, d, $J = 4.3$ Hz, δ_{C} 87.5) for oxymethine, 3.15 (1H, dd, $J = 6.4, 4.9$ Hz, δ_{C} 55.4) for methine and 4.24 (H, dd, $J = 9.1, 6.9$ Hz)/3.84 (1H, dd, $J = 8.7, 3.9$ Hz, δ_{C} 72.6) for oxymethylene]. These signals only represent a methoxy, a phenyl and three aliphatic carbons corresponding to $\text{C}_{10}\text{H}_{11}\text{O}_3$ which is half of the molecular formula for this compound. Therefore, compound **34** is a symmetrical dimer consistent with a lignan skeleton. HMBC correlation of the oxymethine proton (δ_{H} 4.71) with C-6 (δ_{C} 120.1) and C-2 (δ_{C} 111.0) indicated that the ABX system is 1,3,4-trisubstituted with oxygenation at C-3 and C-4. HMBC correlations of the protons at δ_{H} 6.95 (H-1, d, $J = 1.9$ Hz) and 6.77 (H-5, d, $J = 8.1$ Hz) with C-3 (δ_{C} 147.3) which in turn correlated with methoxy protons allowed for the placement of this substituent at C-3. Thus, compound **34** was identified as pinoresinol (Ouyang *et al.*, 2007). Pinoresinol was previously isolated from the root of *Rhus javanica* (Ouyang *et al.*, 2007) and the leaves of *Calotropis gigantea* (Nguyen *et al.*, 2017). This is its first report in the genus *Tephrosia*.




Table 4.21: NMR Data for Compounds 33 and 34 in Acetone-d₆ (600 MHz)

33				34		
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
1				133.8		
2	165.5			111.0	6.95, d, (1.9)	C-7, C-6, C-1, C-4
3	98.7			149.1		
4	179.6			147.3		
5	164.0			116.1	6.77, d, (8.1)	C-1, C-3
6	100.7	6.39, d, (2.2)	C-7, C-8, C-10	120.1	6.82, dd, (8.1, 2.0)	C-7, C-2, C-4
7	164.6			87.5	4.71, d, (4.3)	C-8, C-9, C-6, C-1, C-2
8	95.6	6.62, d, (2.2)	C-6, C-10, C-9, C-7	55.4	3.15, dd, (6.4, 4.9)	C-8, C-7, C-1
9	156.1			72.6	4.24, dd, (9.1, 6.9)	C-8, C-7
					3.84, dd, (8.9, 3.9)	
10	104.3					
1'	114.3					
2'	144.9					
3'	99.7	7.20, s	C-1', C-2', C-4', C-5'			
4'	146.9					
5'	147.4					
6'	103.8	7.51, s	C-3, C-2', C-4', C-1'			
3-OMe				56.4	3.86, s	C-3
5'-OMe	56.9	4.00, s	5'			
5-OH		13.00, s				

4.3: Characterization of Compounds Isolated from *Tephrosia vogelii*


Chromatographic fractionation of an extract of the seedpods of *Tephrosia vogelii* led to the isolation and characterization of twelve compounds. These compounds were vogeliso flavone A (**35**), vogeliso flavone B (**36**), onogenin (**37**), isoponga flavone (**38**), luteolin (**13**), 4',7-dihydroxy-3'-methoxyflavanone (**39**), *trans-p*-hydroxycinnamic acid (**40**), tephrosin (**23**), 2-methoxygliricidol (**41**), dehydrorotenone (**42**), 6a,12a-dehydro- α -toxicarol (**43**) and pinoresinol (**34**). Compounds **35** and **36** are reported here as new compounds.

4.3.1: Vogeliso flavone A (**35**)

Compound **35** was obtained as a white paste. The molecular formula of **35** was established as C₁₇H₁₂O₇ from HRESIMS [molecular ion peak [M+H]⁺ at *m/z* 329.0654 (calcd for C₁₇H₁₃O₇, 329.0656) and [M+Na]⁺ at *m/z* 351.0475 (calcd for C₁₇H₁₂O₇Na, 351.0475)] and NMR data (Table 4.22 and Appendix A35). The UV (λ_{max} 232, 268 and 312 nm) and NMR data [δ_{H} 8.37 for H-2; δ_{C} 156.6 (C-2), 123.9 (C-3) and 178.0 (C-4)] showed characteristic signals for an isoflavone skeleton (Table 4.22 and Appendix A35) (Mabry *et al.*, 1970; Agrawal, 1989). The NMR spectra displayed signals of a methylenedioxy [δ_{H} 5.97 (δ_{C} 102.3)] and a methoxy [δ_{H} 4.01, (δ_{C} 56.7)] group. The NMR spectra also showed signals for four singlet protons (δ_{H} 7.60, 7.07, 6.84 and 6.52). HMBC correlations of the proton at δ_{H} 7.60 with C-7, C-4 and C-9 allowed for its placement at C-5, whereas correlations of the proton at δ_{H} 7.07 with C-10, C-6 and C-7 allowed for its placement at C-8. HMBC correlations of the protons at δ_{H} 6.52 with C-1', C-4', C-5' and C-2' allowed for its placement at C-3', whereas correlations of δ_{H} 6.84 with C-3, C-4', C-5' and C-2' placed it at C-6'. Placement of the methoxy group at C-6 was based on HMBC correlations of its protons (δ_{H} 4.01) with C-6. The methylenedioxy protons showed an HMBC correlation with C-4'/C-5' which supported its placement at these carbons. Based on these spectral data, compound **35** was characterized as 2',7-dihydroxy-6-methoxy-4',5'-

methylenedioxyisoflavone, a new compound that was given the trivial name vogelisoflavone

A.



4.3.2: *Vogelisoflavone B (36)*

Compound **36** was obtained as a white paste. The molecular formula of **36** was deduced as $C_{18}H_{16}O_6$ from its HRESIMS [molecular ion peak $[M+H]^+$ at m/z 329.1021 (calcd for $C_{18}H_{17}O_6$, 329.1020)] and NMR data (Table 4.22 and Appendix A36). An isoflavone skeleton was evident from the UV (λ_{max} 262 and 312 nm) and NMR [δ_H 8.25 for H-2; δ_C 153.0 (C-2), 124.3 (C-3) and 175.3 (C-4)] data (Mabry *et al.*, 1970; Agrawal, 1989). The NMR spectra showed the presence of three methoxy groups [δ_H 3.84 (δ_C 55.6), 3.96 (δ_C 56.6) and 3.99 (δ_C 61.5)]. Further, the NMR data exhibited signals for an AA'XX' set of aromatic coupled protons [δ_H 7.58 and 6.99 (2H, d, $J = 8.7$ Hz)] and a singlet aromatic (δ_H 7.36) proton that was assigned to ring B and A, respectively. HMBC correlation of the singlet proton at δ_H 7.36 with C-4, C-7 and C-9 placed this proton at C-5. Thus, compound **36** was characterized as 7-hydroxy-4',6,8-trimethoxyisoflavone and it is a new compound. Vogeliso flavone B has been suggested as its trivial name.





Table 4.22: NMR Data for Compounds 35 and 36 in Acetone-d₆ (600 MHz)

35				36		
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
2	156.6	8.37, s	C-3, C-1', C-9, C-4	153.0	8.25, s	C-3, C-1', C-9, C-4
3	123.9			124.3		
4	178.0			175.3		
5	105.3	7.60, s	C-9, C-4, C-7	100.4	7.36, s	C-9, C-4, C-7
6	148.2			147.9		
7	154.6			146.2		
8	103.5	7.07, s	C-10, C-6, C-7	136.3		
9	153.5			147.2		
10	117.1			117.6		
1'	113.0			125.7		
2'	152.9			131.0	7.58, d (8.7)	C-3, C-6', C-4'
3'	100.9	6.52, s	C-1', C-4', C-5', C-2'	114.4	6.99, d (8.7)	C-5', C-1', C-4'
4'	150.0			160.4		
5'	142.3			114.4	6.99, d (8.7)	C-3', C-1', C-4'
6'	109.9	6.84, s	C-3, C-4', C-5', C-2'	131.0	7.58, d (8.7)	C-3, C-2', C-4'
6-OMe	56.7	4.01, s	C-6	56.6	3.96, s	C-6
8-OMe				61.5	3.99, s	C-8
4'-OMe				55.6	3.84, s	C-4'
4',5'-OCH ₂ O	102.3	5.97, s	C-4', C-5'			

4.3.3: Onogenin (37)

Compound **37** was obtained as an off-white paste. Its molecular formula was deduced as C₁₇H₁₄O₆ from the HRESIMS [molecular ion [M+H]⁺ at *m/z* 315.0862 (calcd for C₁₇H₁₄O₆, 315.0863)] and NMR data (Table 4.23 and Appendix A37). The presence of an isoflavanone skeleton was evident from UV (λ_{\max} 234, 276 and 302 nm) and NMR data [AMX spin system of δ_{H} 4.55 (dd, *J* = 11.2, 10.7 Hz) for H-2ax, 4.46 (dd, *J* = 10.9, 5.4 Hz) for H-2eq and 4.22 (dd, *J* = 11.6, 5.4 Hz) for H-3; δ_{C} 61.9 (C-2), 38.3 (C-3) and 190.9 (C-4)]. The NMR spectra showed signals for methylenedioxy [δ_{H} 5.94 (δ_{C} 102.2)] and methoxy [δ_{H} 3.75, (δ_{C} 47.1)] groups. Further, NMR spectra revealed signals for two aromatic singlets (δ_{H} 6.72 and 6.67) and an AMX spin system [δ_{H} 7.77 (d, *J* = 8.6 Hz), 6.59 (dd, *J* = 8.6, 2.3 Hz) and 6.41 (d, *J* = 2.3 Hz)]. HMBC correlations of the proton at δ_{H} 7.77 with C-4, C-7 and C-9 allowed for its placement at C-5. This placed the singlet aromatic protons in ring B. HMBC correlations of the singlet aromatic proton at δ_{H} 6.67 with C-3, C-4', C-5' and C-2' allowed for its placement at C-6'. The HMBC correlation of H-6' with C-2' which in turn correlated with the methoxy protons placed the methoxy group at C-2'. HMBC correlations of the methylenedioxy protons with C-4' and C-5' allowed for the placement of the methylenedioxy group at C-4'/C-5'. Based on these spectral data, compound **37** was identified as 7-hydroxy-2'-methoxy-3',4'-methylenedioxyisoflavanone (onogenin). Onogenin was previously isolated from the roots of *Ononis spinosa* (Kovalev *et al.*, 1975) and *Ononis arvensis* (Gampe *et al.*, 2016). This is its first report in the genus *Tephrosia*.



4.3.4: Isopongaflavone (38)

Compound **38** was isolated as a yellow solid. Its molecular formula was deduced as $C_{21}H_{18}O_4$ from the HRESIMS [molecular ion $[M+H]^+$ at m/z 335.1279 (calcd for $C_{21}H_{19}O_4$, 335.1278)] and NMR data (Table 4.23 and Appendix A38). The presence of a flavone skeleton was evident from the UV (λ_{max} 272, 300 and 346 nm) and NMR [δ_H 6.70, s for H-2; δ_C 160.2 for C-2, 108.9 for C-3 and 177.7 for C-4] data (Mabry *et al.*, 1970; Agrawal, 1989). The NMR data showed signals for a methoxy [δ_H 3.98 (δ_C 56.5)] and a 2,2-dimethylchromene [δ_H 1.53 (6H, s, δ_C 28.2), 5.64 (1H, d, $J = 10.0$ Hz, δ_C 127.6) and 6.88 (1H, d, $J = 10.0$ Hz δ_C 115.3)] moiety. Further, the NMR data showed signals for three sets of mutually coupled protons [δ_H 7.88 (m, 2H), 7.53 (m, 2H) and 7.54 (m, 1H)] assigned to an unsubstituted flavone ring B and a singlet aromatic proton δ_H 6.36 assigned to ring A. HMBC correlations of the singlet proton at δ_H 6.36 with C-8, C-5 and C-10 allowed for its placement at C-6. This placed the methoxy group at C-5 and the 2,2-dimethylchromene moiety at C-7/8. The placement of the 2,2-dimethylchromene moiety at C-7/8 was further established from the HMBC correlations of H-4" (δ_H 6.88) with C-8, C-9 and C-7. Based on these spectral data, compound **38** was identified as 5-methoxy-2",2"-dimethylpyrano[5",6":7,8]flavone (isopongaflavone). Isopongaflavone was previously reported from the roots of *Tephrosia elata* (Bentley *et al.*, 1987). This is its first report in this plant.





Table 4.23: NMR Data for Compounds 37 and 38 in Acetone-d₆ (600 MHz)

37				38		
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
2	71.7	4.55, dd (11.2, 10.7) 4.46, dd (10.9, 5.4)	C-3, C-4, C-9, C-1'	160.2		
3	48.2	4.22, dd (11.6, 5.4)	C-2, C-4, C-1', C-2', C-6'	108.9	6.70, s	C-2, C-4, C-10, C-1'
4	190.9			177.7		
5	130.0	7.77, d (8.6)	C-4, C-7, C-9	160.7		
6	111.2	6.59, dd (8.6, 2.3)	C-10	96.7	6.36, s	C-5, C-8, C-10
7	165.0			154.0		
8	103.5	6.41, d (2.3)		102.7		
9	164.6			158.0		
10	115.8			108.9		
1'	117.1			131.8		
2'	153.9			125.9	7.88, m	C-2, C-2'/6', C-4'
3'	96.2	6.72, s	C-1', C-2', C-4', C-5'	129.0	7.53, m	C-1', C-3'/5'
4'	142.0			131.2	7.54, m	C-2'/6'
5'	148.6			129.0	7.53, m	C-1', C-3'/5'
6'	110.5	6.67, s	C-3, C-2', C-4', C-5'	125.9	7.88, m	C-2, C-2'/6', C-4'
2''				78.1		
3''				127.6	5.64, d (10.0)	C-8, C-2'', C-2''-Me ₂
4''				115.3	6.88, d (10.0)	C-7, C-8, C-9, C-3'', C-2''
2''-Me ₂				28.2	1.53, s	C-2'', C-3'', C-2''-Me,
2'-OMe	57.1	3.75, s	C-2'			
5-OMe				56.5	3.98, s	C-5
4',5'-OCH ₂ O	102.2	5.94, s (broad)	C-4', C-5'			


4.3.5: 4',7-Dihydroxy-3'-methoxyflavanone (39)

Compound **39** was obtained as an off-white paste. Its molecular formula was established as C₁₆H₁₄O₅ from the HRESIMS [molecular ion [M+H]⁺ at *m/z* 287.0915 (calcd for C₁₆H₁₅O₄, 287.0914)] and NMR data (Table 4.24 and Appendix A39). A flavanone skeleton was evident from the UV (λ_{\max} 258, 278 and 312 nm) and NMR [AMX spin system of [δ_{H} 5.44 (1H, dd, J = 13.2, 2.9 Hz for H-2), 2.67 (1H, dd, J = 16.7, 2.8 Hz for H-3eq), 3.08 (1H, dd, J = 16.7, 13.1 Hz for H-3ax) and δ_{C} 190.5 for C-4] data (Mabry *et al.*, 1970; Agrawal, 1989). The NMR spectra exhibited signals for a methoxy group at δ_{H} 3.89 (δ_{C} 56.3)]. Further, NMR data showed two sets of ABX spin systems [δ_{H} 7.73 (1H, d, J = 8.6 Hz, δ_{C} 129.5), 6.58 (1H, dd, J = 8.7, 2.3 Hz, δ_{C} 111.2) and 6.43 (1H, d, J = 2.3 Hz, δ_{C} 103.7)] and [δ_{H} 6.87 (1H, d, J = 8.1 Hz, δ_{C} 115.7), 7.01 (1H, dd, J = 8.1, 2.1 Hz, δ_{C} 120.5) and 7.20 (1H, d, J = 2.0 Hz, δ_{C} 111.2)]. HMBC correlations of the deshielded proton at δ_{H} 7.73 with C-4, C-7 and C-9 allowed for its placement at C-5 and its coupling partner protons δ_{H} 6.58 (dd, J = 8.67, 2.3 Hz) and 6.43 (d, J = 2.3 Hz) at C-6 and C-8, respectively. HMBC correlations of the protons at δ_{H} 7.20 (1H, d, J = 2.0 Hz) and 7.01 (1H, dd, J = 8.1, 2.1 Hz) with C-2 allowed for their placement at C-2' and C-6', respectively, indicating that ring B is substituted at C-3' and C-4'. HMBC correlation of H-5' (δ_{H} 6.87) with C-3' which in turn correlated with the methoxy protons allowed for the placement of the methoxy group at C-3'. Compound **39** was identified as 4',7-dihydroxy-3'-methoxyflavanone (Recourt *et al.*, 1991). This compound was previously reported in the roots of *Vicia sativa* (Recourt *et al.*, 1991) but this is its first report in the genus *Tephrosia*.



4.3.6: *Trans-p-hydroxycinnamic Acid (40)*

Compound **40** was obtained as an off-white paste. Its molecular formula $C_9H_8O_3$ was deduced from the HRESIMS molecular ion $[M+H]^+$ at m/z 165.0544 (calcd for $C_9H_9O_3$, 165.0546) and NMR data (Table 4.24 and Appendix A40). The UV (λ_{max} 230 and 310 nm) and NMR data indicated compound **40** was a hydroxycinnamic acid derivative (Harbaum *et al.*, 2007). The 1H NMR exhibited *ortho*-coupled aromatic protons [δ_H 7.54 and 6.89 (2H, d, $J = 8.6$ Hz)] assigned to a disubstituted benzene ring]. Further, the NMR data showed signals for *trans*-oriented olefinic protons [δ_H 7.59 and 6.33 (1H, d, $J = 16.0$ Hz)] and carboxylic carbon at δ_C 168.9. HMBC correlation of one of the *trans*-oriented olefinic proton (δ_H 7.59) with C-2, C-5/9, C-4 and C-1 allowed for its placement at C-3. Based on these spectral data, compound **40** was identified as *trans-p*-hydroxycinnamic acid (Ming *et al.*, 2005). *trans-p*-Hydroxycinnamic acid was previously isolated from *Tephrosia elata* (Atilaw, 2018) but this is its first report in this plant.



40

Table 4.24: NMR Data for Compounds 39 and 40 in Acetone-d₆ (600 MHz)

39				40		
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
1				168.9		
2	80.8	5.44, dd (13.2, 2.9)	C-2', C-6', C-1', C-4	115.9	6.33, d (15.9)	C-4, C-3, C-1
3	44.8	2.67, dd (16.7, 2.8) 3.08, dd (16.7, 13.1)	C-2, C-10, C-1', C-4	145.5	7.59, d (16.0)	C-2, C-5/9, C-4, C-1
4	190.5			127.0		
5	129.5	7.73, d (8.6)	C-9, C-7, C-4	116.7	6.89, d (8.6)	C-4, C-7, C-5/9
6	111.2	6.58, dd (8.7, 2.3)	C-8, C-10	130.8	7.54, d (8.6)	C-6/8, C-7, C-4
7	165.3			160.5		
8	103.7	6.43, d (2.3)	C-6, C-10, C-9, C-7	130.8	7.54, d (8.6)	C-6/8, C-7, C-4
9	164.5			116.7	6.89, d (8.6)	C-4, C-7, C-5/9
10	115.2					
1'	131.8					
2'	111.2	7.20, d (2.0)	C-6', C-2, C-4'			
3'	148.4					
4'	147.8					
5'	115.7	6.87, d (8.1)	C-1', C-3'			
6'	120.5	7.01, dd (8.1, 2.1)	C-2, C-2', C-5', C-4'			
3'-OMe	56.3	3.89, s	C-3'			

4.3.7: 2-Methoxygliricidol (**41**)

Compound **41** was isolated as a white paste. The molecular formula was deduced as C₁₈H₁₆O₇ from its HRESIMS data [M-H₂O]⁺ at *m/z* 327.0869 (calcd C₁₈H₁₇O₇, 345.0969) and NMR data (Table 4.25 and Appendix A41). A rotenoid skeleton was evident from the UV (λ_{\max} 238 and 294 nm) and NMR [δ_{H} 4.56 (1H, dd, *J* = 12.1, 2.5 Hz)/4.45 (1H, dd, *J* = 12.2, 1.1 Hz) for H-6, δ_{H} 4.65 (1H, dd, *J* = 2.5, 1.1 Hz) for H-6a indicating that C-12a (δ_{C} 68.5) is oxygenated] data (Mabry *et al.*, 1970; Agrawal, 1989). The NMR data showed that compound **41** was very similar to compound **19**. The only notable difference was that compound **41** has a hydroxy group at C-9 instead of a methoxy group as in **19**. Therefore, compound **41** was identified as 2-methoxygliricidol (Rastrelli *et al.*, 1999). 2-Methoxygliricidol was previously isolated from *Gliricidia sepium* bark by Rastrelli *et al.*, (1999) but this is its first report in the genus *Tephrosia*.





Table 4.25: NMR Data for Compound 41 in Acetone-d₆ (600 MHz)

41			
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
1	112.4	6.64, s	C-12a, C-1a, C-2, C-3, C-4a
1a	110.1		
2	144.6		
3	152.5		
4	102.0	6.47, s	C-1a, C-2, C-4a, C-3
4a	149.8		
6	64.7	4.56, dd (12.1, 2.5) 4.45, dd (12.2, 1.1)	C-12, C-12a, C-6a, C-4a
6a	77.0	4.65, dd (2.5, 1.1)	C-6a, C-4a, C-12, C-12a
7a	163.2		
8	103.3	6.31, d (2.2)	C-10, C-11a, C-7a
9	166.2		
10	112.0	6.64, dd (8.7, 2.2)	C-8, C-11a
11	130.2	7.75, d (8.7)	C-7a, C-12, C-9
11a	112.2		
12	191.6		
12a	68.5		
2-OMe	56.8	3.60, s	C-2
3-OMe	56.0	3.76, s	C-3

4.3.8: Dehydrorotenone (42)

Compound **42** was isolated as a yellow paste. The molecular formula was deduced as C₂₃H₂₀O₆ from its HRESIMS [molecular ion [M+H]⁺ at *m/z* 393.1330 (calcd C₂₃H₂₁O₆, 393.1330)] and NMR data (Table 4.26 and Appendix A42). A 6a,12a-dehydrorotenoid skeleton was evident from the UV (λ_{\max} 240, 278 and 310 nm) and NMR data [δ_H 5.00 (2H, s) for H-6; δ_C 64.6 for C-6, 156.2 for C-6a and 111.9 for C-12a] (Agrawal, 1989). The NMR data of **42** displayed signals for two methoxy [δ_H 3.96 (δ_C 56.4) and 3.87 (δ_C 56.1)] and 2-isopropenyltetrahydrofuran [δ_H 3.20 (1H, dd, *J* = 15.7, 8.1 Hz/3.53 (1H, dd, *J* = 15.7, 9.9 Hz) for H-4', 5.41 (1H, dd, *J* = 10.0, 7.7 Hz) for H-5', 1.88 (3H, s, for H-8'), 4.98/5.14 (broad-s) for H-7'] groups. Further, the NMR data showed signals for two singlet aromatic protons [δ_H 8.45 and 6.55 and *ortho*-coupled protons [δ_H 8.13, d, *J* = 8.7 Hz and 6.92, d, *J* = 8.6Hz]. The deshielded aromatic proton at δ_H 8.13 showed HMBC correlations with C-7a, C-12 and C-9 which allowed for its placement at C-11 and its coupling partner at C-10. HMBC correlations

of the aromatic singlet protons at δ_{H} 8.45 and 6.55 with C-2 and C-3 placed the methoxy groups at C-2 and C-3. The 2-isopropenyltetrahydrofuran moiety was placed at C-8/C-9 because H-4' had HMBC correlations with C-8 (δ_{C} 113.1), C-7a (δ_{C} 152.4), and C-9 (δ_{C} 165.0). Thus, compound **42** was identified as dehydrorotenone (Carlson *et al.*, 1973; Krupadanam *et al.*, 1977b). Dehydrorotenone was previously isolated from the pods of *Tephrosia villosa* (Krupadanam *et al.*, 1977b) and also from the stems and leaves of *Tephrosia candida* (Roy *et al.*, 1986). This is its first report in this plant.



4.3.9: 6a,12a-Dehydro- α -toxicarol (**43**)

Compound **43** was obtained as a yellow solid. The molecular formula was established as $\text{C}_{18}\text{H}_{16}\text{O}_7$ from its NMR data (Table 4.26 and Appendix A43). An 11-hydroxy-6a,12a-dehydrorotenoid skeleton was evident from the NMR data [δ_{H} 4.99 (3H, s) for H-6 and 13.01 for 11-OH; δ_{C} 67.0 for C-6, 156.9 for C-6a and 110.8 for C-12a]. The NMR data showed the presence of a 2,2-dimethylchromene moiety and two methoxy groups. Further, the NMR data showed signals for three singlet aromatic protons (δ_{H} 8.27, 6.56 and 6.29). The singlet aromatic proton at δ_{H} 6.29 showed HMBC correlations with C-8 and C-11a which allowed for its placement at C-10. HMBC correlations of the aromatic singlet protons at δ_{H} 8.27 and 6.56 with C-2 and C-3 allowed the placement of the methoxy groups at C-2 and C-3. The 2,2-dimethylchromene moiety was placed at C-8/C-9 because H-4' had HMBC correlations with C-8 (δ_{C} 101.1), C-7a (δ_{C} 159.2), and C-9 (δ_{C} 159.7). Thus, compound **43** was identified as

6a,12a-dehydro- α -toxicarol (Lin and Kuo, 1993). This compound was previously reported from *Derris oblonga* (Lin and Kuo, 1993) and *Amorpha fruticosa* (Reisch *et al.*, 1976). This is its first report in this plant.




Table 4.26: NMR Data for Compounds 42 and 43 in Acetone-d₆ (600 MHz)


42				43		
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
1	110.1	8.45, s	C-2, C-3, C-4a, C-12a	110.0	8.27, s	C-2, C-3, C-4a, C-12a
1a	110.7			109.9		
2	144.2			144.3		
3	149.0			149.2		
4	100.5	6.55, s	C-1a, C-2, C-4a	100.7	6.56, s	C-1a, C-2, C-3, C-4a
4a	149.8			149.0		
6	64.6	5.00, s	C-4a, C-6a, C-12a	67.0	4.99, s	C-4a, C-6a, C-12, C-12a
6a	156.2			156.9		
7a	152.4			159.2		
8	113.1			101.1		
9	165.0			159.7		
10	108.9	6.92, d (8.6)	C-8, C-11a	100.8	6.29, s	C-8, C-11a
11	128.0	8.13, d (8.7)	C-7a, C-9, C-12	162.5		
11a	119.1			105.4		
12	174.5			172.5		
12a	111.9			110.8		
4'	31.6	3.20, dd (15.7, 8.1) 3.53, dd (15.7, 9.9)	C-7a, C-8, C-9, C-5', C-6'	114.5	6.64, d (10.1)	C-7a, C-8, C-9, C-6'
5'	130.0	5.41, dd (10.0, 7.7)	C-8, C-6', C-7', C-8'	127.9	5.60, d (10.1)	C-8, C-6', C-7', C-8'
6'	142.9			78.3		
7'	113.2	5.14, s (broad) 4.98, s (broad)	C-5', C-6', C-8'	28.3	1.47, s	C-5', C-6', C-8'
8'	17.2	1.80, s	C-5', C-6', C-7'	28.3	1.47, s	C-5', C-6', C-7'
2-OMe	56.4	3.96, s	2	56.5	3.95, s	2
3-OMe	56.1	3.87, s	3	56.1	3.88, s	3
11-OH					13.01, s	

4.4: Characterization of Compounds Isolated from *Tephrosia elata*

Chromatographic fractionation of the crude extract of the stems of *Tephrosia elata* led to isolation of four compounds; elatisoflavone (**44**), barbigerone (**45**), calopogoniumisoflavone B (**46**) and jamaicin (**47**).

4.4.1: Elatisoflavone (**44**)

Compound **44** was obtained as a white paste. Its molecular formula was deduced as C₂₃H₂₄O₆ from the HRESIMS [molecular ion [M+H]⁺ at *m/z* 397.1642 (calcd for C₂₃H₂₅O₆, 397.1646) and NMR data (Table 4.27 and Appendix A44). The isoflavone skeleton was evident from the UV (λ_{max} 238, 264 and 306 nm) and NMR [δ_{H} 8.12 (1H, s) for H-2; δ_{C} 154.9 for C-2, 122.3 for C-3 and 175.8 for C-4] data (Mabry *et al.*, 1970; Agrawal, 1989). The NMR data showed signals for three methoxy [δ_{H} 3.95 (δ_{C} 56.3), δ_{H} 3.80 (δ_{C} 57.1) and δ_{H} 3.87 (δ_{C} 56.7)] and a 3-methylbut-2-enyl [δ_{H} 3.57 (2H, d, *J* = 7.3 Hz) for methylene, 5.25 (1H, t, *J* = 7.3 Hz) for olefinic methine, 1.67 (3H, s) for methyl and δ_{H} 1.83 (H, s) for methyl] groups. Further, the NMR data exhibited signals for two singlet aromatic protons [δ_{H} 6.98 and 6.78] and *ortho*-coupled protons [δ_{H} 7.89 and 7.06 (1H, d, *J* = 8.7 Hz)]. HMBC correlations of the deshielded proton at δ_{H} 7.89 with C-4 (δ_{C} 175.8), C-7 (δ_{C} 160.4) and C-9 (δ_{C} 156.6) allowed for its placement at C-5 and its coupling partner at C-6. HMBC correlations of the singlet protons at δ_{H} 6.98 (H-3') and 6.78 (H-6') with C-2', C-4' and C-5' placed the three methoxy groups in ring B at C-2', C-4' and C-5'. The placement of the 3-methylbut-2-enyl group at C-8 was consistent with HMBC correlations of H-1" (δ_{H} 3.57) with C-7, C-8 and C-9. Thus, this compound was identified as 7-hydroxy-2',4',5'-trimethoxy-8-(3-methylbut-2-enyl)isoflavone. It is a new compound for which the trivial name elatisoflavone was suggested.



4.4.2: Barbigerone (45)

Compound **45** was isolated as a white paste. Its molecular formula was deduced as $C_{23}H_{22}O_6$ from the HRESIMS [molecular ion $[M+H]^+$ at m/z 395.1487 (calcd for $C_{23}H_{25}O_6$, 395.1489)] and NMR data (Table 4.27 and Appendix A45). The isoflavone skeleton was evident from the UV (λ_{max} 232, 264 and 294 nm) and NMR [δ_H 8.12 (1H, s) for H-2; δ_C 154.9 for C-2, 122.7 for C-3 and 175.4 for C-4] data (Mabry *et al.*, 1970; Agrawal, 1989). The NMR data of this compound were related to that of **44**. The difference was the presence of a 2,2-dimethylchromene moiety [δ_H 1.50, 6H (δ_C 28.2), 5.92, d, $J = 10.0$ Hz (δ_C 131.7) and 6.86, d, $J = 10.0$ Hz (δ_C 115.4)] at C-7/8 in compound **45** instead of the 3-methylbut-2-enyl group in **44**. Compound **45** was, therefore, identified as 2',4',5'-trimethoxy-2'',2''-dimethylpyrano(5'',6'':7,8)isoflavone (barbigerone). Barbigerone was first isolated from *Tephrosia barbiger* (Vilain, 1980) but this is its first report in this plant.





Table 4.27: NMR Data for Compounds 44 and 45 in Acetone-d₆ (600 MHz)

44				45		
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
2	154.9	8.12, s	C-3, C-4, C-9, C-1'	154.9	8.12, s	C-4, C-1', C-9, C-3
3	122.3			122.7		
4	175.8			175.4		
5	125.2	7.89, d (8.7)	C-4, C-7, C-9	127.0	7.94, d (8.8)	C-4, C-7, C-9
6	114.8	7.06, d (8.7)	C-7, C-8, C-10	115.6	6.89, d (8.7)	C-7, C-8, C-10
7	160.4			157.8		
8	116.3			110.3		
9	156.6			153.2		
10	118.7			119.3		
1'	113.8			113.4		
2'	151.1			153.0		
3'	117.7	6.98, s	C-1', C-2', C-4', C-5'	117.7	6.98, s	C-1', C-4', C-5'
4'	144.0			151.3		
5'	153.2			144.0		
6'	99.6	6.78, s	C-3, C-2', C-4', C-5'	99.6	6.79, s	C-2', C-3, C-4'
1''	22.7	3.57, d (7.3)	C-7, C-8, C-9, C-2'', C-3''			
2''	122.7	5.29, t (7.3)	C-1'', C-4'', C-5''	78.5		
3''	132.4			131.7	5.92, d (10.0)	C-8, C-2'', C-4''
4''	25.9	1.67, s	C-2'', C-3'', C-5''	115.4	6.86, d (10.0)	C-7, C-8, C-9, C-2'', C-3''
5''	18.0	1.83, s	C-2'', C-3'', C-4''			
2''-Me ₂				28.2	1.50, s	C-2'', C-3'', C-2''-Me
2'-OMe	56.3	3.95, s	C-2'	56.4	3.88, s	C-2'
4'-OMe	57.1	3.80, s	C-4'	57.1	3.76, s	C-4'
5'-OMe	56.7	3.87, s	C-5'	56.9	3.77, s	C-5'

4.4.3: Calopogoniumisoflavone B (46)

Compound **46** was isolated as a white paste. Its molecular formula was deduced as C₂₁H₁₆O₅ from the HRESIMS [molecular ion [M+H]⁺ at *m/z* 349.1068 (calcd for C₂₁H₁₇O₅, 349.1071)] and NMR data (Table 4.28 and Appendix A46). The isoflavone skeleton was evident from the UV (λ_{max} 230, 264 and 294 nm) and NMR [δ_{H} 8.28 (s, H-2); δ_{C} 153.6 (C-2), 125.0 (C-3) and 175.5 (C-4)] data (Mabry *et al.*, 1970; Agrawal, 1989). The NMR data of this compound showed the presence of a 2,2-dimethylpyrano ring and methylenedioxy residue. Further, the NMR spectra exhibited signals of *ortho*-coupled protons [δ_{H} 7.99 and 6.91 (1H, d, *J* = 8.0 Hz)] and an ABX spin system [δ_{H} 7.19 (1H, d, *J* = 1.8 Hz), 7.11, (1H, dd, *J* = 8.0, 1.8 Hz) and 6.93 (1H, d, *J* = 8.5 Hz)]. The *ortho*-coupled proton at δ_{H} 7.99 showed HMBC correlation with C-4, C-7 and C-9 allowing for its placement at C-5 and its coupling partner at C-6. This implied that the ABX spin system was in ring B. HMBC correlations of the protons at δ_{H} 7.19 (1H, d, *J* = 1.8 Hz) and 7.11 (1H, dd, *J* = 8.0, 1.8 Hz) with C-3 allowed for the placement of the methylenedioxy group at C-3'/4'. Placement of the 2,2-dimethylpyrano ring at C-7/8 was supported by the HMBC correlation of H-4'' with C-7 and C-9. Thus, compound **46** was identified as 4',5'-methylenedioxy-2'',2''-dimethylpyrano(5'',6'':7,8)isoflavone (calopogoniumisoflavone B) (Rao and Murthy, 1985; Sree and Venkata, 1985). Calopogoniumisoflavone B was previously isolated from the roots of *Tephrosia maxima* by Sree and Venkata, (1985) and grains of *Millettia pachyloba* (Mai *et al.*, 2010). This is its first report in this plant.



46

4.4.4: Jamaicin (47)

Compound **47** was isolated as a white paste. Its molecular formula was deduced as $C_{22}H_{18}O_6$ from the HRESIMS [molecular ion $[M+H]^+$ at m/z 379.1177 (calcd for $C_{22}H_{19}O_6$, 379.1177)] and NMR data (Table 4.28 and Appendix A47). The isoflavone skeleton was evident from the UV (λ_{max} 230 and 264) and NMR [δ_H 8.11 (1H, s) for H-2; δ_C 155.0 (C-2), 122.8 (C-3) and 175.3 (C-4)] data (Mabry *et al.*, 1970; Agrawal, 1989). The 1D- and 2D-NMR of this compound (Table 4.28) is closely related with that of **45**. The only difference was the presence of the methylenedioxy group at C-4/5 in compound **47** instead of the methoxy groups at the same positions in **45**. Compound **47** was, therefore, identified as 2'-methoxy-4',5'-methylenedioxy-2'',2''-dimethylpyrano(5'',6'':7,8)isoflavone (jamaicin). Jamaicin was previously isolated from the root of the Jamaican Dogwood *Piscidia erythrina* (Falshaw *et al.*, 1966) and also from the grains of *Millettia pachyloba* (Mai *et al.*, 2010). This is its first report in *Tephrosia*.




Table 4.28: NMR Data for Compounds 46 and 47 in Acetone-d₆ (600 MHz),

46				47		
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
2	153.6	8.28, s	C-3, C-4, C-9	155.0	8.11, s	C-3, C-4, C-9, C-1'
3	125.0			122.8		
4	175.5			175.3		
5	127.0	7.99, d (8.0)	C-4, C-7, C-9	127.0	7.93, d (8.7)	C-4, C-7, C-9
6	115.8	6.91, d (8.2)	C-7, C-8, C-10	115.6	6.89, d (8.6)	C-7, C-8, C-10
7	158.0			157.9		
8	110.2			110.3		
9	153.0			153.0		
10				119.3		
1'	119.2			114.1		
2'	110.5	7.19, d (1.8)	C-3, C-3'	154.1		
3'	148.4			112.0	6.85, s	C-1', C-3', C-4', C-5'
4'				141.8		
5'	108.8	6.93, d (8.5)		149.2		
6'	123.3	7.11, dd (8.0, 1.8)	C-2'	96.1	6.77, s	C-3, C-2', C-4', C-5'
2''	78.6			78.5		
3''	131.8	5.94, d (10.0)	C-8, C-2''	131.8	5.92, d (10.0)	C-8, C-2'', C-2''-Me
4''	115.3	6.87, d (10.0)	C-7, C-2''	115.4	6.86, d (10.1)	C-7, C-9, C-2''
2''-Me ₂	28.2	1.52, s	C-2'', C-3'', C-2''-Me	28.2	1.50, s	C-2'', C-3'', C-2''-Me
2'-OMe				57.1	3.73, s	C-2'
OCH ₂ O	102.1	6.06, s	C-4', C-5'	102.3	5.99, s	C-4', C-5'

4.5: Characterization of Compounds Isolated from *Tephrosia rhodesica*

Chromatographic separation of the crude extract from the stem of *Tephrosia rhodesica* led to the isolation and characterization of eleven compounds; 3-methoxycoumestrol (**48**), glabranin (**49**), 7-*O*-methylglabranin (**50**), liquiritigenin (**51**), naringenin (**52**), rhodiflavan (**53**), 3'-*O*-methylorobol (**54**), genistein (**55**), edunol (**56**), 12a-hydroxyrotenone (**21**) and tephrosin (**23**).

4.5.1: 3-Methoxycoumestrol (**48**)

Compound **48** was isolated as a yellow paste. Its molecular formula was deduced as C₁₆H₁₀O₆ from the HRESIMS [molecular ion [M+H]⁺ at *m/z* 299.0549 (calcd for C₁₆H₁₁O₆, 299.0550)] and NMR data (Table 4.29 and Appendix A48). A coumestan skeleton was evident from the UV (λ_{max} 248, 308 and 348 nm) and NMR [δ_{C} 158.6 (C-2), 104.0 (C-3) and 156.0 (C-4)] data (Mabry *et al.*, 1970; Agrawal, 1989). The NMR spectra exhibited a signal for a methoxy group [δ_{H} 4.00 (δ_{C} 56.9)]. Further, the ¹H NMR spectra displayed signals for a set of ABX spin system [δ_{H} 7.89 (1H, d, *J* = 8.6 Hz), 7.02 (1H, dd, *J* = 8.6, 2.2 Hz) and 6.95 (1H, d, *J* = 2.2 Hz)] and two singlet protons (δ_{H} 7.45 and 7.25). HMBC correlations of the proton at δ_{H} 7.89 with C-4, C-7 and C-8a allowed for its placement at C-5 and its coupling partners δ_{H} 7.02 (1H, dd, *J* = 8.6, 2.2 Hz) and 6.95 (1H, d, *J* = 2.2 Hz) at C-6 and C-8, respectively. The singlet proton at δ_{H} 7.45 was placed at C-10 as it had HMBC correlations with C-3, C-11, C-12 and C-13a. ³J HMBC correlations of the proton at δ_{H} 7.25 with C-11, which in turn correlated with the methoxy protons, placed this substituent at C-11. Based on these spectral data, this compound was identified as 3-methoxycoumestrol. 3-Methoxycoumestrol was previously isolated from alfalfa (*Medicago sativa*) (Bickoff *et al.*, 1966) and the stem of *Vigna angularis* (Guo *et al.*, 2019). This is its first report in this genus.





Table 4.29: NMR Data for Compound 48 in Acetone- d_6 (600 MHz),

48			
Position	δ_C	δ_H , mult. (J in Hz)	HMBC
2	158.6		
3	104.0		
4	156.0		
4a	106.2		
5	123.5	7.89, d (8.6)	C-4, C-7, C-8a
6	114.3	7.02, dd (8.6, 2.2)	
7	160.5		
8	104.1	6.95, d (2.2)	
8a	161.8		
9	115.8		
10	102.8	7.45, s	C-3, C-11, C-12, C-13a
11	147.5		
12	151.1		
13	99.5	7.25, s	C-9, C-11, C-12, C-13a
13a	147.6		
11-OCH ₃	56.9	4.00, s	C-11

4.5.2: *Glabranin* (49)

Compound **49** was isolated as a white paste. Its molecular formula was deduced as $C_{20}H_{20}O_4$ from the HRESIMS [molecular ion $[M+H]^+$ at m/z 325.1433 (calcd for $C_{20}H_{20}O_4$, 325.1433)] together with the NMR data (Table 4.30 and Appendix A49). A 5-hydroxyflavanone skeleton was evident from the UV (λ_{max} 238 and 298 nm) and NMR [AMX spin system: δ_H 5.58 (1H, dd, $J = 12.6, 3.2$ Hz for H-2), 2.85 (1H, m for H-3eq), 3.13 (1H, dd, $J = 17.0, 12.6$ Hz for H-3ax) and 12.12 (1H, s for 5-OH); δ_C 79.7 (C-2), 43.6 (C-3) and 197.2 (C-4)] data (Mabry *et al.*, 1970; Agrawal, 1989). The NMR spectra exhibited signals for a prenyl group [δ_H 3.25 (2H, d, $J = 7.2$ Hz, δ_C 22.3), 5.21 (1H, t, $J = 7.3$ Hz, δ_C 123.7), 1.63 (3H, s, δ_C 25.9) and 1.61 (3H, s, δ_C 17.9)]. Further, the NMR data showed signals for three sets of mutually coupled protons [δ_H 7.59 (2H, m, δ_C 127.1), 7.46 (2H, m, δ_C 129.3) and 7.39 (1H, m, δ_C 129.2)] assigned to


unsubstituted ring B and a singlet proton δ_{H} 6.05 (1H, s) assigned to ring A. HMBC correlations of the singlet proton at δ_{H} 6.05 with C-5 and C-10 allowed for its placement at C-6. The placement of the prenyl group at C-8 was based on the HMBC correlations of H-1'' with C-7, C-8 and C-9. Thus, this compound was identified as 5,7-dihydroxy-8-(3''-methylbut-2''-enyl)flavanone (glabranin). Glabranin was previously isolated from *Glycyrrhiza glabra* (Yuldashev *et al.*, 2000; Biondi *et al.*, 2003, 2005) and also from *Tephrosia purpurea* (Atilaw *et al.*, 2017b). This is, however, its first report in this plant.



49

4.5.3: 7-O-Methylglabranin (50)

Compound **50** was isolated as a white paste. Its molecular formula was deduced as $\text{C}_{21}\text{H}_{24}\text{O}_4$ from the HRESIMS [molecular ion $[\text{M}+\text{H}]^+$ at m/z 341.1749 (calcd for $\text{C}_{21}\text{H}_{25}\text{O}_4$, 341.1747)] and NMR data (Table 4.30 and Appendix A50). A 5-hydroxyflavanone skeleton was evident from the NMR data [AMX spin system: δ_{H} 5.41 (1H, dd, $J = 12.8, 3.1$ Hz for H-2), 2.85 (1H, dd, $J = 17.1, 3.1$ Hz for H-3eq), 3.05 (1H, dd, $J = 17.1, 12.1$ Hz for H-3ax); δ_{C} 78.8 (C-2), δ_{C} 43.6 (C-3), and δ_{C} 196.4 (C-4)] (Mabry *et al.*, 1970; Agrawal, 1989). The NMR data of **50** was closely related to that of **49**. The difference was the presence of a methoxy group [δ_{H} 3.88, 3H (δ_{C} 56.0)] at C-7 in compound **50** rather than a hydroxy group in **49**. Thus, compound **50** was identified as 7-O-methylglabranin (Jayaraman *et al.*, 1980). This compound was previously reported from the roots of *Tephrosia villosa* (Jayaraman *et al.*, 1980) but this is its first report in this plant.



50

Table 4.30: NMR Data for Compounds 49 and 50 in Acetone-d₆ (600 MHz),


49				50		
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
2	79.7	5.58, dd (12.6, 3.2)	C-4, C-1', C-2'/6'	78.8	5.41, dd (12.8, 3.1)	C-1', C-2'/6', C-4
3	43.6	2.85, m 3.13, dd (17.0, 12.6)	C-2, C-4, C-10	43.6	2.85, dd (17.1, 3.1) 3.05, dd (17.1, 12.1)	C-2, C-4, C-10
4	197.2			196.4		
5	162.7			162.8		
6	96.5	6.05, s	C-5, C-7, C-8, C-10	95.7	6.10, s	C-5, C-7, C-8, C-10
7	165.0			165.9		
8	108.3			109.2		
9	160.9			158.9		
10	103.3			103.1		
1'	140.4			139.1		
2'/6'	127.1	7.59, m	C-2, C-2'/6', C-4'	126.1	7.46, m	C- C-2, 2'/6', C-4'
3'/5'	129.4	7.46, m	C-1', C-3'/5'	128.9	7.39, m	C-1', C-3'/5'
4'	129.3	7.39, m	C-2'/6'	129.3	7.42, m	C-2'/6'
1''	22.3	3.25, d (7.2)	C-8, C-7, C-9, C-2''	21.8	3.24, d (8.2)	C-7, C-8, C-9, C-2''
2''	123.7	5.21, t (7.3)	C-4'', C-5''	122.6	5.14, t (7.3)	C-4'', C-5''
3''	131.3			131.3		
4''	25.9*	1.63, s	C-2'', C-3'', C-5''	25.9*	1.67, s	C-2'', C-3'', C-5''
5''	17.9*	1.61, s	C-2'', C-3'', C-4''	17.9*	1.62, s	C-2'', C-3'', C-4''
5-OH		12.12, s			12.13, s	
7-OMe				56.0	3.88, s	C-7

*Interchangeable

*Interchangeable

4.5.4: Liquiritigenin (51)

Compound **51** was isolated as an off-white paste. Its molecular formula was deduced as $C_{15}H_{12}O_4$ from the HRESIMS [molecular ion $[M+H]^+$ at m/z 257.0807 (calcd for $C_{15}H_{13}O_4$, 257.0808)] and NMR data (Table 4.31 and Appendix A51). A flavanone skeleton was evident from the UV (λ_{max} 234, 276 and 312 nm) and NMR [AMX spin system: δ_H 5.45 (1H, dd, $J = 13.0, 2.9$ Hz for H-2), 2.67 (1H, dd, $J = 16.7, 2.9$ Hz for H-3eq) and 3.04 (1H, dd, $J = 16.7, 13.0$ Hz for H-3ax); δ_C 70.5 (C-2), δ_C 44.7 (C-3), δ_C 190.5 (C-4)] data (Mabry *et al.*, 1970; Agrawal, 1989). Further, the NMR data showed signals for AA'XX' set of coupled aromatic protons [δ_H 7.40 and 6.90 (2H, d, $J = 8.6$ Hz)] assigned to ring B and a set of ABX spin systems [δ_H 7.72 (1H, d, $J = 8.7$ Hz), 6.58 (1H, dd, $J = 8.6, 2.3$ Hz) and 6.42 (1H, d, $J = 2.2$ Hz) assigned to ring A]. Thus, compound **51** was identified as 7,4'-dihydroxyflavanone (liquiritigenin) (Recourt *et al.*, 1991). Liquiritigenin has previously been reported from several plants including *Spatholobus suberectus* (Liu *et al.*, 2019) and *Millettia speciosa* (Fu *et al.*, 2016) but this is its first report in the genus *Tephrosia*.



4.5.5: Naringenin (52)

Compound **52** was isolated as an off-white paste. Its molecular formula was deduced as $C_{15}H_{12}O_5$ from the HRESIMS [molecular ion $[M+H]^+$ at m/z 273.0758 (calcd for $C_{15}H_{12}O_5$, 273.0757)] and NMR data (Table 4.31 and Appendix A52). The presence of a 5-hydroxyflavanone skeleton was evident from the UV (λ_{max} 232 and 288 nm) and NMR [δ_H 5.43 (1H, dd, $J = 12.9, 3.1$ Hz for H-2), 2.71 (1H, dd, $J = 17.0, 3.1$ Hz for H-3eq) and 3.15 (1H,

dd, $J = 17.0, 12.9$ Hz for H-3ax); δ_C 79.9, (C-2), 43.5 (C-3) and 196.8 (C-4)] data (Mabry *et al.*, 1970; Agrawal, 1989). The NMR of this compound showed signals for a set of AA'XX' coupled aromatic protons [δ_H 7.41 and 6.89 (2H, d, $J = 8.5$ Hz)] assigned to ring B and two *meta*-coupled aromatic protons [δ_H 5.93 and 5.94 (1H, d $J = 2.2$ Hz)] assigned to ring A. Thus, compound **52** was identified as 5,7,4'-trihydroxyflavanone (naringenin). Naringenin was previously isolated from *Citrus junos* (Heo *et al.*, 2004), *Glycyrrhiza glabra* leaves (Biondi *et al.*, 2005) and the flowers of *Nymphaea mexicana* (Hsu *et al.*, 2013). However, this is its first report in *Tephrosia*.




Table 4.31: NMR data for Compounds 51 and 52 in Acetone-d₆ (600 MHz),

51				52		
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
2	70.5	5.45, dd (13.0, 2.9)	C-4, C-1', C-2'/6'	79.9	5.43, dd (12.9, 3.1)	C-1', C-2'/6'
3	44.7	2.67, dd (16.7, 2.9) 3.04, dd (16.7, 13.0)	C-2, C-4, C-10	43.5	2.71, dd (17.0, 3.1) 3.15, dd (17.0, 12.9)	C-2, C-4, C-1'
4	190.5			196.8		
5	129.5	7.72, d (8.7)	C-4, C-7, C-9			
6	111.2	6.58, dd (8.6, 2.3)	C-10	97.0	5.93, d (2.2)	C-7, C-8, C-10
7	164.5			164.3		
8	103.7	6.42, d (2.2)	C-6, C-7	96.1	5.94, d (1.8)	C-6, C-7, C-10
9	165.3			165.3		
10	115.2			102.8		
1'	131.3			130.9		
2'/6'	129.0	7.40, d (8.5)	C-2, C-2'/6', C-4'	129.0	7.41, d (8.5)	C-2, C-2'/6', C-4'
3'/5'	116.1	6.90, d (8.6)	C-1', C-3'/5'	116.1	6.89, d (8.5)	C-1', C-3'/5'
4'	158.6			158.6		C-2'/6'
5-OH					12.20, s	

4.5.6: Rhodiflavan C (53)

Compound **53** was obtained as an oily paste. Its molecular formula was deduced as $C_{24}H_{28}O_4$ from the HRESIMS molecular ion $[M+H]^+$ at m/z 381.2060 (calcd for $C_{24}H_{29}O_4$, 381.2060) together with NMR data (Table 4.32 and Appendix A53). The presence of a modified flavan-4-ol skeleton was evident from the UV (λ_{max} 230 and 296 nm) and NMR [δ_H 5.55 (1H, dd, $J = 12.9, 2.3$ Hz for H-2), 2.10 (1H, m for H-3eq) and 2.24 (1H, m for H-3ax), 4.69 (1H, t, $J = 2.6$ Hz for H-4); δ_C 79.3 (C-2), 38.8 (C-3), 55.8 (C-4)] data (Mabry *et al.*, 1970; Agrawal, 1989). The NMR data revealed the presence of two prenyl groups (Table 4.32). Further, the NMR data revealed three sets of mutually coupled protons [δ_H 7.54 (2H, m, δ_C 127.5), 7.50 (2H, m, δ_C 129.7) and 7.44 (1H, m, δ_C 129.6] assigned to an unsubstituted ring B, two carbonyl carbons (δ_C 184.3 and 204.6) and a quaternary carbon (δ_C 53.1). Since ring B and C were completely assigned, the prenyl groups, the carbonyl carbons and the quaternary carbon could only be in ring A which is a fully substituted five-membered non-aromatic ring with two carbonyl carbons (Atilaw *et al.*, 2020). This was supported by the HMBC correlations of H-4 (δ_H 4.69) with C-2 (δ_C 79.3), C-8 (δ_C 187.1) and C-9 (δ_C 127.4). The prenyl methylene protons at δ_H 2.45 (H-1'' and H-1''') of both prenyl groups showed HMBC correlations with C-6 (δ_C 204.6), C-7 (δ_C 53.1) and C-8 (δ_C 187.1) placed the two prenyl groups at C-7. Thus, compound **53** was identified as rhodiflavan C (Atilaw *et al.*, 2020). Rhodiflavan C was previously reported from the roots of this plant (Atilaw *et al.*, 2020) but this is its first report from the stem.





Table 4.32: NMR Data for Compound 53 in Acetone-d₆ (600 MHz)

53			
Position	δ_C	δ_H, mult. (J in Hz)	HMBC
2	79.3	5.55, dd (12.4, 2.3)	C-3, C-4, C-1', C-2'/6'
3	38.8	2.10, m 2.24, m	C-2, C-4, C-9, C-1'
4	55.8	4.69, t (2.6)	C-2, C-8, C-9
5	184.3		
6	204.6		
7	53.1		
8	187.1		
9	127.4		
1'	139.8		
2'/6'	127.5	7.54, m	C-2, C-2'/6', C-4'
3'/5'	129.7	7.50, m	C-3'/5', C-1'
4'	129.6	7.44, m	C-2'/6'
1''	33.3	2.45, m	C-6, C-7, C-8, C-2'', C-3'', C-1'''
2''	118.4	4.95, t (7.8)	C-6, C-1'', C-4'', C-5''
3''	136.5		
4''	25.9	1.61, s	C-2'', C-3'', C-5''
5''	17.8	1.57, s	C-2'', C-3'', C-4''
1'''	33.8	2.45, m	C-6, C-7, C-8, C-1'', C-2''', C-3'''
2'''	118.4	4.95, t (7.8)	C-7, C-1''', C-4''', C-5'''
3'''	136.5		
4'''	25.9	1.61, s	C-2''', C-3''', C-5'''
5'''	17.9	1.57, s	C-2'', C-3'', C-4''

4.5.7: 3'-O-Methylorobol (54)

Compound **54** was isolated as a white paste. Its molecular formula was deduced as C₁₆H₁₂O₆ from the HRESIMS [molecular ion [M+H]⁺ at *m/z* 301.0706 (calcd for C₁₆H₁₃O₆, 301.0707)] and NMR data (Table 4.33 and Appendix A54). A 5-hydroxyisoflavone skeleton was evident from the UV (λ_{\max} 228 and 262) and NMR [δ_{H} 8.20 (1H, s for H-2) and 13.04 (1H, s for 5-OH); δ_{C} 154.5 (C-2), 124.1 (C-3) and 181.6 (C-4)] data (Mabry *et al.*, 1970; Agrawal, 1989). The NMR spectra showed signals for a methoxy group [δ_{H} 3.88 (δ_{C} 56.4)]. Further, the ¹H NMR showed signals for *meta*-coupled aromatic protons [δ_{H} 6.29 and 6.42 (1H, d, *J* = 2.0 Hz)] and an ABX spin system [δ_{H} 7.25 (1H, d, *J* = 2.0 Hz), 7.07 (1H, dd, *J* = 8.1, 2.0 Hz) and 6.89 (1H, d, *J* = 8.1 Hz)]. Two of the ABX system protons (δ_{H} 7.25 and 7.07) showed HMBC correlation with C-3 (δ_{C} 124.1) and C-4' (δ_{C} 147.7) placing these protons at C-2' and C-6', respectively, and their coupling partner (δ_{H} 6.89) at C-5'. C-3' showed HMBC correlation with H-5' and methoxy

protons allowing for the placement of the methoxy substituent at C-3' (δ_C 148.0). Based on these spectral data, compound **54** was identified as 5,7,4'-trihydroxy-3'-methoxyisoflavone (3'-*O*-methylorobol). 3'-*O*-Methylorobol was previously reported from *Thermopsis montuna* (Dement and Mabry, 1972). This is its first report in the genus *Tephrosia*.



4.5.8: Genistein (55)

Compound **55** was isolated as a white paste. Its molecular formula was deduced as $C_{15}H_{10}O_5$ from the HRESIMS [molecular ion $[M+H]^+$ at m/z 271.0600 (calcd for $C_{15}H_{10}O_5$, 271.0601)] and NMR data (Table 4.33 and Appendix A55). A 5-hydroxyisoflavone skeleton was evident from the UV (λ_{max} 218 and 262) and NMR [δ_H 8.11 (1H, s for H-2) and 13.01 (1H, s for 5-OH); δ_C 153.9 (C-2), 123.9 (C-3) and 181.4 (C-4)] data (Mabry *et al.*, 1970; Agrawal, 1989; Wang *et al.*, 2007). Further, the NMR exhibited signals for an AA'XX' spin system [$(\delta_H$ 6.74 and 6.90 (2H, d, $J = 8.6$ Hz)] assigned to ring B and *meta*-coupled protons at δ_H 6.26 and 6.38 (1H, d, $J = 1.8$ Hz) assigned to ring A. Thus, compound **55** was identified as 5,7,4'-trihydroxyisoflavone (genistein). Genistein has previously been isolated in many plant species including *Ginkgo biloba* (Wang *et al.*, 2007), *Hericium erinaceum* mycelium (He *et al.*, 2018) and *Tephrosia purpurea* (Atilaw *et al.*, 2017b). This is the first report of genistein in this plant.




Table 4.33: NMR Data for Compounds 54 and 55 in Acetone-d₆ (600 MHz)

54				55		
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
2	154.5	8.20, s	C-3, C-4, C-9	153.9	8.11, s	C-3, C-4, C-9
3	124.1			123.9		
4	181.6			181.4		
5	163.9			163.6		
6	99.9	6.29, d (2.0)	C-7, C-8, C-10	100.3	6.26, d (1.8)	C-8, C-10
7	165.3			163.8		
8	94.5	6.42, d (2.1)	C-6, C-7, C-9, C-10	94.8	6.38, d (1.9)	C-6, C-9, C-10
9	159.0			159.2		
10	106.1			105.4		
1'	123.4			123.2		
2'	113.7	7.25, d (2.0)	C-3, C-1', C-4', C-3', C-6'	131.2	7.45, d (8.6)	C-3, C-2'/6', C-4'
3'	148.0			115.9	6.90, d (8.6)	C-1', C-3'/5'
4'	147.7			158.3		
5'	115.7	6.89, d (8.1)	C-1', C-3', C-4'	115.9	6.90, d (8.6)	C-1', C-3'/5'
6'	122.8	7.07, dd (8.2, 2.0)	C-3, C-2', C-4'	131.2	7.45, d (8.6)	C-3, C-2'/6', C-4'
5-OH		13.04, s			13.01, s	
3'-OMe	56.4	3.88, s	C-2'			

4.5.9: Edunol (56)

Compound **56** was isolated as a white paste. Its molecular formula was deduced as C₂₁H₂₀O₅ from its HRESIMS [molecular ion peak [M+H]⁺ at *m/z* 353.1382 (calcd for C₂₁H₂₁O₅, 353.1382)] and NMR data (Table 4.34 and Appendix A56). A pterocarpan skeleton was evident from the UV (λ_{\max} 234 and 310) and NMR [δ_{H} 3.55 (1H, m)/4.24 (1H, dd, *J* = 10.0, 4.0 Hz) for H-6, 3.52 (1H, m for H-6a) and 5.46 (1H, d, *J* = 6.7 Hz for H-11a); δ_{C} 67.0 (C-6), δ_{C} 41.1 (C-6a) and δ_{C} 79.5; (C-11a)] data (Mabry *et al.*, 1970; Agrawal, 1989). The NMR data showed the presence of a prenyl [δ_{H} 3.29 (2H, d, *J* = 7.4 Hz, δ_{C} 28.4); 5.35 (1H, t, *J* = 7.4 Hz, δ_{C} 123.9), 1.73 (3H, s, δ_{C} 25.9) and 1.73 (3H, s, δ_{C} 17.8)] and a methylenedioxy (δ_{H} 5.91, δ_{C} 102.1) substituent. Further, the NMR data showed signals for four aromatic singlets (δ_{H} 7.16, 6.88, 6.40 and 6.39). HMBC correlations of the singlet proton at δ_{H} 7.16 (H-1) with C-1', C-11a, C-11b, C-4a, C-3 and C-2 allowed for its placement at C-1, whereas the proton at δ_{H} 6.39 showed correlations with C-11b, C-3, C-2 and C-4a allowing for its placement at C-4. HMBC correlation of the protons at δ_{H} 6.88 and 6.40 with C-8 and C-9 placed the methylenedioxy group at C-8/9. Placement of the prenyl to C-2 was based on the HMBC correlations of H-1' (δ_{H} 3.29) with C-1 and C-3. Based on these spectral data, this compound was identified as 3-hydroxy-2-prenyl-8,9-methylenedioxypterocarpan (edunol). Edunol was previously reported from *Brongniartia podalyrioides* and *Tephrosia purpurea* (Reyes-Chilpa *et al.*, 1994; Li *et al.*, 2011). This is its first report in this plant.




Table 4.34: NMR Data for Compound 57 in Acetone-d₆ (600 MHz)

56			
Position	δ_C	δ_H , mult. (<i>J</i> in Hz)	HMBC
1	132.4	7.16, s	C-2, C-3, C-4a, C-11a, C-11b, C-1'
2	112.5		
3	157.0		
4	103.5	6.39, s	C-2, C-3, C-4a, C-11b
4a	155.6		
6	67.0	3.55, m 4.24, dd (10.0, 4.0)	C-4a, C-6a, C-6b, C-11a
6a	41.1	3.52, m	C-6, C-6b, C-10a
6b	119.6		
7	105.9	6.88, s	C-6a, C-8, C-9, C-10, C-10a
8	142.4		
9	148.9		
10	94.0	6.40, s	C-6b, C-8, C-9, C-10a
10a	155.3		
11a	79.5	5.46, d (6.7)	C-1, C-4a, C-6a, C-10a, C-11b
11b	103.5		
1'	28.4	3.29, d (7.4)	C-1, C-2'
2'	123.9	5.35, t (7.4)	C-4', C-5'
3'	132.3		
4'	25.9	1.73, s	C-2', C-3', C-5'
5'	17.8	1.73, s	C-2', C-3', C-4',
OCH ₂ O	102.1	5.91, s	C-8, C-9

4.6: Synthesis of Pyrazoisopongaflavone (57)

Pyrazoisopongaflavone (**57**), a pyrazole derivative of isopongaflavone (**38**), was prepared by using hydrazine monohydrate. It was obtained as an off-white paste. Its molecular formula C₂₁H₂₂O₃N₂ was established from the HRESIMS molecular ion peak [M+H]⁺ at *m/z* 351.1696 (calcd for C₂₁H₂₃O₃N₂, 351.1703) and [M+Na]⁺ at *m/z* 373.1516 (calcd for C₂₁H₂₂O₃N₂Na 373.1523). The NMR data confirmed the presence of a methoxy group at δ_H 3.91 (δ_C 55.9), an unsubstituted benzene ring [δ_H 7.85 (126.6 for C-2''/6''), 7.50 (130.1 for C-3''/5'') and 7.41 (129.5 for C-4'')] and 2',2'-dimethylchromane ring [δ_H 1.80 (δ_C 33.2 for C-3'), 2.60 (δ_C 17.7 for C-4'), 1.32 (δ_C 27.1 for C-2'-Me₂) and 6.02 (δ_C 92.3 for C-8'); δ_C 75.0 (C-2'), 102.4 (C-4'a), 157.4 (C-5'), 99.8 (C-6'), 158.3 (C-7') and 155.7 (C-8'a)] (Table 4.35 and Appendix A57). The pyrazole ring was evident from the ¹³C NMR signals at δ_C 151.6 (C-3), 104.2 (C-4) and 143.4

(C-5) (He *et al.*, 2009). Based on these spectroscopic characteristics, compound **57** was elucidated as 3-(5-hydroxy-7-methoxy-2,2-dimethylchromanyl)-5-phenyl-pyrazole.




Table 4.35: NMR Data for Compound 57 in Acetone-d₆ (600 MHz)

57			
Position	δ_C	δ_H, mult. (<i>J</i> in Hz)	HMBC
2			
3	151.6		
4	104.2	7.34, s	C-3, C-5
5	143.4		
2'	75.0		
3'	33.2	1.80, t (6.8, 6.8)	C-2', C-4', C-4'a, C-2'-Me ₂
4'	17.7	2.64, t (6.8, 6.8)	C-2', C-3', C-4'a, C-5, C-8'a
4'a	102.4		
5'	157.4		
6'	99.8		
7'	158.3		
8'	92.3	6.02, s	
8'a	155.7		
1''	130.5		
2''/6''	126.6	7.85, m	C-2''/6'', C-4''
3''/5''	130.1	7.50, m	C-1'', C-3''/5''
4''	129.5	7.41, m	C-2''/6''
2'-Me ₂	27.1	1.32, s	C-2', C-3', C-2'-Me
7'-OMe	55.9	3.91, s	C-7

4.7: Anti-inflammatory Activity

An assay was conducted to assess the anti-inflammatory activities of the crude extracts as well as the compounds isolated from the aerial parts of *T. linearis*, aerial parts of *T. hildebrandtii*, seedpods of *T. vogelii*, the stem of *T. elata* and stem of *T. rhodesica*. Further, the synergistic anti-inflammatory activities of the different classes of flavonoids were also investigated. This assay was done by measuring the levels of cytokines (IL-1 β , IL-2, IFN- γ , GM-CSF and TNF- α) released from LPS-stimulated PBMCs. The tests relied on the evidence that during inflammation, cytokines are secreted from the PBMCs as part of the inflammatory reaction (Davis *et al.*, 2010). This can be assessed by incubating PBMCs with bacterial LPS (O'Bryan *et al.*, 2000). Therefore, the cytokine release from LPS stimulated PBMC was quantified with or without tested compounds in the supernatant by Luminex. The results of the assays are discussed below.

4.7.1: Activity of Compounds Isolated from Tephrosia linearis

Figure 4.3 shows the results for controls and it is clear that in the presence of LPS, the PBMCs were induced to secrete the cytokines as compared to the medium., It also observed that ibuprofen, the standard drug suppressed the release of the cytokines to 12.2–80.3% of the LPS control except for IL-1 β secretion which was increased to 199.3% (Table 4.36).




Figure 4.3: The LPS stimulated the secretion of the cytokines in comparison to untreated control cells and ibuprofen (mean \pm SD, n=3 for medium and n = 4 for LPS and ibuprofen)¹

As shown in (Figure 4.4 and Table 4.36), the crude extract reduced the production of all cytokines except IL-1 β that slightly increased to about 107.67% in comparison to the LPS control. All the compounds evaluated resulted in decreased release of IL-2, GM-CSF and TNF- α . Compounds **1**, **2**, **4**, **7**, **10**, **13**, **15** and **16** decreased the production of IL-1 β with a strong inhibitory effect occurring in the presence of compound **13**. Except for compounds **3** and **11**, which provoked the production of IL-6, the rest of the compounds reduced their production.

¹ The data used to generate the graphs is presented in Appendix B1, Table B1.




Figure 4.4: The cytokine release after LPS stimulated PMBCs incubated with the crude extracts and isolated compounds from *Tephrosia linearis*²

² The data used to generate the graphs are presented in Appendix B1, Table B2

Table 4.36: The Percentage of Cytokine Release in Comparison to Lipopolysaccharide Control after Incubation with Compounds from *Tephrosia linearis*³

Samples	Percentage cytokine Release				
	IL-1 β	IL-2	IL-6	GM-CSF	TNF- α
Ibuprofen	199.29	80.33	46.46	47.76	12.23
Crude Extract	107.67	17.72	13.91	36.83	4.61
1	68.27	57.60	10.89	17.39	0.92
2	1.18	57.60	0.00	8.63	0.17
3	169.84	17.72	622.32	78.39	1.89
4	75.85	57.60	97.43	83.73	3.15
5	170.51	17.72	43.11	17.39	4.03
6	157.09	17.72	43.39	40.97	2.66
7	53.77	17.72	25.79	32.47	4.03
8	102.34	57.64	19.57	46.89	6.38
9	220.43	57.60	100.00	35.76	12.55
10	40.83	17.72	24.72	48.79	5.01
11	103.28	57.64	238.54	38.92	5.20
12	105.17	57.60	48.33	32.47	4.22
13	0.67	57.60	0.04	8.63	0.17
14	0.80	57.60	0.09	8.63	0.92
15	48.35	57.64	7.23	4.87	1.12
16	109.22	57.64	100.00	92.58	3.64
17	4.81	57.60	0.64	8.63	0.54
18	148.44	17.72	24.94	48.79	3.83

4.7.2: Activity of Compounds Isolated from *Tephrosia hildebrandtii*

The anti-inflammatory activities of the crude extract of *T. hildebrandtii*, as well as the isolated compounds (**25-32**), were assessed for their anti-inflammatory activities. The crude extract decreased the production of IFN- γ , GM-CSF, and TNF- α . However, the crude extract did not affect IL-6 but provoked the production of IL-1 β and IL-2 to 139 % and 106%, respectively, as compared to the LPS control (Table 4.37 and Figure 4.5). Almost, all the compounds showed superior suppression of the cytokines compared to ibuprofen. The strongest inhibition for IL-6 release was observed for compound **27**, an isoflavone that attenuated the production to 0.6% compared to LPS. Similarly, compound **27** attenuated the production of TNF- α to 0.4% compared to LPS. The pterocarpan (compounds **29** and **30**) exhibited the highest reduction in the production of IFN- γ to 2.7% and GM-CSF to 11.0%, respectively, as compared to LPS.

³ The data used for calculation of the percentage cytokine release is presented in the Appendix B1, Table B2

While compounds **25**, **27**, **28**, **30** and **32** suppressed the production of IL-1 β , compounds **26**, **29** and **31** stimulated its production. The strongest inhibition was exhibited by compound **30** which decreased IL-1 β production to 20.2% in comparison to LPS control.




Figure 4.5: The cytokine release after LPS stimulated PMBCs incubated with the crude extracts and isolated compounds from *Tephrosia hildebrandtii*⁴

⁴ The data used to generate the graphs are presented in Appendix B1, Table B2

Table 4.37: The Percentage of Cytokine Release in Comparison to Lipopolysaccharide Control after Incubation with Compounds from *Tephrosia hildebrandtii*⁵

Sample	Percentage Cytokine Release					
	IL-1 β	IL-2	IL-6	IFN- γ	GM-CSF	TNF- α
Ibuprofen	199.3	80.3	46.5	51.2	47.8	12.2
THC	139.0	106.1	100.0	8.6	57.9	3.3
25	32.5	17.7	7.4	35.5	43.0	2.9
26	153.9	17.7	13.0	35.5	48.8	6.4
27	27.1	57.6	0.6	35.5	14.4	0.4
28	77.0	17.7	17.5	35.5	43.0	2.3
29	140.3	17.7	67.8	2.7	48.8	3.1
30	20.2	17.7	5.8	35.5	11.0	1.1
31	146.1	57.6	29.4	8.6	40.0	6.6
32	57.6	57.6	10.0	35.5	1.9	1.5

4.7.3: Activity of Compounds Isolated from *Tephrosia vogelii*

The crude extract, as well as three compounds (35, 36 and 38) obtained from *T. vogelii* seedpods, were assessed for their anti-inflammatory activities. As shown in Figure 4.6 and Table 4.36, all the tested compounds and the crude extract showed a decreased IL-1 β release between 57.9 and 75.2% compared to the LPS control. In comparison, ibuprofen resulted in a decreased IL-1 β release of 25.5% compared to the LPS control. IFN- γ release was decreased between 0.5% and 10.1% when treated with the compounds as well as the crude extract. Likewise, ibuprofen led to a decreased IFN- γ production of 16.8%. All the tested compounds and crude extract were able to decrease the GM-CSF release from the PBMCs. In comparison, the GM-CSF release was reduced to 24.2% in the presence of ibuprofen. The suppression of the release of TNF- α by all the compounds and the crude was more significant than that of ibuprofen.

⁵ The data used for calculation of the percentage cytokine release is presented in the Appendix B1, Table B2




Figure 4.6: The cytokine release after LPS stimulated PMBCs incubated with the crude extracts and isolated compounds from *Tephrosia vogelii*⁶

Table 4.38: The Percentage of Cytokine Release in Comparison to Lipopolysaccharide Control after Incubation with Compounds from *Tephrosia vogelii*⁷

Sample	Percentage Cytokine Release			
	IL-1 β (%)	IFN- γ (%)	GM-CSF (%)	TNF- α (%)
Ibuprofen	25.5	16.8	24.2	32.2
35	65.1	10.1	86.7	22.7
36	16.0	0.5	17.6	2.2
38	57.9	1.4	7.1	0.7
57	74.6	3.9	148.8	8.5
Crude extract	75.2	1.1	66.1	3.2

4.7.4: Activity of Compounds Isolated from *Tephrosia elata*

All the compounds (44-47) tested decreased the production of IL- β , IFN- γ , GM-CSF, and TNF- α though, the activity of ibuprofen was better than most of the compounds. Compound 45

⁶ The data used to generate the graphs are presented in Appendix B1, Table B3 and B4

⁷ The data used for calculation of the percentage cytokine release is presented in the Appendix B1, Table B3 and B4

exhibited relatively strong inhibition by decreasing the production of IFN- γ to 0.3 and TNF- α to 3.4% compared to LPS.

Table 4.39: The Percentage of Cytokine Release in Comparison to Lipopolysaccharide Control after Incubation with Compounds from *Tephrosia elata*⁸

Sample	Percentage Cytokine Release			
	IL-1 β	IFN- γ	GM-CSF	TNF- α
44	65.6	11.9	59.2	28.5
45	30.0	0.3	29.3	3.4
46	46.9	3.5	49.7	16.6
47	91.2	49.2	43.9	56.7
Ibuprofen	25.5	16.8	24.2	32.2




Figure 4.7: The cytokine release after LPS stimulated PMBCs incubated with the crude extracts and isolated compounds from *Tephrosia elata*⁹

⁸ The data used for calculation of the percentage cytokine release is presented in the Appendix B1, Table B3 and B4

⁹ The data used to generate the graphs are presented in Appendix B1, Table B3 and B4

4.7.5: Activity of Compounds Isolated from *Tephrosia rhodesica*

The crude extract decreased the production of IL-1 β , IFN- γ and TNF- α except for GM-CSF which was increased to 188% as compared to the LPS control (Table 4.40 and Figure 4.8). All the compounds (48, 52-56) decreased the production of IL-1 β , IFN- γ except compound 56 which stimulated the production of GM-CSF to about 248.1% compared to ibuprofen (Figure 4.8 and Table 4.40). Compounds 53-55 exhibited a strong reduction of IFN- γ release compared to LPS. Similarly, compound 55 attenuated the production of TNF- α to 5.1% compared to LPS.




Figure 4.8: IL-1 β , IFN- γ , GM-CSF and TNF- α release after LPS stimulated PMBCs incubated with the crude extracts and isolated compounds from *Tephrosia rhodesica*¹⁰

¹⁰ The data used to generate the graphs are presented in Appendix B1, Table B3 and B4

Table 4.40: The Percentage of Cytokine Release in Comparison to Lipopolysaccharide Control after Incubation with Compounds from *Tephrosia rhodesica*¹¹

Sample	Percentage Cytokine Release			
	IL-1 β	IFN- γ	GM-CSF	TNF- α
Ibuprofen	25.5	16.8	24.2	32.2
Crude extract	45.0	0.5	188.1	20.6
48	58.7	2.5	142.5	9.9
52	57.6	5.8	70.2	17.8
53	43.6	1.0	79.9	12.8
54	76.1	0.8	34.7	2.8
55	72.5	0.9	60.6	5.1
56	63.4	3.6	248.1	33.4
57	74.6	3.9	148.8	8.5

4.7.6: Anti-inflammatory Activity of Pyrazoisopongaflavone (57)

Pyrazoisopongaflavone (57) which was structurally modified from isopongaflavone (38) was evaluated for anti-inflammatory activity. Pyrazoisopongaflavone (57) decreased the production of IL- β , IFN- γ , and TNF- α to 74.6, 3.9 and 8.5%, respectively, compared to isopongaflavone (38) which decreased the production of IL- β , IFN- γ and TNF- α to 57.9, 1.4 and 0.7%. Pyrazoisopongaflavone stimulated the production of GM-CSF to about 148% but isopongaflavone reduced its production to 7.1%. It is worth noting that the conversion of some natural products such as curcumin into their pyrazole derivatives enhanced their anti-inflammatory activity (Somchit *et al.*, 2018; Fernández-Moriano *et al.*, 2019). Also, pyrazole derivatives have been found to have potent anti-inflammatory properties and some, such as celecoxib, have been developed into anti-inflammatory drugs (Ismail *et al.*, 2009; McCormack, 2011; Karrouchi *et al.*, 2018). However, in this study, isopongaflavone was found to be more active than its pyrazole derivative, pyrazoisopongaflavone.

¹¹ The data used for calculation of the percentage cytokine release is presented in the Appendix B1, Table B3 and B4

4.7.7: Synergistic Anti-inflammatory Activities of the Isolated compounds

The synergistic anti-inflammatory activities of combinations of flavonoids isolated in this study were evaluated. The combinations were as follows: group 1 (compounds **1-2**, **8**, and **9**), group 2 (compounds **12-17**, **5**), group 3 (compounds **6**, **7**, **10** and **11**), group 4 (compounds **25**, **31** and **32**), group 5 (compounds **26**, **27**) and group 6 (compounds **28 - 30**). As shown in Figure 4.9 and Table 4.41, all the combinations showed a reduction of IL-1 β , IFN- γ , GM-CSF and TNF- α production except group 5 that stimulated the production of GM-CSF to about 184% in comparison to the LPS control. Groups 1-3 reduced the secretion of IL-6, IFN- γ and TNF- α to levels that were not expressively different from the untreated control (medium). Generally, the combinations of flavonoids showed stronger activities than the individual compounds. For instance, lineaflavone B (**2**) was the most active compound among the compounds in group 1 decreasing the production of IL-1 β , IFN- γ , GM-CSF and TNF- α to 1.2, 35.6, 17.4 and 0.2% as compared to LPS, respectively (Table 4.36). However, group 1 decreased the production of IL-1 β , IFN- γ , GM-CSF to 0.3, 0.2, 3.4 and 0.0%, respectively and a similar trend was observed in all other groups. Thus, combining the flavonoids showed synergism.

Generally, the results for anti-inflammatory activities of the isolated compounds and combinations supplement early reports on anti-inflammatory properties of flavonoids (Tordera *et al.*, 1994; Hyun Pyo *et al.*, 2004; Ko *et al.*, 2004; Ibrahim *et al.*, 2007; Huang *et al.*, 2009; Feng *et al.*, 2012; Hu *et al.*, 2017; Ryu *et al.*, 2019). For instance, luteolin (**13**) was earlier found to suppress the NF- κ B pathway and inhibit the release of pro-inflammatory cytokines (Ueda *et al.*, 2002; Seelinger *et al.*, 2008) and in this study, luteolin showed anti-inflammatory effect by reducing the production of IL-1 β , IL-2, IL-6, GM-CSF and TNF- α (Table 4.36).




Figure 4.9: IL-1 β , IFN- γ , GM-CSF and TNF- α release after LPS stimulated PMBCs incubated with the crude extracts and combinations of isolated compounds¹²

Table 4.41: The Percentage of Cytokine Release in Comparison to Lipopolysaccharide Control after Incubation with combinations of isolated compounds¹³

Sample	Percentage Cytokine Release in Comparison LPS Control			
	IL-1 β	IFN- γ	GM-CSF	TNF- α
Ibuprofen	25.5	16.8	24.2	32.2
Group 1	0.3	0.2	3.4	0.0
Group 2	0.1	0.2	3.4	0.1
Group 3	3.4	0.2	2.1	0.1
Group 4	21.1	0.1	3.7	1.0
Group 5	79.4	1.2	184.3	7.9
Group 6	40.0	0.3	12.1	1.7

¹² The data used to generate the graphs are presented in Appendix B1, Table B5. THC = crude extract of *Tephrosia hildebrandtii* and TLC = crude extract of *Tephrosia linearis*.

¹³ The data used to generate the table are presented in Appendix B1, Table B5.

CHAPTER 5: CONCLUSIONS AND RECOMMENDATIONS

5.1: Conclusions

In this study, five plants in the genus *Tephrosia* Pers. (Fabaceae) namely; *Tephrosia linearis*, *Tephrosia hildebrandtii*, *Tephrosia vogelii*, *Tephrosia elata* and *Tephrosia rhodesica* were phytochemically investigated and a total of fifty-six compounds were isolated and characterized. The compounds were evaluated for their anti-inflammatory activities and their synergistic effects.

The specific conclusions drawn from this study are outlined herein.

- i. Phytochemical investigation of the selected plants led to isolation and characterization of eleven new compounds (**1-7**, **25**, **35**, **36** and **44**) and forty-five known compounds (**8-24**, **26-34**, **37-43** and **45-56**) as summarised in Table 5.1. It is worthy to note that isopongaflavone (**38**) was structurally modified to the pyrazole derivative pyrazoisopongaflavone (**57**).

Table 5.1: Summary of the Compounds Characterized from the five *Tephrosia* species

Plant species (part)	New compounds	Known compounds
<i>T. linearis</i> (AP)	Seven (1-7)	Sixteen (8-24)
<i>T. hildebrandtii</i> (AP)	One (25)	Ten (22 , 26-34)
<i>T. vogelii</i> (SD)	Two (35 and 36)	Ten (34 , 37-43)
<i>T. elata</i> (ST)	One (44)	Three (45-47)
<i>T. rhodesica</i> (ST)	-	Eleven (21 , 23 and 48-56)

Key: AP-aerial parts, SD -seedpods and ST-stems

- ii. The treatment of LPS-stimulated PBMCs with the isolated compounds (at 100 μ M) and extracts (100 μ g/mL) showed anti-inflammatory activities by suppressing the production of the pro-inflammatory cytokines (IL-1 β , IL-2, IL-6, IFN- γ , GM-CSF and

TNF- α). Among the compounds that were tested, lineaflavone B (**2**), luteolin (**13**), patuletin-3-*O*-rhamnoside (**16**) and pisatin (**30**) showed the strongest activity.

- iii. The synergistic anti-inflammatory effects of the isolated compounds were also investigated. All the combinations of flavonoids (groups 1-6) showed superior anti-inflammatory activities than the individual flavonoids isolated in this study suggesting anti-inflammatory synergetic effects.

5.2: Recommendations

Based on the results of this study, the recommendations are made as follows:

1. Since the plants investigated led to the isolation of novel compounds and structurally diverse flavonoids with the potential to serve as anti-inflammatory agents, further phytochemical studies should be carried on other parts of these plants.
2. Diverse analogues of the most active compounds should be prepared to optimize their anti-inflammatory effects.
3. The cytotoxicity of the most active compounds should be evaluated to determine their safety.

REFERENCE

- Abdallah, H. M., Almowallad, F. M., Esmat, A., Shehata, I. A., and Abdel-Sattar, E. A. (2015). Anti-inflammatory activity of flavonoids from *Chrozophora tinctoria*. *Phytochemistry Letters*, 13, 74-80.
- Abdel-Kader, M. S. (2001). Phenolic Constituents of *Ononis vaginalis* Roots. *Planta Medica*, 67(04), 388-390.
- Abdulkhaleq, L. A., Assi, M. A., Abdullah, R., Zamri-Saad, M., Taufiq-Yap, Y. H., and Hezmee, M. N. M. (2018). The crucial roles of inflammatory mediators in inflammation: A review. *Veterinary world*, 11(5), 627-635.
- Abegaz, B. M., Ngadjui, B. T., Dongo, E., and Tamboue, H. (1998). Prenylated chalcones and flavones from the leaves of *Dorstenia kameruniana*. *Phytochemistry*, 49(4), 1147-1150.
- Abidi, S. L. (1987). Optical resolution of rotenoids. *Journal of Heterocyclic Chemistry*, 24(3), 845-852.
- Abreu, P. M., and Luis, M. H. (1996). Constituents of *Tephrosia Uniflora*. *Natural Product Letters*, 9(2), 81-86.
- Adauidi, A., Aluwong, T., Salawu, O., and Anuka, J. (2009). Blood pressure, analgesic and anti-inflammatory properties of methanolic extracts of *Tephrosia vogelii* in experimental animals. *Nigerian Veterinary Journal*, 30(3), 37-43.
- Agbeko, R. S., and Peters, M. J. (2011). Chapter 90 - The Innate Immune System. In Fuhrman, B. P. and Zimmerman, J. J. (Eds.), *Pediatric Critical Care (Fourth Edition)* (pp. 1267-1273). Saint Louis: Mosby.
- Aggarwal, B. B., Vijayalekshmi, R. V., and Sung, B. (2009). Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe. *Clinical Cancer Research*, 15(2), 425-430.

- Agnew, A. D. Q. (2013). *Upland Kenya Wild Flowers and Ferns: A Flora of the Flowers, Ferns, Grasses, and Sedges of Highland Kenya* (Third ed.). Nairobi: Nature Kenya, The East Africa Natural History Society.
- Agrawal, P. K. (1989). *Carbon-13 NMR of flavonoids* (Vol. 39). Amsterdam, The Netherlands: Elsevier.
- Ahmad, S. (1986). Natural occurrence of *Tephrosia* flavones. *Phytochemistry*, 25(4), 955-958.
- Al-Ghamdi, F. A. (2013). Morphological Diversity of Some *Tephrosia* Species (Fabaceae) in Saudi Arabia. *American Journal of Plant Sciences*, 04(03), 6.
- Andrei, C. C., Ferreira, D. T., Faccione, M., de Moraes, L. A. B., de Carvalho, M. G., and Braz-Filho, R. (2000). C-prenylflavonoids from roots of *Tephrosia tunicata*. *Phytochemistry*, 55(7), 799-804.
- Atilaw, A. Y. (2018). *Phytochemical investigation of selected Tephrosia species for antiplasmodial and anti-inflammatory principles*. (PhD Thesis), University Of Nairobi, Nairobi.
- Atilaw, Y., Duffy, S., Heydenreich, M., Muiva-Mutisya, L., Avery, V., Erdélyi, M., and Yenesew, A. (2017a). Three Chalconoids and a Pterocarpene from the Roots of *Tephrosia aequilata*. *Molecules*, 22(2), 318.
- Atilaw, Y., Muiva-Mutisya, L., Bogaerts, J., Duffy, S., Valkonen, A., Heydenreich, M., Avery, V. M., Rissanen, K., Erdélyi, M., and Yenesew, A. (2020). Prenylated Flavonoids from the Roots of *Tephrosia rhodesica*. *Journal of Natural Products*, 83(8), 2390-2398.
- Atilaw, Y., Muiva-Mutisya, L., Ndakala, A., Akala, H., Yeda, R., Wu, Y., Coghi, P., Wong, V., Erdélyi, M., and Yenesew, A. (2017b). Four Prenylflavone Derivatives with Antiplasmodial Activities from the Stem of *Tephrosia purpurea* subsp. *leptostachya*. *Molecules*, 22(9), 1514.

- Attiq, A., Jalil, J., Husain, K., and Ahmad, W. (2018). Raging the War Against Inflammation With Natural Products. *Frontiers in Pharmacology*, 9, 976-976.
- Auditeau, E., Chassagne, F., Bourdy, G., Bounlu, M., Jost, J., Luna, J., Ratsimbazafy, V., Preux, P.-M., and Boumediene, F. (2019). Herbal medicine for epilepsy seizures in Asia, Africa and Latin America: A systematic review. *Journal of Ethnopharmacology*, 234, 119-153.
- Banerjee, T., Valacchi, G., Ziboh, V. A., and van der Vliet, A. (2002). Inhibition of TNF α -induced cyclooxygenase-2 expression by amentoflavone through suppression of NF- κ B activation in A549 cells. *Molecular and Cellular Biochemistry*, 238(1), 105-110.
- Banerji, A., Luthria, D. L., and Prabhu, B. R. (1988). Prenylated compounds from *Atalantia racemosa*: isolation and synthesis of two pyranoflavones. *Phytochemistry*, 27(11), 3637-3640.
- Banoub, J., Delmas Jr., G.-H., Joly, N., Mackenzie, G., Cachet, N., Benjelloun-Mlayah, B., and Delmas, M. (2015). A critique on the structural analysis of lignins and application of novel tandem mass spectrometric strategies to determine lignin sequencing. *Journal of Mass Spectrometry*, 50(1), 5-48.
- Barnes, P. J. (1998). Anti-inflammatory Actions of Glucocorticoids: Molecular Mechanisms. *Clinical Science*, 94(6), 557-572.
- Beattie, K. D. (2009). *Phytochemical studies and bioactivity of Centipeda and Eremophila species*. Southern Cross University.
- Bedane, K. G., Kusari, S., Masesane, I. B., Spiteller, M., and Majinda, R. R. T. (2016). Flavanones of *Erythrina livingstoniana* with antioxidant properties. *Fitoterapia*, 108, 48-54.

- Bentley, M. D., Hassanali, A., Lwande, W., Njoroge, P. E. W., Sitayo, E. N. O., and Yatagai, M. (1987). Insect antifeedants from *Tephrosia elata* Deflers. *Insect Science and Its Application*, 8(1), 85-88.
- Bickoff, E. M., Spencer, R. R., Knuckles, B. E., and Lundin, R. E. (1966). 3'-Methoxycoumestrol from Alfalfa: Isolation and Characterization. *Journal of Agricultural and Food Chemistry*, 14(5), 444-446.
- Biljana, B. P. (2012). Historical review of medicinal plants' usage. *Pharmacognosy Review*, 6(11), 1-5.
- Biondi, D. M., Rocco, C., and Ruberto, G. (2003). New Dihydrostilbene Derivatives from the Leaves of *Glycyrrhiza glabra* and Evaluation of Their Antioxidant Activity. *Journal of Natural Products*, 66(4), 477-480.
- Biondi, D. M., Rocco, C., and Ruberto, G. (2005). Dihydrostilbene Derivatives from *Glycyrrhiza glabra* Leaves. *Journal of Natural Products*, 68(7), 1099-1102.
- Bond, W. S. (1977). Toxic reactions and side effects of glucocorticoids in man. *American Journal of Hospital Pharmacy*, 34(5), 479-485.
- Botting, R., and Ayoub, S. S. (2005). COX-3 and the mechanism of action of paracetamol/acetaminophen. *Prostaglandins, Leukotrienes and Essential Fatty Acids*, 72(2), 85-87.
- Brown, E. S. (2009). Effects of glucocorticoids on mood, memory, and the hippocampus: treatment and preventive therapy. *Annals of the New York Academy of Sciences*, 1179(1), 41-55.
- Buttgereit, F., Seibel, M. J. H., and Bijlsma, J. W. J. (2013). 87 - Glucocorticoids. In Rich, R. R., Fleisher, T. A., Shearer, W. T., Schroeder, H. W., Frew, A. J. and Weyand, C. M.

(Eds.), *Clinical Immunology (Fourth Edition)* (pp. 1066-1076). London: Content Repository Only!

Camele, G., Delle Monache, F., Delle Monache, G., and Marini Bettolo, G. B. (1980). Three new flavonoids from *Tephrosia praecans*. *Phytochemistry*, 19(4), 707-709.

Carlson, D. G., Weisleder, D., and Tallent, W. H. (1973). NMR investigations of rotenoids. *Tetrahedron*, 29(18), 2731-2741.

Chang, C.-H., Lin, C.-C., Kadota, S., Hattori, M., and Namba, T. (1995). Flavonoids and a prenylated xanthone from *Cudrania cochinchinensis* var. *gerontogea*. *Phytochemistry*, 40(3), 945-947.

Chang, H. W., Baek, S. H., Chung, K. W., Son, K. H., Kim, H. P., and Kang, S. S. (1994). Inactivation of Phospholipase A2 by Naturally Occurring Biflavonoid, Ochnaflavone. *Biochemical and Biophysical Research Communications*, 205(1), 843-849.

Chang, L. C., Chávez, D., Song, L. L., Farnsworth, N. R., Pezzuto, J. M., and Kinghorn, A. D. (2000). Absolute Configuration of Novel Bioactive Flavonoids from *Tephrosia purpurea*. *Organic Letters*, 2(4), 515-518.

Chang, L. C., Gerhäuser, C., Song, L., Farnsworth, N. R., Pezzuto, J. M., and Kinghorn, A. D. (1997). Activity-Guided Isolation of Constituents of *Tephrosia purpurea* with the Potential to Induce the Phase II Enzyme, Quinone Reductase. *Journal of Natural Products*, 60(9), 869-873.

Chang, S.-H. (1990). Flavonoids, coumarins and acridone alkaloids from the root bark of *Citrus limonia*. *Phytochemistry*, 29(1), 351-353.

Che, C. T., George, V., Ijiru, T. P., Pushpangadan, P., and Andrae-Marobela, K. (2017). Chapter 2 - Traditional Medicine. In Badal, S. and Delgoda, R. (Eds.), *Pharmacognosy* (pp. 15-30). Boston: Academic Press.

- Chen, G.-L., Fan, M.-X., Wu, J.-L., Li, N., and Guo, M.-Q. (2019). Antioxidant and anti-inflammatory properties of flavonoids from *lotus plumule*. *Food Chemistry*, 277, 706-712.
- Chen, L., Deng, H., Cui, H., Fang, J., Zuo, Z., Deng, J., Li, Y., Wang, X., and Zhao, L. (2017). Inflammatory responses and inflammation-associated diseases in organs. *Oncotarget*, 9(6), 7204-7218.
- Chen, Y.-L., Hs, uuml, and Hong, Y. (1958). Constituents of *Tephrosia* Species in Taiwan. I: On the Active Principles of *Tephrosia obovata* MERR. *Yakugaku Zasshi*, 78(2), 198-200.
- Chen, Y.-L., Wang, Y.-S., Lin, Y.-L., Munakata, K., and Ohta, K. (1978). Obovatin, obovatin methyl ether and obovatachalcone, new piscicidal flavonoids from *Tephrosia obovata*. *Agricultural and Biological Chemistry*, 42(12), 2431-2432.
- Chen, Y.-N., Peng, Y., Gao, C.-H., Yan, T., Xu, Z.-F., Qiu, S. X., Cao, W.-H., Deng, L., and Huang, R.-M. (2015). Two New Secondary Metabolites from *Tephrosia purpurea*. *Natural Product Communications*, 10(6), 921 - 922.
- Chen, Y., Yan, T., Gao, C., Cao, W., and Huang, R. (2014). Natural Products from the Genus *Tephrosia*. *Molecules*, 19(2), 1432-1458.
- Chhabra, S. C., and Mahunnah, R. L. A. (1994). Plants Used in Traditional Medicine by Hayas of the Kagera Region, Tanzania. *Economic Botany*, 48(2), 121-129.
- Chibber, S., and Dutt, S. (1982). Tephrothone, a new chalcone from *Tephrosia candida* seeds. *Current Science*.
- Chinniah, A., Mohapatra, S., Goswami, S., Mahapatra, A., Kar, S. K., Mallavadhani, U. V., and Das, P. K. (2009). On the potential of *Tephrosia purpurea* as anti-*Helicobacter pylori* agent. *Journal of Ethnopharmacology*, 124(3), 642-645.

- Conti, B., Tabarean, I., Andrei, C., and Bartfai, T. (2004). Cytokines and fever. *Frontiers in Bioscience*, 9(12), 1433-1449.
- Costa, S. S., Jossang, A., Bodo, B., Souza, M. L. M., and Moraes, V. L. G. (1994). Patuletin Acetylramnosides from *Kalanchoe brasiliensis* as Inhibitors of Human Lymphocyte Proliferative Activity. *Journal of Natural Products*, 57(11), 1503-1510.
- Cragg, G. M., and Newman, D. J. (2013). Natural products: A continuing source of novel drug leads. *Biochimica et Biophysica Acta (BBA) - General Subjects*, 1830(6), 3670-3695.
- Dafam, D., Kagaru, D., Yakubu, P., Umar, M., Ohemu, T., and Udoji, P. (2014). Pharmacognostic studies of the leaves and root of the plant, *Tephrosia vogelii* Hook f (Fabaceae). *Journal of Pharmaceutical and Biomedical Sciences*, 04(07), 619-622.
- Dagne, E., Dinku, B., Gray, A. I., and Waterman, P. G. (1988). Pumilaisoflavones A and B from the seed pods of *Tephrosia pumila*. *Phytochemistry*, 27(5), 1503-1505.
- Dagne, E., Yenesew, A., and Waterman, P. G. (1989). Flavonoids and isoflavonoids from *Tephrosia fulvinervis* and *Tephrosia pentaphylla*. *Phytochemistry*, 28(11), 3207-3210.
- Davis, J. M., Knutson, K. L., Strausbauch, M. A., Crowson, C. S., Therneau, T. M., Wettstein, P. J., Matteson, E. L., and Gabriel, S. E. (2010). Analysis of Complex Biomarkers for Human Immune-Mediated Disorders Based on Cytokine Responsiveness of Peripheral Blood Cells. *Journal of Immunology*, 184(12), 7297-7304.
- de Kloet, E. R., Ortiz Zacarias, N. V., and Meijer, O. C. (2017). Chapter 37 - Manipulating the Brain Corticosteroid Receptor Balance: Focus on Ligands and Modulators. In Fink, G. (Ed.), *Stress: Neuroendocrinology and Neurobiology* (pp. 367-383). San Diego: Academic Press.

- de Oliveira, S., Rosowski, E. E., and Huttenlocher, A. (2016). Neutrophil migration in infection and wound repair: going forward in reverse. *Nature reviews. Immunology*, 16(6), 378-391.
- Dement, A. W., and Mabry, T. J. (1972). Flavonoids of north american species of *Thermopsis*. *Phytochemistry*, 11(3), 1089-1093.
- Desborough, M. J. R., and Keeling, D. M. (2017). The aspirin story – from willow to wonder drug. *British Journal of Haematology*, 177(5), 674-683.
- Dewick, P. M. (2002). *Medicinal natural products: a biosynthetic approach*: John Wiley & Sons.
- Dharani, N., Yenesew, A., Aynekulu, E., Tuei, B., and Jamnadass, R. (2015). *Traditional ethnoveterinary medicine in East Africa: a manual on the use of medicinal plants*. Nairobi, Kenya: The World Agroforestry Centre.
- Dhikav, V., Singh, S., Pande, S., Chawla, A., and Anand, K. S. (2003). Non-steroidal drug-induced gastrointestinal toxicity: mechanisms and management. *Journal, Indian Academy of Clinical Medicine*, 4(4), 315-322.
- Dinarello, C. A. (2010). Anti-inflammatory Agents: Present and Future. *Cell*, 140(6), 935-950.
- Ding, X.-Z., Hennig, R., and Adrian, T. E. (2003). Lipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer. *Molecular Cancer*, 2, 10-10.
- Drini, M. (2017). Peptic ulcer disease and non-steroidal anti-inflammatory drugs. *Australian Prescriber*, 40(3), 91-93.
- Duque, A. G., and Descoteaux, A. (2014). Macrophage cytokines: involvement in immunity and infectious diseases. *Frontiers in Immunology* 5, 491-491.

- Durgaprasad, L., Manoj, K., Hemalatha, R., Ramakrishna, S., Naidu, V. G. M., Venu, T., Vinod, V., Navrinder, K., and Ravinder, N. (2013). Anti-Inflammatory Treatments for Chronic Diseases: A Review. *Inflammation & Allergy - Drug Targets (Discontinued)*, 12(5), 349-361.
- Dzenda, T., Ayo, J., Adelaiye, A., and Adaudi, A. (2007). Ethno-medical and veterinary uses of *Tephrosia vogelii* hook. F.: A review. *Nigerian Veterinary Journal*, 28(3), 24-39.
- Dzoyem, J. P., Nkuete, A. H. L., Ngameni, B., and Eloff, J. N. (2017). Anti-inflammatory and anticholinesterase activity of six flavonoids isolated from *Polygonum* and *Dorstenia* species. *Archives of Pharmacal Research*, 40(10), 1129-1134.
- Falak, A. H., and Shoeb, A. (1987). A New Epoxyflavanone from *Tephrosia Hamiltonii*. *Planta Medica*, 53(02), 220-221.
- Falshaw, C. P., Ollis, W. D., Moore, J. A., and Magnus, K. (1966). The extractives of *Piscidia erythrina* L.—III: The constitutions of lisetin, piscidone and piscerythrone. *Tetrahedron*, 22, 333-348.
- Feng, R., Guo, Z. K., Yan, C. M., Li, E. G., Tan, R. X., and Ge, H. M. (2012). Anti-inflammatory flavonoids from *Cryptocarya chingii*. *Phytochemistry*, 76, 98-105.
- Fernández-Moriano, C., González-Burgos, E., and Pilar Gómez-Serranillos, M. (2019). Curcumin: Current evidence of its therapeutic potential as a lead candidate for anti-inflammatory drugs—an overview. In Brahmachari, G. (Ed.), *Discovery and Development of Anti-Inflammatory Agents from Natural Products* (pp. 7-59): Elsevier.
- Ferreira, V. L., Borba, H. H. L., Bonetti, A. D. F., Leonart, L., and Pontarolo, R. (2018). Cytokines and interferons: types and functions *Autoantibodies and Cytokines*: IntechOpen.

- Fu, M.-q., Xiao, G.-s., Xu, Y.-j., Wu, J.-j., Chen, Y.-l., and Qiu, S.-X. (2016). Chemical Constituents from Roots of *Millettia speciosa*. *Chinese Herbal Medicines*, 8(4), 385-389.
- Funakoshi-Tago, M., Nakamura, K., Tago, K., Mashino, T., and Kasahara, T. (2011). Anti-inflammatory activity of structurally related flavonoids, Apigenin, Luteolin and Fisetin. *International Immunopharmacology*, 11(9), 1150-1159.
- Gachene, C. K. K., and Wortmann, C. S. (2004). Green manure/cover crop technology in eastern and central Uganda: development and dissemination *Green Manure/Cover Crop Systems of Smallholder Farmers* (pp. 219-236): Springer.
- Gampe, N., Darcsi, A., Lohner, S., Béni, S., and Kursinszki, L. (2016). Characterization and identification of isoflavonoid glycosides in the root of Spiny restharrow (*Ononis spinosa* L.) by HPLC-QTOF-MS, HPLC-MS/MS and NMR. *Journal of Pharmaceutical and Biomedical Analysis*, 123, 74-81.
- Ganapaty, S., Nair, V., Devi, D. R., Pannakal, S. T., Laatsch, H., and Dittrich, B. (2014). Rare Prenylated Isoflavones from *Tephrosia calophylla*. *Natural Product Communications*, 9(7), 1934578X1400900713.
- Ganapaty, S., Pannakal, S. T., Srilakshmi, G. V. K., Lakshmi, P., Waterman, P. G., and Brun, R. (2008a). Pumilanol, an antiprotozoal isoflavanol from *Tephrosia pumila*. *Phytochemistry Letters*, 1(4), 175-178.
- Ganapaty, S., Srilakshmi, G. V. K., Pannakal, S. T., and Laatsch, H. (2008b). A Pyranochalcone and Prenylflavanones from *Tephrosia pulcherrima* (Baker) Drumm. *Natural Product Communications*, 3(1), 1934578X0800300111.

- Ganapaty, S., Srilakshmi, G. V. K., Pannakal, S. T., Rahman, H., Laatsch, H., and Brun, R. (2009). Cytotoxic benzil and coumestan derivatives from *Tephrosia calophylla*. *Phytochemistry*, 70(1), 95-99.
- García-Lafuente, A., Guillamón, E., Villares, A., Rostagno, M. A., and Martínez, J. A. (2009). Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease. *Inflammation Research*, 58(9), 537-552.
- Gillett, J. B., Polhill, R. M., and Verdcourt, B. (1971). *Flora of Tropical East Africa*: Royal Botanic Gardens, Kew (K).
- Ginwala, R., Bhavsar, R., Chigbu, D. I., Jain, P., and Khan, Z. K. (2019). Potential Role of Flavonoids in Treating Chronic Inflammatory Diseases with a Special Focus on the Anti-Inflammatory Activity of Apigenin. *Antioxidants (Basel, Switzerland)*, 8(2), 35.
- Go´mez-Garibay, F., Quijano, L., and Rios, T. (1991). Flavanones from *Tephrosia leiocarpa*. *Phytochemistry*, 30(11), 3832-3834.
- Goldstein, J. L., and Cryer, B. (2015). Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. *Drug, Healthcare and Patient Safety*, 7, 31-41.
- Gomes, R. N., Felipe da Costa, S., and Colquhoun, A. (2018). Eicosanoids and cancer. *Clinics*, 73(suppl 1), e530s-e530s.
- Gómez-Garibay, F., Calderón, J., Quijano, L., Téllez, O., del Socorro Olivares, M., and Ríos, T. (1997). An unusual prenyl biflavanol from *Tephrosia tepicana*. *Phytochemistry*, 46(7), 1285-1287.
- Gomez-Garibay, F., Quijano, L., Calderón, J. S., Morales, S., and Rios, T. (1988). Prenylflavanols from *Tephrosia quercetorum*. *Phytochemistry*, 27(9), 2971-2973.

- Gómez-Garibay, F., Téllez-Valdez, O., Moreno-Torres, G., and Calderón José, S. (2002). Flavonoids from *Tephrosia major*. A New Prenyl- β -hydroxychalcone *Zeitschrift für Naturforschung C* (Vol. 57, pp. 579).
- Gomez, F., Calderon, J., and Quijano, L. (1984). Nitenin: A new flavan from *Tephrosia nitens* Beth. *Society Of Chemical Industry*, 17, 632-632.
- Gómez, F., Calderón, J. S., Quijano, L., Domínguez, M., and Ríos, T. (1985a). Viridiflorin, an isoflavone from *Tephrosia viridiflora*. *Phytochemistry*, 24(5), 1126-1128.
- Gómez, F., Quijano, L., Calderón, J. S., Rodríguez, C., and Ríos, T. (1985b). Prenylflavans from *Tephrosia watsoniana*. *Phytochemistry*, 24(5), 1057-1059.
- Gómez, F., Quijano, L., García, G., Calderón, J. S., and Ríos, T. (1983). A prenylated flavan from *Tephrosia madrensis*. *Phytochemistry*, 22(5), 1305-1306.
- Goodman, L. S. (1996). *Goodman and Gilman's the pharmacological basis of therapeutics* (Vol. 1549): McGraw-Hill New York.
- Goppelt-Struebe, M., Wolter, D., and Resch, K. (1989). Glucocorticoids inhibit prostaglandin synthesis not only at the level of phospholipase A2 but also at the level of cyclooxygenase/PGE isomerase. *British Journal of Pharmacology*, 98(4), 1287-1295.
- Grosser, T., Fries, S., and FitzGerald, G. A. (2006). Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. *The Journal of Clinical Investigation*, 116(1), 4-15.
- Guo, F., Zhang, S., Yan, X., Dan, Y., Wang, J., Zhao, Y., and Yu, Z. (2019). Bioassay-guided isolation of antioxidant and α -glucosidase inhibitory constituents from stem of *Vigna angularis*. *Bioorganic Chemistry*, 87, 312-320.
- Gupta, K. R., Krishnamurti, M., and Parthasarathi, L. (1980). Purpurin, a new flavanone from *Tephrosia purpurea* seeds. *Phytochemistry*, 19(6), 1264.

- Hafidh, R. R., Abdulmir, A. S., Jahanshiri, F., Abas, F., Abu Bakar, F., and Sekawi, Z. (2009). Asia is the mine of natural antiviral products for public health. *The Open Complementary Medicine Journal*, 1, 58-68.
- Hämäläinen, M., Nieminen, R., Vuorela, P., Heinonen, M., and Moilanen, E. (2007). Anti-Inflammatory Effects of Flavonoids: Genistein, Kaempferol, Quercetin, and Daidzein Inhibit STAT-1 and NF- κ B Activations, Whereas Flavone, Isorhamnetin, Naringenin, and Pelargonidin Inhibit only NF- κ B Activation along with Their Inhibitory Effect on iNOS Expression and NO Production in Activated Macrophages. *Mediators of Inflammation*, 2007, 045673.
- Hamill, F. A., Apio, S., Mubiru, N. K., Bukenya-Ziraba, R., Mosango, M., Maganyi, O. W., and Soejarto, D. D. (2003). Traditional herbal drugs of Southern Uganda, II: literature analysis and antimicrobial assays. *Journal of Ethnopharmacology*, 84(1), 57-78.
- Hanna, V. S., and Hafez, E. A. A. (2018). Synopsis of arachidonic acid metabolism: A review. *Journal of Advanced Research*, 11, 23-32.
- Harbaum, B., Hubbermann, E. M., Wolff, C., Herges, R., Zhu, Z., and Schwarz, K. (2007). Identification of Flavonoids and Hydroxycinnamic Acids in Pak Choi Varieties (*Brassica campestris* L. ssp. *chinensis* var. *communis*) by HPLC–ESI-MS and NMR and Their Quantification by HPLC–DAD. *Journal of Agricultural and Food Chemistry*, 55(20), 8251-8260.
- Harinantenaina, L., Brodie, P. J., Slebodnick, C., Callmander, M. W., Rakotobe, E., Randrianasolo, S., Randrianaivo, R., Rasamison, V. E., TenDyke, K., Shen, Y., Suh, E. M., and Kingston, D. G. I. (2010). Antiproliferative Compounds from *Pongamiopsis pervilleana* from the Madagascar Dry Forest. *Journal of Natural Products*, 73(9), 1559-1562.

- Harvey, A. L. (2008). Natural products in drug discovery. *Drug Discovery Today*, 13(19), 894-901.
- He, J., Fan, P., Feng, S., Shao, P., and Sun, P. (2018). Isolation and Purification of Two Isoflavones from *Herichium erinaceum* Mycelium by High-Speed Counter-Current Chromatography. *Molecules*, 23(3), 560.
- He, S., Chen, L., Niu, Y.-N., Wu, L.-Y., and Liang, Y.-M. (2009). 1,3-Dipolar cycloaddition of diazoacetate compounds to terminal alkynes promoted by Zn(OTf)₂: an efficient way to the preparation of pyrazoles. *Tetrahedron Letters*, 50(20), 2443-2445.
- Hegazy, M.-E. F., Abd El-Razek, M. H., Nagashima, F., Asakawa, Y., and Paré, P. W. (2009). Rare prenylated flavonoids from *Tephrosia purpurea*. *Phytochemistry*, 70(11), 1474-1477.
- Hegazy, M.-E. F., Mohamed, A. E.-H. H., El-Halawany, A. M., Djemgou, P. C., Shahat, A. A., and Paré, P. W. (2011). Estrogenic Activity of Chemical Constituents from *Tephrosia candida*. *Journal of Natural Products*, 74(5), 937-942.
- Heo, H. J., Kim, M. J., Lee, J. M., Choi, S. J., Cho, H. Y., Hong, B., Kim, H. K., Kim, E., and Shin, D. H. (2004). Naringenin from *Citrus junos* has an Inhibitory Effect on Acetylcholinesterase and a Mitigating Effect on Amnesia. *Dementia and Geriatric Cognitive Disorders*, 17(3), 151-157.
- Heuzé, V., Thiollet, H., Tran, G., Hassoun, P., and Lebas, F. (2018, January 25, 2018, 14:36). Ahuhu (*Tephrosia purpurea*). Retrieved January 11, 2020, from <https://www.feedipedia.org/node/654>
- Hsu, C.-L., Fang, S.-C., and Yen, G.-C. (2013). Anti-inflammatory effects of phenolic compounds isolated from the flowers of *Nymphaea mexicana* Zucc. *Food & Function*, 4(8), 1216-1222.

- Hu, J., Ma, W., Li, N., and Wang, K.-J. (2017). Antioxidant and Anti-Inflammatory Flavonoids from the Flowers of Chuju, a Medical Cultivar of *Chrysanthemum morifolium* Ramat. *Journal of the Mexican Chemical Society*, 61, 282-289.
- Huang, Y.-C., Hwang, T.-L., Chang, C.-S., Yang, Y.-L., Shen, C.-N., Liao, W.-Y., Chen, S.-C., and Liaw, C.-C. (2009). Anti-inflammatory Flavonoids from the Rhizomes of *Helminthostachys zeylanica*. *Journal of Natural Products*, 72(7), 1273-1278.
- Hyun Pyo, K., Kun Ho, S., Hyeun Wook, C., and Sam Sik, K. (2004). Review : Anti-inflammatory Flavonoids: Modulators of Proinflammatory Gene Expression. [Review : Anti-inflammatory Flavonoids: Modulators of Proinflammatory Gene Expression]. *Natural Product Sciences*, 10(1), 1-10.
- Ibrahim, S. R. M., Badr, J. M., Sayed, K. A. E., and Youssef, D. T. A. (2007). A New Cytotoxic Sesquiterpene and Three Anti-inflammatory Flavonoids from Egyptian *Tanacetum santolinoides*. *Natural Product Communications*, 2(11), 1934578X0700201102.
- Ingham, J. L., and Markham, K. R. (1980). Tephrocarpin, a pterocarpan phytoalexin from *Tephrosia bidwilli* and a structure proposal for acanthocarpan. *Phytochemistry*, 21(12), 2969-2972.
- Intekhab, J., and Aslam, M. (2009). Isolation of a flavonoid from *Feronia limonia*. *Journal of Saudi Chemical Society*, 13(3), 295-298.
- Ismail, M. A. H., Lehmann, J., Abou El Ella, D. A., Albohy, A., and Abouzid, K. A. M. (2009). Lonazolac analogues: molecular modeling, synthesis, and in vivo anti-inflammatory activity. *Medicinal Chemistry Research*, 18(9), 725.
- Jain, A., Lodhi, S., and Singhai, A. (2009). Simultaneous estimation of quercetin and rutin in *Tephrosia purpurea* Pers by high performance thin layer chromatography. *Asian Journal of Traditional Medicines*, 4(3), 104-109.

- Jang, D. S., Park, E. J., Kang, Y.-H., Hawthorne, M. E., Vigo, J. S., Graham, J. G., Cabieses, F., Fong, H. H. S., Mehta, R. G., Pezzuto, J. M., and Kinghorn, A. D. (2003). Potential Cancer Chemopreventive Flavonoids from the Stems of *Tephrosia toxicaria*. *Journal of Natural Products*, 66(9), 1166-1170.
- Jang, J.-H., Shin, H. W., Lee, J. M., Lee, H.-W., Kim, E.-C., and Park, S. H. (2015). An Overview of Pathogen Recognition Receptors for Innate Immunity in Dental Pulp. *Mediators of Inflammation*, 2015, 794143-794143.
- Jayaraman, I., Ghanim, A., and Khan, H. A. (1980). A new prenylated flavanone from *Tephrosia villosa*. *Phytochemistry*, 19(6), 1267-1268.
- Jo-Watanabe, A., Okuno, T., and Yokomizo, T. (2019). The Role of Leukotrienes as Potential Therapeutic Targets in Allergic Disorders. *International Journal of Molecular Sciences*, 20(14), 3580.
- Jones, A. W. (2011). Early drug discovery and the rise of pharmaceutical chemistry. *Drug Testing and Analysis*, 3(6), 337-344.
- Juma, W. P., Akala, H. M., Eyase, F. L., Muiva, L. M., Heydenreich, M., Okalebo, F. A., Gitu, P. M., Peter, M. G., Walsh, D. S., Imbuga, M., and Yenesew, A. (2011). Terpurinflavone: An antiplasmodial flavone from the stem of *Tephrosia Purpurea*. *Phytochemistry Letters*, 4(2), 176-178.
- Jung, M. J., Kang, S. S., Jung, H. A., Kim, G. J., and Choi, J. S. (2004). Isolation of flavonoids and a cerebroside from the stem bark of *Albizzia julibrissin*. *Archives of Pharmacal Research*, 27(6), 593.
- Karrouchi, K., Radi, S., Ramli, Y., Taoufik, J., Mabkhot, Y. N., Al-aizari, F. A., and Ansar, M. h. (2018). Synthesis and Pharmacological Activities of Pyrazole Derivatives: A Review. *Molecules*, 23(1), 134.

- Katayama, S., and Lee, J. B. (2003). Prostaglandins and Leukotrienes. In Caballero, B. (Ed.), *Encyclopedia of Food Sciences and Nutrition (Second Edition)* (pp. 4798-4804). Oxford: Academic Press.
- Kerebba, N., Oyedeji, A. O., Byamukama, R., Kuria, S. K., and Oyedeji, O. O. (2019). Pesticidal activity of *Tithonia diversifolia* (Hemsl.) A. Gray and *Tephrosia vogelii* (Hook f.); phytochemical isolation and characterization: A review. *South African Journal of Botany*, *121*, 366-376.
- Khalid, S. A., and Waterman, P. G. (1981). 8-C-Prenylflavonoids from the seed of *Tephrosia bracteolata*. *Phytochemistry*, *20*(7), 1719-1720.
- Khalivulla, S. I., Reddy, B. A. K., Gunasekar, D., Blond, A., Bodo, B., Murthy, M. M., and Rao, T. P. (2008). A new di-O-prenylated isoflavone from *Tephrosia tinctoria*. *Journal of Asian Natural Products Research*, *10*(10), 953-955.
- Khan, H. A., Chandrasekharan, I., and Ghanim, A. (1986). Falciformin, a flavanone from pods of *Tephrosia falciformis*. *Phytochemistry*, *25*(3), 767-768.
- Kim, Y. K., Shin, J. S., and Nahm, M. H. (2016). NOD-Like Receptors in Infection, Immunity, and Diseases. *Yonsei Medical Journal*, *57*(1), 5-14.
- Kisangau, D. P., and Amri, E. (2012). Ethnomedicinal study of plants used in villages around Kimboza forest reserve in Morogoro, Tanzania. *Journal of Ethnobiology and Ethnomedicine*, *8*, 1-9.
- Kishore, H., Reddy, V. B. M., Gunasekar, D., Murthy, M. M., Caux, C., and Bodo, B. (2003). A New Coumestan from *Tephrosia calophylla*. *Chemical and Pharmaceutical Bulletin*, *51*(2), 194-196.

- Ko, H.-H., Weng, J.-R., Tsao, L.-T., Yen, M.-H., Wang, J.-P., and Lin, C.-N. (2004). Anti-inflammatory flavonoids and pterocarpanoid from *Crotalaria pallida* and *C. assamica*. *Bioorganic & Medicinal Chemistry Letters*, 14(4), 1011-1014.
- Kokwaro, J. O. (1976). *Medicinal Plant of East Africa*. Nairobi: East African Literature Bureau.
- Kokwaro, J. O. (2009). *Medicinal plants of east Africa*: University of Nairobi press.
- Kovalev, V. N., Spiridonov, V. N., Borisov, M. I., Kovalev, I. P., Gordienko, V. G., and Kolesnikov, D. D. (1975). Phenolic compounds of *Ononis arvensis* the structure of onogenin. *Chemistry of Natural Compounds*, 11(3), 367-369.
- Krupadanam, G. L. D., Sarma, P. N., Srimannarayana, G., and Rao, N. V. S. (1977a). New C-6 oxygenated rotenoids from *tephrosia villosa* -- villosin, villosone, villol and villinol. *Tetrahedron Letters*, 18(24), 2125-2128.
- Krupadanam, G. L. D., Sarma, P. N., Srimannarayana, G., and Rao, N. V. S. (1977b). New C-6 oxygenated rotenoids from *Tephrosia villosa* - villosin, villosone, villol and villinol. *Tetrahedron Letters*, 18(24), 2125-2128.
- Kumar, S., and Pandey, A. K. (2013a). Chemistry and biological activities of flavonoids: an overview. *TheScientificWorldJournal*, 2013, 162750-162750.
- Kumar, S., and Pandey, A. K. (2013b). Chemistry and Biological Activities of Flavonoids: An Overview. *The Scientific World Journal*, 2013, 16.
- LaPointe, M. C., and Isenović, E. (1999). Interleukin-1 β regulation of inducible nitric oxide synthase and cyclooxygenase-2 involves the p42/44 and p38 MAPK signaling pathways in cardiac myocytes. *Hypertension*, 33(1), 276-282.
- Lee, S.-J., Wood, A. R., Maier, C. G. A., Dixon, R. A., and Mabry, T. J. (1998). Prenylated flavonoids from *Maclura pomifera*. *Phytochemistry*, 49(8), 2573-2577.

- Lee, S. H., Kim, J. Y., Seo, G. S., Kim, Y. C., and Sohn, D. H. (2009). Isoliquiritigenin, from *Dalbergia odorifera*, up-regulates anti-inflammatory heme oxygenase-1 expression in RAW264.7 macrophages. *Inflammation Research*, 58(5), 257-262.
- Leyva-López, N., Gutierrez-Grijalva, E. P., Ambriz-Perez, D. L., and Heredia, J. B. (2016). Flavonoids as Cytokine Modulators: A Possible Therapy for Inflammation-Related Diseases. *International Journal of Molecular Sciences*, 17(6), 921.
- Li, Y., Li, G., Wei, X., Liu, Z., and Xu, H. (2011). Isolation and identification of insecticidal compounds from *Tephrosia purpurea* (Fabaceae) bark and their insecticidal activity. *Acta Entomologica Sinica*, 54(12), 1368-1376.
- Lichtenstein, D. R., Syngal, S., and Wolfe, M. M. (1995). Nonsteroidal antiinflammatory drugs and the gastrointestinal tract the double-edged sword. *Arthritis & Rheumatism*, 38(1), 5-18.
- Lin, L.-C., Pai, Y.-F., and Tsai, T.-H. (2015). Isolation of Luteolin and Luteolin-7-O-glucoside from *Dendranthema morifolium* Ramat Tzvel and Their Pharmacokinetics in Rats. *Journal of Agricultural and Food Chemistry*, 63(35), 7700-7706.
- Lis, K., Kuzawińska, O., and Bałkowiec-Iskra, E. (2014). Tumor necrosis factor inhibitors - state of knowledge. *Archives of Medical Science*, 10(6), 1175-1185.
- Liu, C.-S. K., Yang, S.-L., Roberts, M. F., and Phillipson, J. D. (1989). Flavonol glycosides with acetyl substitution from *Kalanchoe gracilis*. *Phytochemistry*, 28(10), 2813-2818.
- Liu, T., Zhang, L., Joo, D., and Sun, S.-C. (2017). NF-κB signaling in inflammation. *Signal Transduction and Targeted Therapy*, 2, 17023.
- Liu, X.-Y., Zhang, Y.-B., Yang, X.-W., Yang, Y.-F., Xu, W., Zhao, W., Peng, K.-F., Gong, Y., Liu, N.-F., and Zhang, P. (2019). Anti-Inflammatory Activity of Some Characteristic Constituents from the Vine Stems of *Spatholobus suberectus*. *Molecules*, 24(20), 3750.

- Lone, A., and Taskén, K. (2013). Proinflammatory and Immunoregulatory Roles of Eicosanoids in T Cells. *Frontiers in Immunology* 4(130).
- Lopes, J. L. C., Lopes, J. N. C., and Leitao Filho, H. F. (1979). 5-Deoxyflavones from the *Vochysiaceae*. *Phytochemistry*, 18(2), 362.
- Luheshi, G., and Rothwell, N. (1996). Cytokines and Fever. *International Archives of Allergy and Immunology*, 109(4), 301-307.
- Luyengi, L., Lee, I.-S., Mar, W., Fong, H. H. S., Pezzuto, J. M., and Kinghorn, A. D. (1994). Rotenoids and chalcones from *Mundulea sericea* that inhibit phorbol ester-induced ornithine decarboxylase activity. *Phytochemistry*, 36(6), 1523-1526.
- Lwande, W., Bentley, M. D., and Hassanali, A. (1986a). The structure of hildecarpin, an insect antifeedant 6a-hydroxypterocarpan from the roots of *Tephrosia hildebrandtii* Vatke. *Insect Science and Its Application*, 7(4), 501-503.
- Lwande, W., Bentley, M. D., Macfoy, C., Lugemwa, F. N., Hassanali, A., and Nyandat, E. (1987). A new pterocarpan from the roots of *Tephrosia hildebrandtii*. *Phytochemistry*, 26(8), 2425-2426.
- Lwande, W., Greene, C., and Bentley, M. (1985a). Flavonoids from the roots of *Tephrosia elata*. *Journal of Natural Products*, 48(6), 1004-1005.
- Lwande, W., Hassanali, A., Bentley, M., and Monache, F. D. (1986b). 8-C-Prenylated Flavones from the Roots of *Tephrosia hildebrandtii*. *Journal of Natural Products*, 49(6), 1157-1158.
- Lwande, W., Hassanali, A., Njoroge, P. W., Bentley, M. D., Monache, F. D., and Jondiko, J. I. (1985b). A new 6a-hydroxypterocarpan with insect antifeedant and antifungal properties from the roots of *Tephrosia hildebrandtii* vatke. *Insect Science and Its Application*, 6(4), 537-541.

- Ma, H., Hong, M., Duan, J., Liu, P., Fan, X., Shang, E., Su, S., Guo, J., Qian, D., and Tang, Y. (2013). Altered cytokine gene expression in peripheral blood monocytes across the menstrual cycle in primary dysmenorrhea: a case-control study. *PLoS ONE*, 8(2), e55200-e55200.
- Ma, Y. L., Li, Q. M., Van den Heuvel, H., and Claeys, M. (1997). Characterization of flavone and flavonol aglycones by collision-induced dissociation tandem mass spectrometry. *Rapid Communications in Mass Spectrometry*, 11(12), 1357-1364.
- Mabry, T. J., Markham, K. R., and Thomas, M. B. (1970). *The Systematic Identification of Flavonoids*. Bwelin: Springer-Verlag.
- Machocho, A. K., Lwande, W., Jondikoa, J. I., Moreka, L. V. C., and Hassanali, A. (1995). Three New Flavonoids from the Root of *Tephrosia emoroides* and their Antifeedant Activity against the Larvae of the Spotted Stalk Borer *Chilo partellus* Swinhoe. *International Journal of Pharmacognosy*, 33(3), 222-227.
- Madhusudhana, J., Reddy, R. V. N., Reddy, B. A. K., Reddy, M. V. B., Gunasekar, D., Deville, A., and Bodo, B. (2010). Two new geranyl flavanones from *Tephrosia villosa*. *Natural Product Research*, 24(8), 743-749.
- Mahdi, J. G., Mahdi, A. J., Mahdi, A. J., and Bowen, I. D. (2006). The historical analysis of aspirin discovery, its relation to the willow tree and antiproliferative and anticancer potential. *Cell Proliferation*, 39(2), 147-155.
- Mahomoodally, M. F. (2013). Traditional medicines in Africa: an appraisal of ten potent African medicinal plants. *Evidence-Based Complementary and Alternative Medicine*, 2013.
- Mai, H. D. T., Nguyen, T. T. O., Pham, V. C., Litaudon, M., Guéritte, F., Tran, D. T., and Nguyen, V. H. (2010). Cytotoxic Prenylated Isoflavone and Bipterocarpan from *Millettia pachyloba*. *Planta Medica*, 76(15), 1739-1742.

- Malcher-Lopes, R., Franco, A., and Tasker, J. G. (2008). Glucocorticoids shift arachidonic acid metabolism toward endocannabinoid synthesis: a non-genomic anti-inflammatory switch. *European Journal of Pharmacology*, 583(2-3), 322-339.
- Malik, K., Ahmad, M., Zafar, M., Ullah, R., Mahmood, H. M., Parveen, B., Rashid, N., Sultana, S., Shah, S. N., and Lubna. (2019). An ethnobotanical study of medicinal plants used to treat skin diseases in northern Pakistan. *Complementary and Alternative Medicine*, 19(1), 210.
- Maroon, J. C., Bost, J. W., and Maroon, A. (2010). Natural anti-inflammatory agents for pain relief. *Surgical Neurology International*, 1, 80-80.
- McCormack, P. L. (2011). Celecoxib. *Drugs*, 71(18), 2457-2489.
- Menegatti, S., Bianchi, E., and Rogge, L. (2019). Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses. *Frontiers in Immunology* 10, 382-382.
- Ming, D. S., Hillhouse, B. J., Guns, E. S., Eberding, A., Xie, S., Vimalanathan, S., and Towers, G. H. N. (2005). Bioactive compounds from *Rhodiola rosea* (Crassulaceae). *Phytotherapy Research*, 19(9), 740-743.
- Mintah, S. O., Asafo-Agyei, T., Archer, M.-A., Junior, P. A.-A., Boamah, D., Kumadoh, D., Appiah, A., Ocloo, A., Boakye, Y. D., and Agyare, C. (2019). Medicinal Plants for Treatment of Prevalent Diseases *Pharmacognosy-Medicinal Plants*: IntechOpen.
- Mizuno, M., Baba, K., Iinuma, M., and Tanaka, T. (1992). Coumaronochromones from leaves of *Desmodium oxyphyllum*. *Phytochemistry*, 31(1), 361-363.
- Mkindi, A. G., Tembo, Y., Mbega, E. R., Medvecky, B., Kendal-Smith, A., Farrell, I. W., Ndakidemi, P. A., Belmain, S. R., and Stevenson, P. C. (2019). Phytochemical Analysis

- of *Tephrosia vogelii* across East Africa Reveals Three Chemotypes that Influence Its Use as a Pesticidal Plant. *Plants*, 8(12), 597.
- Mogensen, T. H. (2009). Pathogen recognition and inflammatory signaling in innate immune defenses. *Clinical Microbiology Reviews*, 22(2), 240-273.
- Monache, F. D., Labbiento, L., Marta, M., and Lwandet, W. (1986). 4 β -substituted flavans from *Tephrosia hildebrandtii*. *Phytochemistry*, 25(7), 1711-1713.
- Monache, G. D., Scurria, R., Vitali, A., Botta, B., Monacelli, B., Pasqua, G., Palocci, C., and Cernia, E. (1994). Two isoflavones and a flavone from the fruits of *Maclura pomifera*. *Phytochemistry*, 37(3), 893-898.
- Monitto, C. L., Kost-Byerly, S., and Yaster, M. (2011). CHAPTER 15 - Pain Management. In Davis, P. J., Cladis, F. P. and Motoyama, E. K. (Eds.), *Smith's Anesthesia for Infants and Children (Eighth Edition)* (pp. 418-451). Philadelphia: Mosby.
- Muiva-Mutisya, L., Macharia, B., Heydenreich, M., Koch, A., Akala, H. M., Derese, S., Omosa, L. K., Yusuf, A. O., Kamau, E., and Yenesew, A. (2014). 6 α -Hydroxy- α -toxicarol and (+)-tephrodin with antiplasmodial activities from *Tephrosia* species. *Phytochemistry Letters*, 10, 179-183.
- Muiva-Mutisya, L. M., Atilaw, Y., Heydenreich, M., Koch, A., Akala, H. M., Cheruiyot, A. C., Brown, M. L., Irungu, B., Okalebo, F. A., Derese, S., Mutai, C., and Yenesew, A. (2018). Antiplasmodial prenylated flavanonols from *Tephrosia subtriflora*. *Natural Product Research*, 32(12), 1407-1414.
- Muiva, L. M., Yenesew, A., Derese, S., Heydenreich, M., Peter, M. G., Akala, H. M., Eyase, F., Waters, N. C., Mutai, C., Keriko, J. M., and Walsh, D. (2009). Antiplasmodial β -hydroxydihydrochalcone from seedpods of *Tephrosia elata*. *Phytochemistry Letters*, 2(3), 99-102.

- Murthy, M. S. R., and Rao, E. V. (1985). Maxima Isoflavone J: a New O-Prenylated Isoflavone from *Tephrosia maxima*. *Journal of Natural Products*, 48(6), 967-968.
- Mwaura, L., Stevenson, P. C., Ofori, D. A., Anjarwalla, P., Jamnadass, R., and Smith, P. (2013). Pesticidal Plant Leaflet: *Tephrosia vogelii* Hook. f. Nairobi, Kenya: World Agroforestry Centre.
- Mwine, T. J., Van Damme, P., Gerard, K., and Charles, K. (2011). Ethnobotanical survey of pesticidal plants used in South Uganda: Case study of Masaka district. *Journal of Medicinal Plants Research*, 5(7), 1155-1163.
- Nawwar, M. A. M., El-Sissi, H. I., and Barakat, H. H. (1984). Flavonoid constituents of *Ephedra alata*. *Phytochemistry*, 23(12), 2937-2939.
- Nenaah, G. E. (2014). Toxic and antifeedant activities of prenylated flavonoids isolated from *Tephrosia apollinea* L. against three major coleopteran pests of stored grains with reference to their structure–activity relationship. *Natural Product Research*, 28(24), 2245-2252.
- Nguyen, K. D. H., Dang, P. H., Nguyen, H. X., Nguyen, M. T. T., Awale, S., and Nguyen, N. T. (2017). Phytochemical and cytotoxic studies on the leaves of *Calotropis gigantea*. *Bioorganic & Medicinal Chemistry Letters*, 27(13), 2902-2906.
- Norris, D. O., and Carr, J. A. (2013). Chapter 3 - Synthesis, Metabolism, and Actions of Bioregulators. In Norris, D. O. and Carr, J. A. (Eds.), *Vertebrate Endocrinology (Fifth Edition)* (pp. 41-91). San Diego: Academic Press.
- Noverr, M. C., Erb-Downward, J. R., and Huffnagle, G. B. (2003). Production of Eicosanoids and Other Oxylipins by Pathogenic Eukaryotic Microbes. *Clinical Microbiology Reviews*, 16(3), 517-533.

- O'Bryan, M. K., Schlatt, S., Phillips, D. J., de Kretser, D. M., and Hedger, M. P. (2000). Bacterial Lipopolysaccharide-Induced Inflammation Compromises Testicular Function at Multiple Levels in Vivo. *Endocrinology*, *141*(1), 238-246.
- Oberholzer, M. E., Rall, G. J. H., and Roux, D. G. (1974). The concurrence of 12 α -hydroxy- and 12 α -O-methylrotenoids. Isolation of the first natural 12 α -O-methylrotenoids. *Tetrahedron Letters*, *15*(25), 2211-2214.
- Oldfield, V., Dhillon, S., and Plosker, G. L. (2009). Tocilizumab. *Drugs*, *69*(5), 609-632.
- Oray, M., Abu Samra, K., Ebrahimiadib, N., Meese, H., and Foster, C. S. (2016). Long-term side effects of glucocorticoids. *Expert Opinion on Drug Safety*, *15*(4), 457-465.
- Oryema, C., Ziraba, R. B., Omagor, N., and Opio, A. (2010). Medicinal plants of Erute county, Lira district, Uganda with particular reference to their conservation. *African Journal of Ecology*, *48*(2), 285-298.
- Osbourn, A. E., and Lanzotti, V. (2009). *Plant-derived natural products*: Springer.
- Ouyang, M.-A., Wein, Y.-S., Zhang, Z.-K., and Kuo, Y.-H. (2007). Inhibitory Activity against Tobacco Mosaic Virus (TMV) Replication of Pinoresinol and Syringaresinol Lignans and Their Glycosides from the Root of *Rhus javanica* var. roxburghiana. *Journal of Agricultural and Food Chemistry*, *55*(16), 6460-6465.
- Oviedo-Boyso, J., Bravo-Patiño, A., and Baizabal-Aguirre, V. M. (2014). Collaborative Action of Toll-Like and Nod-Like Receptors as Modulators of the Inflammatory Response to Pathogenic Bacteria. *Mediators of inflammation*, *2014*, 16.
- Pahwa, R., and Jialal, I. (2019, 2019 Jun 4). Chronic Inflammation. from <https://www.ncbi.nlm.nih.gov/books/NBK493173/>
- Panche, A. N., Diwan, A. D., and Chandra, S. R. (2016). Flavonoids: an overview. *Journal of Nutritional Science*, *5*, e47-e47.

- Parisi, L., Gini, E., Baci, D., Tremolati, M., Fanuli, M., Bassani, B., Farronato, G., Bruno, A., and Mortara, L. (2018). Macrophage Polarization in Chronic Inflammatory Diseases: Killers or Builders? *Journal of Immunology Research*, 2018, 25.
- Parmar, V. S., Bisht, K. S., Sharma, S. K., Jain, R., Taneja, P., Singh, S., Simonsen, O., and Boll, P. M. (1994). Highly oxygenated bioactive flavones from *Tamarix*. *Phytochemistry*, 36(2), 507-511.
- Pedley, L. (2014). Systematics of *Tephrosia* Pers. (Fabaceae: Millettiae) in Queensland: 1. A summary of the classification of the genus, with the recognition of two new species allied to *T. varians* (F.M.Bailey) C.T.White. *Austrobaileya*, 9(2), 229-243.
- Pelter, A., Ward, R. S., Rao, E. V., and Raju, N. R. (1981). 8-Substituted flavonoids and 3'-substituted 7-oxygenated chalcones from *Tephrosia purpurea*. *Journal of the Chemical Society, Perkin Transactions 1*(0), 2491-2498.
- Pettipher, E. R. (1998). Prostaglandins. In Delves, P. J. (Ed.), *Encyclopedia of Immunology (Second Edition)* (pp. 2024-2027). Oxford: Elsevier.
- Plioukas, M., Gabrieli, C., Lazari, D., and Kokkalou, E. (2016). Phytochemical analysis with the antioxidant and aldose reductase inhibitory capacities of *Tephrosia humilis* aerial parts' extracts. *Natural Product Research*, 30(12), 1366-1372.
- Poluha, R. L., and Grossmann, E. (2018). Inflammatory mediators related to arthrogenic temporomandibular dysfunctions. *Brazilian Journal of Pain*, 1, 60-65.
- Prabhakar, P., Vanangamudi, A., Gandhidasan, R., and Raman, P. V. (1996). Hookerianin: a flavone from *Tephrosia hookeriana*. *Phytochemistry*, 43(1), 315-316.
- Qu, X., Tang, Y., and Hua, S. (2018). Immunological Approaches Towards Cancer and Inflammation: A Cross Talk. *Frontiers in Immunology* 9(563).

- Quijano, L., Malanco, F., and Ríos, T. (1970). The structures of eupalin and eupatolin. Two new flavonol rhamnosides isolated from *Eupatorium ligustrinum* D.C. *Tetrahedron*, 26(12), 2851-2859.
- Raghavendra, G. M., Varaprasad, K., and Jayaramudu, T. (2015). Chapter 2 - Biomaterials: Design, Development and Biomedical Applications. In Thomas, S., Grohens, Y. and Ninan, N. (Eds.), *Nanotechnology Applications for Tissue Engineering* (pp. 21-44). Oxford: William Andrew Publishing.
- Rainsford, K. D. (1984). *Aspirin and the Salicylates*: Elsevier.
- Rainsford, K. D. (2007). Anti-Inflammatory Drugs in the 21st Century. In Harris, R. E., Bittman, R., Dasgupta, D., Engelhardt, H., Flohe, L., Herrmann, H., Holzenburg, A., Nasheuer, H. P., Rottem, S., Wyss, M. and Zwickl, P. (Eds.), *Inflammation in the Pathogenesis of Chronic Diseases: The COX-2 Controversy* (pp. 3-27). Dordrecht: Springer Netherlands.
- Rajani, P., and Sarma, N. (1988). A coumestone from the roots of *Tephrosia hamiltonii*. *Phytochemistry*, 27(2), 648-649.
- Rao, P. P., and Srimannarayana, G. (1980). Tephrosol, a new coumestone from the roots of *Tephrosia villosa*. *Phytochemistry*.
- Rao, V., E., and Prasad, Y. R. (1992a). Prenylated flavonoids from *Tephrosia spinosa*. *Phytochemistry*, 32(1), 183-185.
- Rao, V., Murthy, S. R. M., and Ward, R. S. (1984). Nine isoflavones from *Tephrosia maxima*. *Phytochemistry*, 23(7), 1493-1501.
- Rao, V. E., and Murthy, S. R. M. (1985). Further studies on the isoflavones of *Tephrosia maxima*. *Phytochemistry*, 24(4), 875-876.

- Rao, V. E., and Prasad, R. Y. (1992b). Two chalcones from *Tephrosia spinosa*. *Phytochemistry*, 31(6), 2121-2122.
- Rao, V. E., and Raju, R., N. (1984). Two flavonoids from *Tephrosia purpurea*. *Phytochemistry*, 23(10), 2339-2342.
- Rastrelli, L., Berger, I., Kubelka, W., Caceres, A., De Tommasi, N., and De Simone, F. (1999). New 12a-Hydroxyrotenoids from *Gliricidia sepium* Bark. *Journal of Natural Products*, 62(1), 188-190.
- Rauter, A. P., Ennis, M., Hellwich, K.-H., Herold, B. J., Horton, D., Moss, G. P., and Schomburg, I. (2018). Nomenclature of flavonoids (IUPAC Recommendations 2017). *Pure and Applied Chemistry*, 90(9), 1429.
- Recourt, K., Schripsema, J., Kijne, J. W., van Brussel, A. A. N., and Lugtenberg, B. J. J. (1991). Inoculation of *Vicia sativa* subsp. *nigra* roots with *Rhizobium leguminosarum* biovar *viciae* results in release of nod gene activating flavanones and chalcones. *Plant Molecular Biology*, 16(5), 841-852.
- Reisch, J., Gombos, M., Szendrei, K., and Novak, I. (1976). 6a, 12a-dehydro-alpha-toxicarol, ein neues Rotenoid aus *Amorpha fruticosa*. *Phytochemistry*, 15, 234-235.
- Reyes-Chilpa, R., Gómez-Garibay, F., Quijano, L., Magos-Guerrero, G. A., and Ríos, T. (1994). Preliminary results on the protective effect of (-)-edunol, a pterocarpan from *Brongniartia podalyrioides* (Leguminosae), against *Bothrops atrox* venom in mice. *Journal of Ethnopharmacology*, 42(3), 199-203.
- Ricciotti, E., and FitzGerald, G. A. (2011). Prostaglandins and inflammation. *Arteriosclerosis, Thrombosis, and Vascular Biology* 31(5), 986-1000.
- Rittchen, S., and Heinemann, A. (2019). Therapeutic Potential of Hematopoietic Prostaglandin D2 Synthase in Allergic Inflammation. *Cells*, 8(6), 619.

- Roy, M., Mitra, S. R., Bhattacharyya, A., and Adityachaudhury, N. (1986). Candidone, a flavanone from *Tephrosia candida*. *Phytochemistry*, 25(4), 961-962.
- Ruiz-Cruz, S., Chaparro-Hernández, S., Hernández-Ruiz, K. L., Cira-Chávez, L. A., Estrada-Alvarado, M. I., Ortega, L. E. G., Ornelas-Paz, J., and Mata, M. A. L. (2017). Flavonoids: Important Biocompounds in Food, Flavonoids from Biosynthesis to Human Health: IntechOpen. Retrieved from <http://dx.doi.org/10.5772/67864>. doi: [10.5772/67864](http://dx.doi.org/10.5772/67864)
- Ryu, H. W., Park, M. H., Kwon, O.-K., Kim, D.-Y., Hwang, J.-Y., Jo, Y. H., Ahn, K.-S., Hwang, B. Y., and Oh, S.-R. (2019). Anti-inflammatory flavonoids from root bark of *Broussonetia papyrifera* in LPS-stimulated RAW264.7 cells. *Bioorganic Chemistry*, 92, 103233.
- Saag, K. G., and Furst, D. E. (2013, Oct 30, 2020). Major side effects of systemic glucocorticoids. from <https://www.uptodate.com/contents/major-side-effects-of-systemic-glucocorticoids>
- Samad, T. A., Sapirstein, A., and Woolf, C. J. (2002). Prostanoids and pain: unraveling mechanisms and revealing therapeutic targets. *Trends in Molecular Medicine*, 8(8), 390-396.
- Samuel, V. J., Mahesh, A. R., and Murugan, V. (2019). Phytochemical and pharmacological aspects of *Tephrosia* genus: A brief review. *Journal of Applied Pharmaceutical Science*, 9(03), 117-125.
- Sandhya, S., Venkatramana, K., Vinod, K., Chaitanya, R., Chandrasekhar, J., Sudhakar, K., and Rajeswar, T. (2010). Membrane stabilizing potency of two *Tephrosia* species. *Journal of Phytology*, 2(6), 42-46.

- Sayhan, H., Beyaz, S. I. G., and Çelikleş, A. (2017). The local anesthetic and pain relief activity of alkaloids. In Vasil, G. and Atanas, P. (Eds.), *Alkaloids: Alternatives in Synthesis, Modification and Application* (pp. 57). Croatia: Intech. Retrieved from <https://www.intechopen.com/books/alkaloids-alternatives-in-synthesis-modification-and-application/the-local-anesthetic-and-pain-relief-activity-of-alkaloids>.
- Schäcke, H., Döcke, W.-D., and Asadullah, K. (2002). Mechanisms involved in the side effects of glucocorticoids. *Pharmacology & Therapeutics*, 96(1), 23-43.
- Seelinger, G., Merfort, I., and Schempp, C. M. (2008). Anti-Oxidant, Anti-Inflammatory and Anti-Allergic Activities of Luteolin. *Planta Medica*, 74(14), 1667-1677.
- Selders, G. S., Fetz, A. E., Radic, M. Z., and Bowlin, G. L. (2017). An overview of the role of neutrophils in innate immunity, inflammation and host-biomaterial integration. *Regenerative Biomaterials*, 4(1), 55-68.
- Serhan, C. N., Ward, P. A., and Gilroy, D. W. (2010). *Fundamentals of inflammation*: Cambridge University Press.
- Sherwood, E. R., and Toliver-Kinsky, T. (2004). Mechanisms of the inflammatory response. *Best Practice & Research Clinical Anaesthesiology*, 18(3), 385-405.
- Shu, J., Li, L., Zhou, M., Yu, J., Peng, C., Shao, F., Liu, R., Zhu, G., and Huang, H. (2018). Three new flavonoid glycosides from *Smilax glabra* and their anti-inflammatory activity. *Natural Product Research*, 32(15), 1760-1768.
- Slater, D., Kunnathil, S., McBride, J., and Koppala, R. (2010). Pharmacology of nonsteroidal anti-inflammatory drugs and opioids. *Seminars in Interventional Radiology*, 27(4), 400-411.
- Smalberger, T. M., van den Berg, A. J., and Vlegaar, R. (1973). Flavonoids from *Tephrosia*—VI: The structure of semiglabin and semiglabinol. *Tetrahedron*, 29(19), 3099-3104.

- Smalberger, T. M., Vleggaar, R., and Weber, J. C. (1974). Flavonoids from *Tephrosia*—VII: The constitution and absolute configuration of lupinifolin and lupinifolinol, two flavanones from *Tephrosia lupinifolia* Burch (DC). *Tetrahedron*, 30(21), 3927-3931.
- Smalberger, T. M., Vleggaar, R., and Weber, J. C. (1975). Flavonoids from *Tephrosia*—VIII: The structure of elongatin, an isoflavone from *Tephrosia elongata* E. Mey. *Tetrahedron*, 31(18), 2297-2301.
- Smyth, E. M., and FitzGerald, G. A. (2010). Chapter 150 - Prostaglandin Mediators. In Bradshaw, R. A. and Dennis, E. A. (Eds.), *Handbook of Cell Signaling (Second Edition)* (pp. 1219-1228). San Diego: Academic Press.
- Sofowora, A., Ogunbodede, E., and Onayade, A. (2013). The role and place of medicinal plants in the strategies for disease prevention. *African Journal of Traditional, Complementary, and Alternative Medicines*, 10(5), 210-229.
- Somchit, N., Kimseng, R., Dhar, R., Hiransai, P., Changtam, C., Suksamrarn, A., Chunglok, W., and Chunglok, W. (2018). Curcumin pyrazole blocks lipopolysaccharide-induced inflammation via suppression of JNK activation in RAW 264.7 macrophages. *Asian Pacific Journal of Allergy and Immunology*, 36(3), 184-190.
- Souza, R. F., Silva, G. A. d., Arruda, A. C., Silva, M. N. d., Santos, A. S., Grisólia, D. P. A., Silva, M. B., Salgado, C. G., and Arruda, M. S. P. (2017). A New Prenylisoflavone from the Antifungal Extract of Leaves of *Vatairea guianensis* Aubl. *Journal of the Brazilian Chemical Society*, 28, 1132-1136.
- Souza, R. F. d., Marinho, V. H. S., Silva, G. A. d., Costa-Jr., L. M., Silva, J. K. R. d., Bastos, G. N. T., Arruda, A. C., Silva, M. N. d., and Arruda, M. S. P. (2013). New isoflavones from the leaves of *Vatairea guianensis* Aublé. *Journal of the Brazilian Chemical Society*, 24, 1857-1863.

- Sree, M. M. R., and Venkata, R. E. (1985). Maxima Isoflavone J: a New O-Prenylated Isoflavone from *Tephrosia maxima*. *Journal of Natural Products*, 48(6), 967-968.
- Steele, V. E., Holmes, C. A., Hawk, E. T., Kopelovich, L., Lubet, R. A., Crowell, J. A., Sigman, C. C., and Kelloff, G. J. (1999). Lipoxygenase Inhibitors as Potential Cancer Chemopreventives. *Cancer Epidemiology Biomarkers & Prevention*, 8(5), 467-483.
- Stevenson, P. C., Kite, G. C., Lewis, G. P., Forest, F., Nyirenda, S. P., Belmain, S. R., Sileshi, G. W., and Veitch, N. C. (2012). Distinct chemotypes of *Tephrosia vogelii* and implications for their use in pest control and soil enrichment. *Phytochemistry*, 78, 135-146.
- Strasser, R. (2003). Rural health around the world: challenges and solutions. *Family Practice*, 20(4), 457-463.
- Sugimoto, M. A., Sousa, L. P., Pinho, V., Perretti, M., and Teixeira, M. M. (2016). Resolution of Inflammation: What Controls Its Onset? *Frontiers in Immunology* 7(160).
- Szefel, J., Kruszewski, W. J., and Sobczak, E. (2015). Factors influencing the eicosanoids synthesis *In Vivo*. *BioMed Research International*, 2015, 690692-690692.
- Tabuti, J. R., Lye, K. A., and Dhillon, S. (2003). Traditional herbal drugs of Bulamogi, Uganda: plants, use and administration. *Journal of Ethnopharmacology*, 88(1), 19-44.
- Tang, Y., Liu, J., Zhang, D., Xu, Z., Ji, J., and Wen, C. (2020). Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. *Frontiers in Immunology* 11, 1708-1708.
- Tarus, P. K., Machocho, A. K., Lang'at-Thoruwa, C. C., and Chhabra, S. C. (2002). Flavonoids from *Tephrosia aequilata*. *Phytochemistry*, 60(4), 375-379.

- Taylor, T. N., Taylor, E. L., and Krings, M. (2009). 22 - Flowering Plants. In Taylor, T. N., Taylor, E. L. and Krings, M. (Eds.), *Paleobotany (Second Edition)* (pp. 873-997). London: Academic Press.
- Thèze, J. (1998). Interleukin 2. In Delves, P. J. (Ed.), *Encyclopedia of Immunology (Second Edition)* (pp. 1436-1438). Oxford: Elsevier.
- Thirumurugan, D., Cholarajan, A., Raja, S. S., and Vijayakumar, R. (2018). An Introductory Chapter: Secondary Metabolites Secondary Metabolites: Sources and Applications (pp. 20): IntechOpen. Retrieved from <https://www.intechopen.com/books/secondary-metabolites-sources-and-applications/an-introductory-chapter-secondary-metabolites>. doi: 10.5772/intechopen.79766.
- Tordera, M., Ferrándiz María, L., and Alcaraz María, J. (1994). Influence of Anti-Inflammatory Flavonoids on Degranulation and Arachidonic Acid Release in Rat Neutrophils *Zeitschrift für Naturforschung C* (Vol. 49, pp. 235).
- Torres, M., Wang, J., Yannie, P. J., Ghosh, S., Segal, R. A., and Reynolds, A. M. (2019). Identifying important parameters in the inflammatory process with a mathematical model of immune cell influx and macrophage polarization. *PLOS Computational Biology*, 15(7), e1007172.
- Touqeer, S., Saeed, M. A., and Ajaib, M. (2013). A review on the phytochemistry and pharmacology of genus *Tephrosia*. *Phytopharmacology*, 4(3), 598-637.
- Traish, A., Bolanos, J., Nair, S., Saad, F., and Morgentaler, A. (2018). Do Androgens Modulate the Pathophysiological Pathways of Inflammation? Appraising the Contemporary Evidence. *Journal of Clinical Medicine*, 7(12), 549.

- Tsai, S.-J., Huang, C.-S., Mong, M.-C., Kam, W.-Y., Huang, H.-Y., and Yin, M.-C. (2012). Anti-inflammatory and Antifibrotic Effects of Naringenin in Diabetic Mice. *Journal of Agricultural and Food Chemistry*, 60(1), 514-521.
- Tungmunnithum, D., Thongboonyou, A., Pholboon, A., and Yangsabai, A. (2018). Flavonoids and Other Phenolic Compounds from Medicinal Plants for Pharmaceutical and Medical Aspects: An Overview. *Medicines (Basel, Switzerland)*, 5(3), 93.
- Turman, M. V., and Marnett, L. J. (2010). Prostaglandin Endoperoxide Synthases: Structure, Function, and Synthesis of Novel Lipid Signaling Molecules. In Liu, H.-W. and Mander, L. (Eds.), *Comprehensive Natural Products II* (pp. 35-63). Oxford: Elsevier.
- Turner, M. D., Nedjai, B., Hurst, T., and Pennington, D. J. (2014). Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*, 1843(11), 2563-2582.
- Ueda, H., Yamazaki, C., and Yamazaki, M. (2002). Luteolin as an Anti-inflammatory and Anti-allergic Constituent of *Perilla frutescens*. *Biological and Pharmaceutical Bulletin*, 25(9), 1197-1202.
- Valli, G., Vasanthi, A., Vijayalakshmi, R., and Thanga Thirupathi, A. (2011). Antipyretic and anti-inflammatory activities of *Tephrosia purpurea* root extracts. *International Journal of Pharmaceutical Research and Development*, 3(6), 211-217.
- Valsecchi, A. E., Franchi, S., Panerai, A. E., Sacerdote, P., Trovato, A. E., and Colleoni, M. (2008). Genistein, a natural phytoestrogen from soy, relieves neuropathic pain following chronic constriction sciatic nerve injury in mice: anti-inflammatory and antioxidant activity. *Journal of Neurochemistry*, 107(1), 230-240.
- Vasconcelos, J. N. e., Lima, J. Q., Lemos, T. L. G. d., Oliveira, M. d. C. F. d., Almeida, M. M. B., Andrade-Neto, M., Mafezoli, J., Arriaga, A. M. C., Santiago, G. M. P., and Braz-

- Filho, R. (2009). Estudo químico e biológico de *Tephrosia toxicaria* Pers. *Química Nova*, 32, 382-386.
- Venkata Rao, E., Rajendra Prasad, Y., and Sree Rama Murthy, M. (1994). A prenylated flavanone from *Tephrosia maxima*. *Phytochemistry*, 37(1), 111-112.
- Venkata Rao, E., Venkataratnam, G., and Vilain, C. (1985). Flavonoids from *Tephrosia fulvinervis*. *Phytochemistry*, 24(10), 2427-2430.
- Venkataratnam, G., Rao, E. V., and Vilain, C. (1986). Fulvinervin C, a flavone from *Tephrosia fulvinervis*. *Phytochemistry*, 25(6), 1507-1508.
- Venkiteshwaran, A. (2009). Tocilizumab. *Landes Bioscience*, 1(5), 432-438.
- Vilain, C. (1980). Barbigerone, a new pyranoisoflavone from seeds of *Tephrosia barbigerana*. *Phytochemistry*.
- Vleggaar, R., Kruger, G. J., Smalberger, T. M., and Van Den Berg, A. J. (1978). Flavonoids from tephrosia-XI: The structure of glabratephrin. *Tetrahedron*, 34(9), 1405-1408.
- Voronov, E., Apte, R. N., and Sofer, s. (1999). The Systemic Inflammatory Response Syndrome Related to The Release of Cytokines Following Severe Envenomation. *Journal of Venomous Animals and Toxins*, 5, 5-33.
- Wang, F., Jiang, K., and Li, Z. (2007). Purification and Identification of Genistein in *Ginkgo biloba* Leaf Extract. *Chinese Journal of Chromatography*, 25(4), 509-513.
- Waterman, P. G., and Khalid, S. A. (1980). The major flavonoids of the seed of *Tephrosia apollinea*. *Phytochemistry*, 19(5), 909-915.
- Weinberger, B., Hirsch, D., Yin, K., and Spur, B. W. (2015). Chapter 21 - Lipid Mediators and Lung Function. In Parent, R. A. (Ed.), *Comparative Biology of the Normal Lung (Second Edition)* (pp. 403-421). San Diego: Academic Press.

- Were, O., Munavu, R. M., Lwande, W., and Nyandat, E. (1990). Flavonoids from *Tephrosia interrupta* and *T. linearis*. *Fitoterapia*, 61(4), 372.
- Whitten, P., Kudo, S., and Okubo, K. (1997). Isoflavonoids. In D'Mello, J. P. F. (Ed.), *Handbook of plant and fungal toxicants* (pp. 117-137). New York: CRC Press.
- WHO. (2008). Traditional Medicine. (No. 134). Retrieved July 4, 2013, from World Health Organization <http://www.who.int/mediacentre/factsheets/fs134/en/#>
- Williams, C. (2012). *Medicinal plants in Australia Volume 3: Plants, potions and poisons* (Vol. 3). Sydney, Australia: Rosenberg Publishing.
- Willoughby, D. A., Moore, A. R., and Colville-Nash, P. R. (2000). COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. *The Lancet*, 355(9204), 646-648.
- Wink, M. (2015). Modes of Action of Herbal Medicines and Plant Secondary Metabolites. *Medicines (Basel, Switzerland)*, 2(3), 251-286.
- Wong, R. S. Y. (2019). Role of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Cancer Prevention and Cancer Promotion. *Advances in Pharmacological Sciences*, 2019, 10.
- Wu, J.-Y., Chen, Y.-J., Bai, L., Liu, Y.-X., Fu, X.-Q., Zhu, P.-L., Li, J.-K., Chou, J.-Y., Yin, C.-L., Wang, Y.-P., Bai, J.-X., Wu, Y., Wu, Z.-Z., and Yu, Z.-L. (2020). Chrysoeriol ameliorates TPA-induced acute skin inflammation in mice and inhibits NF- κ B and STAT3 pathways. *Phytomedicine*, 68, 153173.
- Xu, G., Wang, Z., Zhao, B., Liu, N., Yang, S., Liu, Y., Wang, J., and Zhou, X. (2016). Saniculamins A and B, two new flavonoids from *Sanicula lamelligera* hance inhibiting LPS-induced nitric oxide release. *Phytochemistry Letters*, 18, 35-38.
- Xu, M.-J., Wu, B., Ding, T., Chu, J.-H., Li, C.-Y., Zhang, J., Wu, T., Wu, J., Liu, S.-J., Liu, S.-L., Ju, W.-Z., and Li, P. (2012). Simultaneous characterization of prenylated flavonoids

- and isoflavonoids in *Psoralea corylifolia* L. by liquid chromatography with diode-array detection and quadrupole time-of-flight mass spectrometry. *Rapid Communications in Mass Spectrometry* 26(19), 2343-2358.
- Yang, L., Wen, K.-S., Ruan, X., Zhao, Y.-X., Wei, F., and Wang, Q. (2018). Response of Plant Secondary Metabolites to Environmental Factors. *Molecules (Basel, Switzerland)*, 23(4), 762.
- Yao, C., and Narumiya, S. (2019). Prostaglandin-cytokine crosstalk in chronic inflammation. *British Journal of Pharmacology*, 176(3), 337-354.
- Yeneşew, A., Dagne, E., and Waterman, P. G. (1989). Flavonoids from the seed pods of *Tephrosia pumila*. *Phytochemistry*, 28(4), 1291-1292.
- Yeneşew, A., Midiwo, J. O., and Waterman, P. G. (1998). Rotenoids, isoflavones and chalcones from the stem bark of *Millettia usaramensis* subspecies *usaramensis*. *Phytochemistry*, 47(2), 295-300.
- Yiu, T. Y., Faisal, A., Angelica, G.-C., and Sandro, A. (2018). Signaling Pathways in Inflammation and Anti-inflammatory Therapies. *Current Pharmaceutical Design*, 24(14), 1449-1484.
- Yuldashev, M. P., Batirov, E. K., Vdovin, A. D., and Abdullaev, N. D. (2000). Structural study of glabrisoflavone, a novel isoflavone from *Glycyrrhiza glabra* L. *Russian Journal of Bioorganic Chemistry*, 26(8), 784-786.
- Zarghi, A., and Arfaei, S. (2011). Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships. *Iranian Journal of Pharmaceutical Research*, 10(4), 655-683.
- Zhang, J.-K., Li, M., Li, M., Du, K., Lv, J., Zhang, Z.-G., Zheng, X.-K., and Feng, W.-S. (2019a). Four C-geranyl flavonoids from the flowers of *Paulownia fortunei* and their anti-inflammatory activity. *Natural Product Research*, 1-10.

Zhang, J.-M., and An, J. (2007). Cytokines, inflammation, and pain. *International Anesthesiology Clinics*, 45(2), 27-37.


Zhang, Y., Zhou, D., Liu, W., Li, C., Hao, L., Zhang, G., Deng, S., Yang, R., Qin, J., Li, J., and Deng, W. (2019b). Cytotoxic Activity and Related Mechanisms of Prenylflavonoids Isolated from *Mallotus conspurcatus* Croizat. *Chemistry & Biodiversity*, 16(5), e1800465.

APPENDIX A: Spectra for the Isolated Compounds

Appendix A1: Spectra for compound 1


HRESIMS spectrum of compound 1

TLA-28H21#791 RT: 23.02 AV: 1 NL: 6.21E8
F: FTMS + c ESI Full ms [100.00-1000.00]



HRESIMS² spectrum of compound 1

TLA-28H21a #1336 RT: 25.54 AV: 1 NL: 1.30E8
F: FTMS + c ESI Full ms 3433.20@cid35.00 369.15@cid35.00 [100.00-450.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 1

INFU-TLA-28H21_2019-02-11_11-17-58_AV600.10.fid

H1

z_Proton Acetone /NMR-Daten INFU 9




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 1


INFU-TLA-28H21_2019-02-11_11-17-58_AV600.11.fid

C13 with power gated H1 decoupling


z_C13pg Acetone /NMR-Daten INFU 9




^1H - ^1H COSY spectrum of compound 1




HSQC spectrum of compound 1



HMBC spectrum of compound 1




NOESY spectrum of compound 1



Appendix A2: Spectra for compound 2


HRESIMS spectrum of compound 2

TLA-55B16#414 RT: 19.43 AV: 1 NL: 6.08E7
F: FTMS + c ESI Full ms [100.00-1000.00]




TLA-55B16 # 1180 RT: 22.17 AV: 1 NL: 3.80E8


F: FTMS + c ESI Full ms3 419.19@cid35.00 401.17@cid35.00 [110.00-450.00]




NMR spectrum (600 MHz, Acetone-*d*₆) of compound 2




¹³C NMR spectrum (150 MHz, Acetone-*d*₆) of compound 2




^1H - ^1H COSY spectrum of compound 2




HSQC spectrum of compound 2



HMBC spectrum of compound 2




NOESY spectrum of compound 2




Appendix A3: Spectra for compound 3

HRESIMS spectrum of compound 3


TLA-31A3517 RT:27.35 AV:1 RF:6.00,3NL:6.47E6
F:FTMS + c ESI Full ms [100.00-1000.00]




TLA-31A33 #1548 RT:27.29 AV:1 NL:3.41E7
F:FTMS + c ESI Full ms2 387.16@cid35.00 [105.00-400.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 3




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 3




^1H - ^1H COSY spectrum of compound 3




HSQC spectrum of Compound 3



HMBC spectrum of compound 3




NOESY spectrum of compound 3




Appendix A4: Spectra for compound 4

HRESIMS spectrum of compound 4


TLA-55B19 #549 RT: 25.10 AV: 1 NL: 9.35E7
 F: FTMS + c ESI Full ms [100.00-1000.00]




TLA-55B19 #1384RT26.11AV:1 NL3.41E7
 F: FTMS + c ESI Full ms3 401.18@cid35.00 369.15@cid35.00 [100.00-450.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 4




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 4




^1H - ^1H -COSY Spectrum of Compound 4




HSQC spectrum of compound 4



HMBC spectrum of compound 4




NOESY spectrum of compound 4




Appendix A5: Spectra for compound 5

HRESIMS spectrum of compound 5


TLA-55C6 #628-658 RT:11.79-12.25 AV:8 RF:6.00,3 NL:4.72E7
 F: FTMS + c ESI Full ms [100.00-1000.00]




TLA-55C6 #544 RT:12.40 AV:1 NL:2.01E7
 F: FTMS + c ESI Full ms 315.09@cid35.00 300.06@cid35.00 [80.00-350.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 5




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 5




^1H - ^1H -COSY spectrum of compound 5




HSQC spectrum of compound 5



HMBC spectrum of compound 5



NOESY spectrum of compound 5



Appendix A6: Spectra for compound 6


HRESIMS spectrum of compound 6

TLA-40A#1241 RT:23.82 AV:1 NL:1.45E8
F: FTMS + c ESI Full ms [100.00-1000.00]




TLA-40A#1242 RT:23.84 AV:1 NL:3.53E6


F: FTMS + c ESI Full ms 3 381.13 @cid35.00 339.12 @cid15.00 [90.00-400.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 6




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 6




^1H - ^1H -COSY spectrum of compound 6




HSQC spectrum of compound 6



HMBC spectrum of compound 6




NOESY spectrum of compound 6




Appendix A7: Spectra for compound 7

HRESIMS spectrum of compound 7


TLA-52B1#339 RT:16.65 AV:1 NL:2.19E7
 F:FTMS + c ESI Full ms [100.00-1000.00]




TLA-52B1#908 RT:16.60AV:1 NL:1.36E5
 F:FTMS + c ESI Full ms 2371.15@cid35.00 [100.00-400.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 7




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 7




^1H - ^1H -COSY spectrum of compound 7




HSQC spectrum of compound 7



HMBC spectrum of compound 7




NOESY spectrum of compound 7




Appendix A8: Spectra for compound 8

HRESIMS spectrum of compound 8


TLA-41B14 #690 RT: 21.05 AV: 1 RF: 6.00,3 NL: 1 ³²F6
 F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 8




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 8




¹H-¹H-COSY spectrum of compound 8



HSQC spectrum of compound 8




HMBC spectrum of compound 8




Appendix A9: Spectra for compound 9

HRESIMS spectrum of compound 9


TLA-55B6 #285 RT: 12.62 AV: 1 RF: 6.00,3 NL: 3.46F7
 F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 9




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 9




¹H-¹H-COSY spectrum of compound 9



HSQC spectrum of compound 9




HMBC spectrum of compound 9




Appendix A10: Spectra for compound 10

HRESIMS spectrum of compound 10


TLA-55C13 #351 RT: 18.64 AV: 1 RF: 6.00,3 NL: 1.0076
 F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 10




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 10




¹H-¹H-COSY spectrum of compound 10



HSQC spectrum of compound 10




HMBC spectrum of compound 10




Appendix A11: Spectra for compound 11

HRESIMS spectrum of compound 11


TLA-55C12 #298 RT: 15.84 AV: 1 RF: 6.00,3 NL: 8.5755
 F: FTMS + c ESIFull ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 11




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 11




¹H-¹H-COSY spectrum of compound 11



HSQC spectrum of compound 11




HMBC spectrum of compound 11




Appendix A12: Spectra for compound 12

HRESIMS spectrum of compound 12


TLA-55C10 #262 RT: 13.92 AV: 1 RF: 6.00,3 NL: 7.6555
 F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 12




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 12




¹H-¹H-COSY spectrum of compound 12



HSQC spectrum of compound 12




HMBC spectrum of compound 12




Appendix A13: Spectra for compound 13

HRESIMS spectrum of compound 13


TLA-28M43 #242 RT: 12.83 AV: 1 RF: 6.00,3 NL: 2 24F6
 F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 13




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 13




¹H-¹H-COSY spectrum of compound 13



HSQC spectrum of compound 13




HMBC spectrum of compound 13




Appendix A14: Spectra for compound 14

HRESIMS spectrum of compound 14


TLA-55C7 #234 RT: 12.40 AV: 1 RF: 6.00,3 NL: 1.4756
F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 14




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 14




¹H-¹H-COSY spectrum of compound 14



HSQC spectrum of compound 14




HMBC spectrum of compound 14




Appendix A15: Spectra for compound 15

HRESIMS spectrum of compound 15


TLA-55A8 #385 RT: 20.28 AV: 1 NL: 9.55E6
F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 15




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 15




¹H-¹H-COSY spectrum of compound 15



HSQC spectrum of compound 15




HMBC spectrum of compound 15




Appendix A16: Spectra for compound 16

HRESIMS spectrum of compound 16


TLA-28N610 #319 RT: 10.75 AV: 1 RF: 6.00,3 NL: F 245F
 F: FTMS + c ESI Full ms [100.00-1000.00]




1H NMR spectrum (600 MHz, Acetone- d_6) of compound 16




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 16




¹H-¹H-COSY spectrum of compound 16



HSQC spectrum of compound 16




HMBC spectrum of compound 16




Appendix A17: Spectra for compound 17

HRESIMS spectrum of compound 17


TLA-28N507 #352 RT: 11.83 AV: 1 RF: 6.00,3 NL: 6.14E6
 F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 17




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 17




¹H-¹H-COSY spectrum of compound 17



HSQC spectrum of compound 17




HMBC spectrum of compound 17




Appendix A18: Spectra for compound 18

HRESIMS spectrum of compound 18

TLA-55A3 #305 RT: 16.04 AV: 1 RF: 6.00,3 NL: 3.24F6
 F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 18




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 18


INFU-TLA-55A3_2019-02-13_13-19-27_AV600.11.fid
C13 with power gated H1 decoupling
z_C13pg Acetone /NMR-Daten INFU 36




¹H-¹H-COSY spectrum of compound 18



HSQC spectrum of compound 18




HMBC spectrum of compound 18




Appendix A19: Spectra for compound 19


¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 19




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 19




^1H - ^1H -COSY spectrum of compound 19




HSQC spectrum of compound 19



HMBC spectrum of compound 19




NOESY spectrum of compound 19




Appendix A20: Spectra for compound 20

HRESIMS spectrum of compound 20


TLA-41B9 #614 RT: 18.71 AV: 1 RF: 6.00,3 NL: 6.00F6
 F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 20




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 20




¹H-¹H-COSY spectrum of compound 20



HSQC spectrum of compound 20




HMBC spectrum of compound 20




Appendix A21: Spectra for compound 21

HRESIMS spectrum of compound 21


TLA-55A4 #323 RT: 17.14 AV: 1 RF: 6.00,3 NL: 5.17E5
 F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 21




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 21




¹H-¹H-COSY spectrum of compound 21



HSQC spectrum of compound 21




HMBC spectrum of compound 21




Appendix A22: Spectra for compound 22

HRESIMS spectrum of compound 22


TLA-41B10 #624 RT: 19.01 AV: 1 RF: 6.00,3 NL: 8.7076
 F: FTMS + c ESI Full ms [100.00-1000.00]




1H NMR spectrum (600 MHz, Acetone- d_6) of compound 22




^{13}C NMR spectrum (150 MHz, Acetone- d_6) of compound 22




^1H - ^1H -COSY spectrum of compound 22



HSQC spectrum of compound 22




HMBC spectrum of compound 22




Appendix A23: Spectra for compound 23

HRESIMS spectrum of compound 23


TLA-41B8 #578 RT: 17.57 AV: 1 RF: 6.00,3 NL: 1.3^eF7
 F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 23




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 23




¹H-¹H-COSY spectrum of compound 23



HSQC spectrum of compound 23




HMBC spectrum of compound 23




Appendix A24: Spectra for compound 24

HRESIMS spectrum of compound 24


TLA-41B7 #518 RT: 15.75 AV: 1 NL: 1.73E7
 F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 24




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 24




¹H-¹H-COSY spectrum of compound 24



HSQC spectrum of compound 24




HMBC spectrum of compound 24




Appendix A25: Spectra for compound 25

HRESIMS spectrum of compound 25


THA-51E2_367_15 #1562 RT: 27.05 AV: 1 NL: 1.66E6
F: FTMS + c ESI Full ms2 367.15@cid15.00 [100.00-600.00]




THA-51E2_367_15 #1564 RT: 27.08 AV: 1 NL: 1.31E6
F: FTMS + c ESI Full ms2 367.15@cid35.00 [100.00-600.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 25




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 25




¹³C DEPT134 NMR spectrum (150 MHz, Acetone-d₆) of compound 25




¹H-¹H-COSY spectrum of compound 25



HSQC spectrum of compound 25




HMBC spectrum of compound 25




Appendix A26: Spectra for compound 26

HRESIMS spectrum of compound 26


THA-29D5 #680 RT: 17.55 AV: 1 NL: 8.80E7
 F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 26




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 26




¹H-¹H-COSY spectrum of compound 26



HSQC spectrum of compound 26




HMBC spectrum of compound 26




Appendix A27: Spectra for compound 27

HRESIMS spectrum of compound 27


THA-29F6 #742 RT: 19.15 AV: 1 NL: 9.19E6
F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 27




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 27




¹H-¹H-COSY spectrum of compound 27



HSQC spectrum of compound 27




HMBC spectrum of compound 27




Appendix A28: Spectra for compound 28

HRESIMS spectrum of compound 28


THA-29F1 #614 RT: 16.28 AV: 1 NL: 5.62E5
 F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 28




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 28




¹H-¹H-COSY spectrum of compound 28



HSQC spectrum of compound 28




HMBC spectrum of compound 28




Appendix A29: Spectra for compound 29

HRESIMS spectrum of compound 29


THA01_181013235313 #440 RT: 13.14 AV: 1 NL: 4.05E4
F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 29




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 29




¹H-¹H-COSY spectrum of compound 29



HSQC spectrum of compound 29




HMBC spectrum of compound 29




Appendix A30: Spectra for compound 30

HRESIMS spectrum of compound 30


THR-451 #573 RT: 14.64 AV: 1 NL: 1.78E6
 F: FTMS + c ESI Full ms [100.00-1000.00]




1H NMR spectrum (600 MHz, Acetone- d_6) of compound 30




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 30




¹H-¹H-COSY spectrum of compound 30



HSQC spectrum of compound 30




HMBC spectrum of compound 30




Appendix A31: Spectra for compound 31

HRESIMS spectrum of compound 31


THR-454 #832 RT: 18.96 AV: 1 RF: 6.00,3 NL: 5.76^{F7}
 F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 31




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 31




¹H-¹H-COSY spectrum of compound 31



HSQC spectrum of compound 31




HMBC spectrum of compound 31




Appendix A32: Spectra for compound 32

HRESIMS spectrum of compound 32


THR-453 #764 RT: 18.43 AV: 1 RF: 6.00,3 NL: 3.47F7
F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 32




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 32




¹H-¹H-COSY spectrum of compound 32



HSQC spectrum of compound 32




HMBC spectrum of compound 32




Appendix A33: Spectra for compound 33

HRESIMS spectrum of compound 33


THA568-21G7 #488 RT: 15.79 AV: 1 NL: 1.50E7
 F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 33




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 33




¹H-¹H-COSY spectrum of compound 33



HSQC spectrum of compound 33




HMBC spectrum of compound 33




Appendix A34: Spectra for compound 34

HRESIMS spectrum of compound 34


THA568-21G1 #421 RT: 13.29 AV: 1 NL: 9.98E6
 F: FTMS + c ESI Full ms [100.00-1000.00]




1H NMR spectrum (600 MHz) of compound 34




¹³C NMR spectrum (150 MHz, CD₃OD) of compound 34




¹H-¹H-COSY spectrum of compound 34



HSQC spectrum of compound 34



HMBC spectrum of compound 34




Appendix A35: Spectra for compound 35


HRESIMS spectrum of compound 35

TVP-53C4 #445 RT: 13.78 AV: 1 RF: 6.00,3 NL: 1.30E7


F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 35




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 35




¹H-¹H-COSY spectrum of compound 35



HSQC spectrum of compound 35




HMBC spectrum of compound 35




Appendix A36: Spectra for compound 36

HRESIMS spectrum of compound 36


TVP-13Q10 #487 RT: 14.84 AV: 1 RF: 6.00,3 NL: 5.17E6
F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 36




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 36




¹H-¹H-COSY spectrum of compound 36



HSQC spectrum of compound 36




HMBC spectrum of compound 36




Appendix A37: Spectra for compound 37

HRESIMS spectrum of compound 37


TVP-53C5 #504 RT: 15.53 AV: 1 NL: 4.15E7
F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 37




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 37




¹H-¹H-COSY spectrum of compound 37



HSQC spectrum of compound 37




HMBC spectrum of compound 37




Appendix A38: Spectra for compound 38

HRESIMS spectrum of compound 38


TVP889-22D #1085 RT: 19.79 AV: 1 NL: 5.66E8
F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 38




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 38




¹H-¹H-COSY spectrum of compound 38



HSQC spectrum of compound 38




HMBC spectrum of compound 38



Appendix A39: Spectra for compound 39

HRESIMS spectrum of compound 39

TVP-13Q6 #417 RT: 12.62 AV: 1 NL: 5.28E7
 F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 39


INFU-TVP-13Q62_2019-06-26_12-55-55_AV600.10.fid

H1


z_Proton Acetone /NMR-Daten INFU 35




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 39




¹H-¹H-COSY spectrum of compound 39



HSQC spectrum of compound 39




HMBC spectrum of compound 39




Appendix A40: Spectra for compound 40

HRESIMS spectrum of compound 40


TVP-13Q2 #303 RT: 9.45 AV: 1 NL: 2.73E6
F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 40




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 40




¹H-¹H-COSY spectrum of compound 40



HSQC spectrum of compound 40




HMBC spectrum of compound 40




Appendix A41: Spectra for compound 41

HRESIMS spectrum of compound 41


TVP-13Q3 #386 RT: 11.78 AV: 1 NL: 8.78E7
 F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 41




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 41




¹H-¹H-COSY spectrum of compound 41



HSQC spectrum of compound 41




HMBC spectrum of compound 41




Appendix A42: Spectra for compound 42


¹H NMR spectrum (600 MHz, CDCl₃) of compound 42




¹³C NMR spectrum (150 MHz, CDCl₃) of compound 42




¹H-¹H-COSY spectrum of compound 42



HSQC spectrum of compound 42




HMBC spectrum of compound 42




Appendix A43: Spectra for compound 43

HRESIMS spectrum of compound 43


TVP889-15E #681 RT: 21.45 AV: 1 NL: 1.01E8
 F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, CDCl₃) of compound 43




¹³C NMR spectrum (150 MHz, CDCl₃) of compound 43




¹H-¹H-COSY spectrum of compound 43



HSQC spectrum of compound 43




HMBC spectrum of compound 43




Appendix A44: Spectra for compound 44

HRESIMS spectrum of compound 44


TVS-56C7 #607 RT: 18.38 AV: 1 NL: 2.04E8
F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 44




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 44




¹H-¹H-COSY spectrum of compound 44



HSQC spectrum of compound 44




HMBC spectrum of compound 44




Appendix A45: Spectra for compound 45

HRESIMS spectrum of compound 45


TVS-56C7 #655 RT: 19.84 AV: 1 NL: 1.08E8
F: FTMS + c ESI Full ms [100.00-1000.00]




1H NMR spectrum (600 MHz, Acetone- d_6) of compound 45




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 45




¹H-¹H-COSY spectrum of compound 45



HSQC spectrum of compound 45




HMBC spectrum of compound 45




Appendix A46: Spectra for compound 46

HRESIMS spectrum of compound 46


TVS-56C1 #687 RT: 21.77 AV: 1 NL: 2.48E8
F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 46




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 46




¹H-¹H-COSY spectrum of compound 46



HSQC spectrum of compound 46




HMBC spectrum of compound 46




Appendix A47: Spectra for compound 47

HRESIMS spectrum of compound 47


TVS-56C7 #689 RT: 20.91 AV: 1 NL: 2.60E7
F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 47




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 47




¹H-¹H-COSY spectrum of compound 47



HSQC spectrum of compound 47



HMBC spectrum of compound 47



Appendix A48: Spectra for compound 48


HRESIMS spectrum of compound 48

:\PHD 2019\...TRR\TRR-61E-B\TRR-62C1


5/2/19 10:00:57 PM

RR-62C1 #626 RT: 22.61 AV: 1 NL: 6.46E6


FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 48




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 48




¹H-¹H-COSY spectrum of compound 48



HSQC spectrum of compound 48




HMBC spectrum of compound 48




Appendix A49: Spectra for compound 49

HRESIMS spectrum of compound 49

TRS-63B4 #592 RT: 21.17 AV: 1 NL: 1.82E8
 F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 49




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 49


INFU-TRS-63B4_2019-05-09_10-51-45_AV600.11.fid
C13 with power gated H1 decoupling
z_C13pg Acetone /NMR-Daten INFU 11




^1H - ^1H -COSY spectrum of compound 49



HSQC spectrum of compound 49




HMBC spectrum of compound 49




Appendix A50: Spectra for compound 50

HRESIMS spectrum of compound 50


TRS07_181014040620 #697 RT: 20.30 AV: 1 NL: 8.0055
 F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, CDCl₃) of compound 50




¹³C NMR spectrum (150 MHz, CDCl₃) of compound 50




¹H-¹H-COSY spectrum of compound 50



HSQC spectrum of compound 50




HMBC spectrum of compound 50




Appendix A51: Spectra for compound 51

HRESIMS spectrum of compound 51


TRS-65D5 #326 RT: 12.49 AV: 1 NL: 1.15E7
F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 51




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 51




¹H-¹H-COSY spectrum of compound 51



HSQC spectrum of compound 51




HMBC spectrum of compound 51




Appendix A52: Spectra for compound 52

HRESIMS spectrum of compound 52


TRS-65D7 #362 RT: 13.92 AV: 1 NL: 2.33E6
F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 52




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 52




¹H-¹H-COSY spectrum of compound 52



HSQC spectrum of compound 52




HMBC spectrum of compound 52




Appendix A53: Spectra for compound 53

HRESIMS spectrum of compound 53


TRR-60D2 #649 RT: 21.94 AV: 1 NL: 1.83E8
 F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 53




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 53




¹H-¹H-COSY spectrum of compound 53



HSQC spectrum of compound 53




HMBC spectrum of compound 53




Appendix A54: Spectra for compound 54

HRESIMS spectrum of compound 54


TRS-65D9 #368 RT: 14.10 AV: 1 NL: 2.20E7
F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 54




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 54




¹H-¹H-COSY spectrum of compound 54



HSQC spectrum of compound 54




HMBC spectrum of compound 54




Appendix A55: Spectra for compound 55

HRESIMS spectrum of compound 55


TRIS-65D10 #357 RT: 13.93 AV: 1 NL: 1.19E7
F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 55




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 55




¹H-¹H-COSY spectrum of compound 55



HSQC spectrum of compound 55




HMBC spectrum of compound 55




Appendix A56: Spectra for compound 56

HRESIMS spectrum of compound 56


TRS-63B2 #580 RT: 20.78 AV: 1 NL: 2.88E7
 F: FTMS + c ESI Full ms [100.00-1000.00]




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 56




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 56




¹H-¹H-COSY spectrum of compound 56



HSQC spectrum of compound 56




HMBC spectrum of compound 56




Appendix A57: Spectra for compound 57

HRESIMS spectrum of compound 57




¹H NMR spectrum (600 MHz, Acetone-d₆) of compound 57




¹³C NMR spectrum (150 MHz, Acetone-d₆) of compound 57


INFU-S4P-62A6_2019-05-06_13-35-46_AV600.11.fid
C13 with power gated H1 decoupling
z_C13pg Acetone /NMR-Daten INFU 26




^1H - ^1H -COSY spectrum of compound 57



HSQC spectrum of compound 57



HMBC spectrum of compound 57



APPENDIX B: Data for Anti-Inflammatory Assay

APPENDIX B1: Table Results for Anti-inflammatory Assay

Table B1: Results of controls (mean \pm SD, n=3 for medium and n=4 for LPS and ibuprofen)

Controls		Cytokine release [pg/ml]					
		IL-1 β	IL-2	IL-6	IFN- γ	GM-CSF	TNF α
Medium	mean	616.95	6.59	29213.73	27.04	163.32	417.09
	SD	178.00	1.51	22861.52	8.10	2.39	356.67
LPS	mean	651.20	9.91	42900.00	42.60	168.60	656.66
	SD	343.02	1.99	0.00	18.84	47.34	48.84
Ibuprofen	mean	1297.77	7.96	19931.71	21.82	80.53	80.29
	SD	54.04	1.59	5357.24	12.44	8.18	6.78

Table B2: Results for Cytokine release (pg/ml) after LPS stimulated PMBCs incubated with isolated compounds and crude extracts from *Tephrosia linear* and *T. hidebrandtii*¹⁴

Samples	Cytokine release [pg/ml]					
	IL-1 β	IL-2	IL-6	IFN- γ	GM-CSF	TNF- α
Medium	820.55	5.71	2821.58	35.53	165.71	14.93
Medium	539.48	5.71	41919.60	26.17	160.93	695.07
Medium	490.81	8.34	42900.00	19.41	163.33	541.28
LPS	148.06	8.34	42900.00	15.11	12.08	723.15
LPS	867.29	8.34	42900.00	57.09	210.89	657.19
LPS	717.47	12.46	42900.00	51.79	177.44	607.52
LPS	872.00	10.52	42900.00	46.43	117.47	638.77
Ibuprofen	1248.97	8.34	22460.36	10.28	82.25	84.40
Ibuprofen	1356.05	8.34	18570.75	39.20	88.51	74.54
Ibuprofen	1331.35	5.71	25559.62	16.44	82.25	87.70
Ibuprofen	1254.72	9.47	13136.10	21.37	69.08	74.54
1	444.56	5.71	4670.13	15.11	29.33	6.07
2	7.65	5.71	0.00	15.11	<14.55	1.09
3	1106.02	1.76	266973.99	1.15	132.16	12.39
4	493.96	5.71	41795.72	15.11	141.17	20.67
5	1110.37	1.76	18492.90	1.15	29.33	26.44
6	1022.97	1.76	18614.32	1.15	69.08	17.48
7	350.15	1.76	11062.37	15.11	54.75	26.44
8	666.47	5.71	8393.81	15.11	79.05	41.92
9	1435.44	5.71	42900.00	15.11	60.29	82.42

¹⁴ Isolated compounds and ibuprofen were evaluated at 100 μ m and the plant crude extract was evaluated at 100 μ g/mL.

Samples	Cytokine release [pg/ml]					
	IL-1 β	IL-2	IL-6	IFN- γ	GM-CSF	TNF- α
10	265.90	1.76	10603.96	15.11	82.25	32.88
11	672.59	5.71	102332.57	14.42	65.63	34.17
12	684.87	<5.71	20732.99	<15.11	54.75	27.73
13	4.37	<5.71	18.17	<15.11	<14.55	1.09
14	314.85	5.71	3102.34	<15.11	8.21	7.33
15	711.26	5.71	>42900.00	2.44	156.09	23.87
16	31.34	<5.71	273.39	<15.11	<14.55	3.56
17	966.63	1.76	10699.86	13.40	82.25	25.16
TLC	701.13	1.76	5965.31	<15.11	62.09	30.30
25	211.81	1.76	3178.91	<15.11	72.47	18.75
26	1002.29	1.76	5583.01	<15.11	82.25	41.92
27	176.44	<5.71	252.14	<15.11	24.21	2.32
28	501.32	1.76	7503.57	<15.11	72.47	14.93
29	913.40	1.76	29074.63	1.15	82.25	20.03
30	131.49	1.76	2485.24	<15.11	18.58	7.33
31	951.61	5.71	12621.06	3.65	67.36	43.22
32	375.02	<5.71	4290.28	<15.11	3.22	9.85
THC	905.08	10.52	>42900.00	3.65	97.57	21.31

TLC – crude extract from *T. linearis*

THC – crude extract from *T. hildebrandtii*

Table B3: Results of controls (mean \pm SD, n=3)

Controls		Cytokine release [pg/ml]			
		IL-1 β	IFN- γ	GM-CSF	TNF α
Medium	mean	892.01	178.61	40.90	139.39
	SD	72.62	38.29	7.02	65.45
LPS	mean	14532.78	8876.79	427.98	8295.07
	SD	1354.00	1764.07	77.51	988.00
Ibuprofen	mean	3703.12	1493.90	103.75	2672.63
	SD	441.66	146.93	17.54	333.15
Ibuprofen	% of LPS control	25.48	16.83	24.24	32.22

Table B4: Results for Cytokine release (pg/ml) after LPS stimulated PMBCs incubated with isolated compounds and crude extracts from *Tephrosia vogelii*, *T. elata* and *T. rhodesica*¹⁵

Samples	Concentration	Cytokine release [pg/ml]			
		IL-1 β	IFN- γ	GM-CSF	TNF- α
35	100 μ M	9462.05	897.55	370.99	1878.78
36	100 μ M	2323.22	43.06	75.31	183.83
38	100 μ M	8418.14	121.10	30.16	61.57
44	100 μ M	9537.92	1058.28	253.42	2364.94
45	100 μ M	4361.17	27.51	125.49	278.81
46	100 μ M	13251.15	4371.17	187.76	4701.73
47	100 μ M	6810.24	314.62	212.69	1380.12
48	100 μ M	6337.58	85.40	341.78	1064.32
52	100 μ M	8367.57	512.77	300.30	1477.27
53	100 μ M	11061.86	72.73	148.61	228.65
54	100 μ M	10534.45	82.18	259.46	422.54
55	100 μ M	9219.65	317.65	1061.74	2770.18
56	100 μ M	8526.89	217.13	609.91	823.50
57	100 μ M	10846.16	341.83	636.70	701.32
TVC	100 μ g/ml	10926.34	93.51	283.08	267.69
TRC	100 μ g/ml	6534.53	44.32	805.18	1705.53

TVC – the crude extract of *T. vogelii*


TRC – the crude extract of *T. rhodesica*

¹⁵ Isolated compounds and ibuprofen were evaluated at 100 μ m and the plant crude extract was evaluated at 100 μ g/mL.

Table B5: Results for Cytokine release (pg/ml) after LPS stimulated PMBCs incubated with combination of isolated compounds and crude extracts from

Group	Compound	Concentration	Cytokine release [pg/ml]			
			IL-1 β	IFN- γ	GM-CSF	TNF- α
1	1	100 μ M	35.93 \pm 7.90	15.11 \pm 0.00	14.55 \pm 0.00	2.39 \pm 0.00
	2					
	3					
	4					
	8					
	9					
2	5	100 μ M	11.35 \pm 2.84	15.11 \pm 0.00	14.55 \pm 0.00	8.59 \pm 0.00
	12					
	13					
	14					
	15					
	16					
	17					
	6					
3	7	100 μ M	489.92 \pm 77.43	15.11 \pm 0.00	8.87 \pm 5.93	10.59 \pm 1.75
	10					
	11					
4	25	100 μ M	3068.36 \pm 550.46	7.44 \pm 2.61	15.75 \pm 13.77	78.84 \pm 14.95
	31					
	32					
5	26	100 μ M	11544.17 \pm 1529.60	107.70 \pm 9.38	788.55 \pm 111.83	657.12 \pm 138.41
	27					
6	28	100 μ M	5816.37 \pm 1925.60	21.88 \pm 9.33	51.78 \pm 34.14	136.77 \pm 130.10
	29					
	30					
Crude extract of <i>T. hidebrandtii</i>		10 μ g/ml	2594.11 \pm 147.62	950.60 \pm 240.84	72.71 \pm 10.48	1638.64 \pm 86.94
Crude extract of <i>T. linearis</i>		10 μ g/ml	2745.63 \pm 305.94	582.78 \pm 12.53	84.40 \pm 16.59	1417.03 \pm 307.13

APPENDIX B2: Certificate of Analysis



CTL.

ELIGAND: 13-06-0019
LAGERUNG: RAA, Pos. 29/80/81

PRODUCT DATA SHEET – ePBMC® Uncharacterized Cryopreserved Human PBMC

Catalog No.: CTL-UP1

Product name: ePBMC® - Uncharacterized Cryopreserved Human PBMC

Size: >10x10⁶ cells / vial

Description: Human PBMC (Peripheral Blood Mononuclear Cells) isolated from leukopacks and frozen in CTL-CryoABC™ serum-free freezing medium. These leukopacks were ethically collected from healthy donors with no risk of breaching privacy. Tested negative for HBsAg, HBcAb, HCV, HTLV I/II and STS by serology; as well as HIV I, HCV and WNV by NAT (nucleic acid testing)

Performance: T cell functionality by ELISPOT equivalent to fresh cells

Applications: PBMCs are suited for T cell monitoring in ELISPOT, ELISA, cytokine bead arrays, tetramer/ pentamer, and cytokine capture assays or any assay that requires live functional PBMC

Recommended test concentration: Investigators are advised to determine optimal concentrations for individual applications. CTL recommends of 100,000 to 800,000 cells / well concentration for ELISPOT

Stability and Storage: Cryopreserved cells are shipped in a dry cryoshipper, and should be unpacked immediately upon receipt. Short-term storage of cells (24h) at -80°C is acceptable, but should be minimized to ensure maximum stability. For long-term storage, cryopreserved cells should be stored in liquid nitrogen. Thawed samples must be used immediately and have a finite life span in culture. Avoid repeated freeze-thaw cycles!

Long-term Storage: -169°C to -196°C (must be on liquid nitrogen (LN2) vapor)

Thawing: Thaw protocol included

Usage: **FOR RESEARCH USE ONLY! Not intended for direct therapeutic or diagnostic use in humans or animals, or for use in in vitro diagnostic procedures!**

Characterization results: PBMCs from 3 donors, 1 vial each to Pharmacelsus GmbH, Dr. Tanja Wolf

Sample ID#	HHU20181025	HHU20181023	HHU20181002	x	x
Ethnicity	African/American	Pacific Islander	Caucasian	---	---
Age	38	38	34	---	---
Gender	Male	Male	Female	---	---
ABO/Rh	O/Pos	B/Pos	A/Pos	---	---

SFC - Spot Forming Cells

RI _____ June 10, 2019
CTL Representative _____ Date

C.T.L., 20521 Chagrin Blvd., Shaker Heights, Ohio 44122 USA
Tel (216) 791-5084 • Toll Free (888) 791-4005 • Fax (216) 791-8814 • www.immunospot.com

Certificate of analysis

ProcartaPlex

Cat. number: **PPX-07-MXXGRJX** Name: **Human Custom ProcartaPlex 7-plex**
96 tests/7 analytes

Lot number: **214139000** Expiry date: **2020-06**

Components		Quantity	Lot	Store at
S10011EX	Standard Mix A	2 each	187440101	2-8°C
B-07-MXXGRJX-EX	7-plex Beads	1 x 5ml (1x)	213797000	2-8°C
BK-07-MXXGRJX-EX	7-plex det.AB	1 x 3,5ml (1x)	213798000	2-8°C
RBEX/46	Reading Buffer	1 x 40ml	18103753	2-8°C
WBEX/28	10x Wash Buffer	1 x 25ml	18093505	2-8°C
SA-PE	Streptavidin-PE	1 x 5ml	202532000	2-8°C
UABEX/11	Universal Assay Buffer 1x	1 x 10ml	18124434	2-8°C
SVM104	Black Microplate Lid	1 each		2-8°C
SVM16	Plate Covers	8 each		2-8°C
SVM183	PCR 8-Tube Strip	2 each		2-8°C
SVM182	Flat bottom Plate (black)	1 each		2-8°C

Standard Mix A Lot#187440101

Provided below is a table of Standard 1 (Std1) value for each analyte in each tube when prepared according to the "Preparing Standard" procedure of the Manual.

Analyte	Std1 Concentration (pg/ml)	ULOQ / LLOQ (pg/ml)
		Determined in cell culture medium
Λ GM-CSF	59600	59600 / 15
Λ IFN-gamma	61900	61900 / 15
Λ TNF-alpha	35200	35200 / 8,59
IL-10	6950	6950 / 1,70
X IL-12p70	25200	25200 / 6,15
IL-13	13800	13800 / 3,37
IL-17A	9300	9300 / 2,27
IL-18	67800	67800 / 17
X IL-1beta	8150	8150 / 1,99
X IL-2	23400	23400 / 5,71
IL-21	41500	41500 / 10
IL-22	77900	77900 / 19
IL-23	70700	70700 / 17
IL-27	71500	71500 / 17
IL-4	40900	40900 / 9,99
IL-5	42000	10500 / 10
X IL-6	42900	42900 / 10
IL-9	24600	24600 / 6,01

7-plex Beads Lot#213797000

Target Name	Bead Number	Std1 Concentration pg/ml	Standard
GM-CSF	44	59600	Standard Mix A
IFN-gamma	43	61900	Standard Mix A
IL-1beta	18	8150	Standard Mix A
IL-12p70	34	25200	Standard Mix A
IL-2	19	23400	Standard Mix A
IL-6	25	42900	Standard Mix A
TNF-alpha	45	35200	Standard Mix A

Analytical information:

This product has been tested by Quality Control and passed internal specifications.

Quality control:



For Research Use Only. Not for use in diagnostic procedures. If you have any further questions about this Certificate of Analysis, please contact Technical Services at 1-800-955-6288 (US and Canada) or 1-760-603-7200, x2 (all other countries). For inquiries, contact us at "thermofisher.com/askaquestion"



CTL

PRODUCT DATA SHEET – ePBMC® Uncharacterized Cryopreserved Human PBMC

Catalog No.: CTL-UP1

Product name: ePBMC® - Uncharacterized Cryopreserved Human PBMC

Size: >10x10⁶ cells / vial

Description: Human PBMC (Peripheral Blood Mononuclear Cells) isolated from leukopacks and frozen in CTL-CryoABC™ serum-free freezing medium. These leukopacks were ethically collected from healthy donors with no risk of breaching privacy. Tested negative for HBsAg, HBcAb, HCV, HTLV I/II and STS by serology; as well as HIV I, HCV and WNV by NAT (nucleic acid testing)

Performance: T cell functionality by ELISPOT equivalent to fresh cells

Applications: PBMCs are suited for T cell monitoring in ELISPOT, ELISA, cytokine bead arrays, tetramer/ pentamer, and cytokine capture assays or any assay that requires live functional PBMC

Recommended test concentration: Investigators are advised to determine optimal concentrations for individual applications.
CTL recommends of 100,000 to 800,000 cells / well concentration for ELISPOT

Stability and Storage: Cryopreserved cells are shipped in a dry cryoshipper, and should be unpacked immediately upon receipt. Short-term storage of cells (24h) at -80°C is acceptable, but should be minimized to ensure maximum stability. For long-term storage, cryopreserved cells should be stored in liquid nitrogen. Thawed samples must be used immediately and have a finite life span in culture. Avoid repeated freeze-thaw cycles!

Long-term Storage: -169°C to -196°C (must be on liquid nitrogen (LN2) vapor)

Thawing: Thaw protocol included

Usage: **FOR RESEARCH USE ONLY!** Not intended for direct therapeutic or diagnostic use in humans or animals, or for use in in vitro diagnostic procedures!

Characterization results: PBMCs from 3 donors, 1 vial each to Pharmacelsus GmbH, Dr. Tanja Wolf

Sample ID#	HHU20190620	HHU20190709	HHU20190624	x	x
Ethnicity	Hispanic	Caucasian	Caucasian	---	---
Age	22	54	41	---	---
Gender	Female	Male	Male	---	---
ABO/Rh	O/Pos	AB/Pos	AB/Pos	---	---

SFC= Spot Forming Cells

ZSB

CTL Representative

Aug. 16, 2019

Date

C.T.L., 20521 Chagrin Blvd., Shaker Heights, Ohio 44122 USA
Tel (216) 791-5084 • Toll Free (888) 791-4005 • Fax (216) 791-8814 • www.immunospot.com

Certificate of analysis

ProcartaPlex

Cat. number: **PPX-06-MXKA3ZU**
96 tests/6 analytes

Name: **Human Custom ProcartaPlex 6-plex**

Lot number: **218832-000**

Expiry date: **2020-08**

Components

Components	Quantity	Lot	Store at
S10011EX Standard Mix A	2 each	187440101	2-8°C
B-06-MXKA3ZU-EX 6-plex Beads	1 x 5ml (1x)	218571-000	2-8°C
BK-06-MXKA3ZU-EX 6-plex det.AB	1 x 3,5ml (1x)	218572-000	2-8°C
RBEX/46 Reading Buffer	1 x 40ml	19045685	2-8°C
WBEX/28 10x Wash Buffer	1 x 25ml	19045686	2-8°C
SA-PE Streptavidin-PE	1 x 5ml	202532000	2-8°C
UABEX/11 Universal Assay Buffer 1x	1 x 10ml	18124434	2-8°C
SVM104 Black Microplate Lid	1 each		2-8°C
SVM16 Plate Covers	8 each		2-8°C
SVM183 PCR 8-Tube Strip	2 each		2-8°C
SVM182 Flat bottom Plate (black)	1 each		2-8°C

6-plex Beads Lot#218571-000

Target Name	Bead Number	Std1 Concentration pg/ml	Standard
GM-CSF	44	59600	Standard Mix A
IFN-gamma	43	61900	Standard Mix A
IL-1beta	18	8150	Standard Mix A
IL-2	19	23400	Standard Mix A
IL-6	25	42900	Standard Mix A
TNF-alpha	45	35200	Standard Mix A

Analytical information:

This product has been tested by Quality Control and passed internal specifications.

Quality control:



For Research Use Only. Not for use in diagnostic procedures. If you have any further questions about this Certificate of Analysis, please contact Technical Services at 1-800-955-6288 (US and Canada) or 1-760-603-7200, x2 (all other countries). For inquiries, contact us at "thermofisher.com/askaquestion"

Anti-inflammatory Flavanones and Flavones from *Tephrosia linearis*

Richard Oriko Owor, Kibrom Gebrehiwot Bedane, Sebastian Zühlke, Solomon Derese, George Otieno Ong'amo, Albert Ndakala,* and Michael Spiteller*

Cite This: *J. Nat. Prod.* 2020, 83, 996–1004

Read Online

ACCESS |

Metrics & More

Article Recommendations

Supporting Information



ABSTRACT: Phytochemical analysis of a methanol–dichloromethane (1:1) extract of the aerial parts of *Tephrosialinearis* led to the isolation of 18 compounds. Seven of these, namely, lineaflavones A–D (1–4), 6-methoxygeraldone (5), 8''-acetylobovatin (6), and 5-hydroxy-7-methoxysaniculamin A (7) are new compounds. The compounds were characterized based on their NMR and HRMSⁿ data. The anti-inflammatory effects of the crude extract and isolated compounds were evaluated by measuring the levels of interleukins (IL-1 β , IL-2, and IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF), and tumor necrosis factor- α (TNF- α) in lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells (PBMCs). The crude extract inhibited the release of all cytokines except IL-1 β , which slightly increased in comparison to the LPS control. All the tested compounds suppressed the production of IL-2, GM-CSF, and TNF- α . Whereas compounds 1, 2, 4–8, 10–15, 17, and 18 decreased production of IL-6, compounds 1, 2, 4, 7, 10, 13–15, and 17 inhibited the release of IL-1 β . It is worth noting that most of the compounds tested showed a superior reduction in cytokines release compared to the reference drug ibuprofen.

Plants of the genus *Tephrosia* Pers. (Fabaceae) mainly inhabit tropical and subtropical regions with over 30 species occurring in Kenya.¹ Many of the species have been used ethnomedicinally to alleviate diverse illnesses.^{2,3} Phytochemical investigations of some of these plants by our research group have led to the isolation of a chalcone,⁴ rotenoids,⁵ flavanonols,⁶ and flavones⁷ that are biologically active. Also, the genus *Tephrosia* is reported to elaborate other bioactive flavonoids such as flavanones, isoflavones, and pterocarpanes.^{8,9} Some of these flavonoids also exhibit anti-inflammatory properties. For instance, genistein found in *Tephrosia toxicaria*¹⁰ reduces peripheral and central nuclear factor- κ B (NF- κ B) and the nitric oxide system as well as pro-inflammatory cytokine over-activation,¹¹ while naringenin, common in the family Fabaceae, decreases the production of TNF- α ,¹² and apigenin inhibits TNF- α -induced NF- κ B.¹³

In Kenya, the juice of boiled leaves of *Tephrosialinearis* (Willd.) Pers. is used traditionally to treat a broad spectrum of ailments in infants.¹⁴ An earlier phytochemical investigation on the roots of this plant led to the isolation of rotenone, deguelin, tephrosin, and 12a-hydroxyrotenone.¹⁵ In our continued effort

to investigate *Tephrosia* species, the aerial parts of *T. linearis* were investigated phytochemically leading to the isolation and identification of 18 compounds, of which seven are new. Herein, are discussed the isolation, structure elucidation, and anti-inflammatory effects of these compounds. To evaluate the anti-inflammatory effects of the crude plant extract and the isolated compounds, lipopolysaccharide (LPS)-stimulated cytokine release of peripheral blood mononuclear cells (PBMCs) was quantified through measurement of the levels of IL-1 β , IL-2, IL-6, GM-CSF, and TNF- α .

RESULTS AND DISCUSSION

The crude extract of the aerial parts of *T. linearis* was subjected to silica gel and Sephadex LH-20 column chromatography,

Received: September 24, 2019

Published: March 10, 2020





Synergistic anti-inflammatory activities of a new flavone and other flavonoids from *Tephrosia hildebrandtii* vatke

Richard Oriko Owor^{a,b,c} , Kibrom Gebreheiwot Bedane^{b,d}, Yolande Ikala Openda^a, Sebastian Zühlke^b, Solomon Derese^a, George Ong'amo^e, Albert Ndakala^a and Michael Spiteller^b

^aDepartment of Chemistry, University of Nairobi, Nairobi, Kenya; ^bInstitute of Environmental Research (INFU), Department of Chemistry and Chemical Biology, Chair of Environmental Chemistry and Analytical Chemistry, TU Dortmund, Dortmund, Germany; ^cDepartment of Chemistry, Busitema University, Tororo, Uganda; ^dDepartment of Chemistry, Addis Ababa University, Addis Ababa, Ethiopia; ^eSchool of Biological Sciences, University of Nairobi, Nairobi, Kenya

ABSTRACT


A new flavone, named hildeflavone (1) along with 7 other known flavonoids were isolated from the aerial parts of *Tephrosia hildebrandtii* Vatke. Their characterisation was based on NMR and MS data analysis. The anti-inflammatory properties of the crude extract, isolated compounds and combination of the compounds were investigated in lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells (PBMCs). Treatment of the LPS-stimulated PBMCs with the isolated flavonoids at a concentration of 100 μ M significantly reduced the production of interleukins (IL-1 β , IL-2 and IL-6), interferon-gamma (IFN- γ), granulocyte macrophage-colony stimulating factor (GM-CSF) and tumour necrosis factor-alpha (TNF- α). It was also found that the combination of a flavone and flavanones exhibited remarkable synergistic anti-inflammatory effects on the production of the cytokines.

ARTICLE HISTORY


Received 26 December 2019
Accepted 10 February 2020

KEYWORDS

Fabaceae; *Tephrosia hildebrandtii*; flavonoid; anti-inflammatory; hildeflavone; cytokine; synergy



CONTACT M. Spiteller  michael.spiteller@tu-dortmund.de; A. Ndakala  andakala@uonbi.ac.ke

 Supplemental data for this article can be accessed at <https://doi.org/10.1080/14786419.2020.1736065>.

© 2020 Informa UK Limited, trading as Taylor & Francis Group



Isoflavones from the seedpods of *Tephrosia vogelii* and pyrazoisopongaflavone with anti-inflammatory effects

Richard Oriko Owor^{a,b,c,*}, Solomon Derese^a, Kibrom Gebreheiwot Bedane^d, Sebastian Zühlke^b, Albert Ndakala^{a,**}, Michael Spitteller^{b,**}

^a Department of Chemistry, University of Nairobi, P.O. Box 30197-00100, Nairobi, Kenya

^b Institute of Environmental Research (INFU), Department of Chemistry and Chemical Biology, TU Dortmund, Otto-Hahn-Str. 6, 44221 Dortmund, Germany

^c Department of Chemistry, Busitema University, P.O. Box 236, Tororo, Uganda

^d Department of Chemistry, Addis Ababa University, P.O. Box 33658, Addis Ababa, Ethiopia

ARTICLE INFO

Keywords:

Tephrosia vogelii
Vogelisoiflavone
Pyrazoisopongaflavone
Isopongaflavone
Anti-inflammatory
Cytokine

ABSTRACT

Phytochemical investigation of *Tephrosia vogelii* seedpods led to the isolation of twelve compounds: vogelisoiflavone A (1), vogelisoiflavone B (2), isopongaflavone (3), onogenin, luteolin, 4',7-dihydroxy-3'-methoxyflavanone, *trans-p*-hydroxycinnamic acid, tephrosin, 2-methoxyglyricidol, dehydrorotenone, 6a,12a-dehydro- α -toxicarol and pinoresinol. Compounds 1 and 2 are reported as new natural products. Isopongaflavone (3) was structurally modified using hydrazine to pyrazoisopongaflavone (4). These compounds were characterized based on their NMR and HRESIMS data. Further, four compounds (1–4) were evaluated for their anti-inflammatory effects in lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells (PBMCs). Treatment of the LPS-stimulated PBMCs with the compounds at a concentration of 100 μ M suppressed the secretion of interleukin IL-1 β interferon-gamma (IFN- γ), granulocyte macrophage-colony stimulating factor (GM-CSF) and tumour necrosis factor-alpha (TNF- α).

1. Introduction

Tephrosia vogelii Hook.f. Pers. is widely distributed in tropical Africa and is commonly known as fish bean or Vogel's tephrosia [1,2]. This plant is widely cultivated in Africa for fishing, protecting crops against mole rats, pests and for soil enrichment [3–7]. It is also an important ethnomedicinal plant used to manage a variety of ailments including scabies, yaws and constipation [8,9]. The diverse traditional uses of *T. vogelii* have stimulated various studies on its phytochemical and pharmacological properties. Extracts and isolates from *T. vogelii* have exhibited varied activities including insecticidal, molluscicidal and piscicidal activities [1,4,6,10–12]. Most of the entomotoxic and ichthotoxic properties of *T. vogelii* are attributed to rotenoids especially deguelin, rotenone, tephrosin, α -toxicarol and sarcolobine that have been reported to be abundant in the plant [11,13,14]. The plant also elaborates other flavonoids that are non-entomotoxic and non-ichthotoxic such as rutin, quercetin-3-arabinopyranoside, obovatin-5-O-methylether, quercetin-3-O-galactoside and *Z*-tephrostachin [13–16]. Interestingly, some of these flavonoids such as rutin, quercetin-3-O-galactoside have been shown to possess anti-inflammatory properties through modulation of

inflammatory mediators especially cytokines [17,18].

In our continued efforts to study the anti-inflammatory flavonoids from *Tephrosia* plants [19,20], the phytochemical constituents of *T. vogelii* seedpods were investigated leading to isolation of two new isoflavones along with ten known compounds. Considering that conversion of some natural products such as curcumin into their pyrazole derivative enhanced their anti-inflammatory activity [21,22], in this study, one of the flavonoids (isopongaflavone) was structurally modified to its pyrazole derivative and evaluated for its anti-inflammatory activity. It is also worth noting that pyrazole derivatives are potent anti-inflammatory agents and some have been developed into anti-inflammatory drugs such as celecoxib, lonazolac and mepirizole [23–25]. Herein, the isolation, structural elucidation, structure modification, and anti-inflammatory activities of the compounds isolated from the seedpods of *T. vogelii* are described.

2. Experimental

2.1. General experimental procedures

The instrumentation and reagents used were as described in our

* Corresponding author at: Department of Chemistry, University of Nairobi, P.O. Box 30197-00100, Nairobi, Kenya.

** Corresponding authors.

E-mail addresses: roriko@sci.busitema.ac.ug (R.O. Owor), andakala@uonbi.ac.ke (A. Ndakala), michael.spitteller@tu-dortmund.de (M. Spitteller).

<https://doi.org/10.1016/j.fitote.2020.104695>

Received 15 May 2020; Received in revised form 23 July 2020; Accepted 28 July 2020

Available online 01 August 2020

0367-326X/ © 2020 Elsevier B.V. All rights reserved.